

- Aaronson, KD, 862(ab)
 Aaronson, RA, 932(ab)
 Abbott, GL, 911(ab)
 Abdel-Dayem, HM, 842(ab), 857(ab), 864(ab), 876(ab), 921(ab), 942(ab), 943(ab), 959(ab), 968(ab)
 Abdel-Nabi, H, 747(ab), 748(ab), 818(ab), 906(ab), 908(ab)
 Abe, Y, 33
 Abello, R, 834(ab), 858(ab), 909(ab)
 Abello, RR, 901(ab)
 Abeysekera, BF, 1916(le)
 Abitbol, C, 798(ab), 841(ab), 915(ab)
 Abraham, T, 959(ab)
 Abramovici, J, 897(ab)
 Abrams, DN, 523
 Abrams, P, 779(ab), 818(ab)
 Abrams, PG, 25, 216
 Abrashkin, S, 450, 538
 Aburano, T, 844(ab), 997
 Abu-Zidan, F, 942(ab)
 Acharya, K, 770(ab)
 Achong, DM, 941(ab)
 Ackerhalt, R, 818(ab)
 Ackerman, RH, 782(ab)
 Ackerman, RJ, 895(ab)
 Ackermann, RF, 838(ab), 900(ab)
 Ackery, D, 903(ab)
 Adam, MJ, 923(ab), 924(ab)
 Adam, WE, 813(ab), 835(ab), 1393
 Adams, HR, 1249
 Adams, R, 320
 Adelstein, SJ, 826(ab), 882(ab), 883(ab), 932(ab), 1856
 Adkins, R, 857(ab)
 Adzamli, IK, 839(ab)
 Aengevaeren, W, 861(ab)
 Aengevaeren, WRM, 1723
 Afeworth, M, 798(ab)
 Affana, RS, 857(ab)
 Agnew, JE, 744(ab)
 Agostini, D, 810(ab)
 Agostini, M, 779(ab)
 Agrawal, M, 474
 Aguilar, F, 863(ab)
 Ahmad, M, 817(ab), 840(ab), 901(ab), 917(ab), 1095
 Ahmed, A, 905(ab)
 Ahonen, A, 912(ab)
 Aikawa, T, 917(ab)
 Aizawa, T, 811(ab)
 Akanabe, H, 458
 Akers, MS, 288, 638, 770(ab), 801(ab), 810(ab), 828(ab), 871(ab)
 Akiyama, Y, 885(ab)
 Akkermans, L, 795(ab)
 Akoun, G, 746(ab)
- Alajaji, G, 821(ab)
 Alavi, A, 88, 328, 692, 731(ab), 733(ab), 753(ab), 754(ab), 762(ab), 772(ab), 773(ab), 802(ab), 811(ab), 830(ab), 834(ab), 898(ab), 965(ab), 1106, 1589, 1607
 Albert, R, 730(ab)
 Alberti, W, 845(ab)
 Albright, MJ, 813(ab)
 Alderson, PO, 787(ab), 819(ab), 936(ab)
 Al-Doohan, S, 902(ab)
 Alexander, M, 961(ab)
 Alexopoulos, D, 834(ab)
 Al-Ghussain, NM, 857(ab)
 Al-Hasani, S, 922(ab)
 Ali, A, 769(ab), 855(ab)
 Allen, A, 844(ab)
 Allilaire, JF, 897(ab)
 Allison, DJ, 841(ab)
 Allsop, P, 738(ab)
 Allwright, S, 799(ab)
 Allwright, SJ, 857(ab)
 Al-Mohannadi, S, 943(ab)
 Al-Nahas, AA, 823(ab)
 Alpert, N, 961(ab)
 Alpert, NM, 776(ab), 782(ab), 797(ab)
 Alvarez, VL, 778(ab), 831(ab)
 Alves, W, 802(ab), 898(ab), 965(ab)
 Alves, WM, 1607
 Alyea, K, 786(ab)
 Ambrose, J, 834(ab)
 Ambrose, KR, 923(ab)
 Amini, SB, 867(ab)
 Ammar, IA, 817(ab)
 Amox, D, 778(ab)
 Anders, G, 880(ab)
 Andersen, AR, 896(ab)
 Anderson, G, 874(ab)
 Anderson, HL, 767(ab)
 Anderson, LE, 827(ab), 907(ab)
 Anderson, LL, 933(ab)
 Anderson, QN, 858(ab)
 Ando, A, 921(ab)
 Ando, I, 921(ab)
 Andreu, J, 1470
 Andrew, M, 1819
 Andrews, J, 836(ab)
 Anema, PC, 806(ab)
 Angelberger, P, 731(ab)
 Angello, DA, 1172
 Ansari, A, 886(ab)
 Ansari, S, 803(ab)
 Antar, MA, 859(ab)
 Antich, P, 902(ab)
 Antico, VF, 1885, 1946
 Antman, EM, 821(ab)
 Antonescu, A, 740(ab)
 Antoni, G, 782(ab), 783(ab)
 Antonovic, A, 905(ab)
- Apicella, A, 93, 772(ab), 802(ab)
 Apostolidis, DL, 1257
 Appelbaum, FR, 828(ab)
 Appelbaum, J, 779(ab)
 Appelman, EH, 930(ab)
 Applebaum, FR, 826(ab)
 Applegate, GR, 700
 Arano, Y, 832(ab)
 Araujo, LI, 775(ab), 808(ab)
 Arcamano, M, 833(ab)
 Archer, CM, 773(ab), 818(ab), 939(ab)
 Archer CM, 773(ab)
 Areeda, J, 739(ab)
 Arevalo, M, 794(ab)
 Arimizu, N, 738(ab), 858(ab), 865(ab), 910(ab)
 Arnold, RJ, N576, N994
 Arnold, S, 747(ab)
 Arnott, RN, 738(ab)
 Aroesty, JM, 870(ab)
 Arrington, ER, 2046
 Arsenault, A, 800(ab), 807(ab)
 Ashley, CA, 968(ab)
 Assayag, P, 820(ab)
 Atcher, R, 832(ab), 834(ab), 925(ab)
 Atkins, HL, 165, 811(ab), 1848
 Atkinson, D, 813(ab)
 Auerbach, B, 786(ab)
 Aulich, A, 771(ab)
 Ausema, L, 768(ab)
 Austin, M, 751(ab), 831(ab)
 Austin, ML, 787(ab)
 Autran, B, 746(ab)
 Avedissian, MG, 1281
 Avioli, LV, 774(ab)
 Awdeh, M, 842(ab)
 Axworthy, D, 779(ab)
 Axworthy, DB, 793(ab)
 Azar, H, 883(ab)
- Babich, J, 809(ab)
 Babich, JW, 474, 836(ab), 911(ab)
 Bacharach, SL, 420, 780(ab), 807(ab), 1966
 Bachelor, MA, 926(ab)
 Bachur, R, 750(ab)
 Badach, V, 845(ab)
 Badenhorst, PN, 914(ab)
 Badger, CC, 826(ab), 828(ab)
 Bading, JR, 852(ab)
 Baerga, ID, 742(ab), 920(ab)
 Bahar, RH, 942(ab)
 Bailey, DL, 872(ab), 964(ab), 1865
 Baillet, GY, 38
 Baird, F, 786(ab)
 Baker, J, 764(ab), 887(ab)
 Baker, SR, 843(ab)
- Bakker, WH, 768(ab)
 Bakr, SA, 922(ab)
 Balasubramanian, N, 748(ab), 941(ab)
 Balch, CM, 844(ab)
 Baldas, J, 1240
 Ballard, JG, 497, 756(ab)
 Ballardie, FW, 784(ab)
 Ballemer, PJ, 629
 Ballester, M, 862(ab)
 Balliet, R, 965(ab)
 Ballinger, J, 760(ab), 829(ab)
 Ballinger, JR, 812(ab), 1621
 Balon, H, 850(ab), 959(ab)
 Balu, D, 1464
 Ban, R, 770(ab), 944(ab)
 Ban, T, 866(ab), 1302, 1775
 Bandyopadhyay, D, 859(ab)
 Bannochie, CJ, 848(ab)
 Banzo, I, 1277(le)
 Baranczuk, RA, 844(ab)
 Baranowska-Kortylewicz, J, 883(ab)
 Baranowska-Kortylewicz, J, 882(ab), 919(ab)
 Barbagallo, S, 764(ab), 887(ab), 964(ab)
 Barber, HB, 891(ab)
 Barbet, J, 907(ab), 1358
 Bares, R, 841(ab)
 Baris, I, 913(ab)
 Barker, W, 93
 Barker, WW, 772(ab)
 Barker WW, 802(ab)
 Barnes, J, 903(ab)
 Barnette, MS, 794(ab)
 Barnhart, AJ, 848(ab)
 Baron, JC, 897(ab)
 Baron, LA, 832(ab)
 Barone, FC, 794(ab)
 Barrett, HH, 891(ab), 892(ab)
 Barrett, J, 847(ab)
 Barrett, JS, 815(ab)
 Barrio, JR, 735(ab), 752(ab), 761(ab)
 Barron, BJ, 270, 967(ab)
 Bartenstein, P, 856(ab)
 Barton, D, 799(ab)
 Barzilai, B, 771(ab)
 Bash, SA, 894(ab)
 Bassingthwaite, JB, 798(ab), 808(ab)
 Bauer, J, 751(ab)
 Baum, RP, 786(ab), 847(ab), 904(ab)
 Bauman, JM, 1737(le)
 Bazzochi, G, 887(ab)
 Beachler, A, 861(ab)
 Beaney, RP, 843(ab)
 Beaumier, P, 779, 793(ab)
 Beaumier, PA, 216, 933(ab), 932(ab)
 Beaumier, PL, 777(ab), 932(ab)
 Becher, R, 867(ab)
- Beck, N, 965(ab)
 Becker, DV, 833(ab)
 Becker, J, 963(ab)
 Becker, LC, 755(ab), 757(ab)
 Beckers, C, 815(ab), 929(ab)
 Beekhuis, H, 605
 Behrenbeck, T, 801(ab)
 Bejany, D, 841(ab)
 Bekdik, CF, 913(ab)
 Belinka, BA, 831(ab)
 Belisle, EH, 828(ab)
 Bellani, N, 864(ab), 959(ab)
 Beller, GA, 301, 756(ab), 790(ab), 1456
 Belletire, J, 742(ab)
 Bellil, D, 729(ab), 750(ab), 780(ab)
 Bellinger, RL, 959(ab)
 Bellon, EM, 734(ab)
 Belzberg, AS, 962(ab)
 Bendreim, B, 730(ab)
 Bendriem, B, 741(ab), 801(ab), 893(ab), 898(ab), 932(ab)
 Bendriem, B, 761(ab)
 Benedetto, AR, 269, 561, 566
 Benjamin, R, 901(ab)
 Bentl, R, 888(ab)
 Bentley, SJ, 748(ab)
 Berg, G, 581, 1386
 Berg, J, 497
 Berger, H, 859(ab), 901(ab)
 Berger, HJ, 787(ab), 934(ab)
 Berger, MS, 838(ab)
 Bergh, JR, 966(ab), 1737(le)
 Bergin, JD, 756(ab)
 Bergin, P, 837(ab)
 Bergman, SR, 730(ab)
 Bergmann, SR, 187, 351, 768(ab), 807(ab), 808(ab), 825(ab), 837(ab), 1489, 1798, 1843
 Bergsland, J, 1464
 Bergstein, P, 773(ab)
 Berkopec, JM, 826(ab), 906(ab)
 Berkovic, SF, 751(ab), 831(ab)
 Berman, D, 729(ab), 739(ab), 740(ab), 750(ab), 757(ab), 795(ab)
 Berman, DS, 301, 729(ab), 750(ab), 780(ab), 837(ab), 853(ab), 1718
 Bergman, RM, 882(ab)
 Berná, L, 862(ab)
 Bernay, I, 913(ab)
 Bernstein, I, 828(ab)
 Bernstein, T, 756(ab)
 Berridge, MS, 927(ab), 928(ab)
 Berry, JM, 924(ab)
 Besozzi, MC, 960(ab)
 Bettinardi, V, 892(ab)

Page numbers followed by (ab) indicate abstracts.

Page numbers followed by (le) indicate letters.

N preceding a page number indicates an article appearing in *Newslines*.

- Bettman, L, 737(ab)
 Beyar, R, 1657
 Bhadkamkar, V, 819(ab)
 Bhadkamkar, VA, 844(ab)
 Bhat, S, 1563
 Bianco, JA, 797(ab)
 Bice, AN, 797(ab), 825(ab), 879(ab), 893(ab), 1554
 Bidwell, JK, 412
 Biersack, HJ, 110, 744(ab), 758(ab), 805(ab), 856(ab), 879(ab), 922(ab), 923(ab), N1765
 Bielendorf, J, 1718
 Bigler, RE, 777(ab), 833(ab)
 Bigner, DD, 778(ab)
 Bihl, H, 804(ab)
 Bijvoet, OLM, 775(ab)
 Bilaniuk, L, 1607
 Billard, C, 812(ab)
 Billick, S, 811(ab)
 Billinghurst, MW, 523
 Billings, J, 88, 731(ab), 761(ab), 762(ab), 803(ab), 830(ab), 834(ab)
 Billings, JJ, 773(ab)
 Bilodeau, L, 800(ab)
 Bischof-Delaloye, A, 301, 1018, 1646
 Bischof-Delaloye, B, 809(ab)
 Bishop, N, 45
 Bishop, PT, 773(ab)
 Bisi, G, 820(ab)
 Biskupiak, JE, 808(ab)
 Bisson, G, 117
 Black, KL, 913(ab)
 Blackman, M, 812(ab)
 Bladin, PF, 751(ab), 831(ab)
 Blahd, W, 894(ab)
 Blasberg, R, 792(ab)
 Blasberg, RG, 839(ab), 899(ab), 1676
 Blaser, CB, 787(ab)
 Blau, M, 839(ab)
 Blaufox, MD, 666, 723, 841(ab)
 Blayney, D, 813(ab)
 Blend, MJ, 884(ab)
 Block, N, 841(ab)
 Blokland, JAK, 775(ab)
 Blomqvist, G, 927(ab)
 Blood, DK, 312, 863(ab)
 Blood, KMT, 965(ab)
 Bloomfield, PM, 775(ab)
 Blue, PW, 127
 Blumenthal, RD, 826(ab)
 Blumhardt, R, 860(ab), 1737(le)
 Boazi, M, 106
 Bochner, M, 887(ab)
 Bockisch, A, 110, 758(ab), 805(ab), 856(ab), 879(ab), 922(ab)
 Boer, Hde, 885(ab)
 Bok, B, 820(ab)
 Bokhari, F, 908(ab)
 Bol, A, 797(ab)
 Bolgos, GL, 767(ab)
 Bolman, RM III, 781(ab)
 Bomanji, J, 758(ab), 823(ab)
 Boniface, GR, 683
 Bonino, C, 742(ab)
 Bonnyman, J, 1240
 Bonow, RO, 420, 780(ab), 807(ab), 1966
 Bonte, FJ, 719
 Bonte FJ, 771(ab)
 Boogaerts, M, 2022
 Bookman, M, 909(ab)
 Boothe, TE, 93
 Borges-Neto, S, 790(ab)
 Bormans, G, 743(ab), 936(ab), 940(ab)
 Borrero, G, 967(ab)
 Boruchowsky, S, 768(ab)
 Bosley, M, 772(ab)
 Bosley, T, 802(ab)
 Bosslet, K, 904(ab)
 Bossuyt, A, 741(ab), 875(ab), 1342
 Bossuyt-Piron, C, 741(ab), 921(ab), 925(ab)
 Botelho, MF, 744(ab)
 Botsch, H, 812(ab)
 Böttger, A, 875(ab)
 Botvinick, E, 810(ab)
 Botvinick, EH, 760(ab), 861(ab), 869(ab)
 Boucher, CA, 301, 740(ab)
 Boudreau, R, 961(ab), 967(ab)
 Boudreau, RJ, 1399, 1881
 Boug, EW, 872(ab)
 Boulet, A, 787(ab)
 Boulos, P, 808(ab), 809(ab), 908(ab), 909(ab)
 Bourdreau, RJ, 732(ab)
 Bourgoigne, J, 944(ab)
 Bourguignon, M, 812(ab)
 Bourguignon, MH, 810(ab)
 Boutin, R, 793, 934(ab)
 Bouvier, A, 766(ab)
 Boxer, DI, 1318
 Boyce, TM, 760(ab)
 Boyers, AS, 796(ab)
 Boyko, OB, 752(ab)
 Braat, SH, 791(ab)
 Brachman, M, 844(ab)
 Bradford, J, 812(ab)
 Bradley, E, 826(ab)
 Bradshaw, J, 776(ab)
 Brand, R, 845(ab)
 Brandhorst, I, 758(ab), 917(ab)
 Brasch, RC, 840(ab)
 Braun, AR, 899(ab)
 Braunstein, P, 700
 Brechbiel, MW, 672, 763(ab), 848(ab)
 Brechner, RR, 851(ab)
 Breedveld, FC, 889(ab), 2017
 Breeman, WAP, 768(ab)
 Breitz, H, 779(ab)
 Brendel, AJ, 904(ab), 916(ab)
 Brennan, K, 932(ab)
 Brenner, J, 844(ab)
 Bresnahan, DR, 801(ab)
 Bresnahan, JF, 801(ab)
 Breznock, B, 1702
 Briandet, P, 961(ab)
 Briele, B, 758(ab), 805(ab), 856(ab)
 Brihaye, C, 817(ab), 818(ab), 1025
 Brill, AB, 796(ab), 828(ab), 833(ab), 908(ab), 1848
 Brill, DR, N133, N1431
 Bristow, D, 964(ab), 979(ab)
 Britcher, SF, 930(ab)
 Britton, KE, 748(ab), 758(ab), 823(ab), 942(ab)
 Brixner, D, 940(ab)
 Broadhurst, P, 868(ab)
 Brocchini, SJ, 832(ab)
 Brochet, E, 820(ab)
 Brodack, JW, 788(ab), 910(ab), 968(ab)
 Broder, S, 581
 Brodie, JD, 741(ab)
 Brodin, T, 1224
 Brökelmann, J, 758(ab)
 Bronca, GA, 1616
 Brookeman, V, 1456
 Broussard, W, 905(ab)
 Brown, D, 860(ab)
 Brown, EJ, Jr, 165
 Brown, J, 841(ab)
 Brown, MA, 187, 1798
 Brown, ML, 764(ab), 804(ab), 1280(ie)
 Brown, MP, N1582
 Brown, MW, 848(ab)
 Brown, P, 826(ab)
 Brown, PH, 873(ab)
 Brown, RS, 759(ab)
 Brown, S, 828(ab)
 Brücke, T, 731(ab)
 Bruix, J, 1279(ie)
 Brunetti, A, 51, 581, 1676
 Brunken, R, 729(ab), 837(ab)
 Brunken, RC, 838(ab), 846(ab), 863(ab), 867(ab)
 Bruns, HD, 741(ab)
 Bruonanno, FS, 782(ab)
 Brush, JE, 780(ab)
 Bubeck, B, 720
 Buchegger, F, 809(ab), 1646
 Buchi, M, 845(ab), 846(ab)
 Buchsbaum, D, 912(ab)
 Buck, JL, 622
 Budd, J, 967(ab)
 Budinger, TF, 745(ab), 760(ab), 765(ab)
 Buell, U, 791(ab), 805(ab), 819(ab), 841(ab), 1018
 Buhr, W, 744(ab)
 Buijs, W, 758(ab), 885(ab)
 Bull, JMC, 789(ab)
 Bunko, H, 870(ab)
 Buonanno, F, 961(ab)
 Buonanno, FS, 782(ab)
 Buonocore, E, 925(ab), 960(ab)
 Burchell, J, 758(ab)
 Burchiel, SW, 1351
 Burgess, BA, 1892
 Burgess, J, 810(ab)
 Burgin, J, 766(ab)
 Burgua, B, 779(ab)
 Burke, JF, 1538
 Burns, A, 895(ab)
 Burns, HD, 849(ab), 923(ab), 930(ab), 931(ab)
 Burt, RW, 422
 Busche, HS, 833(ab)
 Bushe, H, 833(ab)
 Busuttil, RW, 1507
 Butler, SP, 787(ab), 819(ab), 936(ab)
 Butler, WF, 894(ab)
- Buxton, RB, 782(ab), 797(ab)
 Buzzard, A, 819(ab)
 Byrd, BF, 1737(le)
 Byrd, BL, 763(ab), 935(ab)
 Caccamo, L, 888(ab)
 Cahoon, JL, 765(ab)
 Caldwell, JH, 194, 798(ab), 846(ab)
 Callaghan, JJ, 1321
 Callahan, AP, 848(ab)
 Callahan, RJ, 385, 805(ab), 817(ab)
 Calvert, X, 1279(ie)
 Camargo, EE, 916(ab)
 Camilleri, M, 764(ab)
 Camin, L, 301
 Camli, U, 811(ab)
 Camponovo, E, 622
 Camps, JAJ, 889(ab), 2017
 Canales, M, 860(ab)
 Caner, BE, 913(ab)
 Cannon, PJ, 312
 Cannon, RO, III, 1966
 Cantineau, R, 926(ab)
 Carabell, SC, 827(ab)
 Cardella, JF, 1399
 Carey, J, 836(ab), 1476
 Cargill, EB, 892(ab)
 Caride, VJ, 1424
 Carlson, KE, 821(ab), 928(ab)
 Carlson, RA, 893(ab), 963(ab)
 Carney, PL, 374, 935(ab)
 Carnochan, P, 911(ab)
 Carpenter, D, 932(ab)
 Carr, EA, Jr, 1464
 Carrasquillo, JA, 320, 903(ab), 906(ab), 909(ab), 915(ab), 1311
 Carrera, GF, 754(ab)
 Carril, JM, 1277(ie)
 Carrió, I, 862(ab)
 Carroll, M, 1464
 Carroll, MJ, 823(ab)
 Carroll, TR, 773(ab)
 Carry, MM, 288
 Carson, RE, 745(ab), 746(ab), 807(ab), 824(ab), 825(ab), 839(ab), 899(ab), 1386
 Carter, R, 474, 836(ab)
 Carton, E, 896(ab)
 Caruana, V, 1408
 Carvacho, OF, 849(ab)
 Carvalho, PA, 821(ab)
 Cashman, P, 868(ab)
 Cassidy, E, 927(ab)
 Castaigne, A, 810(ab)
 Castaneda, AR, 1176
 Castle, VP, 1819
 Catafau, AM, 1470
 Catz, Z, 836(ab), 914(ab)
 Caudry, M, 904(ab)
 Caunt, JF, 891(ab)
 Cawthon, MA, 1737(ie)
 Cayla, J, 762(ab), 825(ab), 877(ab)
 Celentano, L, 51
 Cerino, M, 1271
 Cerqueira, M, 194, 629, 769(ab)
 Cerqueira, MD, 703
 Cha, SD, 867(ab)
 Chamberlain, MJ, 1627
 Chan, B, 731(ab)
 Chanana, AD, 1342
 Chandraratna, PA, 821(ab)
 Chang, AE, 320
 Chang, JY, 93, 772(ab), 802(ab)
 Chang, W, 731(ab), 834(ab), 851(ab)
 Chaovapong, W, 762(ab)
 Chapman, NJ, 764(ab)
 Chapman, PR, 1589
 Charalambous, C, 876(ab)
 Charalel, J, 944(ab), 945(ab)
 Charkes, ND, 794(ab)
 Charnsangavej, C, 1012
 Charuzi, Y, 780(ab)
 Chase, TN, 896(ab)
 Chatterton, B, 765(ab), 795(ab)
 Chaudhuri, M, 815(ab)
 Chaudhuri, T, 787(ab)
 Chaudhuri, TK, 815(ab)
 Chawluk, J, 772(ab)
 Chawluk, JB, 965(ab), 1607
 Chayes, Z, 944(ab), 945(ab)
 Checkneva, YY, 66
 Cheesman, EH, 1892
 Chelliah, M, 792(ab)
 Chen, C, 1280(ie)
 Chen, C-A, 924(ab), 930(ab)
 Chen, C-T, 880(ab), 960(ab)
 Chen, DCP, 886(ab)
 Chen, GTY, 777(ab)
 Chen, J-J, 1249
 Chen, LF, 810(ab)
 Cheng, M, 789(ab)
 Cherry, SR, 766(ab), 911(ab)
 Chesis, PL, 732(ab), 931(ab)
 Chiang, K, T26D
 Chieng, PU, 861(ab)
 Chierchia, S, 869(ab)
 Chierchia, SL, 873(ab)
 Child, JS, 838(ab)
 Chin, M, 810(ab)
 Chin, O, 886(ab)
 Chines, A, 774(ab)
 Chinol, M, 856(ab), 1047
 Chiou, PF, 871(ab)
 Chiron, C, 812(ab)
 Chiu, KW, 773(ab), 818(ab)
 Chiu, M, 757(ab)
 Chiueh, CC, 1249
 Choi, Y, 735(ab)
 Chouraqui, P, 729(ab), 780(ab)
 Chow, SP, 774(ab)
 Chowdhury, S, 804(ab)
 Chowdhury, SC, 921(ab)
 Choy, D, 918(ab)
 Christiaens, L, 752(ab), 926(ab)
 Christie, MS, 563
 Christman, D, 730(ab), 761(ab), 801(ab)
 Christman, DR, 741(ab), 771(ab), 776(ab), 893(ab), 898(ab)
 Chua, EL, 959(ab)
 Chugani, HT, 801(ab), 896(ab)
 Chumpradit, S, 803(ab),

- 830(ab)
Chung, J-K, 903(ab),
906(ab), 915(ab)
Chung, WS, 760(ab), 869(ab)
Cianflone, D, 873(ab)
Ciaravino, J, 771(ab)
Cios, KJ, 816(ab)
Civelek, AC, 885(ab)
Claessens, R, 758(ab)
Claessens, RAMJ, 943(ab)
Clanton, J, 803(ab)
Clanton, JA, 563
Clarke, G, 808(ab), 809(ab)
Clarke, L, 884(ab)
Clarke, LP, 876(ab)
Clarke, SE, 174
Clausen, M, 813(ab),
835(ab), 1393
Clavo, A, 759(ab)
Clavo, AC, 832(ab)
Cleator, IG, 962(ab)
Clement, R, 859(ab)
Clements, IP, 1280(le)
Clinthorne, N, 777(ab)
Clorius, JH, 784(ab),
789(ab), 909(ab), 910(ab),
911(ab)
Coakley, AJ, 562
Coates, G, 853(ab), 1819
Coca, FJ, 398
Cocanougher, MK, 749(ab)
Coenen, HH, 110, 895(ab),
1367
Coffey, JL, 1117
Cogneau, M, 797(ab)
Cohan, ES, 882(ab)
Cohen, A, 809(ab)
Cohen, MB, 1616
Cohen, RM, 581, 1249
Cohen, VI, 1079
Cohn, PF, 165
Colcher, D, 320, 672
Coleman, M, 755(ab),
756(ab)
Coleman, R, 755(ab), 1318
Coleman, RE, 752(ab),
790(ab), 968(ab)
Colina, M, 760(ab)
Collen, MJ, 233
Collier, BD, 120, 857(ab)
Collier-Geulette, A, 897(ab)
Collins, C, 25
Collins, J, 908(ab), 918(ab)
Collins, JA, 407
Collins, L, 776(ab), 839(ab)
Collins, LT, 1946
Collins, P, 887(ab)
Collmann, J, 960(ab)
Colombo, F, 742(ab),
831(ab), 869(ab)
Colston, JT, 860(ab)
Comar, D, 766(ab)
Comerota, A, 782(ab)
Conandini, A, 908(ab)
Connell, JM, 763(ab)
Connor, W, 817(ab)
Conradty, A, 757(ab)
Constantinides, C, 864(ab),
959(ab)
Conte, F, 959(ab)
Conti, PS, 929(ab)
Conversano, A, 869(ab)
Conway, T, 783(ab)
Cooke, CD, 806(ab)
- Cooper, E, 760(ab)
Cooper, JA, 743(ab),
744(ab), 852(ab)
Cooper, MD, 899(ab)
Cooper, SG, 1111
Cootjans, J, 896(ab)
Coppola, R, 896(ab)
Corbett, JR, 288, 638,
770(ab), 801(ab), 810(ab),
828(ab), 871(ab)
Corlja, M, 939(ab)
Correia, J, 961(ab)
Correia, JA, 776(ab), 782(ab)
Corstens, F, 736(ab),
758(ab), 861(ab), 885(ab)
Corstens, FHM, 943(ab),
1723
Corwin, LA, 966(ab)
Costa, DC, 895(ab), 1917(le)
Côté, C, 1727
Couch, MW, 1916(le)
Coughlin, DJ, 831(ab)
Coulter, SE, 1133
Counsell, RE, 768(ab),
849(ab), 1088
Courey, M, 883(ab), 884(ab)
Courtenay-Luck, N, 1636
Courter, JH, 928(ab)
Cousin, N, 871(ab)
Courtris, G, 855(ab)
Covell, DG, 903(ab)
Coveny, J, 773(ab)
Coveney, JR, 937(ab)
Cradduck, TD, 815(ab)
Crass, JR, 1881
Crawley, JCW, 818(ab)
Creasey, AA, 819(ab)
Crews, L, 789(ab)
Croft, BY, 882(ab), N277,
N92
Croghan, G, 908(ab)
Crombez, D, 936(ab)
Cronin, B, 813(ab)
Crook, JE, 763(ab), 935(ab)
Crossman, D, 841(ab)
Crouzel, C, 825(ab), 877(ab)
Crouzel, M, 825(ab), 877(ab)
Cukier, A, 916(ab)
Cullom, S, 884(ab)
Cullom, SJ, 876(ab)
Cunningham, TM, 869(ab)
Cuocolo, A, 51, 780(ab),
807(ab), 941(ab), 1422(le)
Curchod, S, 1646
Custer, TR, 907(ab)
Cutler, C, 732(ab), 743(ab)
Cyr, S, 773(ab)
Czerniak, A, 737(ab),
768(ab)
Dach, JL, 960(ab)
DaCosta, MC, 1875
Daddona, P, 787(ab)
Daddona, PE, 906(ab)
Dae, M, 760(ab)
Dae, MW, 810(ab), 861(ab),
869(ab)
Daemen, BJJ, 789(ab)
Daghigian, F, 791(ab)
Daher, S, 933(ab)
Dahlen, DD, 852(ab)
Dalal, K, 932(ab)
Dalinka, MK, 754(ab)
Daly, MJ, 1422(le)
- Dam, M, 896(ab)
Damjanov, A, 936(ab)
Damjanov, I, 936(ab)
Danaie, J, 963(ab)
Danais, S, 781(ab)
Danielsen, R, 1972
Danielski, E, 490
Danilov, SM, 1686
Dannals, R, 838(ab)
Dannals, RF, 423, 731(ab),
740(ab), 741(ab), 750(ab),
849(ab), 929(ab), 930(ab),
931(ab)
Dansereau, R, 886(ab)
Das, DK, 859(ab)
Das Gupta, AK, 921(ab)
Dasgupta, P, 868(ab)
Daube-Witherspoon, ME,
745(ab), 746(ab), 824(ab),
825(ab), 1386
Daugherty, A, 763(ab)
David, R, 424
Davidson, B, 808(ab),
809(ab), 908(ab), 909(ab)
Davidson, BR, 891(ab)
Davidson, G, 765(ab)
Davies, R, 760(ab), 829(ab)
Davis, C, N1144
Davis, JL, 2002
Davis, JW, 1166, 1273
Davis, LP, 967(ab)
Davis, MA, 1047
Davis, MJ, 548, 1738(le)
Davison, A, 757(ab), 938(ab)
De Abreu, S, 913(ab)
Dean, C, 808(ab), 809(ab)
Dean, GW, 1297
Dean, RT, 793(ab), 794(ab),
934(ab)
De Backker, C, 2022
de la Blaquier, P, 819(ab)
de Bruine, F, 781(ab)
DeCarle, D, 851(ab)
Decoster, P, 797(ab)
Dedrick, RL, 839(ab)
Deecke, L, 731(ab)
Dees, SM, 1559
DeForge, LE, 768(ab)
DeFulvio, J, 747(ab),
901(ab), 936(ab)
De Geeter, F, 875(ab),
926(ab)
DeGeorge, JJ, 928(ab)
de Goeij, JMM, 650
DeGrado, TR, 1211
de Groot, TI, 929(ab)
Dehdashti, F, 754(ab)
Dehmer, GJ, 861(ab)
de Jesus, OT, 927(ab)
DeJesus, OT, 924(ab),
930(ab), 935(ab)
de Jong, PE, 605
Delage, M, 907(ab), 1358
de la Fuente, C, 1277(le)
Delaloye, B, 809(ab), 1646
DeLand, FH, 1129
Delaney, ML, 1875
de Lange, MJ, 1219
Delbeke, D, 15, 1917(le)
Deleide, C, 742(ab)
de Leon, MJ, 771(ab)
Delforge, J, 825(ab), 877(ab)
de Lima, JJP, 744(ab)
Delmon-Moingeon, L,
- 938(ab)
Delolye, B, 301
del Rosario, RB, 832(ab)
Delvecchio, A, 817(ab)
Demer, L, 846(ab)
Demer, LL, 838(ab)
Demonceau, G, 1902
DeNardo, GL, 763(ab),
778(ab), 827(ab), 884(ab),
907(ab)
Denays, R, 798(ab), 915(ab),
966(ab), 1337, 1825, 1982
Dence, C, 351
Dence, CS, 730(ab)
Denecke, H, 907(ab)
Denis, M, 746(ab)
Dent, J, 795(ab)
de Paulis, T, 803(ab)
DePuey, EG, 441
Depuey, EG, 757(ab)
DePuey, EG, 419, 740(ab),
749(ab), 795(ab)
Derbekyan, V, 181
Derenzo, SE, 745(ab),
765(ab)
De Roo, M, 743(ab),
795(ab), 896(ab), 936(ab),
940(ab), 1902, 2022
DeRoo, MC, 1018
Desai, J, 734(ab)
Deshpande, SV, 763(ab)
DeSisto, WC, 821(ab)
DesLauriers, AG, 897(ab)
DeSombre, E, 925(ab)
DeSombre, ER, 833(ab),
883(ab), 924(ab)
de Swart, H, 791(ab)
Deutch, R, 876(ab)
Deutsch, E, 732(ab), 742(ab),
743(ab), 772(ab), 831(ab),
849(ab), 936(ab)
Deutsch, EA, 837(ab)
Deveny, DM, 916(ab)
DeVito, RP, 2029
Devos, P, 896(ab)
Devous, MD, 719
Devous, MD, Sr, 742(ab),
751(ab), 771(ab)
deVries, DJ, 806(ab)
DeVroom, HL, 839(ab)
Dewanjee, M, 859(ab),
890(ab)
Dewanjee, MK, 737(ab),
921(ab), 922(ab)
Dewey, S, 730(ab), 761(ab),
801(ab)
Dewey, SL, 741(ab), 821(ab),
898(ab), 932(ab)
Dexus, F, 836(ab)
de Zeeuw, D, 605, 1219
Dezsi, L, 781(ab)
Dhawan, V, 839(ab), 1483
Dhekne, RD, 725, 786(ab),
941(ab)
Dhokia, B, 1636
Diamanti, CI, 762(ab)
Diamond, M, 899(ab)
Diamond, PD, 744(ab)
Diaz, P, 817(ab)
Diaz-Ball, FL, 962(ab)
DiChiuro, G, 581
Diedrich, K, 922(ab)
- Diehl, V, 843(ab)
Dietz, H, 910(ab)
Digby, W, 791(ab)
Digby, WM, 892(ab),
824(ab)(ab)
Diksic, M, 783(ab), 913(ab)
Dilehay, GL, 1870
Dilmanian, FA, 796(ab)
Dilsizian, V, 740(ab), 1149
Dilworth, JA, 773(ab)
Dilworth, JR, 939(ab)
Dimitrakopoulou, A,
789(ab), 909(ab), 910(ab),
911(ab)
Ding, Y-S, 753(ab), 782(ab),
783(ab)
DiSimone, RN, 127
Divgi, CR, 746(ab), 809(ab)
Dobbeleir, A, 794(ab),
817(ab), 818(ab)
Dobbeleir, AA, 1025
Dobkin, JA, 965(ab)
Doddona, PE, 859(ab)
Doerr, R, 747(ab), 748(ab)
Doerr, RJ, 908(ab)
Dom, R, 896(ab)
Domogatsky, SP, 66
Don, S, 799(ab)
Dondi, M, 615
Donohoe, KJ, 874(ab)
Doo, E, 873(ab)
Dorsky, S, 1408
Dorst, JK, 737(ab)
Dosio, F, 888(ab)
Dougan, H, 925(ab)
Douglass, KH, 740(ab)
Dowd, M, 899(ab)
Dowdley, JE, 542
Dowell, S, 750(ab)
Drane, WE, 622, 1568
Drasne, D, 407
Drealan, BF, 918(ab)
Dreikorn, K, 784(ab)
Driedger, AA, 1627
Driscoll, E, 767(ab)
Driver, MS, 832(ab)
Drouin, G, 944(ab)
Drozynski, CA, 1351
Duara, R, 93, 772(ab),
802(ab)
Dubovsky, E, 774(ab)
Dubovsky, EV, 823(ab),
2054
Dubovsky, J, 774(ab)
duCret, R, 961(ab), 967(ab)
duCret, RP, 1399, 1881
Dudley, NE, 1420(le)
Dulac, O, 812(ab)
Duman, Y, 913(ab)
Duncan, C, 905(ab)
Dunn, D, 796(ab)
Dunn, E, 855(ab)
Dunn, EK, 1563
Dunn, J, 773(ab)
Dunn, TJ, 937(ab)
Dunning, AJ, 780(ab)
Dupon, JW, 840(ab)
Dupont, F, 791(ab)
Dupras, G, 800(ab), 807(ab)
DuPree, ES, 895(ab)
Durack, L, 814(ab), 826(ab)
Durski, K, 885(ab)
Dutta, A, 761(ab)
Dwarkin, HJ, N12, 265,

- 736(ab), 869(ab), 1559
 Dwyer, JH, 729(ab)
 Dydek, GJ, 127
 Dylewski, J, 859(ab)
- Eary, JF, 25, 814(ab),
 826(ab), 828(ab), 969(ab)
 Ebbe, S, 932(ab)
 Ebert, M, 803(ab)
 Eckelman, WC, 1079, 1830
 Eckerman, K, 833(ab)
 Eckerman, KF, 2002
 Eddy, J, 581
 Edgerton, ER, 497
 Edwards, B, 773(ab), 818(ab)
 Edwards, DS, 773(ab)
 Edwards, PG, 773(ab)
 Eersels, J, 921(ab)
 Efange, SMN, 732(ab),
 761(ab)
 Egan, R, 781(ab)
 Eggi, DF, 233
 Ehrenkaufer, R, 783(ab)
 Ehrenkaufer, RLE, 920(ab)
 Ehrhardt, G, 849(ab)
 Eisenberg, B, 2046
 Eisner, RL, 796(ab)
 Ejiri, K, 897(ab)
 Eklem, M, 873(ab)
 Elashoff, J, 750(ab)
 Elder, RC, 732(ab)
 El-Etri, M, 772(ab)
 Elgazzar, AH, 943(ab)
 Ell, P, 808(ab)
 Ell, PJ, 895(ab), 1917(le),
 1018
 Elliott, D, 961(ab)
 Elmaleh, DR, 797(ab),
 928(ab)
 El-Sayed, M, 943(ab)
 Elsinga, PhH, 789(ab)
 Elson, MK, 857(ab), 906(ab),
 918(ab)
 El-Tahtawy, A, 814(ab)
 Emran, AM, 725, 1741
 Emrich, D, 779, 757(ab),
 800(ab)
 Endo, K, 747(ab), 785(ab),
 786(ab), 832(ab), 840(ab),
 862(ab), 885(ab), 889(ab),
 919(ab), 2050
 Endo, M, 865(ab), 866(ab),
 892(ab)
 Eng, W, 741(ab)
 Eng, W-S, 923(ab), 930(ab),
 931(ab)
 Engelbretson, D, 775(ab)
 Engelman, K, 328
 Engelman, R, 859(ab)
 Engelstad, BL, 840(ab),
 968(ab)
 Engenhart, R, 909(ab),
 911(ab)
 English, R, 821(ab)
 Enrich, D, 758(ab)
 Enslinger, W, 836(ab)
 Epenetos, AA, 819(ab), 1636
 Epps, LA, 787(ab), 794(ab)
 Epstein, AL, 827(ab)
 Ercan, MT, 913(ab)
 Erdman, KL, N438
 Erlandsson, K, 722
 Erlemann, R, 856(ab)
 Ernstthal, HL, 566
- Erwin, WD, 769(ab),
 855(ab), 902(ab)
 Eschner, W, 757(ab), 800(ab)
 Eshima, D, 720, 743(ab),
 823(ab), 943(ab), 1955
 Esperanza, L, 819(ab)
 Esposito, S, 51
 Esquerre, J-P, 398, 1738(le)
 Esser, PD, 124
 Essiambre, R, 790(ab)
 Estabrook, A, 936(ab)
 Esterbrooks, D, 730(ab)
 Esterhai, JL, 754(ab)
 Estorch, M, 862(ab)
 Eterović, D, 417, 560
 Eto, K, 942(ab)
 Ettinger, R, 942(ab)
 Evans, A, 776(ab), 839(ab)
 Evans, AC, 765(ab), 1056,
 1483
 Evans, H, 775(ab)
 Evans, ML, 852(ab)
 Ezquerra, NF, 806(ab)
- Fabbender, D, 800(ab)
 Faber, TL, 638, 770(ab),
 801(ab), 871(ab)
 Fabian, C, 844(ab)
 Fahey, FH, 227, 233
 Falke, THM, 769(ab)
 Fand, I, 848(ab)
 Fantinato, LC, 940(ab)
 Farrell, E, 747(ab), 818(ab)
 Faubion, C, 818(ab)
 Fawcett, HD, 57
 Fawdry, RM, 1946
 Fawwaz, RA, 819(ab),
 890(ab), 936(ab)
 Fayad, F, 798(ab), 890(ab),
 944(ab)
 Fazekas, F, 1607
 Fazio, F, 742(ab), 831(ab),
 869(ab), 873(ab), 888(ab)
 Fazzini, PF, 820(ab)
 Feiglin, DH, 734(ab)
 Feine, U, 804(ab)
 Feinendegen, LE, 739(ab),
 771(ab), 829(ab), 895(ab)
 Feinsod, M, 240
 Feinstein-Jaffe, I, 106
 Feistel, H, 751(ab)
 Feitsma, HJJ, 2017
 Feitsma, RIJ, 889(ab)
 Feld, T, 1830
 Fennesy, DR, 941(ab)
 Fer, M, 779(ab)
 Ferency, GF, 466, 784(ab)
 Ferris, SH, 771(ab)
 Ferrone, S, 390, 936(ab)
 Fetterman, RC, 800(ab),
 863(ab)
 Fettich, G, 943(ab)
 Feyerabend, A, 874(ab),
 944(ab)
 Fiedotin, AF, 845(ab)
 Fielding, S, 903(ab)
 Fields, ALA, 836(ab)
 Fiete, RD, 892(ab)
 Fig, L, 740(ab)
 Fig, LM, 481, 833(ab),
- 843(ab), 850(ab), 1476
 Figulla, HR, 779(ab)
 Filippone, A, 850(ab)
 Filmer, RB, 799(ab)
 Findley, DO, 1373
 Fink-Bennett, D, 850(ab)
 Finkler, NJ, 904(ab)
 Finn, R, 320, 807(ab)
 Finn, RD, 581, 899(ab),
 928(ab), 1249, 1676
 Fioravanti, C, 923(ab)
 Fiore, F, 823(ab)
 Fischman, 1123
 Fischman, A, 859(ab)
 Fischman, AJ, 385, 556,
 817(ab), 889(ab), 890(ab),
 901(ab), 917(ab), 1095,
 1149, 1538, 1911
 Fishbein, M, 750(ab)
 Fisher, D, 779(ab), 828(ab)
 Fisher, P, 1702
 Fisher, RS, 750(ab), 764(ab)
 Fisher, S, 815(ab), 847(ab),
 884(ab), 912(ab)
 Fisher, SJ, 832(ab)
 Fishman, AJ, 805(ab)
 Fitten, LJ, 1616
 Flanagan, RJ, 925(ab)
 Fleming, CJ, 799(ab)
 Fletcher, JE, 903(ab)
 Fletcher, JW, 840(ab),
 856(ab)
 Flickinger, FW, 754(ab)
 Flores, F, 915(ab)
 Floru, S, 737(ab)
 Flower, M, 813(ab), 903(ab)
 Flower, MA, 766(ab)
 Floyd, C, 755(ab)
 Flynn, B, 1176
 Fogelman, I, 1318
 Fogler, WE, 794(ab)
 Folks, R, 757(ab), 795(ab)
 Folks, RD, 806(ab), 894(ab)
 Ford, EH, 809(ab), 828(ab),
 1550
 Fordham, EW, 769(ab),
 855(ab)
 Forell, BW, 1373
 Formiconi, AR, 880(ab)
 Forstrom, LA, 804(ab)
 Foster, N, 895(ab)
 Foster, NL, 895(ab)
 Foulon, M, 798(ab), 1825
 Fowble, BF, 1113
 Fowler, D, 811(ab), 823(ab),
 943(ab)
 Fowler, DR, 729(ab)
 Fowler, J, 771(ab), 801(ab)
 Fowler, JS, 730(ab), 741(ab),
 753(ab), 761(ab), 776(ab),
 782(ab), 783(ab), 821(ab),
 898(ab), 932(ab)
 Fox, MR, 940(ab)
 Fox, PT, 141
 Fragasso, G, 869(ab),
 873(ab)
 Franceschi, G, 779(ab)
 Franceschini, M, 928(ab)
 Franchi, R, 615
 Francis, B, 320
 Francis, BE, 1249
 Franck, N, 897(ab)
 Frank, R, 965(ab)
 Frank, TL, 755(ab)
- Frankel, A, 246
 Franken, PR, 817(ab),
 818(ab), 1025
 Fraser, R, 795(ab)
 Fratkin, MJ, 1257
 Freasier, RE, 816(ab)
 Freeman, GL, 860(ab)
 Freeman, LM, 723
 Freeman, S, 838(ab)
 Freitas, JE, 736(ab), 1559
 French, WJ, 38
 Frenkel, A, 240, 737(ab),
 1657
 Freshler, A, 761(ab)
 Freundlich, M, 841(ab)
 Frey, GD, 872(ab)
 Frick, D, 730(ab)
 Frick, MP, 876(ab)
 Fridrich, R, 301
 Friedberg, C, 841(ab)
 Friedland, B, 806(ab)
 Friedland, RP, 771(ab), 1386
 Friedman, HS, 778(ab)
 Friedman, J, 729(ab),
 740(ab), 750(ab), 1718
 Frincke, J, 778(ab)
 Frincke, JM, 905(ab)
 Fritzberg, A, 779(ab),
 793(ab), 849(ab)
 Fritzberg, A.R, 25, 216,
 743(ab), 777(ab), 793(ab),
 832(ab), 924(ab), 932(ab),
 933(ab), 940(ab)
 Froelich, JM, 725
 Front, D, 240, 246, 737(ab),
 1657, 1731
 Frost, JJ, 740(ab), 750(ab),
 849(ab), 930(ab), 931(ab)
 Fuccello, AJ, 805(ab)
 Fuchs, H, 835(ab)
 Fudo, T, 863(ab), 866(ab)
 Fuentes, RT, 917(ab),
 965(ab)
 Fujibayashi, Y, 923(ab),
 1838
 Fujii, R, 783(ab), 866(ab)
 Fujii, T, 918(ab), 943(ab)
 Fujimori, K, 903(ab)
 Fujisawa, Y, 965(ab)
 Fujita, T, 150, 862(ab), 1977
 Fujiwara, S, 902(ab)
 Fujiwara, T, 33, 2012,
 739(ab), 788(ab), 1421(le)
 Fujiwara, Y, 864(ab)
 Fukuchi, M, 919(ab)
 Fukuda, H, 33, 866(ab),
 885(ab)
 Fukuda, N, 865(ab), 866(ab)
 Fukuyama, H, 150
 Fulham, MJ, 581
 Fullager, P, N1144
 Fulton, RR, 872(ab),
 964(ab), 1865
 Fünfgeld, M, 812(ab)
 Furrer, T, 1960
 Furunishi, H, 914(ab)
 Fuster, V, 1445
- Gaggi, R, 615
 Gagne, GM, 747(ab),
 940(ab)
 Gagnon, A, 865(ab), 1271
 Gagnon, D, 800(ab), 807(ab)
 Gal, R, 770(ab)
 Gale, B, 841(ab)
 Gale, WT, 905(ab)
 Galie, E, 729(ab), 811(ab)
 Gallagher, BM, 1351
 Gallagher, KP, 860(ab)
 Galmarini, D, 888(ab)
 Galt, JR, 894(ab)
 Gambhir, SS, 359, 735(ab),
 824(ab), 838(ab), 846(ab),
 867(ab), 1507
 Gan, M, 1616
 Gandsman, EJ, 872(ab)
 Ganey, MV, 1892
 Gansow, OA, 320, 672,
 848(ab)
 Ganti, G, 775(ab), 880(ab),
 964(ab), 1787
 Ganz, W, 798(ab), 841(ab),
 915(ab), 922(ab), 944(ab)
 Ganz, WI, 890(ab), 1935
 Garcia, A, 1470
 Garcia, E, 757(ab), 795(ab)
 Garcia, EV, 441, 806(ab),
 894(ab)
 Garcia, O, 787(ab)
 Gardner, KA, 873(ab)
 Garg, PK, 778(ab)
 Garland, DE, 857(ab)
 Garrity, ST, 1892
 Garty, I, 15, 748(ab),
 1917(le)
 Garty, II, 890(ab)
 Garza, D, 859(ab), 865(ab),
 866(ab)
 Gasparaitis, A, 963(ab)
 Gasper, SR, 808(ab)
 Gasperoni, R, 779(ab)
 Gaston-Parry, D, 764(ab),
 887(ab)
 Gatley, J, 925(ab)
 Gatley, SJ, 833(ab), 883(ab),
 924(ab), 1211
 Gautherot, E, 907(ab), 1358
 Gauthier, G, 766(ab)
 Geatti, O, 1476
 Geltman, EM, 771(ab),
 837(ab), 1489, 1798
 Genna, S, 796(ab)
 Gennarelli, T, 802(ab)
 Gentili, A, 734(ab)
 George, AE, 771(ab)
 George, JK, 802(ab)
 George, T, 750(ab)
 Gerbrands, JJ, 806(ab)
 Gerdes, J, 822(ab)
 Germano, G, 745(ab)
 Gernsheimer, T, 629
 Gersh, BJ, 801(ab)
 Gerson, R, 796(ab)
 Gerundini, P, 869(ab),
 873(ab), 888(ab), 1018,
 1415
 Geuting, B, 739(ab)
 Geyer, AB, 745(ab), 765(ab)
 Ghaddar, FK, 876(ab)
 Ghiron, J, 920(ab)
 Ghrayeb, J, 794(ab), 934(ab)
 Giandinoto, S, 920(ab)

- Gibbons, RJ, 801(ab),
1280(ie)
Gibbs, B, 964(ab)
Gibson, RE, 736(ab),
741(ab), 896(ab), 923(ab),
930(ab), 931(ab), 1079
Gilardi, MC, 869(ab)
Gilbert, S, 786(ab), 873(ab)
Gildersleeve, DL, 733(ab),
752(ab), 767(ab), 783(ab),
859(ab), 929(ab)
Gilgien, W, 1646
Gilland, DR, 756(ab),
882(ab)
Gillespie, D, 803(ab)
Gillum, K, 928(ab)
Gilyon, K, 827(ab)
Gin, N, 918(ab)
Ginsberg, HN, 787(ab)
Ginsberg, MD, 93, 772(ab)
Giuliani, DC, 1550
Givel, J-C, 1646
Gjedde, A, 731(ab)
Glaser, AM, 886(ab)
Glazebrook, GA, 914(ab)
Gidman, S, 741(ab)
Gleason, T, 754(ab)
Gleishman, S, 844(ab)
Glick, SJ, 755(ab), 756(ab),
816(ab), 876(ab), 881(ab),
1666
Glisson, B, 819(ab)
Glöckner, W, 805(ab),
819(ab)
Głowniak, JV, 767(ab),
873(ab), 1182
Go, RT, 759(ab), 861(ab)
Godoy-Sánchez, N, 772(ab)
Gofinch, S, 793(ab)
Golazeski, T, 817(ab)
Goldberg, R, 798(ab)
Goldberg, RK, 749(ab)
Golden, RN, 814(ab)
Goldenberg, DM, 748(ab),
809(ab), 826(ab), 828(ab),
848(ab), 888(ab), 962(ab)
Goldenberg, H, 809(ab)
Goldman, ME, 1445
Goldman, S, 750(ab),
849(ab)
Goldman-Leiken, RE,
827(ab), 888(ab)
Goldman-Leikin, R, 888(ab)
Goldsmith, SJ, N276, 490,
599, 737(ab), 754(ab),
785(ab), 804(ab), 815(ab),
856(ab), 1018, 1445, 1875,
N1921
Goldstein, RA, 707, 846(ab)
Gona, J, 748(ab), 818(ab)
Gona, JM, 1464
Gonzales, AC, 1737(ie)
Gonzalez, A, 811(ab)
Goodenday, LS, 816(ab)
Goodgold, HM, 267, 856(ab)
Goodman, MM, 925(ab),
960(ab)
Goodwin, DA, 762(ab)
Goossens, I, 841(ab)
Gordon, DG, 871(ab)
Gordon, RE, 856(ab)
Goris, ML, 826(ab)
Gose, EE, 961(ab)
Gottschalk, A, 916(ab)
Gould, K, 866(ab)
Gould, KL, 707, 775(ab),
845(ab), 846(ab), 859(ab),
865(ab), 880(ab), 909(ab),
964(ab), 966(ab), 1787
Grady, CL, 771(ab), 899(ab),
1386
Graf, G, 835(ab)
Grafton, S, 735(ab), 791(ab),
913(ab)
Grafton, ST, 752(ab),
761(ab), 879(ab)
Graham, LS, 851(ab), 1616
Graham, MM, 466, 735(ab),
784(ab), 789(ab), 838(ab),
852(ab), 873(ab), 879(ab),
911(ab)
Gralla, RJ, 746(ab)
Granowska, M, 748(ab)
Granowski, M, 758(ab)
Gransow, OA, 763(ab)
Grant, LM, 924(ab)
Graves, W, 935(ab)
Gray, LL, 1182
Gray, MA, 832(ab), 933(ab)
Green, MA, 742(ab),
768(ab), 791(ab), 807(ab),
848(ab), 920(ab), 1843
Green, MR, 778(ab)
Green, MV, 420, 807(ab),
1966
Greenberg, H, 759(ab),
883(ab), 884(ab), 918(ab)
Greenberg, J, 811(ab)
Greenberg, JH, 781(ab)
Greene, J, 823(ab)
Greer, K, 755(ab)
Gregg, GM, 852(ab)
Grégoire, J, 800(ab), 807(ab)
Gregory, C, 944(ab)
Grenier, R, 770(ab)
Grieron, JR, 342, 789(ab),
846(ab)
Griffin, M, 774(ab)
Griffin, T, 828(ab)
Griffin, TW, 908(ab)
Griffiths, DV, 773(ab),
818(ab)
Gripenberg, J, 1546
Grobmann, K, 739(ab)
Groch, MW, 422, 769(ab),
855(ab), 902(ab)
Groshar, D, 246
Gross, MD, 768(ab),
849(ab), 1088
Gross-Glenn, K, 802(ab)
Grossman, HB, 912(ab)
Grossman, ZD, 747(ab),
963(ab)
Gruenewald, SM, 1885,
1946
Grunbaum, Z, 194, 814(ab)
Grund, FM, 906(ab)
Grütter, D, 1960
Guérin, J, 916(ab)
Gueratty, A, 1297
Guiberteau, MJ, T26A
Guilarte, T, 741(ab)
Guilarte, TR, 930(ab)
Guillaume, M, 752(ab),
817(ab), 818(ab), 821(ab),
926(ab), 1025
Guillon, JM, 746(ab)
Guiraud, RF, 398
Gulechyn, K, 760(ab)
Gulenchyn, KY, 812(ab),
1621
Gullberg, GT, 497, 755(ab),
756(ab), 882(ab)
Guns, M, 741(ab)
Gupta, N, 730(ab)
Gupta, NC, 876(ab)
Gurl, NJ, 1264
Gustilo, RB, 858(ab)
Guth, WR, 852(ab)
Guth-Tougelidis, B, 845(ab),
867(ab)
Gutkowski, RF, 265
Guyot, M, 904(ab), 916(ab)
Guze, BH, 913(ab)
Guzzardi, R, 128
Gwalter, I, 891(ab)
Gwilliam, ME, 738(ab)
Haber, E, 785(ab)
Haber, SB, 1351
Habif, DV, 819(ab)
Hackney, D, 1607
Haden, HT, 1032
Hadjian, RA, 1351
Hadley, SW, 216, 793(ab),
832(ab), 924(ab), 932(ab)
Hagius, JT, 643(ab)
Haka, MS, 735(ab), 767(ab),
783(ab)
Hakim, TS, 1297
Halama, JR, 1870
Halbfab, HG, 748(ab)
Halgren, E, 894(ab)
Hall, GM, 738(ab)
Hall, JT, 1012
Hall, TC, 809(ab), 828(ab),
962(ab)
Hall, TR, 1507
Halldin, C, 742(ab), 783(ab),
927(ab)
Hallman, C, 538
Halmqvist, F, 927(ab)
Halpern, S, 778(ab)
Halpern, SE, 894(ab)
Ham, H, 915(ab), 1337,
1825
Ham, HR, 794(ab), 798(ab),
817(ab), 818(ab), 966(ab),
1025, 1982
Hamada, S, 1713
Hamamoto, K, 760(ab),
792(ab), 805(ab), 864(ab),
878(ab), 918(ab), 943(ab),
1192
Hamill, JJ, 2029
Hanabery, JW, 407
Hanelin, L, 779(ab), 793(ab)
Hanelin, LG, 959(ab)
Hanna, M, Jr, 909(ab)
Hanner, JS, 1568
Hanrath, P, 791(ab)
Hansen, HE, 796(ab)
Hansen, HJ, 809(ab),
828(ab)
Hansen, WP, 385
Hanson, MW, 752(ab)
Hantraye, PH, 731(ab),
762(ab)
Harada, K, 150
Harcke, HT, 799(ab)
Harding, P, 795(ab)
Hardman, N, 809(ab)
Hardy, M, 890(ab)
Hardy, P, 897(ab)
Harisiadis, L, 827(ab)
Harold, WH, 830(ab)
Harp, G, 769(ab)
Harper, PV, 833(ab), 883(ab)
Harre, R, 910(ab)
Harrington, A, 812(ab)
Harris, CC, 129, 962(ab),
968(ab)
Harris, JM, 965(ab)
Harrison, C, 778(ab)
Harrold, WH, 1342
Hartley, C, 131
Hartman, KM, 733(ab)
Hartshorne, MF, 1577,
1737(ie), 2046
Hartsough, NE, 891(ab)
Hartz, RK, 964(ab)
Hasegawa, N, 770(ab),
944(ab)
Hashimoto, M, 770(ab)
Hashimoto, S, 809(ab),
853(ab)
Haspel, MV, 909(ab)
Hassan, IM, 842(ab),
864(ab), 959(ab)
Hassan, N, 784(ab)
Hatabu, H, 786(ab)
Hatano, K, 515
Hatano, Y, 718
Hatazawa, J, 33, 515,
917(ab), 1809
Hathaway, G, 960(ab)
Hauler, JA, 778(ab)
Hauman, H, 896(ab)
Haumont, D, 1337, 1982
Hawk, TC, 735(ab)
Hawkins, PN, 847(ab)
Hawkins, R, 1136
Hawkins, RA, 735(ab),
863(ab), 877(ab), 879(ab),
913(ab), 942(ab), 1507
Hawkins, WG, 881(ab)
Haxby, JV, 771(ab)
Hayashi, H, 738(ab)
Hayashi, M, 863(ab), 1713
Hayashida, K, 591, 1713
Haynie, T, 738(ab)
Haynie, TP, 836(ab),
844(ab), 858(ab), 905(ab),
909(ab), 966(ab), 1012,
2058
Heal, A, 759(ab), 884(ab)
Heal, AV, 876(ab), 883(ab),
918(ab)
Healy, SA, 786(ab)
Heckmatt, J, 784(ab)
Hedrick, WR, 127
Heeg, MJ, 936(ab)
Hegge, J, 797(ab)
Heiba, S, 841(ab)
Heidendaal, G, 791(ab)
Heidenreich, P, 835(ab)
Heim, ME, 910(ab)
Heinemann, WR, 732(ab),
936(ab)
Heironimus, JD, 1737(ie)
Heller, LI, 863(ab)
Helling, D, 773(ab)
Helling, DE, 937(ab)
Hellman, C, 450
Hellman, R, 737(ab),
859(ab), 922(ab)
Hellman, RS, 120, 599,
754(ab), 1018
Hellstrom, I, 907(ab)
Hellstrom, KE, 907(ab)
Hellwig, B, 659
Helm, L, 743(ab)
Helus, F, 789(ab), 909(ab),
910(ab), 911(ab)
Hemingway, A, 1636
Hemmila, JM, 857(ab)
Hendel, RC, 730(ab)
Hendricks, JL, 835(ab)
Henes, CG, 771(ab), 837(ab),
1489, 1798
Henkin, R, 729(ab)
Henkin, RE, N1294, 1577,
1870
Henn, F, 730(ab)
Henning, A, 867(ab)
Henrich, M, 739(ab)
Henry, LA, 875(ab)
Henze, E, 813(ab), 835(ab),
1393
Heo, J, 749(ab), 820(ab),
862(ab), 863(ab)
Herberman, R, 905(ab)
Herbst, AL, 883(ab)
Hermansen, F, 775(ab)
Hermle, L, 812(ab)
Herold, T, 921(ab)
Herranz, R, 1470
Herrero, P, 807(ab), 825(ab)
Herrmann, A, 786(ab)
Herry, JY, 941(ab)
Herscovitch, P, 807(ab),
824(ab), 825(ab), 839(ab),
899(ab)
Hersovitch, P, 899(ab)
Hertel, A, 786(ab), 847(ab),
904(ab)
Hertzberg, VS, 837(ab)
Herzog, H, 771(ab), 895(ab)
Heurich, AE, 1563
Heusser, Ch, 809(ab)
Heyl, B, 787(ab), 860(ab)
Heyman, S, 697, 1268
Heynen, MJ, 2022
Heyns, ADP, 914(ab)
Hichwa, RD, 873(ab)
Hicks, K, 775(ab), 865(ab),
1787
Hidaka, A, 786(ab)
Higaki, S, 813(ab)
Higashino, H, 760(ab)
Higazi, E, 857(ab)
Higginbotham-Ford, EA,
748(ab)
Higley, B, 773(ab), 818(ab)
Higuchi, S, 830(ab)
Hijdra, A, 781(ab)
Hilger, HH, 903(ab)
Hill, TC, 1018, 1892
Hilleman, D, 730(ab)
Hilliard, S, 818(ab)
Hilson, AJW, 744(ab)
Himelman, R, 760(ab)
Himi, T, 865(ab), 866(ab)
Hines, J, 834(ab)
Hiraki, T, 921(ab)
Hirata, K, 1302
Hirata, Y, 853(ab)
Hirota, Y, 508
Hirsch, JI, 1257
Hiruma, A, 796(ab)

- Hisada, K. 844(ab), 870(ab), 897(ab), 907(ab), 921(ab), 939(ab), 997
 Hishinuma, T. 902(ab)
 Hitchens, RE. 964(ab)
 Hitzenmann, R. 730(ab), 741(ab), 761(ab), 801(ab)
 Hixon, JB. 760(ab)
 Hladik, WB. 1351
 Hnatowich, DJ. 793(ab), 819(ab), 828(ab), 908(ab), 1575(le)
 Hochberg, RB. 209
 Hodgson, GS. 913(ab)
 Hoefnagel, CA. 912(ab)
 Hoesel, Qv. 758(ab)
 Hoffer, PB. 209
 Hoffman, EJ. 745(ab), 791(ab), 892(ab)
 Hoffman, JM. 735(ab), 752(ab), 761(ab), 791(ab), 879(ab)
 Hoffmann, TJ. 874(ab), 877(ab), 920(ab), 938(ab), 939(ab)
 Hoffmann, A. 842(ab)
 Hoffmann, RG. 754(ab)
 Hoh, CK. 821(ab)
 Holcomb, HH. 816(ab)
 Holden, J. 797(ab)
 Holden, JE. 1211
 Holder, LE. 843(ab)
 Hollerman, JJ. 858(ab)
 Holm, L-E. 720
 Holm, S. 796(ab)
 Holman, BL. 301, 757(ab), 821(ab), 938(ab), 1018
 Holmes, RA. 1814, 874(ab), 877(ab), 917(ab), 920(ab), 938(ab), 939(ab), 964(ab), 965(ab), 966(ab), N1440, N1931
 Holohan, KM. 788(ab)
 Holt, P. 820(ab)
 Holte, S. 765(ab)
 Hom, J. 771(ab)
 Homma, H. 780(ab)
 Honda, N. 770(ab), 944(ab)
 Hong, WP. 940(ab)
 Honos, G. 790(ab)
 Hood, T. 833(ab)
 Hoogma, RPLM. 769(ab)
 Hoogmartens, M. 743(ab)
 Hooker, GR. 1636
 Hooper, HR. 812(ab), 836(ab), 961(ab)
 Hooper, PM. 961(ab)
 Hoory, S. 859(ab)
 Hörl, G. 786(ab), 847(ab), 904(ab)
 Hori, M. 881(ab)
 Horii, H. 783(ab), 866(ab)
 Horning, SJ. 826(ab)
 Hornof, WJ. 1702
 Horowitz, JA. 809(ab), 828(ab), 962(ab)
 Horowitz, M. 765(ab), 795(ab), 887(ab)
 Horrocks, JA. 891(ab)
 Hosain, F. 737(ab)
 Hoshi, H. 157, 337, 1101
 Hosoba, M. 267, 870(ab)
 Hosono, M. 885(ab)
 Hotze, A. 758(ab), 805(ab), 856(ab), 885(ab), 858(ab), 942(ab), 835(ab), 891(ab), 755(ab)
- Hovinga, TKK. 605
 Howard, JL. 967(ab)
 Hows, JM. 784(ab)
 Hoy, K. 924(ab)
 Hu, X. 880(ab)
 Huang, SC. 359, 735(ab), 752(ab), 761(ab), 791(ab), 824(ab), 867(ab), 879(ab), 1507
 Huang, S-J. 1249
 Huberty, JP. 968(ab)
 Hubner, KF. 960(ab)
 Hubner, KH. 925(ab)
 Huda, W. 260, 2062
 Huesman, RH. 745(ab), 765(ab)
 Hughes, A. 924(ab)
 Hundeshagen, H. 910(ab), 1278(le)
 Hung, G. 857(ab)
 Hung, GL. 886(ab)
 Hung, JC. 804(ab)
 Hunter, R. 828(ab)
 Huntley, TE. 857(ab)
 Huret, JD. 897(ab)
 Hurley, JR. 833(ab)
 Hurtig, HI. 965(ab), 1607
 Hurwitz, GA. 1627
 Hussein, A. 968(ab)
 Hutchins, G. 912(ab)
 Hutchins, GD. 735(ab), 767(ab), 829(ab), 837(ab), 860(ab), 892(ab)
 Hutchinson, RJ. 884(ab)
 Hutton, BF. 872(ab), 964(ab), 1865
 Hutton, I. 818(ab)
 Huysmans, D. 736(ab)
 Hwang, D-R. 351, 730(ab), 930(ab), 1205
 Hylderides, MD. 216, 793(ab), 832(ab), 924(ab)
 Hyun, M. 729(ab)
 Ichiya, Y. 802(ab)
 Ida, M. 915(ab)
 Ido, T. 33, 515, 739(ab), 783(ab), 788(ab), 930(ab), 965(ab), 1809, 2012
 Idoine, J. 165
 Igarashi, M. 811(ab)
 Iida, H. 796(ab), 830(ab), 878(ab)
 Iida, Y. 786(ab), 803(ab)
 Inuma, T. 866(ab)
 Inuma, TA. 885(ab)
 Iio, A. 760(ab), 792(ab), 805(ab), 864(ab), 878(ab)
 Iio, M. 813(ab)
 Ikehira, H. 885(ab)
 Ikkala, E. 1546
 Imahori, Y. 783(ab)
 Imakita, S. 591
 Imazeki, K. 738(ab), 910(ab)
 Inaba, T. 824(ab)
 Inagaki, Y. 865(ab), 866(ab)
 Inglete, E. 301
 Ingvar, C. 1224
 Inoue, T. 895(ab)
 Intenzo, CM. 856(ab), 858(ab), 942(ab)
 Interrante, VL. 835(ab)
 Inuzuka, E. 796(ab), 856(ab), 879(ab), 922(ab)
 Hovinga, TKK. 605
 Howard, JL. 967(ab)
 Hows, JM. 784(ab)
 Hoy, K. 924(ab)
 Hu, X. 880(ab)
 Huang, SC. 359, 735(ab), 752(ab), 761(ab), 791(ab), 824(ab), 867(ab), 879(ab), 1507
 Ishilevsky, G. 240, 246, 737(ab)
 Iqbal, A. 883(ab)
 Irngartinger, G. 784(ab)
 Irvin, GL. III. 886(ab)
 Isaacson, O. 762(ab)
 Ishibashi, A. 853(ab)
 Ishibashi, M. 868(ab), 869(ab), 942(ab)
 Ishida, Y. 868(ab), 881(ab)
 Ishii, Y. 840(ab)
 Ishikawa, A. 830(ab)
 Ishikawa, M. 150
 Ishimura, J. 919(ab)
 Ishiwata, K. 33, 515, 739(ab), 1809, 2012
 Ishiyama, N. 897(ab)
 Isitman, AT. 120, 754(ab)
 Iskandrian, A. 749(ab), 820(ab)
 Iskandrian, AS. 862(ab), 863(ab)
 Isoda, H. 258
 Israel, O. 240, 246, 737(ab), 1731
 Issachar, D. 450, 538
 Itami, J. 738(ab), 910(ab)
 Ito, H.. 916(ab)
 Ito, K. 33
 Ito, M. 788(ab), 917(ab)
 Ito, S. 883(ab)
 Itoh, H. 1192
 Itoh, K. 2042
 Itoh, M. 33, 515, 813(ab), 1809
 Iuliucci, JD. 787(ab)
 Ivanov, Z. 1240
 Ivanovic, M. 875(ab)
 Iversen, L. 741(ab)
 Iwai, K. 930(ab)
 Iwasaki, R. 718
 Iwasaki, Y. 887(ab), 900(ab), 1977
 Iwata, R. 33, 930(ab), 965(ab)
 Izard, ME. 683
 Jabir, A. 963(ab)
 Jabir, AM. 890(ab), 893(ab)
 Jabir, M. 761(ab)
 Jackson, CB. 1865
 Jackson, G. 759(ab), 777(ab)
 Jackson, GA. 832(ab)
 Jackson, JS. 918(ab)
 Jackson, RE. 1737(ab)
 Jacobs, GL. 746(ab), 825(ab)
 Jacobs, L. 824(ab)
 Jacobson, AF. 703
 Jaffé, D. 944(ab)
 Jafri, RA. 823(ab)
 Jagust, WJ. 765(ab)
 James, HL. 807(ab)
 Jamieson, D. 898(ab)
 Jamieson, DG. 965(ab), 1607
 Jansen, DE. 845(ab)
 Jansons, D. 874(ab)
 Janssen, AGM. 650
 Janssen, C. 741(ab)
 Janssens, J. 795(ab)
 Jarden, JO. 839(ab)
 Jardez, H. 788(ab)
 Jarritt, PH. 891(ab)
 Jaszczak, R. 755(ab)
- Jay, M. 836(ab)
 Jeandot, R. 904(ab), 916(ab)
 Jensen, M. 402
 Jeremy, RW. 755(ab)
 Jerushalmi, J. 240
 Jewell, WR. 844(ab)
 Jewett, DM. 822(ab), 926(ab), 927(ab), 930(ab)
 Jingran, S. 775(ab)
 Jiang, Z. 742(ab)
 Jin, YT. 367
 Jinnouchi, S. 157, 337, 1101
 Jivan, S. 923(ab)
 Jobling, T. 758(ab)
 Joel, DD. 1342
 Joensuu, H. 912(ab)
 Joestgen, TM. 120
 John, C. 832(ab), 938(ab), 939(ab)
 John, CS. 773(ab)
 John, E. T57(ab)
 Johns, WD. 855(ab)
 Johnson, D. 836(ab)
 Johnson, DK. 374, 908(ab), 935(ab)
 Johnson, JA. 563
 Johnson, JW. 767(ab), 777(ab)
 Johnson, LL. 312, 863(ab)
 Johnson, M. 782(ab)
 Johnson, RF, Jr. 840(ab)
 Johnson, T. 814(ab)
 Johnson, TK. 1133, 1399
 Johnson, VE. 880(ab)
 Johnston, GS. 412
 Jolesz, FA. 839(ab)
 Joliot, M. 766(ab)
 Jolles, PR. 1589
 Jones, AG. 757(ab), 938(ab)
 Jones, DW. 896(ab)
 Jones, ME. 806(ab)
 Jones, RH. 420, 790(ab)
 Jones, T. 775(ab), 808(ab)
 Jones, WT. 784(ab)
 Jonk, A. 912(ab)
 Jönsson, P-E. 1224
 Jouve, B. 810(ab)
 Joyce, M. 767(ab)
 Joyner, AR. 873(ab)
 Julian, B. 774(ab)
 Julien, P. 734(ab), 853(ab)
 Jung, Y-W. 929(ab)
 Jungehülsing, M. 842(ab)
 Jungkind, D. 747(ab)
 Juni, J. 1280(le)
 Juni, JE. 869(ab)
 Kabalka, GW. 960(ab)
 Kadmon, D. 1205
 Kadowaki, K. 830(ab)
 Kagan, A. 564
 Kagaya, A. 865(ab), 866(ab), 908(ab)
 Kahn, D. 754(ab), 914(ab)
 Kahn, JK. 288, 801(ab), 810(ab), 828(ab)
 Kaiser, HJ. 791(ab)
 Kaiser, KP. 739(ab)
 Kait, H. 729(ab)
 Kalbhenn, C. 899(ab)
 Kaiff, V. 837(ab)
 Kallus, MA. 833(ab), 884(ab)
 Kalofonos, HP. 819(ab), 1636
 Kaltenbach, M. 847(ab)
 Kalus, ME. 829(ab)
 Kam, J. 960(ab)
 Kamada, T. 868(ab), 881(ab)
 Kamano, T. 770(ab), 944(ab)
 Kambara, H. 863(ab), 866(ab), 1775
 Kameyama, M. 1809
 Kamholz, SL. 1563
 Kaminski, MS. 227
 Kaneko, M. 258
 Kanno, I. 830(ab), 878(ab)
 Kanno, T. 897(ab)
 Kano, K. 853(ab)
 Kanoh, T. 2050
 Kao, Ch. 871(ab)
 Kao, S. 754(ab)
 Kaplan, EH. 827(ab), 888(ab)
 Kaplan, IL. 874(ab), 1408
 Kaplan, ME. 918(ab)
 Kaplan, P. 833(ab)
 Kaplan, WD. 845(ab)
 Kapoor, R. 838(ab), 911(ab)
 Karczewski, DA. 940(ab)
 Karimeddi, M. 730(ab)
 Karp, JS. 766(ab)
 Karpowicz, W. 751(ab)
 Karstens, JH. 819(ab)
 Kasabali, B. 884(ab)
 Kasagi, K. 786(ab)
 Kashab, M. 110
 Kashi, R. 826(ab)
 Kasina, S. 25, 743(ab), 933(ab), 940(ab)
 Kasliwal, R. 792(ab)
 Kassabian, V. 944(ab)
 Kassis, AI. 826(ab), 827(ab), 882(ab), 883(ab), 904(ab), 919(ab), 932(ab), 933(ab), 1856
 Katabuchi, T. 767(ab), 1713
 Kataoka, K. 897(ab)
 Kataoka, M. 864(ab)
 Kato, K. 811(ab)
 Katz, PG. 1032
 Katzenellenbogen, JA. 753(ab), 788(ab), 821(ab), 910(ab), 928(ab)
 Kaufman, D. 811(ab)
 Kawahara, S. 853(ab)
 Kawai, C. 862(ab), 863(ab), 866(ab), 1775
 Kawai, R. 899(ab)
 Kawakami, K. 743(ab), 915(ab)
 Kawamura, M. 792(ab), 805(ab), 864(ab), 878(ab), 938(ab)
 Kawamura, Y. 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
 Kawanaka, M. 919(ab)
 Kawashima, K. 515
 Kayden, DS. 800(ab)
 Kayden DS. 770(ab)
 Kazikiewicz, JM. 827(ab), 888(ab), 933(ab)
 Kearfott, KJ. 1378
 Keating, MJ. 905(ab)
 Keeling, AA. 843(ab)
 Keeling, C. 2063(le)

- Keeling, CA, 255
 Keen, RL, 127
 Keenan, AM, 733(ab), 753(ab)
 Kelley, RE, 93
 Kelly, JD, 773(ab), 818(ab)
 Kemeny, N, 809(ab)
 Kemper, D, 867(ab)
 Kemshead, J, 903(ab)
 Kenemans, P, 758(ab)
 Kennedy, RL, 879(ab)
 Ker, M, 892(ab)
 Kermani, S, 913(ab)
 Kessler, RM, 803(ab)
 Kester, RC, 45
 Ketring, AR, 966(ab), 1814
 Kewan, Y, 864(ab)
 Keyeux, A, 788(ab)
 Keyser, R, 964(ab)
 Khafagi, FA, 481
 Khalifah, RG, 924(ab)
 Khan, N, 864(ab)
 Khare, SS, 836(ab)
 Khaw, B-A, 385, 762(ab), 785(ab), 817(ab), 859(ab), 901(ab), 1911
 Kiat, H, 739(ab), 740(ab), 750(ab)
 Kiefer, H, 908(ab)
 Kiesewetter, DO, 899(ab), 928(ab)
 Kiethelm, AG, 823(ab)
 Kiffel, T, 855(ab)
 Kikuchi, H, 150
 Kilbourn, MR, 753(ab), 822(ab), 926(ab)
 Kim, C, 966(ab)
 Kim, CK, 737(ab), 754(ab), 785(ab), 804(ab), 815(ab)
 Kim, CS, 858(ab), 1268
 Kim, E, 738(ab)
 Kim, EE, 834(ab), 858(ab), 901(ab), 905(ab), 909(ab), 966(ab), 1012, T26B
 Kim, KT, 913(ab)
 Kim, S, 856(ab)
 Kim, SM, 858(ab), 942(ab)
 Kimmig, B, 909(ab), 911(ab)
 Kimura, K, 868(ab), 881(ab)
 Kimura, S, 930(ab)
 Kimura, Y, 918(ab), 943(ab)
 Kinders, RJ, 828(ab)
 King, D, 764(ab), 887(ab)
 King, J, 861(ab)
 King, M, 813(ab)
 King, MA, 755(ab), 756(ab), 816(ab), 835(ab), 876(ab), 881(ab), 1616, 1666
 King, PT, 741(ab)
 King, RB, 873(ab)
 King, SB, 740(ab)
 Kinomura, S, 739(ab), 2012
 Kinoshita, K, 157, 337, 1101
 Kinser, JA, 1960
 Kinsey, B, 928(ab)
 Kinuya, K, 897(ab)
 Kinuya, S, 844(ab), 907(ab), 997
 Kira, Y, 866(ab)
 Kirchgessner, H, 390
 Kirchhoff, JR, 936(ab)
 Kirchner, PT, 851(ab), 872(ab)
 Kirk, GA, 894(ab), 905(ab)
 Kirk, KL, 1249
 Kirkeeide, RL, 845(ab), 846(ab)
 Kirkwood, J, 905(ab)
 Kirsch, C-M, 907(ab)
 Kirsh, R, 794(ab)
 Kirshenbaum, J, 821(ab)
 Kitabatake, A, 868(ab), 881(ab)
 Kiyoasawa, M, 772(ab), 802(ab)
 Klarn, S, 920(ab)
 Klausenke, G, 779(ab)
 Kleerup, EC, 834(ab)
 Klein, HA, 850(ab), 905(ab)
 Klein, HH, 757(ab)
 Klein, MJ, 856(ab)
 Kleinhans, E, 791(ab), 841(ab)
 Klibanov, A, 762(ab)
 Klibanov, AL, 1686
 Kling, AS, 1616
 Kling, GA, 967(ab)
 Kling, P, 1367
 Klinkowstein, RE, 964(ab)
 Kloppenborg, D, 885(ab)
 Kloppenborg, P, 736(ab)
 Kluger, A, 771(ab)
 Knapp, FF, 797(ab), 817(ab), 818(ab)
 Knapp, FF, Jr, 829(ab), 848(ab), 923(ab), 925(ab), 1025, N1765
 Knapp, RC, 904(ab)
 Knapp, WH, 798(ab), 800(ab)
 Knaw, BA, 1095
 Knesarek, K, 755(ab), 816(ab), 876(ab), 881(ab), 1666
 Knight, LC, 817(ab)
 Knoop, BO, 880(ab)
 Knopf, WD, 845(ab)
 Knopp, R, 879(ab)
 Knox, SJ, 826(ab)
 Knust, EJ, 798(ab)
 Kobayashi, A, 70, 864(ab)
 Kober, G, 847(ab)
 Kobilik, P, 1702
 Kochanny, MJ, 821(ab)
 Koehler, U, 829(ab)
 Koeppe, R, 895(ab)
 Koeppe, RA, 873(ab)
 Koga, S, 897(ab)
 Koh, WJ, 789(ab)
 Kohlen, S, 797(ab)
 Koizumi, M, 747(ab), 832(ab), 885(ab), 889(ab), 919(ab)
 Kojima, A, 508
 Kojima, T, 813(ab)
 Kolanowski, J, 797(ab)
 Kolkmeyer, J, 797(ab)
 Kollmann, M, 817(ab)
 Kolodny, GM, 240, 737(ab), 874(ab)
 Komatani, A, 719
 Komtebedde, J, 1702
 Kondo, M, 866(ab)
 Kong, B, 749(ab), 820(ab), 862(ab), 863(ab)
 Konietzko, N, 845(ab)
 Konings, AWT, 789(ab)
 Konishi, J, 150, 747(ab),
 Kirk, KL, 1249
 Kirkwood, J, 905(ab)
 Kirsch, C-M, 907(ab)
 Kirsh, R, 794(ab)
 Kirshenbaum, J, 821(ab)
 Kitabatake, A, 868(ab), 881(ab)
 Kiyoasawa, M, 772(ab), 802(ab)
 Klarn, S, 920(ab)
 Klausenke, G, 779(ab)
 Kleerup, EC, 834(ab)
 Klein, HA, 850(ab), 905(ab)
 Klein, HH, 757(ab)
 Klein, MJ, 856(ab)
 Kleinhans, E, 791(ab), 841(ab)
 Klibanov, A, 762(ab)
 Klibanov, AL, 1686
 Kling, AS, 1616
 Kling, GA, 967(ab)
 Kling, P, 1367
 Klinkowstein, RE, 964(ab)
 Kloppenborg, D, 885(ab)
 Kloppenborg, P, 736(ab)
 Kluger, A, 771(ab)
 Knapp, FF, 797(ab), 817(ab), 818(ab)
 Knapp, FF, Jr, 829(ab), 848(ab), 923(ab), 925(ab), 1025, N1765
 Knapp, RC, 904(ab)
 Knapp, WH, 798(ab), 800(ab)
 Knaw, BA, 1095
 Knesarek, K, 755(ab), 816(ab), 876(ab), 881(ab), 1666
 Knight, LC, 817(ab)
 Knoop, BO, 880(ab)
 Knopf, WD, 845(ab)
 Knopp, R, 879(ab)
 Knox, SJ, 826(ab)
 Knust, EJ, 798(ab)
 Kobayashi, A, 70, 864(ab)
 Kober, G, 847(ab)
 Kobilik, P, 1702
 Kochanny, MJ, 821(ab)
 Koehler, U, 829(ab)
 Koeppe, R, 895(ab)
 Koeppe, RA, 873(ab)
 Koga, S, 897(ab)
 Koh, WJ, 789(ab)
 Kohlen, S, 797(ab)
 Koizumi, M, 747(ab), 832(ab), 885(ab), 889(ab), 919(ab)
 Kojima, A, 508
 Kojima, T, 813(ab)
 Kolanowski, J, 797(ab)
 Kolkmeyer, J, 797(ab)
 Kollmann, M, 817(ab)
 Kolodny, GM, 240, 737(ab), 874(ab)
 Komatani, A, 719
 Komtebedde, J, 1702
 Kondo, M, 866(ab)
 Kong, B, 749(ab), 820(ab), 862(ab), 863(ab)
 Konietzko, N, 845(ab)
 Konings, AWT, 789(ab)
 Konishi, J, 150, 747(ab),
 Kuhn, LR, 799(ab)
 Kulkarni, PV, 902(ab)
 Kumagai, T, 830(ab)
 Kumar, A, 771(ab), 899(ab)
 Kumar, SJ, 799(ab)
 Kung, HF, 88, 367, 731(ab), 761(ab), 762(ab), 773(ab), 803(ab), 830(ab), 834(ab), 926(ab), 939(ab)
 Kung, M-P, 88, 731(ab), 762(ab), 773(ab), 803(ab), 834(ab), 926(ab)
 Kung, S, 830(ab)
 Kung HF, 803(ab)
 Kuni, C, 961(ab), 967(ab)
 Kuni, CC, 1881
 Kunz, R, 813(ab)
 Kuperus, JH, 38
 Kupranick, D, 1902
 Kurata, C, 70, 864(ab)
 Kuroki, M, 747(ab)
 Kurono, T, 892(ab)
 Kursh, ED, 784(ab)
 Kushner, M, 802(ab), 898(ab)
 Kushner, MJ, 811(ab), 965(ab), 1607
 Kusilek, LD, 918(ab)
 Kusumoto, K, 965(ab)
 Kuwabara, Y, 802(ab)
 Kuwert, T, 771(ab), 895(ab)
 Kwan, SYI, 918(ab)
 Kwiatkowski, F, 295, 871(ab)
 Kwok, CS, 777(ab), 1036
 Laçon, JP, 825(ab)
 Lagunas-Solar, MC, 849(ab), 968(ab), 1182
 Lahiri, A, 773(ab), 818(ab), 868(ab)
 Lake, RR, 1616
 Lam, CF, 872(ab)
 LaManna, MM, 867(ab)
 Lambert, B, 904(ab)
 Lambert, D, 916(ab)
 Lambert, R, 759(ab), 790(ab), 865(ab), 944(ab)
 Lamberts, SWJ, 768(ab)
 Lambotte, L, 815(ab), 929(ab)
 Lambrecht, RM, 922(ab), 1132
 Lameris, JS, 768(ab)
 Lamki, L, 130, 738(ab), 858(ab)
 Lamki, LK, 905(ab)
 Lamki, LM, 819(ab), 836(ab), 844(ab), 858(ab), T26C
 Lammertsma, AA, 775(ab), 808(ab)
 Lamoureux, F, 781(ab)
 Lamoureux, G, 894(ab)
 Lamoureux, J, 781(ab)
 LaMuraglia, GM, 817(ab)
 Lancaster, JL, 130
 Landthaler, M, 907(ab)
 Lane, WW, 737(ab)
 Lang, L, 1205
 Lange, HW, 771(ab)
 Langen, K-J, 771(ab), 895(ab)
 Langleben, D, 1297
 Långström, B, 742(ab), 782(ab), 783(ab), 927(ab)
 Lannoye, GS, 901(ab), 926(ab), 930(ab), 931(ab)
 Lantto, T, 1332
 Lanza, RC, 806(ab)
 Laperrière, J, 944(ab)
 Laperrière, L, 807(ab)
 Lapointe, J, 1271
 Lapointe, S, 944(ab)
 Larcos, G, 754(ab), 1885
 Larner, JM, 209
 Larson, KB, 901(ab)
 Larson, S, 320
 Larson, SM, 581, 746(ab), 809(ab), 909(ab), 928(ab), 1311, 1693, 1966
 Lasher, JC, 1737(le)
 Lashford, L, 903(ab)
 Lassen, NA, 775(ab), 796(ab), 896(ab)
 Latham, IA, 773(ab), 818(ab)
 Lattimer, JC, 966(ab)
 Laurin, NR, 1627
 Lau-Wong, MM, 918(ab)
 LaVallee, DK, 936(ab)
 Lavender, JP, 738(ab), 819(ab), 847(ab)
 Lavender, PJ, 1636
 Law, MP, 766(ab)
 Lawrence, D, 934(ab)
 Lawson, MS, 523
 Lawson, WE, 165
 Lawton, RG, 832(ab)
 Lazarus, CR, 174
 Lazewatsky, J, 870(ab)
 Lazzari, S, 779(ab)
 Lear, JL, 792(ab), 838(ab), 874(ab), 900(ab), 944(ab)
 Leblanc, A, 1281
 LeBlanc, A, 775(ab)
 Leclef, B, 788(ab)
 Leclerc, Y, 117
 Leclairec, J, 941(ab)
 Lecomte, JL, 766(ab)
 Lecomte, R, 766(ab)
 Le Doussal, J-M, 907(ab), 1358
 Lee, BI, 751(ab)
 Lee, H-B, 666, 841(ab)
 Lee, J, 747(ab)
 Lee, KH, 886(ab)
 Lee, KJ, 781(ab)
 Lee, ME, 959(ab)
 Lee, RE, 809(ab), 828(ab)
 Lee, S-D, 1708
 Lee, Y-CC, 763(ab), 935(ab)
 Lefebvre, B, 759(ab)
 Lefkowitz, DM, 876(ab)
 Lefort, G, 904(ab)
 Legaut, F, 897(ab)
 Leichner, PK, 881(ab)
 Leinsinger, G, 907(ab)
 Lemaire, C, 752(ab)
 Lemasson, P, 766(ab)
 Lentle, BC, 961(ab)
 Leon, JA, 936(ab)
 Leon, M, 915(ab)
 Leonard, JC, 890(ab)
 Leoncini, M, 820(ab)
 Lepp, EK, 853(ab)
 Leppo, JA, 281, 730(ab).

- 756(ab), 833(ab), 1500
 Lerner, CA, 834(ab)
 Leroy, RF, 751(ab)
 Lette, J, 1271
 Leuven, KU, 871(ab)
 Léveillé, J, 759(ab), 865(ab), 1902
 Lever, J, 740(ab)
 Lever, JR, 750(ab), 803(ab)
 Leville, J, 1018
 Levin, DR, 246
 Levine, AH, 1111
 Levine, G, 905(ab)
 Levine, RL, 745(ab)
 Levorato, M, 615
 Levy, D, 901(ab)
 Levy, R, 826(ab), 828(ab), 895(ab)
 Levy, RD, 1297
 Lew, AS, 729(ab), 837(ab)
 Lewellen, TK, 789(ab), 797(ab), 825(ab), 846(ab), 852(ab), 879(ab), 893(ab), 1554
 Lewis, CA, 891(ab)
 Lewis, I, 903(ab)
 Lewis, JP, 827(ab)
 Leysen, J, 741(ab)
 Leyssen, J, 926(ab)
 Li, QS, 755(ab), 757(ab)
 Li, S, 851(ab)
 Liang, C-C, 960(ab)
 Liang, Z, 755(ab)
 Liberatore, FA, 787(ab)
 Libson, K, 732(ab), 742(ab), 743(ab), 849(ab)
 Libson, KF, 837(ab)
 Lich, LL, 791(ab), 901(ab)
 Licitira, G, 128
 Liebert, M, 60, 777(ab), 912(ab)
 Lietzenmayer, R, 813(ab)
 Liewendahl, K, 1546
 Likungu, J, 829(ab)
 Limburg, M, 781(ab)
 Lin, H-C, 1708
 Lin, S, 901(ab)
 Lin, W-C, 960(ab)
 Linden, A, 842(ab), 843(ab), 903(ab)
 Line, B, 934(ab)
 Link, JM, 342, 789(ab), 808(ab), 846(ab), 852(ab), 911(ab), 928(ab)
 Linkesch, W, 1005
 Links, J, 731(ab)
 Links, JM, 740(ab), 755(ab), 816(ab), 849(ab)
 Lio, M, 902(ab)
 Lisbona, R, 181, 1297
 Lisic, EC, 925(ab)
 Lister-James, J, 793(ab), 794(ab), 934(ab)
 Liu, BL, 367, 939(ab)
 Liu, CZ, 939(ab)
 Liu, R-S, 871(ab), 1708
 Livesey, JC, 814(ab)
 Livni, E, 797(ab), 928(ab)
 Llorens, V, 1277(le)
 Lo, JM, 832(ab), 938(ab), 939(ab)
 Loats, H, 750(ab), 838(ab)
 Loats, HL, 816(ab)
 Loats, S, 838(ab)
 Loats, SE, 816(ab)
 Loc'h, C, 731(ab), 762(ab), 825(ab), 898(ab)
 Locke, E, 1095
 Loeve, W, 768(ab)
 Loewenstein, DA, 802(ab)
 Logan, J, 730(ab), 761(ab), 801(ab), 898(ab)
 Logan, KW, 964(ab)
 Logothetis, C, 836(ab)
 Logue, MB, 965(ab)
 Lohe, Evd, 739(ab)
 Loken, MK, 1881
 Lomeña, F, 1279(le)
 Lomeña, FJ, 1470
 London, J, 1117
 Long, DT, 835(ab)
 Longino, MA, 1088
 Longo, D, 909(ab)
 Lora, ME, 1311
 Lorenz, WJ, 910(ab)
 Lorre, JP, 742(ab), 877(ab)
 Losinno, F, 615
 Losse, B, 829(ab)
 Lotke, PA, 733(ab)
 Lötter, MG, 914(ab)
 Lotze, MT, 1311
 Lowe, JL, 742(ab)
 Löwenhielm, P, 722
 Lowenstein, E, 917(ab)
 Lubin, E, 450, 538
 Lubowski, D, 764(ab), 887(ab)
 Lubs, H, 802(ab)
 Lucchesi, BR, 767(ab)
 Lucignani, G, 792(ab), 831(ab), 869(ab)
 Luckey, MM, 1875
 Lucraft, H, 903(ab)
 Ludwig, H, 1005
 Lumia, FJ, 867(ab)
 Lundell, G, 721
 Lunghi, F, 742(ab)
 Lurain, J, 827(ab)
 Lusins, J, 1739(le)
 Lusins, JO, 490
 Lusson, J-R, 295
 Lutz, RJ, 839(ab)
 Luxen, A, 735(ab), 752(ab)
 Lyle, FM, 871(ab)
 Lynne, C, 841(ab)
 Lyons, E, 749(ab), 820(ab)
 Lyons, N, 754(ab), 764(ab), 851(ab), 887(ab)
 Lyss, AP, 788(ab)
 Lyster, DM, 925(ab)
 Ma, GQ, 886(ab)
 Maas, KW, 799(ab)
 MacDonald, JR, 937(ab)
 MacDonald, RN, 836(ab)
 Macey, DJ, 778(ab), 827(ab), 884(ab)
 MacFarlane, JK, 962(ab)
 MacGregor, R, 761(ab), 898(ab)
 MacGregor, RR, 741(ab)
 Mach, J-P, 809(ab), 1646
 Machac, J, 750(ab), 834(ab), 1445
 Machida, K, 770(ab), 944(ab)
 Machulla, HJ, 798(ab)
 MacIntyre, WJ, 861(ab)
 Mackay, BC, 782(ab)
 Mackie, TR, 883(ab)
 Maddahi, J, 301, 729(ab), 739(ab), 740(ab), 750(ab), 757(ab), 795(ab), 837(ab), 1718
 Maddai, J, 780(ab)
 Madden, J, 759(ab), 883(ab), 884(ab)
 Madden, JA, 876(ab)
 Maddox, A, 765(ab), 795(ab), 887(ab)
 Madsen, JL, 402
 Madsen, MT, 851(ab), 872(ab)
 Madsen, SL, 848(ab)
 Maecke, HR, 1235
 Maeda, H, 897(ab)
 Maeda, T, 738(ab)
 Maffioli, L, 869(ab), 1415
 Magata, Y, 803(ab), 866(ab), 887(ab), 900(ab)
 Magill, CA, 923(ab)
 Magnani, P, 888(ab)
 Magoun, S, 918(ab)
 Mahan, M, 961(ab)
 Maheu, LJ, 773(ab)
 Mahmarian, JJ, 749(ab), 760(ab), 780(ab)
 Mahmoud, AH, 943(ab)
 Mahoney, DK, 735(ab), 761(ab), 879(ab)
 Maickel, RP, 920(ab)
 Maier-Borst, W, 909(ab)
 Maisey, MM, 174
 Maisey, MN, 820(ab)
 Makai, T, 150
 Makler, PT, Jr, 1117
 Makoroff, K, 920(ab)
 Makrigiorgos, G, 826(ab), 883(ab), 1856
 Malak, TA, 767(ab)
 Malbrain, S, 2022
 Maley, BL, 747(ab)
 Malik, AB, 852(ab)
 Mallette, S, 481
 Malmin, RE, 852(ab)
 Malmud, LS, 817(ab)
 Maloney, P, 915(ab)
 Maloney, PJ, 1311, 1693
 Malov, AG, 1686
 Mamiya, T, 770(ab), 944(ab)
 Mamontova, AG, 66
 Manco-Johnson, M, 874(ab)
 Mandeli, JP, 1875
 Mandelkern, M, 894(ab)
 Mandell, GA, 799(ab)
 Manglos, SH, 881(ab), 961(ab)
 Mangner, T, 837(ab)
 Mangner, TJ, 926(ab)
 Mann, U, 896(ab)
 Manning, R, 803(ab)
 Manor, E, 804, 815(ab)
 Manspeaker, P, 833(ab)
 Manzel, L, 827(ab)
 Maranhao, V, 867(ab)
 Marchetta, F, 615
 Marciano, D, 863(ab), 877(ab), 913(ab), 942(ab)
 Marcus, CS, N1584
 Marian, AJ, 760(ab)
 Marian, G, 749(ab)
 Marian, M, 908(ab)
 Marin-Grez, M, 909(ab), 911(ab)
 Marino, GG, 251
 Markand, ON, 751(ab)
 Markham, J, 825(ab)
 Markusse, HM, 889(ab), 2017
 Marmion, M, 773(ab)
 Marmion, ME, 937(ab)
 Marmor, A, 1657
 Maron, BJ, 780(ab)
 Marquis, J, 760(ab)
 Marret, S, 776(ab)
 Marrett, S, 839(ab), 875(ab)
 Marrett, TS, 765(ab)
 Marsano, L, 559
 Marsch, S, 820(ab), 863(ab)
 Marsden, PK, 766(ab)
 Marsh, JD, 757(ab)
 Martell, AE, 763(ab), 848(ab), 922(ab)
 Martin, CC, 745(ab), 927(ab)
 Martin, GL, 808(ab)
 Martin, GV, 194, 798(ab), 846(ab)
 Martin, JL, 732(ab)
 Martin, M, 907(ab), 1358
 Martin, NL, 843(ab)
 Martin, P, 828(ab)
 Martin, W, 818(ab)
 Martin, WRW, 761(ab)
 Martinez, F, 1113
 Martinez, M, 863(ab)
 Martinot, JL, 897(ab)
 Martynov, AV, 1686
 Marwick, TH, 759(ab)
 Marwick, TH, 861(ab)
 Masdeu, J, 811(ab)
 Maseri, A, 808(ab)
 Mash, D, 761(ab)
 Mason, MD, 754(ab)
 Massuger, L, 758(ab)
 Masuda, K, 802(ab), 914(ab)
 Masuda, Y, 865(ab), 866(ab)
 Masui, H, 746(ab)
 Masure, MC, 812(ab)
 Matarrese, M, 742(ab), 831(ab), 869(ab)
 Mather, SJ, 748(ab), 758(ab)
 Mathias, CJ, 753(ab), 763(ab), 768(ab), 788(ab), 791(ab), 807(ab), 821(ab), 901(ab), 910(ab), 1205, 1843
 Mathis, C, 822(ab)
 Mathis, CA, 342
 Mathog, RH, 967(ab)
 Martinez, SJ, 398
 Matsubara, N, 868(ab), 881(ab)
 Matsuda, H, 897(ab), 939(ab)
 Matsueda, GR, 785(ab)
 Matsumori, A, 862(ab)
 Matsumoto, K, 923(ab), 1838
 Matsumoto, M, 508
 Matsumoto, S, 760(ab)
 Matsumoto, T, 885(ab)
 Matsunaga, M, 858(ab)
 Matsunari, I, 844(ab)
 Matsuoka, K, 942(ab)
 Matsuoka, Y, 747(ab)
 Matsushima, H, 832(ab)
- Matsuza, T, 33, 739(ab), 788(ab), 902(ab), 1809, 2012
 Mattar, AG, 1627
 Mattera, JA, 800(ab), 863(ab)
 Matthiesen, S, 542
 Matzku, S, 390
 Maublant, JC, 295, 860(ab), 865(ab), 871(ab)
 Maul, FD, 847(ab), 904(ab)
 Maurer, AH, 764(ab), 782(ab), 794(ab), 817(ab)
 Maurer, H, 849(ab)
 Maurer, SB, 966(ab)
 Mausner, L, 890(ab)
 Mausner, LF, 921(ab), 923(ab), 935(ab)
 Maxon, HR, 732(ab), 837(ab)
 Mayaud, C, 746(ab)
 Mayberg, HS, 740(ab), 750(ab)
 Mayoral, G, 936(ab)
 Mayoral, JL, 936(ab)
 Maziére, B, 731(ab), 762(ab), 825(ab), 898(ab)
 Maziére, M, 731(ab), 762(ab)
 Mazoyer, B, 812(ab)
 Mazoyer, BM, 766(ab), 825(ab), 877(ab), 897(ab)
 Mazzotta, JC, 735(ab), 752(ab), 761(ab), 791(ab), 801(ab), 879(ab), 896(ab), 913(ab)
 McAfee, JG, 659, 747(ab), 881(ab), 940(ab), 963(ab)
 McCabe, RP, 909(ab)
 McCall, MJ, 762(ab), 763(ab)
 McCallum, RW, 764(ab), 882(ab)
 McCandless, BK, 743(ab), 744(ab)
 McCartney, WH, 497, 756(ab), 835(ab)
 McClanahan, TB, 860(ab)
 McConnell, DS, 1088
 McConnell, TP, 776(ab)
 McCready, VR, 813(ab)
 McDiarmid, SA, 942(ab)
 McDougall, IR, 255, 407, 2063(le)
 McElwain, TJ, 474, 836(ab)
 McEver, R, 787(ab)
 McEwan, AJ, 812(ab), 836(ab), 914(ab), 961(ab)
 McFalls, EO, 808(ab)
 McFarland, WD, 964(ab)
 McGhie, AI, 828(ab)
 McGhie, I, 288, 770(ab), 801(ab), 810(ab), 871(ab)
 McGrath, MA, 961(ab)
 McGuire, AH, 788(ab), 791(ab)
 McGuire, R, 819(ab)
 McIndoe, DW, 1424
 McIntyre, WJ, 759(ab)
 McKay, DR, 683
 McKay, WJ, 751(ab), 831(ab)
 McKenzie, CG, 1636
 McKnight, R, 834(ab)
 McKusick, K, 301, 740(ab)

- McLean, M, 866(ab)
 McLean, R, 754(ab),
 764(ab), 851(ab), 887(ab)
 McNamara, M, 754(ab)
 McNutt, K, 917(ab)
 McPherson, DW, 848(ab),
 925(ab)
 McRae, T, 771(ab)
 McSharry, B, 730(ab)
 McSherry, B, 833(ab)
 McTigue, M, 762(ab)
 Meares, CF, 762(ab), 763(ab)
 Mease, RC, 923(ab), 934(ab),
 935(ab)
 Meerdink, DJ, 756(ab), 1500
 Meier, DE, 1875
 Meignan, M, 734(ab),
 746(ab)
 Meijer, S, 1219
 Meikle, SR, 872(ab), 964(ab)
 Meinken, GE, 787(ab),
 923(ab), 934(ab), 935(ab),
 1848
 Meldolesi, U, 820(ab)
 Melega, WP, 735(ab),
 752(ab), 761(ab)
 Melin, JA, 788(ab), 797(ab)
 Meller, ST, 474, 836(ab)
 Melogran, J, 1079
 Meltzer, CC, 750(ab)
 Mena, FJ, 806(ab)
 Mena, I, 599, 806(ab),
 864(ab), 887(ab), 967(ab)
 Mena, IG, 38, 1018
 Mendelsohn, J, 746(ab)
 Meneguetti, JC, 916(ab)
 Meng, M, 367
 Merbach, A, 743(ab)
 Merchant, B, 748(ab),
 906(ab)
 Merhige, ME, 846(ab),
 859(ab), 865(ab), 866(ab)
 Merlet, P, 810(ab)
 Mertens, J, 741(ab), 921(ab),
 926(ab)
 Mesa-Tesada, R, 936(ab)
 Messa, C, 831(ab)
 Messian, O, 820(ab)
 Metz, JT, 899(ab)
 Meury, V, 792(ab)
 Meyer, E, 900(ab), 1069
 Meyer, G-J, 880(ab), 910(ab)
 Meyer, KL, 849(ab)
 Meyne, NG, 780(ab)
 Miceva, S, 823(ab)
 Michael, RH, 843(ab)
 Michaels, E, 942(ab)
 Michalek, SM, 1464
 Michel, C, 797(ab)
 Michigishi, T, 844(ab)
 Middelheim, AZ, 794(ab)
 Midha, K, 731(ab)
 Milhaud, G, 855(ab)
 Miller, C, 542
 Miller, DD, 787(ab), 860(ab)
 Miller, DS, 827(ab)
 Miller, JH, 799(ab), 857(ab)
 Miller, KM, 937(ab)
 Miller, LR, 764(ab)
 Miller, PR, 967(ab)
 Miller, R, 778(ab), 828(ab)
 Miller, S, 855(ab)
 Miller, TR, 781(ab), 808(ab),
 834(ab), 2036
 Milligan, T, 1032
 Millin, J, 856(ab)
 Mills, BJ, 754(ab)
 Mills, SL, 827(ab), 907(ab)
 Milo, TJ, 961(ab)
 Min, CY, 1693
 Minkin, E, 731(ab)
 Minn, H, 912(ab)
 Minnaar, P, 914(ab)
 Minoshima, S, 738(ab),
 858(ab), 910(ab)
 Minturn, MA, 141
 Mintun, MA, 788(ab),
 901(ab)
 Miraldi, F, 784(ab), 879(ab)
 Mirelli, M, 615
 Miron, SD, 734(ab)
 Mirzadeh, S, 672, 968(ab)
 Misaki, T, 786(ab)
 Misra, HK, 793(ab)
 Mistry, R, 174
 Mitchell, DM, 901(ab)
 Mitchell, M, 25
 Mitsuka, S, 913(ab)
 Miura, RS, 466, 784(ab)
 Miura, S, 830(ab), 878(ab)
 Miyagawa, M, 760(ab),
 792(ab), 878(ab)
 Miyagawa, N, 918(ab)
 Miyake, M, 802(ab)
 Miyaoka, RS, 893(ab)
 Miyoshi, T, 150, 858(ab)
 Mizuno, T, 258
 Mochizuki, T, 760(ab),
 805(ab), 864(ab), 878(ab),
 943(ab)
 Mock, BH, 920(ab)
 Mock, BM, 799(ab)
 Model, HI, 789(ab)
 Model, JG, 895(ab)
 Mody, FV, 846(ab), 867(ab)
 Moeller, F, 805(ab)
 Moeller, JR, 564, 839(ab),
 1483
 Moerlein, SM, 763(ab),
 804(ab), 822(ab), 901(ab),
 926(ab), 930, 931(ab)
 Mogami, H, 792(ab),
 805(ab), 864(ab), 878(ab),
 943(ab)
 Mohammed, MMJ, 864(ab),
 959(ab)
 Möhring, K, 784(ab)
 Mohuiddin, S, 730(ab)
 Moi, M, 763(ab)
 Moins, N, 860(ab)
 Moisan, A, 941(ab)
 Mojiminiyi, OA, 1420(ie)
 Möllenstädt, S, 531
 Möller, F, 856(ab)
 Momose, T, 902(ab)
 Monaghan, P, 754(ab)
 Mondorf, UF, 495(ab)
 Monetti, N, 615
 Monroe, LA, 786(ab)
 Montalecot, G, 917(ab)
 Montemaggi, P, 769(ab)
 Montilla, L, 826(ab)
 Moolenaar, AJ, 769(ab)
 Moore, DA, 922(ab)
 Moore, RH, 913(ab)
 Moore, SC, 806(ab)
 Moore, WH, 786, 918(ab),
 1741
 Moragas, M, 1470
 Moran, RD, 894(ab)
 Morell, EM, 889(ab)
 Moreno, AJ, 962(ab)
 Moretti, J-L, 1018
 Morgan, AC, 25, 216
 Morgan, AC, Jr, 777(ab)
 Morgan, C, 779(ab)
 Morgan, JP, 870(ab)
 Morgan, RA, 599, 1018,
 1892, 1902
 Morgan, WA, 782(ab)
 Morguet, A, 757(ab),
 779(ab), 800(ab)
 Mori, A, 914(ab)
 Mori, H, 897(ab), 939(ab)
 Mori, K, 718
 Mori, Y, 915(ab)
 Morita, S, 942(ab)
 Morozumi, R, 868(ab),
 881(ab)
 Morrel, EM, 1538
 Morris, D, 923(ab)
 Morris, JG, 683, 1865
 Morris, JM, 905(ab)
 Morrison, DW, 914(ab)
 Morse, BS, 1550
 Morser, J, 787(ab)
 Mortelmans, L, 871(ab),
 896(ab), 1992, 2022
 Morton, T, 920(ab)
 Moscatelli, G, 779(ab),
 908(ab)
 Moser, KM, 1531
 Moses, WW, 745(ab)
 Mosimann, F, 1646
 Moskowitz, B, 246
 Motekaitis, RJ, 922(ab)
 Motta-Hennessy, C, 848(ab),
 888(ab)
 Moulton, JS, 837(ab)
 Mountford, PJ, 562
 Mountz, JM, 895(ab)
 Moyes, JSE, 474, 836(ab)
 Muecke, T, 765(ab)
 Muehllehner, G, 766(ab)
 Mueller, SP, 806(ab),
 867(ab)
 Mukai, T, 866(ab), 887(ab),
 900(ab), 1775, 1977
 Mukherjee, J, 924(ab),
 930(ab)
 Mulholland, CK, 932(ab)
 Mulholland, GK, 822(ab),
 926(ab), 930(ab)
 Mullani, N, 775(ab),
 865(ab), 909(ab), 966(ab),
 1787
 Mullani, NA, 707, 846,
 880(ab), 964(ab)
 Müller, Ch, 1005
 Müller, H, 784(ab)
 Müller, SP, 845(ab), 886(ab)
 Müller-Suur, C, 1986
 Müller-Suur, R, 1986
 Mullholland, GK, 822(ab)
 Mumper, RJ, 836(ab)
 Munoz, L, 810(ab)
 Munz, DL, 748(ab), 757(ab),
 758(ab), 779(ab), 800(ab),
 917(ab)
 Murakami, M, 830(ab),
 878(ab)
 Murakawa, M, 718
 Murase, K, 760(ab), 792(ab),
 805(ab), 864(ab), 878(ab),
 1192
 Murata, H, 870(ab)
 Murata, K, 916(ab)
 Murayama, H, 746(ab),
 892(ab)
 Murphy, KA, 878(ab)
 Murphy, P, 1136
 Murphy, PH, 941(ab), 1741,
 1918
 Murphy, RA, 762(ab),
 803(ab)
 Murray, JL, 819(ab)
 Murrell, M, 741(ab)
 Musachio, JL, 803(ab)
 Muschel, MJ, 312
 Muto, MG, 904(ab), 933(ab)
 Muz, J, 967(ab)
 Muza, M, 808(ab), 838(ab),
 911(ab)
 Muzik, O, 895(ab)
 Muzykantov, VR, 1686
 Mycars, DW, 187
 Mylonakis, T, 798(ab),
 915(ab)
 Naeem, M, 758(ab)
 Nagle, CE, 736(ab), 959(ab)
 Nair, M, 864(ab), 959(ab)
 Najafi, A, 939(ab)
 Najm, YC, 820(ab)
 Nakahashi, H, 783(ab),
 824(ab), 866(ab)
 Nakai, T, 747(ab), 785(ab),
 840(ab), 885(ab), 889(ab),
 919(ab)
 Nakajima, K, 825(ab),
 844(ab), 870(ab), 997
 Nakajima, S, 738(ab)
 Nakamura, K, 809(ab)
 Nakano, H, 811(ab)
 Nakano, S, 157, 337, 1101
 Nakata, S, 792(ab)
 Nakatsuka, I, 803(ab)
 Nanbu, I, 870(ab)
 Narabayashi, I, 853(ab)
 Narra, RK, 1830
 Natale, RB, 25
 Natarajan, TK, 731(ab),
 741(ab)
 Neben, T, 932(ab)
 Neblock, D, 787(ab)
 Nedelman, MA, 787(ab),
 793(ab), 794(ab), 906(ab),
 934(ab)
 Need, JL, 968(ab)
 Needleman, M, 385, 1095
 Neely, H, 785(ab)
 Nelp, WB, 25, 828(ab)
 Nelson, AD, 784(ab),
 879(ab)
 Nelson, DH, 966(ab)
 Nelson, R, 963(ab)
 Nenov, VI, 894(ab)
 Neufang, KFR, 842(ab)
 Neumann, PH, 852(ab)
 Neumann, RD, 906(ab),
 941(ab), 1311
 Neumann, W, 773(ab)
 Neumann, WL, 937(ab)
- Newman, D, 810(ab)
 Newton, RS, 768(ab)
 Ng, AK, 819(ab)
 Ng, CK, 1211
 Nguyen, NTB, 733(ab),
 767(ab)
 Nichols, K, 757(ab), 795(ab)
 Nickles, RJ, 745(ab),
 927(ab), 930(ab), 935(ab),
 965(ab)
 Nickoloff, EL, 124
 Nicol, PD, 785(ab)
 Nicolas, JM, 788(ab)
 Nicosia, S, 883(ab)
 Niemann, H, 748(ab)
 Nieminen, U, 1546
 Nienaber, C, 729(ab),
 837(ab)
 Nienaber, CA, 359, 838(ab),
 846(ab)
 Niino, M, 760(ab)
 Niklason, LT, 876(ab)
 Nilson, TE, 943(ab)
 Nimmon, C, 942(ab)
 Nimmon, CC, 758(ab),
 823(ab)
 Nishihara, M, 830(ab)
 Nishikawa, A, 919(ab)
 Nishikawa, J, 813(ab),
 902(ab)
 Nishikimi, N, 458
 Nishimura, K, 916(ab)
 Nishimura, T, 591, 767(ab),
 1713
 Nishizasa, S, 150
 Nishizawa, S, 900(ab), 1977
 Nissen, HP, 923(ab)
 Nitsch, J, 797(ab)
 Niwa, H, 258
 Niwayama, H, 865(ab),
 866(ab)
 Noda, H, 767(ab)
 Noda, S, 942(ab)
 Noël, P, 798(ab), 915(ab),
 966(ab)
 Nohara, N, 746(ab), 892(ab),
 1337, 1825, 1982
 Nohara, R, 866(ab)
 Nohara, T, 863(ab)
 Nolan, J, 963(ab)
 Noon, GP, 780(ab), 1405
 Nordberg, A, 742(ab)
 Nordman, E, 912(ab)
 Nordrehaug, JE, 1972
 Normand, B, 865(ab)
 Noronha, JG, 928(ab)
 Norrgren, K, 1224
 North, DL, 872(ab)
 Northover, JMA, 748(ab)
 Nosco, D, 773(ab)
 Nosco, DL, 937(ab)
 Nossiff, N, 762(ab), 859(ab)
 Nossiff, ND, 1095
 Noto, R, 731(ab), 834(ab)
 Notohamiprodjo, G,
 798(ab), 800(ab)
 Noujaim, AA, 202
 Novales-Diaz, JA, 181
 Noz, ME, 835(ab)
 Nunes, J, 1036
 Nunn, AD, 1830
 Nupnau, WA, 852(ab)
 Nusynowitz, ML, 561
 Nuyts, J, 871(ab), 1992

Nybäck, H, 742(ab)	O'Tuama, L, 838(ab) Owens, ES, 1676	Pavia, J, 1470 Pavlosky, WF, 1627	Pizer, SM, 835(ab) Pizzetti, G, 873(ab)	Rall, B, 739(ab) Ram, S, 783(ah), 968(ah)
Shulgin				
Shulgin, A, 822(ab)	790(ab), 1456	887(ab), 890(ab)	Subramanian, R, 797(ab)	917(ab), 944(ab)
Shulkin, BL, 843(ab), 1819	Smitherman, TC, 542, 861(ab)	Staudacher, RS, 760(ab)	Suehiro, M, 919(ab)	Tal, I, 874(ab)
Sia, B, 751(ab), 831(ab)	Smits, P, 861(ab), 1723	Stedman, RJ, 936(ab)	Suematsu, T, 853(ab)	Talbot, JN, 855(ab)
Sicat, M, 749(ab), 862(ab)	Smye, SW, 45	Stefan, H, 751(ab)	Suess, E, 731(ab)	Tamaki, N, 718, 862(ab), 863(ab), 866(ab), 887(ab), 1302, 1775
Siccardi, AG, 749(ab)	Snape, W, 887(ab)	Stehlin, JS, 25	Suetens, P, 871(ab), 1992	Tamura, K, 853(ab)
Siddiqui, AR, 799(ab)	Snook, D, 1636	Stein, E, 845(ab)	Sugabaker, P, 320	Tan, P, 964(ab)
Siegel, BA, 788(ab)	Snyder, AL, 771(ab)	Steinberg, ME, 733(ab)	Sugimoto, H, 822(ab)	Tanabe, M, 858(ab)
Siegel, JA, 764(ab), 782(ab), 794(ab), 960(ab)	Soares, J, 841(ab)	Steiner, M, 731(ab)	Sukalac, R, 817(ab)	Tanada, S, 150, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab), 943(ab)
Siegel, ME, 821(ab), 824(ab), 886(ab)	Soares, J, Jr, 916(ab)	Steis, RG, 909(ab)	Sullivan, MJ, 843(ab)	Tanaka, E, 746(ab), 870(ab), 892(ab)
Siegel, R, 750(ab)	Sobel, BE, 837(ab), 1489, 1798	Stella, A, 615	Sullivan, TJ, 959(ab)	Tanaka, T(ab), A811(ab)
Siffring, PA, 730(ab)	Sobnack, R, 748(ab)	Stephens, R, 828(ab)	Summers, D, 2063	Tani, A, 868(ab), 881(ab)
Sigal, SL, 863(ab)	Sobotka, PA, 1870	Stlepelewski, Z, 763(ab), 923(ab), 934(ab), 935(ab)	Sumerson, GA, 908(ab), 935(ab)	Tanigaki, S, 965(ab)
Sigurdson, ER, 809(ab)	Soini, I, 1332	Stevens, S, 828(ab)	Summerville, DA, 1176	Taniguchi, M, 870(ab)
Silberstein, EB, 748(ab), 774(ab), 903(ab)	Sokoloff, L, 792(ab)	Stevenson, LW, 846(ab), 867(ab)	Sun, L, 794(ab)	Taren, J, 833(ab)
Silbiger, M, 759(ab), 883(ab), 884(ab), 918(ab)	Solanki, K, 823(ab)	Stewart, CA, 824(ab), 857(ab), 886(ab)	Sun, LK, 934(ab)	Tashiro, K, 866(ab)
Silbiger, ML, 876(ab)	Solomon, H, 849(ab)	Stewart, R, 793(ab)	Sun, TTH, 763(ab), 935(ab)	Tateno, M, 895(ab)
Silverstein, EA, 874(ab), 888(ab)	Solomon, HF, 741(ab), 923(ab), 930(ab), 931(ab)	Stewart, RE, 829(ab), 850(ab), 860(ab)	Sunderland, JJ, 745(ab), 927(ab), 930(ab)	Tateno, Y, 866(ab), 885(ab)
Simon, H, 739(ab)	Solomon, RW, 737(ab), 785(ab), 815(ab)	Stickney, DR, 905(ab)	Suneja, SK, 113	Tattanelli, M, 908(ab)
Simon, TR, 542, 861(ab)	Solot, G, 757(ab)	Stochl, M, 908(ab)	Surachino, J, 785(ab)	Tatum, JL, 1257
Simonson, RB, 778(ab)	Som, P, 831(ab), 1848	Stöcklin, G, 110, 895(ab), 1367	Susskind, H, 830(ab), 1342	Taupier, MA, 886(ab)
Simpfendorfer, CC, 759(ab)	Sondel, J, 818(ab)	Stokely, EM, 638	Sutorik, A, 926(ab)	Tauxe, NW, 864(ab)
Simpkin, DJ, 883(ab)	Sonnemaker, R, 786(ab)	Stone-Elander, S, 927(ab)	Suzuki, A, 770(ab)	Tauxe, WN, 814(ab), 887(ab), 890(ab), 905(ab)
Simpson, NR, 928(ab)	Sood, A, 834(ab)	Stoub, EW, 2029	Suzuki, N, 813(ab)	Tawk, TC, 761(ab)
Sindelar, W, 320	Sood, V, 1079	Strand, S-E, 722, 1224	Suzuki, T, 914(ab)	Taylor, A, 943(ab), 1955
Singer, H., 731(ab)	Sood, VK, 940(ab)	Strashun, A, 855(ab), 1445	Svensson, W, 813(ab)	Taylor, A, Jr, 720, 823(ab)
Singh, A, 1814	Soper, NDW, 1420(le)	Strashun, AM, 1563	Swanson, D, 797(ab)	Taylor, AT, 743(ab)
Singh, M, 851(ab)	Sorby, PJ, 683	Stratton, JR, 629	Swanson, W, 789(ab)	Taylor-Papadimitriou, J, 758(ab)
Singletary, E, 819(ab)	Sorgentoni, K, 731(ab), 811(ab), 834(ab)	Straub, RF, 811(ab)	Swainey, LC, 850(ab), 874(ab), 1408	Teal, JS, 113
Sintsyn, VV, 66	Sostre, S, 885(ab)	Strauss, A, 777(ab), 833(ab)	Swinford, RD, 165	Teaster, B, 924(ab)
Sinusas, AJ, 756(ab), 790(ab), 1456	Soucy, JP, 781(ab)	Strauss, EB, 1111	Swyler, AJ, 754(ab)	Tebbe, U, 800(ab)
Sinzinger, H, 1005	Sowton, E, 820(ab)	Strauss, HW, 301, 385, 729(ab), 734(ab), 739(ab), 740(ab), 762(ab), 797(ab), 805(ab), 817(ab), 859(ab), 868(ab), 869(ab), 889(ab), 890(ab), 901(ab), 913(ab), 917(ab), 1095, 1123, 1149, 1538, 1911	Sy, WM, N431, 734(ab), 1919	Teixeira, JM, 867(ab)
Sirr, SA, 858(ab), 1133, 1399	Spaulding, M, 818(ab)	Strauss, J, 798(ab), 841(ab), 915(ab)	Sycharo, JJ, 364(ab)	Teixeira, LR, 916(ab)
Sisson, JA, 481	Spehl, M, 915(ab), 1337	Strauss, LG, 784(ab), 789(ab), 909(ab), 910(ab), 911(ab)	Syrjälä, MT, 1546	Telepak, RJ, 1737(ie)
Sisson, JC, 767(ab), 884(ab), 1476	Speller, RD, 891(ab)	Straw, J, 787(ab)	Syrota, A, 731(ab), 766(ab), 810(ab), 812(ab), 825(ab), 877(ab), 897(ab), 898(ab)	Templeton, GH, 638
Sivolapenko, GB, 1636	Spence, AM, 838(ab), 911(ab)	Stremmel, W, 798(ab)	Szabó, Z, 829(ab)	Temponi, M, 390, 936(ab)
Sjögren, H-O, 1224	Spencer, P, 760(ab)	Stringham, LM, 1814	Szilvasi, I, 748(ab)	Tenorio, L, 759(ab), 884(ab)
Skinner, RWS, 768(ab)	Spencer, RP, 737(ab)	Stritzke, P, 599, 785(ab)	Tabata, R, 914(ab)	Tenorio, LE, 918(ab)
Skrade, B, 770(ab)	Spicer, JA, 843(ab), 844(ab), 1281	Stritzke, PH, 1875	Tada, M, 2012	Terada, H, 897(ab)
Slade, S, 778(ab)	Spicer, KM, 872(ab)	Strnat, MAP, 847(ab)	Taddei, G, 735(ab)	Teran, JL, 800(ab)
Slater, JB, 894(ab)	Spies, SM, 827(ab), 888(ab), 933(ab), 874(ab), 888(ab)	Stroble, MB, 781(ab)	Taegtmeier, HT, 789(ab)	Teras, M, 892(ab)
Slichter, SJ, 629	Spies, WG, 827(ab), 874(ab), 888(ab), 933(ab)	Strother, SC, 564, 839(ab), 1483	Taguchi, T, 864(ab)	Terra-Filho, M, 916(ab)
Slinkin, MA, 1686	Spinelli, A, 779(ab)	Stroup, SD, 908(ab)	Tahara, T, 802(ab)	Terui, S, 904(ab), 1198
Slizofski, WJ, 1739(le)	Spranzi, E, 908(ab)	Strubel, T, 773(ab)	Tai, K, 734(ab)	Tewson, T, 909(ab), 966(ab)
Sloan, G, 799(ab)	Squicciarini, SA, 829(ab)	Strubel, TW, 937(ab)	Taillefer, R, 759(ab), 790(ab), 865(ab), 1902	Tewson, TJ, 789(ab), 928(ab)
Sloboda, R, 266	Srinivasan, A, 25, 793(ab), 933(ab), 940(ab)	Stuart, DD, 1399	Tak, T, 821(ab)	Thakur, ML, 747(ab), 901(ab), 936(ab)
Sloboda, RS, 836(ab)	Spivak, SC, 1848	Stubbs, CC, 764(ab)	Takada, Y, 853(ab)	Theissen, P, 842(ab), 843(ab), 903(ab)
Smalling, RW, 846(ab)	Srivastava, PC, 925(ab)	Stubbs, JB, 764(ab), 882(ab)	Takagi, H, 743(ab)	Théroux, P, 800(ab)
Smart, R, 754(ab), 764(ab), 887(ab)	Srivastava, SC, 787(ab), 811(ab), 890(ab), 921(ab), 923(ab), 934(ab), 935(ab)	Studer, A, 1646	Takahashi, A, 830(ab)	Thieme, AM, 821(ab)
Smart, RC, 851(ab)	Stabin, M, 415, 833(ab)	Stulzaft, O, 731(ab), 898(ab)	Takahashi, H, 858(ab)	Thien, T, 1723
Smeltzer, SL, 845(ab)	Stabin, MG, 599, 763(ab), 2002	Stumpf, MJ, 816(ab)	Takahashi, K, 878(ab)	Thomas, C, 879(ab)
Smith, AP, 796(ab)	Stanley, PC, 852(ab)	Stunkard, AJ, 692	Takahashi, M, 258, 508	Thomas, DGT, 1636
Smith, CG, 967(ab)	Stark, V, 833(ab), 883(ab)	Stuttle, AW, 738(ab)	Takahashi, T, 739(ab), 917(ab), 944(ab), 2012	Thomas, FD, 659, 881(ab), 940(ab), 961(ab)
Smith, GJW, 916(ab)	Starling, MR, 1737(le)	Stuyck, J, 2022	Takahashi, T, 33	Thomas, SR, 732(ab), 1117
Smith, GS, 771(ab)	Starr, CW, 872(ab)	Styles, J, 808(ab), 809(ab)	Takano, H, 767(ab)	Thomas, WC, Jr, 842(ab)
Smith, GT, 877(ab), 960(ab)	Stathis, M, 803(ab)	Su, FM, 793, 849(ab)	Takashashi, T, 770(ab)	Thomforde, GM, 764(ab)
Smith, H, 873(ab)	Stauber, RE, 814(ab).	Subramanian, G, 659, 940(ab)	Takayama, T, 997	Thompson, C, 806(ab)
Smith, HE, 803(ab)		Subramanian, K, 963(ab)	Takehara, Y, 258	Thompson, CJ, 765(ab), 1056
Smith, J, 836(ab)			Takemura, Y, 923(ab)	Thonmart, B, 820(ab)
Smith, JJ, 941(ab)			Takeshita, G, 897(ab)	Thonoor, CM, 1916(ie)
Smith, KF, 312			Takeuchi, A, 897(ab)	Thoolen, M, 773(ab)
Smith, L, 906(ab)			Taki, J, 844(ab), 870(ab)	Thoolen, MJ, 787(ab)
Smith, Q, 838(ab)			Taki, S, 844(ab)	Thornton, B, 780(ab)
Smith, R, 917(ab)			Subramanian, K, 963(ab),	
Smith, RH, 832(ab)				
Smith, T, 818(ab)				
Smith, WH, 756(ab)				

- McLean, M, 866(ab)
 McLean, R, 754(ab),
 764(ab), 851(ab), 887(ab)
 McNamara, M, 754(ab)
 McNutt, K, 917(ab)
 McPherson, DW, 848(ab),
 925(ab)
 McRae, T, 771(ab)
 McSharry, B, 730(ab)
 McSherry, B, 833(ab)
 McTigue, M, 762(ab)
 Meares, CF, 762(ab), 763(ab)
 Mease, RC, 923(ab), 934(ab),
 935(ab)
 Meerdink, DJ, 756(ab), 1500
 Meier, DE, 1875
 Meignan, M, 734(ab),
 746(ab)
 Meijer, S, 1219
 Meikle, SR, 872(ab), 964(ab)
 Meinken, GE, 787(ab),
 923(ab), 934(ab), 935(ab),
 1848
 Meldolesi, U, 820(ab)
 Melega, WP, 735(ab),
 752(ab), 761(ab)
 Melin, JA, 788(ab), 797(ab)
 Meller, ST, 474, 836(ab)
 Melogrania, J, 1079
 Meltzer, CC, 750(ab)
 Mena, FJ, 806(ab)
 Mena, I, 599, 806(ab),
 864(ab), 887(ab), 967(ab)
 Mena, IG, 38, 1018
 Mendelsohn, J, 746(ab)
 Meneguetti, JC, 916(ab)
 Meng, M, 367
 Merbach, A, 743(ab)
 Merchant, B, 748(ab),
 906(ab)
 Merhige, ME, 846(ab),
 859(ab), 865(ab), 866(ab)
 Merlet, P, 810(ab)
 Mertens, J, 741(ab), 921(ab),
 926(ab)
 Mesa-Tesada, R, 936(ab)
 Messa, C, 831(ab)
 Messian, O, 820(ab)
 Metz, JT, 899(ab)
 Meury, V, 792(ab)
 Meyer, E, 900(ab), 1069
 Meyer, G-J, 880(ab), 910(ab)
 Meyer, KL, 849(ab)
 Meyne, NG, 780(ab)
 Miceva, S, 823(ab)
 Michael, RH, 843(ab)
 Michaels, E, 942(ab)
 Michalek, SM, 1464
 Michel, C, 797(ab)
 Michigishi, T, 844(ab)
 Middelheim, AZ, 794(ab)
 Midha, K, 731(ab)
 Milhaud, G, 855(ab)
 Miller, C, 542
 Miller, DD, 787(ab), 860(ab)
 Miller, DS, 827(ab)
 Miller, JH, 799(ab), 857(ab)
 Miller, KM, 937(ab)
 Miller, LR, 764(ab)
 Miller, PR, 967(ab)
 Miller, R, 778(ab), 828(ab)
 Miller, S, 855(ab)
 Miller, TR, 781(ab), 808(ab),
 834(ab), 2036
 Milligan, T, 1032
 Millin, J, 856(ab)
 Mills, BJ, 754(ab)
 Mills, SL, 827(ab), 907(ab)
 Milo, TJ, 961(ab)
 Min, CY, 1693
 Minkin, E, 731(ab)
 Minn, H, 912(ab)
 Minnaar, P, 914(ab)
 Minoshima, S, 738(ab),
 858(ab), 910(ab)
 Minturn, MA, 141
 Mintun, MA, 788(ab),
 901(ab)
 Miraldi, F, 784(ab), 879(ab)
 Mirelli, M, 615
 Miron, SD, 734(ab)
 Mirzadeh, S, 672, 968(ab)
 Misaki, T, 786(ab)
 Misra, HK, 793(ab)
 Mistry, R, 174
 Mitchell, DM, 901(ab)
 Mitchell, M, 25
 Mitsuka, S, 913(ab)
 Miura, RS, 466, 784(ab)
 Miura, S, 830(ab), 878(ab)
 Miyagawa, M, 760(ab),
 792(ab), 878(ab)
 Miyagawa, N, 918(ab)
 Miyake, M, 802(ab)
 Miyaoka, RS, 893(ab)
 Miyoshi, T, 150, 858(ab)
 Mizuno, T, 258
 Mochizuki, T, 760(ab),
 805(ab), 864(ab), 878(ab),
 943(ab)
 Mock, BH, 920(ab)
 Mock, BM, 799(ab)
 Model, HI, 789(ab)
 Model, JG, 895(ab)
 Mody, FV, 846(ab), 867(ab)
 Moeller, F, 805(ab)
 Moeller, JR, 564, 839(ab),
 1483
 Moerlein, SM, 763(ab),
 804(ab), 822(ab), 901(ab),
 926(ab), 930, 931(ab)
 Mogami, H, 792(ab),
 805(ab), 864(ab), 878(ab),
 943(ab)
 Mohammed, MMJ, 864(ab),
 959(ab)
 Möhring, K, 784(ab)
 Mohuiddin, S, 730(ab)
 Moi, M, 763(ab)
 Moins, N, 860(ab)
 Moisan, A, 941(ab)
 Mojiminiyi, OA, 1420(ie)
 Möllenstädt, S, 531
 Möller, F, 856(ab)
 Momose, T, 902(ab)
 Monaghan, P, 754(ab)
 Mondorf, UF, 495(ab)
 Monetti, N, 615
 Monroe, LA, 786(ab)
 Montalecot, G, 917(ab)
 Montemaggi, P, 769(ab)
 Montilla, L, 826(ab)
 Moolenaar, AJ, 769(ab)
 Moore, DA, 922(ab)
 Moore, RH, 913(ab)
 Moore, SC, 806(ab)
 Moore, WH, 786, 918(ab),
 1741
 Moragas, M, 1470
 Moran, RD, 894(ab)
 Morell, EM, 889(ab)
 Moreno, AJ, 962(ab)
 Moretti, J-L, 1018
 Morgan, AC, 25, 216
 Morgan, AC, Jr, 777(ab)
 Morgan, C, 779(ab)
 Morgan, JP, 870(ab)
 Morgan, RA, 599, 1018,
 1892, 1902
 Morgan, WA, 782(ab)
 Morguet, A, 757(ab),
 779(ab), 800(ab)
 Mori, A, 914(ab)
 Mori, H, 897(ab), 939(ab)
 Mori, K, 718
 Mori, Y, 915(ab)
 Morita, S, 942(ab)
 Morozumi, R, 868(ab),
 881(ab)
 Morrel, EM, 1538
 Morris, D, 923(ab)
 Morris, JG, 683, 1865
 Morris, JM, 905(ab)
 Morrison, DW, 914(ab)
 Morse, BS, 1550
 Morser, J, 787(ab)
 Mortelmans, L, 871(ab),
 896(ab), 1992, 2022
 Morton, T, 920(ab)
 Moscatelli, G, 779(ab),
 908(ab)
 Moser, KM, 1531
 Moses, WW, 745(ab)
 Mosimann, F, 1646
 Moskowitz, B, 246
 Motekaitis, RJ, 922(ab)
 Motta-Hennessy, C, 848(ab),
 888(ab)
 Moulton, JS, 837(ab)
 Mountford, PJ, 562
 Mountz, JM, 895(ab)
 Moyes, JSE, 474, 836(ab)
 Muecke, T, 765(ab)
 Muehllehner, G, 766(ab)
 Mueller, SP, 806(ab),
 867(ab)
 Mukai, T, 866(ab), 887(ab),
 900(ab), 1775, 1977
 Mukherjee, J, 924(ab),
 930(ab)
 Mulholland, CK, 932(ab)
 Mulholland, GK, 822(ab),
 926(ab), 930(ab)
 Mullani, N, 775(ab),
 865(ab), 909(ab), 966(ab),
 1787
 Mullani, NA, 707, 846,
 880(ab), 964(ab)
 Müller, Ch, 1005
 Müller, H, 784(ab)
 Müller, SP, 845(ab), 886(ab)
 Müller-Suur, C, 1986
 Müller-Suur, R, 1986
 Mullholland, GK, 822(ab)
 Mumper, RJ, 836(ab)
 Munoz, L, 810(ab)
 Munz, DL, 748(ab), 757(ab),
 758(ab), 779(ab), 800(ab),
 917(ab)
 Murakami, M, 830(ab),
 878(ab)
 Murakawa, M, 718
 Murase, K, 760(ab), 792(ab),
 805(ab), 864(ab), 878(ab),
 1192
 Murata, H, 870(ab)
 Murata, K, 916(ab)
 Murayama, H, 746(ab),
 892(ab)
 Murphy, KA, 878(ab)
 Murphy, P, 1136
 Murphy, PH, 941(ab), 1741,
 1918
 Murphy, RA, 762(ab),
 803(ab)
 Murray, JL, 819(ab)
 Murrell, M, 741(ab)
 Musachio, JL, 803(ab)
 Muschel, MJ, 312
 Muto, MG, 904(ab), 933(ab)
 Muz, J, 967(ab)
 Muza, M, 808(ab), 838(ab),
 911(ab)
 Muzik, O, 895(ab)
 Muzykantov, VR, 1686
 Myears, DW, 187
 Mylonakis, T, 798(ab),
 915(ab)
 Naeem, M, 758(ab)
 Nagle, CE, 736(ab), 959(ab)
 Nair, M, 864(ab), 959(ab)
 Najafi, A, 939(ab)
 Najm, YC, 820(ab)
 Nakahashi, H, 783(ab),
 824(ab), 866(ab)
 Nakai, T, 747(ab), 785(ab),
 840(ab), 885(ab), 889(ab),
 919(ab)
 Nakajima, K, 825(ab),
 844(ab), 870(ab), 997
 Nakajima, S, 738(ab)
 Nakamura, K, 809(ab)
 Nakano, H, 811(ab)
 Nakano, S, 157, 337, 1101
 Nakata, S, 792(ab)
 Nakatsuka, I, 803(ab)
 Nanbu, I, 870(ab)
 Narabayashi, I, 853(ab)
 Narra, RK, 1830
 Natale, RB, 25
 Natarajan, TK, 731(ab),
 741(ab)
 Neben, T, 932(ab)
 Neblock, D, 787(ab)
 Nedelman, MA, 787(ab),
 793(ab), 794(ab), 906(ab),
 934(ab)
 Need, JL, 968(ab)
 Needleman, M, 385, 1095
 Neely, H, 785(ab)
 Nelp, WB, 25, 828(ab)
 Nelson, AD, 784(ab),
 879(ab)
 Nelson, AH, 794(ab)
 Nelson, CW, 1172
 Nelson, DH, 966(ab)
 Nelson, R, 963(ab)
 Nenov, VI, 894(ab)
 Neufang, KFR, 842(ab)
 Neumann, PH, 852(ab)
 Neumann, RD, 906(ab),
 941(ab), 1311
 Neumann, W, 773(ab)
 Neumann, WL, 937(ab)
 Newman, D, 810(ab)
 Newton, RS, 768(ab)
 Ng, AK, 819(ab)
 Ng, CK, 1211
 Nguyen, NTB, 733(ab),
 767(ab)
 Nichols, K, 757(ab), 795(ab)
 Nickles, RJ, 745(ab),
 927(ab), 930(ab), 935(ab),
 965(ab)
 Nickoloff, EL, 124
 Nicol, PD, 785(ab)
 Nicolas, JM, 788(ab)
 Nicosia, S, 883(ab)
 Niemann, H, 748(ab)
 Nieminen, U, 1546
 Nienaber, C, 729(ab),
 837(ab)
 Nienaber, CA, 359, 838(ab),
 846(ab)
 Niino, M, 760(ab)
 Niklason, LT, 876(ab)
 Nilson, TE, 943(ab)
 Nimmon, C, 942(ab)
 Nimmon, CC, 758(ab),
 823(ab)
 Nishihara, M, 830(ab)
 Nishikawa, A, 919(ab)
 Nishikawa, J, 813(ab),
 902(ab)
 Nishikimi, N, 458
 Nishimura, K, 916(ab)
 Nishimura, T, 591, 767(ab),
 1713
 Nishizasa, S, 150
 Nishizawa, S, 900(ab), 1977
 Nissen, HP, 923(ab)
 Nitsch, J, 797(ab)
 Niwa, H, 258
 Niwayama, H, 865(ab),
 866(ab)
 Noda, H, 767(ab)
 Noda, S, 942(ab)
 Noël, P, 798(ab), 915(ab),
 966(ab)
 Nohara, N, 746(ab), 892(ab),
 1337, 1825, 1982
 Nohara, R, 866(ab)
 Nohara, T, 863(ab)
 Nolan, J, 963(ab)
 Noon, GP, 780(ab), 1405
 Nordberg, A, 742(ab)
 Nordman, E, 912(ab)
 Nordrehaug, JE, 1972
 Normand, B, 865(ab)
 Noronha, JG, 928(ab)
 Norrgren, K, 1224
 North, DL, 872(ab)
 Northover, JMA, 748(ab)
 Nosco, D, 773(ab)
 Nosco, DL, 937(ab)
 Nossiff, N, 762(ab), 859(ab)
 Nossiff, ND, 1095
 Noto, R, 731(ab), 834(ab)
 Notohamiprodjo, G,
 798(ab), 800(ab)
 Noujaim, AA, 202
 Novales-Diaz, JA, 181
 Noz, ME, 835(ab)
 Nunes, J, 1036
 Nunn, AD, 1830
 Nupnau, WA, 852(ab)
 Nusynowitz, ML, 561
 Nuyts, J, 871(ab), 1992

- Nybäck, H, 742(ab)
- Oates, E, 889(ab), 963(ab)
- Oba, H, 897(ab)
- Oberdorfer, F, 789(ab), 909(ab), 911(ab)
- Obrador, D, 862(ab)
- O'Connell, JW, 869(ab)
- O'Connell, RA, 811(ab)
- O'Connell, WC, 810(ab)
- O'Connor, MK, 265, 1135, 1280(le)
- Oda, Y, 866(ab)
- Odano, I, 830(ab)
- Odeh, N, 899(ab)
- O'Donnell, S, 762(ab), 859(ab)
- Oehr, P, 110, 758(ab), 879(ab)
- Oei, HY, 785(ab)
- Oepen, G, 812(ab)
- Oettgen, HF, 809(ab)
- O'Grady, LF, 738(ab), 827(ab), 907(ab)
- Ohbayashi, K, 853(ab)
- Ohno, K, 770(ab)
- Ohta, H, 2050
- Otake, H, 942(ab)
- Otake, T, 902(ab)
- Ohtani, H, 863(ab), 866(ab), 1775
- Ojemann, GA, 838(ab)
- Ojima, F, 917(ab)
- Oka, H, 767(ab)
- Okada, H, 892(ab)
- Okada, J, 738(ab), 858(ab), 910(ab)
- Okamoto, K, 936(ab)
- Okazawa, H, 885(ab)
- Olbrich, HG, 847(ab)
- Old, LJ, 809(ab)
- Oldfield, EH, 839(ab)
- Olea, E, 816(ab), 942(ab)
- O'Leary, DH, 1892
- Oliverio, R, 889(ab)
- Ollinger, JM, 736(ab)
- Olson, DM, 896(ab)
- Oluwoli, S, 890(ab)
- Ong, RL, 813(ab)
- Ono, S, 902(ab)
- Ono, Y, 830(ab)
- Oonuma, N, 858(ab)
- Oosterlinck, A, 871(ab), 1992
- O'Rear, J, 1616
- Orellana, P, 942(ab), 963(ab)
- Oria, R, 1424
- Oriuchi, N, 895(ab)
- Orlandi, C, 773(ab), 787(ab), 792(ab)
- Ornish, D, 845(ab)
- Orth, F, 910(ab)
- Oshima, M, 458
- Oster, ZH, 165, 831(ab)
- Ostrzega, E, 780(ab), 837(ab)
- Oswald, SG, 1321
- Oswald, WM, 265, 1135
- Otani, H, 859(ab)
- Otsuka, M, 802(ab)
- Otsuka, S, 866(ab)
- Otsuki, H, 792(ab), 1676
- Ott, RJ, 766, 813(ab)
- Ottaviani, M, 898(ab)
- Otto, CA, 930(ab), 932(ab)
- O'Tuama, L, 838(ab)
- Owens, ES, 1676
- Ouwunwanne, A, 921(ab), 968(ab)
- Ozzello, L, 819(ab)
- Paakkinen, S, 1332
- Paans, AMJ, 789(ab)
- Paas, M, 845(ab)
- Pablo, J, 761(ab)
- Pabst, H-W, 531
- Pace, L, 1966
- Pacifici, R, 774(ab)
- Paczolt, E, 817(ab)
- Paczolt, EA, 782(ab), 794(ab)
- Paik, CH, 832(ab), 940(ab), 1693
- Pak, K, 787(ab)
- Pak, KY, 793(ab), 859(ab), 901(ab), 906(ab), 934(ab)
- Palac, RT, 1172, 1182
- Palestro, C, 1445
- Palestro, CJ, 737(ab), 754(ab), 785(ab), 804(ab), 815(ab)
- Palevsky, HI, 733(ab)
- Palinke, T, 935(ab)
- Palma, J, 787(ab)
- Palme, DF, 826(ab), 906(ab)
- Palmer, E, 734(ab)
- Palmer, EL, 556
- Palmer, MR, 761(ab)
- Pan, M, 924(ab)
- Pan, M-L, 833(ab), 883(ab), 924(ab)
- Pan, S, 88, 731(ab), 803(ab), 830(ab), 834(ab)
- Papapoulos, SE, 775(ab)
- Pappas, D, 886(ab)
- Pappatta, S, 897(ab)
- Parikh, SR, 888(ab)
- Paris, E, 909(ab)
- Park, CH, 856(ab), 858(ab), 942(ab)
- Park, HM, 751(ab)
- Parker, BA, 778(ab)
- Parker, JA, 855(ab), 870(ab), 874(ab)
- Parker, RD, 731(ab)
- Parkey, R, 770(ab)
- Parkey, RW, 638, 902(ab)
- Parkin, A, 45
- Parkinson, D, 804(ab), 822(ab)
- Parviaainen, S, 892(ab)
- Pascal, S, 772(ab), 802(ab)
- Pascual, J, 967(ab)
- Passeri, A, 880(ab)
- Patel, BA, 827(ab), 888(ab), 933(ab)
- Patel, D, 789(ab)
- Patel, N, 754(ab)
- Paterson, W, 812(ab)
- Patlak, CS, 899(ab)
- Patterson, J, 2063(le)
- Patterson, RE, 796(ab)
- Pauwels, EKJ, 769(ab), 775(ab), 889(ab), 2017
- Pauwels, S, 815(ab), 929(ab)
- Pavel, DG, 816(ab), 942(ab), 963(ab)
- Pavia, D, 744(ab)
- Pavia, J, 1470
- Pavlosky, WF, 1627
- Pawlak-Byczkowska, EJ, 828(ab)
- Pawlowska, TR, 1636
- Pawlyk, D, 826(ab), 962(ab)
- Payne, JK, 742(ab)
- Peacock, WJ, 896(ab)
- Peake, G, 772(ab)
- Peake, J, 936(ab)
- Pearlson, G, 731(ab)
- Pearson, VD, 1737(le)
- Pelizzari, CA, 777(ab)
- Pellikka, PA, 801(ab)
- Penney, BC, 755(ab), 756(ab), 816(ab), 835(ab), 876(ab), 881(ab), 1666
- Pepys, MB, 847(ab)
- Perentesis, P, 320
- Perlman, SB, 745(ab), 965(ab)
- Perlmutter, AD, 799(ab)
- Perlmutter, M, 761(ab)
- Perlmutter, MM, 752(ab)
- Perri, JL, 794(ab)
- Perry, DJ, 791(ab)
- Perry, JR, 497, 755(ab), 756(ab), 835(ab)
- Peters, AM, 738(ab), 784(ab), 841(ab), 842(ab)
- Peters, T, 839(ab)
- Petersen, M, 2063(le)
- Petersen, RK, 796(ab)
- Peterson, G, 925(ab)
- Peterson, M, 255
- Petry, NA, 895(ab)
- Petry, NS, 860(ab)
- Pettavel, J, 1646
- Peycelon, P, 295
- Phaneuf, DC, 759(ab)
- Phelps, ME, 359, 735(ab), 752(ab), 761(ab), 791(ab), 801(ab), 824(ab), 838(ab), 846(ab), 863(ab), 867(ab), 879(ab), 896(ab), 1507
- Philippe, L, 418
- Phillips, P, 838(ab)
- Phillips, RA, 1445
- Phillips, RKS, 748(ab)
- Phillips, SF, 764(ab)
- Phillips, WJ, 764(ab)
- Phillips, WT, 1737(le)
- Philpot, M, 895(ab)
- Philpot, GW, 763(ab)
- Piager, B, 766(ab)
- Picard, M, 301, 599
- Pich, S, 757(ab)
- Piepsz, A, 798(ab), 915(ab), 966(ab), 1337, 1825, 1982
- Piera, C, 1470
- Piers, DA, 605, 1219
- Piketty, C, 855(ab)
- Pilcher, G, 773(ab)
- Pilcher, GD, 937(ab)
- Pillai, MRA, 832(ab), 938(ab), 939(ab)
- Pinney, KG, 928(ab)
- Piotrowski, B, 886(ab)
- Pippin, JJ, 288
- Pisani, TL, 733(ab), 767(ab), 932(ab)
- Pistochi, E, 908(ab)
- Piwnica-Worms, D, 757(ab), 938(ab)
- Rabinovitch, M, 810(ab)
- Rabito, CA, 912(ab), 942(ab)
- Radosevich, JA, 827(ab)
- Radtke, RA, 752(ab)
- Rafael, JA, 744(ab)
- Raffel, D, 797(ab)
- Raffel, DM, 1211
- Raftery, EB, 868(ab)
- Rahimtoola, SH, 821(ab)
- Raichle, ME, 791(ab), 901(ab)
- Rajagopalan, R, 937(ab)
- Rajfer, J, 967(ab)
- Rall, B, 739(ab)
- Ram, S, 783(ab), 968(ab)
- Ramanna, L, 734(ab), 844(ab), 853(ab), 915(ab)
- Ramos-Cabatian, A, 1737(le)
- Rancurel, G, 781(ab)
- Ranganath, MV, 880(ab)
- Ranger, NT, 1056
- Rango, M, 811(ab), 898(ab)
- Ransom, RW, 923(ab)
- Rao, H, 564
- Rao, S, 855(ab)
- Rao, TN, 743(ab), 933(ab), 940(ab)
- Rapoport, SI, 771(ab), 928(ab), 1386
- Rasey, JS, 194, 342, 735(ab), 789(ab), 814(ab)
- Ratib, O, 838(ab)
- Ratiiff, B, 779(ab)
- Raubitshek, A, 672
- Rauch, A, 731(ab), 834(ab)
- Raval, B, 789(ab)
- Ravert, H, 740(ab), 750(ab), 838(ab)
- Ravert, HT, 731(ab), 741(ab), 849(ab), 929(ab), 930(ab), 931(ab)
- Ray, DL, N1768
- Rayiman, RR, 892(ab)
- Raymond, GM, 873(ab)
- Raynaud, C, 731(ab), 781(ab), 810(ab), 812(ab), 877(ab)
- Razumenic, N, 772(ab)
- Rea, DW, 831(ab)
- Real, FX, 746, 809(ab)
- Reba, RC, 733(ab), 736(ab), 832(ab), 878(ab), 896(ab), 940(ab), 1079, 1693
- Reddy, N, 887(ab)
- Rees, M, 45
- Regelmann, W, 967(ab)
- Reggiani, P, 888(ab)
- Rehm, PJ, 861(ab)
- Rehm, PK, 759(ab)
- Reiber, JHC, 806(ab)
- Reiche, W, 841(ab)
- Reichmann, K, 106
- Reid, RC, 878(ab)
- Reid, RH, 812(ab), 1621
- Reidel, G, 531
- Reifenrath, C, 829(ab)
- Reijs, AEM, 806(ab)
- Reilley, J, 88, 731(ab), 762(ab), 830(ab), 834(ab)
- Reilly, J, 773(ab)
- Reiner, BI, 412
- Reiners, C, 845(ab), 886(ab)
- Reiners, CHR, 867(ab)
- Reinke, E, 935(ab)
- Reisch, J, 771(ab)
- Reitelman, C, 799(ab)
- Reivich, M, 772(ab), 781(ab), 802(ab), 811(ab), 898(ab), 965(ab), 1607
- Reker, DM, 840(ab)
- Rembisch, RA, 859(ab)
- Reno, J, 793(ab), 933(ab)
- Reno, JM, 25, 216
- Reske, SN, 791(ab), 797(ab), 805(ab), 819(ab)
- Respondek, M, 697
- Resser, K, 740(ab)

- Reubi, JC, 768(ab)
 Reuland, P, 804(ab)
 Reynolds, JC, 320, 903(ab), 906(ab), 909(ab), 915(ab), 1106, 1311, 1693
 Rhamy, R, 841(ab)
 Rhodes, CG, 808(ab)
 Ricart, MJ, 1470
 Richard, MD, 747(ab), 901(ab), 936(ab)
 Riche, D, 762(ab)
 Richman, P, 748(ab)
 Richter, KY, 969(ab)
 Riesen, A, 1235
 Rifkin, MD, 901(ab)
 Rigo, P, 791(ab), 1902
 Rigo, PM, 1018
 Rilinger, N, 748(ab)
 Ritchie, J, 769(ab)
 Ritter, W, 1235
 Ritter-Hrncirik, CA, 747(ab), 963(ab)
 Riva, P, 779(ab), 908(ab)
 Rivera, J, 912(ab)
 Rizzo, G, 869(ab)
 Roa, PS, 741(ab)
 Robb, SO, 918(ab)
 Robb, T, 765(ab)
 Robbins, MS, 937(ab)
 Robbins, T, 850(ab)
 Roberts, R, 749(ab)
 Roberts, W, 759(ab), 883(ab), 884(ab), 918(ab)
 Robertson, JM, 38
 Robinson, D, 874(ab)
 Robinson, DW, 917(ab)
 Robinson, GD, 781(ab)
 Robinson, R, 859(ab)
 Robinson, RG, 843(ab), 844(ab), 966(ab)
 Robinson, RP, 737(ab), 922(ab)
 Robinson, WL, 251
 Rocco, T, 740(ab)
 Rocco, TP, 1149
 Roddie, ME, 841(ab)
 Rodman, MS, 794(ab)
 Rodriguez, AA, 962(ab)
 Roeske, J, 777(ab)
 Roesler, H, 1960
 Roger, P, 904(ab)
 Rogers, L, 863(ab)
 Rogers, PE, 374, 935(ab)
 Rogers, VE, 873(ab)
 Rogers, WL, 777(ab)
 Rogic, M, 773(ab)
 Roland, J, 794(ab)
 Rollmann, O, 110
 Romeral, LMD, 861(ab)
 Rommer, P, 796(ab)
 Rommney, B, 124
 Roodt, A, 732(ab), 849(ab)
 Roodt, JP, 914(ab)
 Roosen, N, 895(ab)
 Ropchan, J, 894(ab)
 Rosa, C, 749(ab)
 Rose, C, 810(ab)
 Rose, P, 828(ab)
 Rosebrough, SF, 747(ab), 963(ab)
 Roselli, M, 320, 672
 Rosen, CD, 857(ab)
 Rosen, JM, 787(ab), 819(ab)
 Rosen, M, 1607
 Rosen, ST, 827(ab), 888(ab), 933(ab)
 Rosenbaum, RC, 412
 Rosenblum, M, 819(ab)
 Rosenspire, KC, 735(ab), 752(ab), 767(ab), 783(ab)
 Rosenstein, LM, 1574(le)
 Rosenstein, N, 781(ab)
 Rosenthal, MS, 875(ab)
 Rosenthal, L, 810(ab)
 Roskopf, M, 659
 Ross, C, 731(ab)
 Ross, PD, 1166, 1273
 Rossetti, C, 792(ab), 831(ab)
 Rossetti, E, 873(ab)
 Rosso, J, 746(ab)
 Roth, SC, 747(ab), 748(ab), 906(ab)
 Rotmensch, J, 777(ab), 834(ab), 883(ab)
 Rottenberg, DA, 564, 1483, 839(ab)
 Rouleau, D, 766(ab)
 Rovert, HT, 741(ab)
 Rowe, CC, 751(ab), 831(ab)
 Rowe, RW, 789(ab), 866(ab), 878(ab)
 Rowell, N, 911(ab)
 Roy, A, 181
 Royston, I, 778(ab)
 Rozanski, A, 729(ab), 740(ab), 750(ab), 1718
 Rubin, RH, 385, 805(ab), 817(ab), 889(ab), 890(ab), 1095, 1538
 Rubinstein, M, 798(ab)
 Rubinstein, M, 897(ab), 915(ab), 966(ab), 1337, 1982
 Rubinstein, MI, 843(ab)
 Ruch, J, 1079
 Ruddy, T, 760(ab), 829(ab)
 Ruether, W, 805(ab)
 Rufini, V, 769(ab)
 Ruhlmann, J, 805(ab), 856(ab)
 Ruiz, M, 756(ab)
 Rupich, R, 774(ab)
 Ruszkowski, M, 793(ab), 819(ab), 828(ab), 908(ab)
 Rusinek, H, 835(ab)
 Russell, CD, 823(ab), 943(ab), 1955, 2054
 Russell, KJ, 814(ab)
 Rust, M, 917(ab)
 Ruth, TJ, 923(ab)
 Rüther, W, 856(ab)
 Ryan, JM, 868(ab)
 Ryan, JP, 823(ab)
 Ryan, JW, 883(ab)
 Ryo, UY, 559, 836(ab), 918(ab)
 Rysavy, JA, 876(ab)
 Rytel, MW, 754(ab)
 Sabha, M, 942(ab)
 Sacker, DF, 831(ab), 1848
 Sackett, JF, 965(ab)
 Sadek, S, 921(ab), 968(ab)
 Sadlo, HB, 749(ab)
 Sadotz, B, 750(ab)
 Sadotz, B, 740(ab), 849(ab)
 Saga, T, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab)
 Sago, M, 767(ab)
 Saha, G, 861(ab)
 Saha, GB, 759(ab)
 Said, J, 915(ab)
 Saito, T, 739(ab), 762(ab)
 Saji, H, 150, 803(ab), 863(ab), 866(ab), 900(ab), 1302, 1775
 Sajjad, M, 922(ab), 1132
 Sakahara, H, 747(ab), 1311
 Sakai, K, 830(ab)
 Sakamoto, J, 809(ab)
 Sakata, K, 864(ab)
 Sakata, S, 885(ab)
 Sakharov, IV, 1686
 Sakuma, S, 458
 Salk, D, 818(ab), 819(ab)
 Salvatore, M, 51, 941(ab), 1422(le)
 Samaratunga, RC, 837(ab)
 Samejima, N, 738(ab)
 Sampathkumaran, KS, 2036
 Samuels, LD, 267
 Sanders, JA, 1412
 Sanders, WE, Jr, 1405
 Sanderson, J, 793(ab), 933(ab)
 Sandler, MP, 15, 563, 1917(le)
 Sanger, JJ, 835(ab)
 Sanderson, L, 833(ab)
 Santoro, GM, 820(ab)
 Saris, SC, 839(ab), 899(ab)
 Sarti, G, 779(ab)
 Sartori, CG, 925(ab)
 Sasaki, H, 878(ab), 917(ab)
 Sasaki, Y, 895(ab)
 Sato, N, 746(ab)
 Sato, T, 739(ab), 2012
 Sato, Y, 916(ab)
 Savage, S, 756(ab)
 Savi, A, 869(ab)
 Savino, P, 772(ab), 802(ab)
 Savoie, JC, 2063(le)
 Savolainen, S, 1546
 Savory, CG, 1321
 Sax, FL, 780(ab)
 Sayle, BA, 57
 Scassellati, GA, 908(ab)
 Schaible, TF, 787(ab)
 Russell, CD, 823(ab), 943(ab), 1955, 2054
 Schapiro, MB, 771(ab)
 Schatz, N, 772(ab)
 Scheffel, UA, 803(ab)
 Scheidler, J, 907(ab)
 Schelberg, HR, 359
 Schelbert, H, 729(ab)
 Schelbert, HR, 735(ab), 824(ab), 837(ab), 838(ab), 846(ab), 867(ab)
 Schicha, H, 842(ab), 843(ab), 903(ab)
 Schiefelbein, M, 843(ab)
 Schiepers, CW, 824(ab), 886(ab)
 Schiepers, CWJ, 821(ab)
 Schifelbein, M, 844(ab)
 Schijf, Ch, 758(ab)
 Schieler, DJ, 893(ab), 898(ab), 932(ab)
 Schlag, P, 789(ab), 910(ab), 911(ab)
 Schlemper, EO, 938(ab)
 Schlessel, JS, 1342
 Schlom, J, 320, 672
 Schlyer, D, 730(ab), 761(ab)
 Schlyer, DJ, 741(ab), 776(ab)
 Schmall, B, 928(ab)
 Schmid, U, 390
 Schmidt, RP, 836(ab)
 Schmidt, U, 798(ab), 800(ab)
 Schneidau, TA, 1079
 Schneider, RF, 940(ab)
 Schneider, V, 775(ab)
 Schnur, G, 813(ab)
 Schnur, W, 903(ab)
 Schober, O, 856(ab), 880(ab)
 Schoeps, K-O, 783(ab)
 Schoser, K, 813(ab)
 Schoukroun, C, 766(ab)
 Schraube, P, 911(ab)
 Schroder, LE, 837(ab)
 Schroeder, KW, 764(ab)
 Schröff, R, 779(ab), 933(ab)
 Schröff, RW, 25
 Schultheis, P, 847(ab)
 Schwager, M, 359, 735(ab), 767(ab), 829(ab), 837(ab), 860(ab), 862(ab), 892(ab), 930(ab)
 Schwartz, AN, 466, 784(ab)
 Schwartz, C, 843(ab)
 Schwarz, A, 904(ab)
 Schwarzkopf, R, 1278(le)
 Schweighardt, S, 748(ab)
 Schwender, SW, 849(ab), 1088
 Schwendner, SW, 768(ab)
 Schwesinger, WH, 815(ab)
 Schyler, D, 801(ab)
 Sciaccia, B, 863(ab)
 Sciaigà, R, 820(ab)
 Sciammarella, M, 873(ab)
 Sciuk, J, 856(ab)
 Scott, JA, 556
 Scott, PL, 832(ab)
 Scrimger, J, 2063(le)
 Scrimger, JW, 260
 Seabold, J, 268
 Seabold, JE, 754(ab), 1264
 Sease, D, 859(ab), 866(ab)
 Sease, DR, 865(ab)
 Sebree, L, 797(ab)
 Seccamani, E, 908(ab)
 Sechtem, U, 903(ab)
 Secter, B, 914(ab)
 Sedvall, G, 742(ab)
 Seeger, LL, 1136
 Segall, GM, 548, 1738(le)
 Sekel, R, 754(ab)
 Sekela, ME, 780(ab)
 Seki, H, 997
 Seldin, DW, 312
 Sell, TL, 420
 Senda, M, 776(ab), 782(ab), 916(ab), 961(ab), 1302
 Senokwitsch, R, 531
 Seo, IS, 732(ab)
 Seo, S, 1809
 Sephton, RG, 913(ab)
 Serafini, A, 798(ab), 841(ab), 859(ab), 915(ab), 944(ab)
 Serafini, AN, 737(ab), 748(ab), 890(ab), 921(ab), 922(ab), 1935
 Serafini, F, 911(ab)
 Sergienko, VB, 1686
 Sergott, R, 772(ab), 802(ab)
- Sér. JB, 905(ab)
 Servis, KL, 813(ab), 814(ab)
 Seto, M, 844(ab)
 Setoain, J, 1470
 Severson, AR, 857(ab)
 Sevrin, R, 1616
 Sfakianakis, CN, 841(ab)
 Sfakianakis, G, 859(ab), 890(ab), 963(ab)
 Sfakianakis, GN, 737(ab), 798(ab), 886(ab), 893(ab), 915(ab), 922(ab)
 Sfakianakis, GN, 944(ab)
 Sgouros, G, 777(ab)
 Shafer, RB, 918(ab)
 Shafique, I, 885(ab)
 Shah, A, 905(ab)
 Shaheen, OH, 174
 Sham, JST, 918(ab)
 Shankland, EG, 814(ab)
 Shankwiler, RA, 1577
 Shapiro, B, 481, 833(ab), 836(ab), 850(ab), 1476
 Sharir, T, 1657
 Sharkey, RM, 809(ab), 826(ab), 828(ab), 848(ab), 888(ab), 962(ab)
 Sharp, PF, 1134
 Shatkin, B, 165
 Shaw, SM, 920(ab)
 Shealy, D, 833(ab)
 Shearman, D, 765(ab), 795(ab), 887(ab)
 Shefer, RE, 964(ab)
 Sheldon, J, 849(ab)
 Shelton, DK, 959(ab)
 Shelton, ME, 351, 730(ab), 768(ab), 807(ab), 1843
 Shen, W, 751(ab)
 Shen, Y, 770(ab)
 Shepherd, J, 758(ab)
 Sheppstone, BJ, 1420(le)
 Sherman, CT, 838(ab)
 Sherman, PS, 733(ab), 752(ab), 767(ab), 783(ab), 930(ab), 932(ab)
 Sherwood, DF, 868(ab)
 Shewmon, DA, 896(ab)
 Shiba, K, 897(ab), 939(ab)
 Shibasaki, T, 895(ab)
 Shida, K, 802(ab)
 Shields, AF, 789(ab)
 Shih, W-J, 559, 918(ab)
 Shihab-Eldeen, A, 921(ab)
 Shimizu, K, 746(ab)
 Shimoni, A, 450
 Shin, SY, 1693
 Shinohara, M, 2042
 Shionoya, S, 358
 Shishido, F, 830(ab)
 Shiue, C, 730(ab)
 Shiue, C-Y, 753(ab), 898(ab), 932(ab)
 Shlomo, IB, 1657
 Shmerling, RH, 855(ab)
 Shnyra, AA, 66
 Shochat, D, 933(ab)
 Shooper, JD, 567
 Short, M, 808(ab), 809(ab), 908(ab)
 Short, MD, 891(ab)
 Shuke, N, 997, 844(ab), 903(ab), 909(ab), 915(ab)
 Shuler, SE, 786(ab)

- Shulgin, A, 822(ab)
 Shulkin, BL, 843(ab), 1819
 Sia, B, 751(ab), 831(ab)
 Sicat, M, 749(ab), 862(ab)
 Sicardi, AG, 749(ab)
 Siddiqui, AR, 799(ab)
 Siegel, BA, 788(ab)
 Siegel, JA, 764(ab), 782(ab), 794(ab), 960(ab)
 Siegel, ME, 821(ab), 824(ab), 886(ab)
 Siegel, R, 750(ab)
 Siffring, PA, 730(ab)
 Sigal, SL, 863(ab)
 Sigurdson, ER, 809(ab)
 Silberstein, EB, 748(ab), 774(ab), 903(ab)
 Silbiger, M, 759(ab), 883(ab), 884(ab), 918(ab)
 Silbiger, ML, 876(ab)
 Silverstein, EA, 874(ab), 888(ab)
 Simon, H, 739(ab)
 Simon, TR, 542, 861(ab)
 Simonson, RB, 778(ab)
 Simpfendorfer, CC, 759(ab)
 Simpkin, DJ, 883(ab)
 Simpson, NR, 928(ab)
 Sindelar, W, 320
 Singer, H, 731(ab)
 Singh, A, 1814
 Singh, M, 851(ab)
 Singletary, E, 819(ab)
 Sintsyn, VV, 66
 Sinusas, AJ, 756(ab), 790(ab), 1456
 Sinzinger, H, 1005
 Sirr, SA, 858(ab), 1133, 1399
 Sisson, JA, 481
 Sisson, JC, 767(ab), 884(ab), 1476
 Sivolapenko, GB, 1636
 Sjögren, H-O, 1224
 Skinner, RWS, 768(ab)
 Skrade, B, 770(ab)
 Slade, S, 778(ab)
 Slater, JB, 894(ab)
 Slichter, SJ, 629
 Slinkin, MA, 1686
 Slizofski, WJ, 1739(le)
 Sloan, G, 799(ab)
 Sloboda, R, 266
 Sloboda, RS, 836(ab)
 Smalling, RW, 846(ab)
 Smart, R, 754(ab), 764(ab), 887(ab)
 Smart, RC, 851(ab)
 Smeltzer, SL, 845(ab)
 Smith, AP, 796(ab)
 Smith, GG, 967(ab)
 Smith, GJW, 916(ab)
 Smith, GS, 771(ab)
 Smith, GT, 877(ab), 960(ab)
 Smith, H, 873(ab)
 Smith, HE, 803(ab)
 Smith, J, 836(ab)
 Smith, JJ, 941(ab)
 Smith, KF, 312
 Smith, L, 906(ab)
 Smith, Q, 838(ab)
 Smith, R, 917(ab)
 Smith, RH, 832(ab)
 Smith, T, 818(ab)
 Smith, WH, 756(ab), 790(ab), 1456
 Smitherman, TC, 542, 861(ab)
 Smits, P, 861(ab), 1723
 Smye, SW, 45
 Snape, W, 887(ab)
 Snook, D, 1636
 Snyder, AL, 771(ab)
 Soares, J, 841(ab)
 Soares, J, Jr, 916(ab)
 Sobel, BE, 837(ab), 1489, 1798
 Sobnack, R, 748(ab)
 Sobotka, PA, 1870
 Soini, I, 1332
 Sokoloff, L, 792(ab)
 Solanki, K, 823(ab)
 Solomon, H, 849(ab)
 Solomon, HF, 741(ab), 923(ab), 930(ab), 931(ab)
 Solomon, RW, 737(ab), 785(ab), 815(ab)
 Solot, G, 757(ab)
 Som, P, 831(ab), 1848
 Sondel, J, 818(ab)
 Sonnemaker, R, 786(ab)
 Sood, A, 834(ab)
 Sood, V, 1079
 Sood, VK, 940(ab)
 Soper, NDW, 1420(ie)
 Sorby, PJ, 683
 Sorgentoni, K, 731(ab), 811(ab), 834(ab)
 Sostre, S, 885(ab)
 Soucy, JP, 781(ab)
 Sowton, E, 820(ab)
 Spaulding, M, 818(ab)
 Spehl, M, 915(ab), 1337
 Speller, RD, 891(ab)
 Spence, AM, 838(ab), 911(ab)
 Spencer, P, 760(ab)
 Spencer, RP, 737(ab)
 Spicer, JA, 843(ab), 844(ab), 1281
 Spicer, KM, 872(ab)
 Spies, SM, 827(ab), 888(ab), 933(ab), 874(ab), 888(ab), 933(ab)
 Spies, WG, 827(ab), 874(ab), 888(ab), 933(ab)
 Spinelli, A, 779(ab)
 Spranzi, E, 908(ab)
 Squicciarini, SA, 829(ab)
 Srinivasan, A, 25, 793(ab), 933(ab), 940(ab)
 Srivastava, SC, 1848
 Srivastava, PC, 925(ab)
 Srivastava, SC, 787(ab), 811(ab), 890(ab), 921(ab), 923(ab), 934(ab), 935(ab)
 Stabin, M, 415, 833(ab)
 Stabin, MG, 599, 763(ab), 2002
 Stadalknik, RC, 269, 733(ab), 814(ab), 879(ab), 1519
 Stambler, BS, 870(ab)
 Stanchfield, WR, 1399
 Standke, RH, 295
 Stanley, PC, 852(ab)
 Stark, V, 833(ab), 883(ab)
 Starling, MR, 1737(ie)
 Starr, CW, 872(ab)
 Stathis, M, 803(ab)
 Stauber, RE, 814(ab), 887(ab), 890(ab), 899(ab), 908(ab), 920(ab), 935(ab), 936(ab)
- Subramanian, R, 797(ab)
 Staudacher, RS, 760(ab)
 Stedman, RJ, 936(ab)
 Stefan, H, 751(ab)
 Stehlin, JS, 25
 Stein, E, 845(ab)
 Steinberg, ME, 733(ab)
 Steiner, M, 731(ab)
 Steis, RG, 909(ab)
 Stella, A, 615
 Stephens, R, 828(ab)
 Steplewski, Z, 763(ab), 923(ab), 934(ab), 935(ab)
 Stevens, S, 828(ab)
 Stevenson, LW, 846(ab), 867(ab)
 Stewart, CA, 824(ab), 857(ab), 886(ab)
 Stewart, R, 793(ab)
 Stewart, RE, 829(ab), 850(ab), 860(ab)
 Stickney, DR, 905(ab)
 Stoehl, M, 908(ab)
 Stöcklin, G, 110, 895(ab), 1367
 Stokely, EM, 638
 Stone-Elander, S, 927(ab)
 Stoub, EW, 2029
 Strand, S-E, 722, 1224
 Strashun, A, 855(ab), 1445
 Strashun, AM, 1563
 Stratton, JR, 629
 Straub, RF, 811(ab)
 Strauss, A, 777(ab), 833(ab)
 Strauss, EB, 1111
 Strauss, HW, 301, 385, 729(ab), 734(ab), 739(ab), 740(ab), 762(ab), 797(ab), 805(ab), 817(ab), 859(ab), 868(ab), 869(ab), 889(ab), 890(ab), 901(ab), 913(ab), 917(ab), 1095, 1123, 1149, 1538, 1911
 Strauss, J, 798(ab), 841(ab), 915(ab)
 Strauss, LG, 784(ab), 789(ab), 909(ab), 910(ab), 911(ab)
 Straw, J, 787(ab)
 Stremmel, W, 798(ab)
 Stringham, LM, 1814
 Stritzke, P, 599, 785(ab)
 Stritzke, PH, 1875
 Strnat, MAP, 847(ab)
 Stroble, MB, 781(ab)
 Strother, SC, 564, 839(ab), 1483
 Stroupe, SD, 908(ab)
 Strubel, T, 773(ab)
 Strubel, TW, 937(ab)
 Stuart, DD, 1399
 Stubbs, CC, 764(ab)
 Stubbs, JB, 764(ab), 882(ab)
 Studer, A, 1646
 Stulzaft, O, 731(ab), 898(ab)
 Stumpf, MJ, 816(ab)
 Stunkard, AJ, 692
 Stuttle, AWJ, 738(ab)
 Stuyck, J, 2022
 Styles, J, 808(ab), 809(ab)
 Su, FM, 793, 849(ab)
 Subramanian, G, 659, 940(ab)
 Subramanian, K, 963(ab), 917(ab), 944(ab), 2012
 Takahashi, T, 33
 Takano, H, 767(ab)
 Takashashi, T, 770(ab)
 Takeyama, T, 997
 Takehara, Y, 258
 Takemura, Y, 923(ab)
 Takeshita, G, 897(ab)
 Takeuchi, A, 897(ab)
 Taki, J, 844(ab), 870(ab)
 Taki, S, 844(ab)
 Takishima, T, 770(ab), 917(ab), 944(ab)
 Tal, I, 874(ab)
 Talbot, JN, 855(ab)
 Tamaki, N, 718, 862(ab), 863(ab), 866(ab), 887(ab), 1302, 1775
 Tamura, K, 853(ab)
 Tan, P, 964(ab)
 Tanabe, M, 858(ab)
 Tanada, S, 150, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab), 943(ab)
 Tanaka, E, 746(ab), 870(ab), 892(ab)
 Tanaka, T(ab), A811(ab)
 Tani, A, 868(ab), 881(ab)
 Tanigaki, S, 965(ab)
 Taniguchi, M, 870(ab)
 Taren, J, 833(ab)
 Tashiro, K, 866(ab)
 Tateno, M, 895(ab)
 Tateno, Y, 866(ab), 885(ab)
 Tattanelli, M, 908(ab)
 Tatum, JL, 1257
 Taupier, MA, 886(ab)
 Tauxe, NW, 864(ab)
 Tauxe, WN, 814(ab), 887(ab), 890(ab), 905(ab)
 Tawk, TC, 761(ab)
 Taylor, A, 943(ab), 1955
 Taylor, A, Jr, 720, 823(ab)
 Taylor, AT, 743(ab)
 Taylor-Papadimitriou, J, 758(ab)
 Teal, JS, 113
 Teaster, B, 924(ab)
 Tebbe, U, 800(ab)
 Teixeira, JM, 867(ab)
 Teixeira, LR, 916(ab)
 Telepak, RJ, 1737(ie)
 Templeton, GH, 638
 Temponi, M, 390, 936(ab)
 Tenorio, L, 759(ab), 884(ab)
 Tenorio, LE, 918(ab)
 Terada, H, 897(ab)
 Teran, JL, 800(ab)
 Teras, M, 892(ab)
 Terra-Filho, M, 916(ab)
 Terui, S, 904(ab), 1198
 Tewson, T, 909(ab), 966(ab)
 Tewson, TJ, 789(ab), 928(ab)
 Thakur, ML, 747(ab), 901(ab), 936(ab)
 Theissen, P, 842(ab), 843(ab), 903(ab)
 Théroux, P, 800(ab)
 Thieme, AM, 821(ab)
 Thien, T, 1723
 Thomas, C, 879(ab)
 Thomas, DGT, 1636
 Thomas, FD, 659, 881(ab), 940(ab), 961(ab)
 Thomas, SR, 732(ab), 1117
 Thomas, WC, Jr, 842(ab)
 Thomforde, GM, 764(ab)
 Thompson, C, 806(ab)
 Thompson, CJ, 765(ab), 1056
 Thonnart, B, 820(ab)
 Thonoor, CM, 1916(ie)
 Thoolen, M, 773(ab)
 Thoolen, MJ, 787(ab)
 Thornton, B, 780(ab)

- Thorpe, H, 923(ab)
 Thurber, M, 756(ab)
 Ticheler, C, 885(ab)
 Tikofsky, RS, 599
 Tilbury, R, 909(ab), 928(ab), 966(ab)
 Tilbury, RS, 1136
 Tilyou, SM, N137, N139, N271, N279, N427, N435 N569, N987, N1139, N1141, N1435, N1579, N1761
 Tilyou, T, N11
 Timmis, AD, 820(ab)
 Tindel, NL, 753(ab)
 Tintner, R, 771(ab)
 Tirindelli, D, 779(ab)
 Titelbaum, DS, 1113
 Tjoe, M, 886(ab)
 Tobes, MC, 1476
 Todd, CEC, 1318
 Todd-Pokropek, A, 807(ab)
 Todd-Pokropek, AE, 893(ab), 963(ab)
 Togashi, M, 2042
 Toita, T, 858(ab)
 Tolman, GL, 1351
 Toman, AS, 779(ab)
 Tomitani, T, 746(ab), 776(ab)
 Tomiyoshi, K, 895(ab)
 Tompkins, RG, 889(ab), 1538
 Tonami, N, 844(ab), 870(ab), 907(ab), 997
 Tonan, AS, 758(ab)
 Tondeur, M, 798(ab), 915(ab), 966(ab), 1337, 1825
 Toney, MA, 962(ab)
 Toorongian, S, 752(ab)
 Toorongian, SA, 926(ab)
 Topitz, A, 731(ab)
 Topol, EJ, 862(ab)
 Toporoff, SJ, 845(ab)
 Toppet, V, 915(ab), 1337
 Tor, Y, 106
 Torchilin, V, 762(ab)
 Torchilin, VP, 1686
 Torizuka, K, 840(ab)
 Torizuka, T, 718
 Toyama, H, 870(ab), 897(ab)
 Tracey, KP, 914(ab)
 Treffert, JD, 2029
 Tremaine, WJ, 764(ab)
 Trentham, DE, 855(ab)
 Tresgallo, M, 863(ab)
 Treves, ST, 1176
 Triebel, JG, 542
 Troncone, L, 769(ab)
 Trout, A, 788(ab)
 Troutner, DE, 832(ab), 938(ab), 939(ab)
 Trudeau, WL, 733(ab), 879(ab)
 Trumoer, J, 538
 Trumper, J, 450
 Tsai, D, 809(ab), 850(ab)
 Tschudy, J, 797(ab)
 Tse, JW, 202
 Tsen, O, 833(ab)
 Tsui, BMW, 497, 755(ab), 756(ab), 835(ab), 882(ab), 891(ab)
 Tsuji, S, 897(ab)
 Tudor, S, 1574(lc)
 Tulchinsky, M, 733(ab), 941(ab)
 Tulip, TH, 773(ab)
 Tume, SS, 821(ab), 842(ab)
 Tune, L, 731(ab)
 Tune, LE, 731(ab)
 Tung, C, 755(ab)
 Tupper, LK, 961(ab)
 Turnbull, GL, 962(ab)
 Turner, DA, 902(ab)
 Turner, FE, 767(ab), 1182
 Turner, JH, 683
 Tweddell, AC, 818(ab)
 Tyldesley, S, 923(ab)
 Tyson, I, 759(ab), 883(ab), 884(ab)
 Tyson, IB, 918(ab)
 Tzourio, N, 781(ab), 812(ab), 877(ab)
 Uchida, H, 892(ab)
 Udeisman, R, 1420(lc)
 Uebis, R, 791(ab)
 Ueda, N, 918(ab)
 Uehara, T, 591, 739(ab), 767(ab), 901(ab), 1713
 Uematsu, S, 865(ab)
 Uematsu, S, 738(ab), 910(ab)
 Uemura, K, 830(ab), 878(ab)
 Ueno, T, 811(ab)
 Uhland, W, 826(ab)
 Ultee, ME, 778(ab), 831(ab)
 Umbrecht, G, 848(ab)
 Umezaki, N, 942(ab)
 Underwood, DA, 759(ab), 861(ab)
 Unger, B, 906(ab)
 Unger, EF, 807(ab)
 Unger, M, 905(ab)
 Unger, MW, 748(ab)
 Uno, K, 738(ab), 858(ab), 910(ab)
 Uno, Y, 838(ab)
 Urbain, JL, 795(ab)
 Vaalburg, W, 789(ab), 929(ab)
 Vacher, J, 766(ab)
 Vadhan, S, 738(ab)
 Vahabzadeh, MR, 940(ab)
 Valenzuela, GA, 764(ab)
 Valette, H, 810(ab)
 Valk, PE, 745(ab), 760(ab), 765(ab)
 Valkema, R, 775(ab)
 Vallabhajosula, S, 599, 785(ab), 856(ab), 1445
 Valle, G, 917(ab), 965(ab)
 Valois, JM, 825(ab), 877(ab)
 VanBrocklin, HF, 753(ab), 821(ab), 910(ab), 928(ab)
 van Buul, M, 780(ab)
 van Buul, MMC, 785(ab)
 Van den Abbeele, AD, 883(ab), 932(ab)
 Vander Borght, T, 815(ab), 929(ab)
 van der Hem, GK, 605, 1219
 Vanderheyden, J-L, 743(ab), 779(ab), 793(ab), 849(ab), 933(ab)
 van der Mey, AGL, 769(ab)
 van der Schoot, J, 780(ab)
 Vandevivere, J, 794(ab), 817(ab), 818(ab), 1025
 Van Dort, M, 733(ab), 859(ab)
 Van Dort, ME, 752(ab), 767(ab), 783(ab)
 van Gils, APG, 769(ab)
 Van Heertum, RL, 748(ab), 811(ab), 1018
 van Kroonenburgh, MJPG, 769(ab), 889(ab), 2017
 van Luijk, WHJ, 1219
 Van Moffaert, G, 752(ab)
 Van Nerom, C, 743(ab), 936(ab), 940(ab)
 Van Nostrand, D, 1321
 Vanoverschelde, JL, 797(ab)
 VanPachterbeke, T, 915(ab), 1337, 1982
 Vanregemorter, J, 875(ab)
 van Royen, EA, 780(ab), 781(ab), 785(ab)
 Van Thiel, DH, 814(ab), 887(ab), 890(ab)
 Van Train, D, 729(ab)
 Van Train, K, 739(ab), 750(ab), 757(ab), 795(ab), 1718
 Van Train, KF, 780(ab)
 Vantrappen, G, 795(ab)
 van Vlies, B, 780(ab)
 van Weeren, FH, 650
 Vaquer, R, 855(ab), 1445
 Vaquer, RA, 1563
 Vargas, FS, 916(ab)
 Varheyen, R, 758(ab)
 Vassiliadis, J, 834(ab)
 Vassos, A, 778(ab)
 Vaughan, ATM, 843(ab), 933(ab)
 Vaupel, P, 913(ab)
 Vazquez, S, 741(ab)
 Vecchietti, G, 779(ab)
 Vedernikov, AY, 1686
 Vega, A, 754, 804(ab)
 Vekshtein, VI, 821(ab)
 Vela, S, 2046
 Velchik, MG, 328, 692, 731(ab), 754(ab), 834(ab), 884(ab), 1106
 Ven, Hvd, 922(ab)
 Venant, P, 810(ab)
 Venkatesan, P, 779(ab), 793(ab)
 Vera, DR, 733(ab), 814(ab), 879(ab), 1519
 Verani, MS, 749(ab), 760(ab), 780(ab), 1405
 Verba, J, 894(ab)
 Verbeeten, B, 781(ab)
 Verbruggen, A, 743(ab), 936(ab), 940(ab), 2022
 Verhagen, A, 929(ab)
 Verhoye, CM, 879(ab)
 Verreault, J, 117
 Verrey, B, 766(ab)
 Verstraeten, F, 798(ab), 1825
 Verweij, A, 806(ab)
 Vessella, RL, 826(ab), 906(ab)
 Vester, EG, 829(ab)
 Veyre, A, 295, 865(ab)
- Walsh, RA, 792(ab)
 Waltman, A, 734(ab)
 Wang, F, 700
 Wang, L, 851(ab)
 Wang, S-C, 840(ab)
 Wang, SJ, 871(ab), 1708
 Wang, TST, 787(ab), 819(ab), 936(ab)
 Ware, RW, 1737(lc)
 Wasie, T, 890(ab)
 Washburn, LC, 763(ab), 935(ab)
 Waschnich, RD, 1166, 1273
 Watanabe, H, 824(ab)
 Watanabe, K, 157, 337, 1101
 Watanabe, M, 796(ab)
 Watanabe, T, 737(ab)
 Watanabe, Y, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
 Volkman, R, 858(ab)
 Volkow, N, 741(ab), 771(ab), 898(ab)
 Volkow, ND, 730(ab), 761(ab), 801(ab), 830(ab), 831(ab), 898(ab)
 Volpe, M, 51, 941(ab)
 von Eschenbach, A, 836(ab)
 von Rensburg, AJ, 914(ab)
 Voorhees, WD, 848(ab)
 Vorne, M, 1332
 Vorstman, B, 841(ab)
 Vosberg, H, 829(ab)
 Voth, E, 757(ab), 800(ab)
 Vowden, P, 45
 Vuletic, T, 765(ab)
 Vyska, K, 798(ab), 800(ab)
 Wackers, FJ, 770(ab), 800(ab), 863(ab)
 Wackers, FJT, 301
 Waddington, W, 808(ab), 809(ab), 908(ab)
 Waddington, WA, 891(ab)
 Wagner, H, Jr, 838(ab)
 Wagner, HN, Jr, 731(ab), 740(ab), 741(ab), 750(ab), 803(ab), 816(ab), 849(ab), 885(ab), 929(ab), 930(ab), 931(ab), N1283
 Wagner, JG, 815(ab)
 Wagner, RH, 1577, 1870
 Wahl, RL, 60, 759(ab), 777(ab), 793(ab), 815(ab), 832(ab), 847(ab), 850(ab), 884(ab), 912(ab)
 Wahner, HW, 1918
 Wakita, K, 783(ab), 866(ab)
 Walker, BS, 542, 861(ab)
 Walker, KZ, 683
 Walker, MR, 933(ab)
 Walker, PJ, 872(ab)
 Walker-Andrews, S, 836(ab)
 Wall, RM, 312
 Wallace, S, 901(ab), 1012
 Wallach, SM, 937(ab)
 Wallis, JW, 781(ab), 808(ab), 834(ab), 2036
 Walovitch, RC, 792(ab), 870(ab), 1892, 1902
 Walroth, J, 873(ab)
 Walsh, MN, 837(ab), 1489, 1798
 Walsh, R, 860(ab)

- Wernicke, PG, 843(ab)
 Wernovsky, G, 1176
 Wessels, BW, 777(ab),
 826(ab), 827(ab)
 Wester, DW, 940(ab)
 Wetzel, E, 910(ab)
 White, DL, 968(ab)
 White, JA, 805(ab)
 White, M, 760(ab)
 White, TA, 892(ab)
 White DL, 840(ab)
 Widén, L, 927(ab)
 Wiebe, LI, 202
 Wieland, DM, 733(ab),
 735(ab), 752(ab), 767(ab),
 783(ab), 859(ab), 929(ab)
 Wiens, L, 814(ab)
 Wierenga, RA, 789(ab)
 Wierzbinski, B, 918(ab)
 Wiese, H, 1278(ie)
 Wijnhoven, GPJ, 650
 Wijns, W, 797(ab)
 Wilbur, DS, 25, 216,
 793(ab), 832(ab), 924(ab),
 932(ab)
 Wilkening, D, 793(ab)
 Wilkinson, D, 45
 Wilkinson, R, 385, 1095
 Wilkinson, RA, 805(ab),
 889(ab), 890(ab), 913(ab),
 917(ab), 1538
 Willerson, JT, 770(ab),
 810(ab)
 Williams, A, 1814
 Williams, CC, 837(ab)
 Williams, CM, 842(ab),
 1916(ie)
 Williams, JH, Jr, 1531
 Williams, KA, 788(ab),
 868(ab)
 Williams, LE, 1373
 Williams, SJ, 1892
 Wilson, A, 838(ab)
 Wilson, AA, 731(ab),
 740(ab), 741(ab), 750(ab),
 849(ab), 930(ab), 931(ab),
 929
 Wilson, AF, 1531
 Wilson, DG, 914(ab)
 Wilson, HH, 852(ab)
 Wilson, MA, 965(ab)
 Wilson, PD, 731(ab)
 Wilson, RA, 767(ab), 1172
 Winker, KH, 804(ab)
 Winkler, C, N1765
 Winzelberg, GC, 419
 Wiseman, C, 813(ab)
 Wishart, J, 765(ab), 795(ab),
 887(ab)
 Wissing, JR, 227
 Witaniowski, LS, 961(ab)
 Witherspoon, LR, 786(ab),
 1571
 Withiam, M, 934(ab)
 Witsenboer, TJ, 650
 Włodkowski, T, 748(ab)
 Wolf, AP, 730(ab), 741(ab),
 753(ab), 761(ab), 771(ab),
 776(ab), 782(ab), 783(ab),
 801(ab), 821(ab), 898(ab),
 932(ab)
 Wolf, F, 751(ab)
 Wolf, W, 813(ab), 814(ab)
 Wolfangel, RG, 811(ab)
 Wolfstein, I, 768(ab)
 Wollenhaupt, J, 842(ab)
 Wong, C, 739(ab), 757(ab),
 795(ab)
 Wong, DF, 731(ab), 741(ab),
 930(ab)
 Wong, JYC, 1373
 Wong, LF, 845(ab)
 Wong, WH, 880(ab), 964(ab)
 Wood, MJ, 968(ab)
 Woodhouse, C, 793(ab)
 Woodhouse, CS, 25
 Woodle, ES, 1519
 Woods, M, 793(ab)
 Woods, SD, 735(ab),
 789(ab), 873(ab)
 Woodward, WR, 1182
 Woolfenden, JM, 891(ab)
 Wooten, WW, 720
 Wootton, R, 847(ab)
 Worth, RM, 751(ab)
 Woulfe, S, 773(ab)
 Woulfe, SR, 937(ab)
 Wright, DC, 839(ab),
 899(ab)
 Wright, SD, 852(ab)
 Wu, J-C, 1708
 Wu, LC, 871(ab), 1708
 Xia, N, 861(ab)
 Yacoub, T, 968(ab)
 Yagyu, T, 783(ab)
 Yamada, K, 902(ab)
 Yamada, L, 1616
 Yamada, M, 792(ab),
 805(ab), 878(ab), 943(ab)
 Yamada, N, 921(ab)
 Yamada, S, 902(ab)
 Yamada, T, 862(ab)
 Yamagishi, H, 866(ab)
 Yamaguchi, K, 33
 Yamamoto, H, 904(ab),
 1198
 Yamamoto, K, 887(ab)
 Yamamoto, M, 746(ab)
 Yamamoto, S, 1464
 Yamamoto, YL, 913(ab)
 Yamasaki, T, 866(ab),
 892(ab)
 Yamashita, K, 863(ab),
 866(ab), 1302, 1775
 Yamashita, M, 824(ab),
 866(ab)
 Yamashita, T, 746(ab),
 892(ab)
 Yamazaki, K, 738(ab)
 Yamazaki, N, 70, 864(ab)
 Yamazaki, S, 965(ab)
 Yamazaki, T, 914(ab)
 Yan, Y, 824(ab)
 Yanai, K, 741(ab)
 Yanai, M, 917(ab)
 Yang, CJC, 1264
 Yang, F, 759(ab)
 Yang, FE, 777(ab)
 Yang, L, 829(ab)
 Yang, LD, 740(ab)
 Yang, NC, 881(ab)
 Yano, T, 458
 Yano, Y, 849(ab), 932(ab)
 Yaoita, H, 739(ab)
 Yaouanq, J, 941(ab)
 Yarchoan, R, 581
 Yarmush, ML, 889(ab),
 1538
 Yasillo, NJ, 899(ab)
 Yasuda, T, 739(ab), 868(ab),
 869(ab)
 Yeatman, L, 838(ab)
 Yee, C, 796(ab)
 Yeh, SDJ, 746(ab), 809(ab)
 Yeh, SH, 871(ab), 1708
 Yen, C-K, 1702
 Yeoh, E, 765(ab)
 Yester, MV, 823(ab),
 876(ab)
 Yeung, DWC, 774(ab),
 918(ab)
 Yew, WW, 918(ab)
 Yokoyama, A, 803(ab),
 832(ab), 923(ab), 1838
 Yokoyama, K, 320, 844(ab),
 907(ab), 997, 1693
 Yonekura, Y, 150, 803(ab),
 862(ab), 863(ab), 866(ab),
 887(ab), 900(ab), 916(ab),
 923(ab), 1302, 1775, 1838,
 1977
 Yorke, ED, 777(ab)
 Yoshida, A, 862(ab)
 Yoshida, H, 508
 Yoshida, K, 865(ab), 866(ab)
 Yoshiii, F, 88, 93, 802(ab)
 Yoshikawa, E, 892(ab)
 Yoshikawa, K, 738(ab),
 813(ab), 858(ab), 910(ab)
 Yoshimoto, T, 1809
 Yoshioka, S, 33
 Yoshitake, A, 803(ab)
 Young, D, 731(ab)
 Young, H, 808(ab), 809(ab)
 Young, LT, 731(ab)
 Young, T, 741(ab)
- Yu, MD, 920(ab)
 Yuan, J, 732(ab), 965(ab)
 Yudd, AP, 811(ab)
 Yui, N, 885(ab)
 Yung, B, 774(ab)
 Zabel, PL, 1627
 Zafrir, N, 450
 Zalutsky, MR, 778(ab)
 Zankowich, R, 843(ab)
 Zanzi, I, 1342
 Zanzonico, PB, 777(ab),
 833(ab)
 Zapol, WM, 917(ab)
 Zaret, BL, 770(ab), 800(ab)
 Zasler, ND, 1032
 Zeeberg, BR, 736(ab),
 878(ab)
 Zeidler, H, 842(ab)
 Zeller, JA, 733(ab)
 Zemach, D, 538
 Zhang, Y, 940(ab)
 Zhao, XD, 756(ab)
 Zhu, JB, 797(ab), 1554
 Zhu, L, 367
 Zielinski, CC, 1005
 Zielinski, JE, 209
 Ziessman, HA, 233
 Zilbovicius, M, 812(ab)
 Zilleruelo, G, 798(ab),
 841(ab), 915(ab)
 Zilkens, KM, 805(ab)
 Zimmer, AM, 827(ab),
 874(ab), 888(ab), 933(ab)
 Zimmerman, H, 1960
 Zimmerman, R, 802(ab)
 Zimmerman, RA, 1607
 Zimmerman, RE, 599,
 806(ab)
 Zinn, KR, 791(ab)
 Zinsmeister, AR, 764(ab)
 Zito, F, 831(ab)
 Zlatkin, MB, 754(ab)
 Zoghbi, SS, 916(ab)
 Zuccalá, A, 615
 Zupanc, ML, 965(ab)
 Zurawski, VR, Jr, 904(ab)
 Zwaz, ST, 737(ab), 768(ab)

A

- Abdomen, irradiation, gastrointestinal functional disturbances.** 765ab(5)
- Abscess**
detection of focal inflammation
In-111 chemotactic peptide, 805ab(5)
scintigraphy, Ga-67 citrate and Tc-99m albumin, 385
- distribution of cell-bound activity, leukocytes, In-111 oxine and Tc-99m HM-PAO, 804ab(5)
- hemodialysis access site infection, radionuclide diagnosis, 804ab(5)
- infection of lower extremity, white blood cell scan, MRI, 856ab(5)
- infectious complications in orthopedic surgery, Tc-99m HM-PAO-labeled leukocytes, 804ab(5)
- inflammation imaging, HM-PAO-labeled leukocytes, 805ab(5)
- localization by Tc-99m monoclonal antibody, subacute and chronic inflammatory lesions, 805ab(5)
- myocardial formation, detection, In-111 leukocyte scintigraphy, 703
- potential agent for labeling leukocytes, positron-emitting copper, 920ab(5)
- subperiosteal, "cold" spot on bone scan, 857ab(5)
- Tc-99m-SnF₂ colloid kit, leukocyte labeling, preparation and evaluation, 1257
- Absorptometry**
dual-photon: *see* Dual-photon absorptiometry
single-photon, reproducibility, clinical setting, 775ab(5)
- Accelerator**, SDIO awards, N580
- Acetate**, fluoroacetate uptake and, glucose metabolic rate, 900ab(5)
- Acetazolamide**, SPECT IMP imaging, regional ischemia, 782ab(5)
- Acetylcholinesterase**, inhibitor, C-11, simple preparation, 822ab(5)
- Achalasia**, assessment and follow-up, esophageal dilation, 851ab(5)
- Acid phosphatase**, prostatic, prostatic carcinoma, 3ab(2)
- Acquired immunodeficiency syndrome (AIDS)**
apical pattern of Ga-67 lung uptake, aerosolized pentamidine, 744ab(5)
diagnostic role of nuclear medicine, 1935
HIV-positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)
- HIV-related lymphocytic alveolitis, Tc-99m DTPA lung clearance, gallium scans, 746ab(5)
- Tc-99m albumin and Ga-67 citrate, lung scanning, HIV-positive patients, 917ab(5)
- treatment of dementia complex with AZT, reversal, brain metabolic abnormalities, 581
- utility of 24-hour gallium images, acute pulmonary processes, 888ab(5)
- Adenocarcinoma**, radioimmunodetection, antibody cocktail development, 935ab(5)
- Adenomata**, low sensitivity of parathyroid

- scintigraphy, new subtraction method, detectability, 885ab(5)
- Adenosine**
infusion, comparative efficacy, dipyridamole-Tl-201 perfusion imaging, 730ab(5)
Tl-201 SPECT, ischemic heart disease, 1745ab(10)
- Adrenal glands**, occult lung metastasis of pheochromocytoma, I-131 MIBG scintigraphy, 885ab(5)
- Aerosols**
radioaerosol containment system, 1ab(2)
Tc-99m, lung ventilation scintigraphy, 744ab(5)
Tc-99m DTPA, scans, ventilator-dependent patients, 743ab(5)
Tc-99m HM-PAO, pulmonary clearance, new application, 743ab(5)
- Aging**
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
normal
CT, MR and PET, 1607
longitudinal PET, CT scans, 772ab(5)
-related reduction, nutrient hepatic blood flow, 1748ab(10)
- Alcohol**
imaging of *in vivo* chemistry, N1286
intoxication, decreased brain metabolism, 801ab(5)
Klebsiella pneumoniae osteomyelitis, three-phase radionuclide bone imaging, 1412
- Algorithms**
application of stopping criteria, iterative maximum likelihood-EM reconstruction, SPECT, 882ab(5)
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
elimination of K_i from least squares optimization, rate parameters, three-compartment model, 879ab(5)
iterative, filtered backprojection, cone beam tomography, 882ab(5)
iterative least squares reconstruction, regularization, emission tomography, 880ab(5)
myocardial perfusion tomography, 1746ab(10)
nature of background, radionuclide ventriculography, 872ab(5)
percent hypoperfused myocardium, Tl-201 SPECT, 750ab(5)
PET-MRI volume matching, evaluation, 875ab(5)
reconstruction
non-stationary SPECT image noise, 1746ab(10)
radial long-axis tomography, Tl-201 SPECT, 881ab(5)
- Alkaline phosphatase**
bone scintigraphy, stress fractures, military basic trainees, 3ab(2)
placental, antibody guided diagnosis, glioma, 1636
- Allograft**, renal, radionuclide scintigraphy, aspiration biopsy, 785ab(5)
- Alzheimer's disease**
- cerebral blood flow, multi-infarct dementia and, 772ab(5)
cerebral glucose metabolism
effect, disease severity, 965ab(5)
F-18 FDG, PET, 771ab(5)
correlation of visual symptoms, regional cerebral glucose metabolism, 772ab(5)
dementia, CT, MR and PET, 1607
F-18 deoxyglucose PET and I-123 QNB SPECT, dementia, 896ab(5)
longitudinal PET and CT scans, 772ab(5)
one year follow-up of dementia, rCBF/PET correlations, 895ab(5)
parietal hypometabolism, tissue atrophy, PET studies, 895ab(5)
quantitative analysis, Tc-99m HM-PAO SPECT, 806ab(5)
regional cerebral blood flow, SPECT, 771ab(5)
- Ambulatory cardiac monitoring device**
cardiovascular nuclear medicine, the next step, 1123
- continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
left ventricular diastolic filling, 868ab(5)
- American College of Nuclear Physicians (ACNP)**
market planning seminar, N440
petition to change 10 CFR 35, N1296
testimony on DOE 1990 budget, N1148
- American College of Physicians (ACP)**, award to David E. Kuhl, N1148
- American College of Radiology**, RVS close to implementation, Harvard study, second phase, N271
- Amino acids**
cerebral uptake, C-11 L-methionine, PET, 838ab(5)
uptake in brain, kinetic modeling approaches, 880ab(5)
- Amiodarone**, pneumonitis, Tc-99m DTPA aerosol washout rates, 916ab(5)
- Ammonia-13**, kinetics in lung, positron emission computed tomography, smokers and nonsmokers, 866ab(5)
- Amyloidosis**
diagnostic imaging, 847ab(5)
plasma turnover studies, serum amyloid P component, 847ab(5)
Tc-99m (V) DMSA uptake, 2050
- Angina**
anti-anginal agents, effects with PET, 866ab(5)
left ventricular wall motion, stress myocardial perfusion, Tc-99m MIBI, 864ab(5)
prediction of future cardiac events, dipyridamole Tl-201 SPECT, 861ab(5)
silent ischemia, significance, positive thallium stress test, 863ab(5)
- Angiocardiography, radionuclide**
first-pass iridium-191m, evaluation, ventricular function, 450
- Os-191/Ir-191m generator, silica gel, triiododecylmethylammonium chloride, 538
- pulmonary uptake of thallium-201, exercise, 788ab(5)
- Angiography, radionuclide**
alternate R-wave, 1280(lc)

Page numbers followed by ab(x) indicate abstracts and month.

Page numbers followed by (le) indicate letter.

Page numbers preceded by N indicate articles appearing in *Newsline*.

Angioplasty

blood-pool, functional assessment, total artificial heart, 1405
diagnosis of coronary artery disease, left ventricular function, 1966
first-pass
bicycle exercise, silent myocardial ischemia, 868ab(5)
treadmill exercise, 770ab(5)
imaging thrombi, improved formulation, I-123 fragment E1, 817ab(5)
left ventricular function, assisted circulation, artificial heart, 780ab(5)
left ventricular pressure-volume analysis, 420(le) quantification of amplitude images, gated radionuclide heart studies, 1393 simultaneous Tc-99m MIBI, myocardial perfusion imaging, 38 Tl-201 perfusion and, during exercise, coronary artery disease, 818ab(5)
ventriculography, percutaneous aortic balloon valvuloplasty, 867ab(5)

Angioplasty

coronary
coronary artery disease diagnosis, PET, 845ab(5)
detection of area at risk, Tc-99m RP-30, 791ab(5)
myocardial reperfusion assessment, Tc-99m isonitrile, 821ab(5)
PTCA, relief of chronic ischemia, 838ab(5)
renal artery stenosis, renal blood flow change, captopril, 841ab(5)

Angiotensin converting enzyme

diagnostic use of inhibitors, radioisotope evaluation, unilateral renal artery stenosis, 605

intrarenal plasma flow, essential hypertension, 6ab(4)

radioimmunoimaging of lung vessels, 1686

Antibodies

antigen-binding site protection, radiolabeling, higher immunoreactive fraction, 932ab(5)
anti-mouse, biodistribution, intact and Fab fragments of mAb, 847ab(5)

astatin-211-labeled, 832ab(5)

bifunctional, CEA as metabolic indicator, colon carcinoma, 905ab(5)

cocktail development, radioimmunodetection, adenocarcinoma, 935ab(5)

human anti-murine complex formation and biodistribution, cancer patients, 1311

detection, murine mAb administration, 908ab(5)

immunoglobulin complex formation, 10ab(4)

In-111 ZCE 025 monoclonal antibody, colorectal carcinoma, 906ab(5)
patients not injected with murine mAb, 1749ab(10)

para-iodophenyl conjugates, synthesis, radioiodination, 924ab(5)

labeled with radioiodine atoms, full retention, immunoreactivity, 831ab(5)

labeling, Cu-64 p-carboxalkylphenyldithiocarbazones, 848ab(5)

native and glycosylated, comparison, *in vitro* behavior, 933ab(5)

radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)

radiolabeled, kinetics, penetration into micrometastatic cell clusters, 777ab(5)

remote high level iodinations, 933ab(5)

tumor-specific mouse/human chimeric, Tc-99m

labeling, human γ 3 constant region, 934ab(5)
Antimony-118, tellurium-118 generator development, PET application, 849ab(5)
 α_1 -Antitrypsin, deficiency, comparison of V/Q and CT, 1755ab(10)
Anxiety, imaging of *in vivo* chemistry, N1288
Aorta
diagnosis of dissection, radionuclide imaging, 1727
pressure change, myocardial performance, radionuclide ventriculography, 1657
Arteriography
PET and
coronary artery disease severity, 846ab(5)
coronary artery stenosis reversal, cholesterol lowering, 845ab(5)
pulmonary, PIOPED study, N279
Artery
renal: *see* Renal artery
small vessels, NMR velocity measurements, 1753ab(10)
Arthritis
inflammatory, imaging with Tc-99m IgG, 2017 new agent for radiation synovectomy, holmium-166 FHMA, 856ab(5)
septic, lumbar facet joint, bone SPECT imaging, 1408
Arthroplasty
asymptomatic cementless hip, bone scanning, femoral component, 858ab(5)
porous coated hip, three-phase bone scan, indium white blood cell scintigraphy, 1321
Ascites, early, tumor model, 5-[I-123]iodo-2'-deoxyuridine, 882ab(5)
Asia and Oceania Congress 1988, scientific highlights, N431
Assays
noninvasive test, colonic transit in man, 764ab(5)
Whitaker test and diuresis renogram, position-dependent discrepancies, obstructive uropathy, 2ab(4)
Astatine-211
design and construction, radiochemistry facility, 968ab(5)
labeled antibodies, 832ab(5)
labeled F(ab'), fragment, immunoreactivity, tumor uptake, 778ab(5)
Astatine-211 17-alpha-astatovinyl-11-beta-methoxy-estradiol, biological behavior, 925ab(5)
Atherosclerotic lesions, imaging with In-111 IgG, iliac and femoral vessels, 817ab(5)
Atherosclerosis
cardiovascular nuclear medicine, the next step, 1123
In-111 LDL imaging, 787ab(5), 788ab(5)
localization with monoclonal antibody, 859ab(5)
radionuclide imaging, nonspecific polyclonal immunoglobulin G, 1095
renal artery stenosis, outcome of treatment, quantitative renography, 1946
Atomic Energy Control Board (AECB), phase I of cancer cluster study, N1147
Atrial natriuretic peptide, glomerular filtration rate, essential hypertension, 941ab(5)
Attenuation correction
compensation for cone beam SPECT, maximum likelihood reconstruction, 881ab(5)
dual energy, optimum energies, SPECT, 5ab(2)
emission and transmission SPECT data combination, 835ab(5)
esophageal transit scintigraphy, effect of projection, 850ab(5)
left anterior oblique projection, peak-to-scatter ratio, gastric emptying, 233
multiresolution method, PET, 880ab(5)
nonuniform cardiac SPECT imaging, 497
heart SPECT, iterated radial post correction method, 870ab(5)
PET, application, masked orbiting transmission source, 1056
spectral attenuation ciphers, Tl-201 paradigm, 1744ab(10)
thallium SPECT, differential attenuation, thallium photons, 1746ab(10)
three-dimensional coefficients, distribution for SPECT, chest, 128le
Tl-201 myocardial tomography, solution, inferior wall attenuation, 398
whole-body PET, adaptive filtering, transmission profiles, 1751ab(10)
Autoradiography
differential intratumor localization, two monoclonal antibodies, mice bearing transplantable human tumors, 1758ab(10)
dual-isotope, quantitative difference mapping, 874ab(5)
dual-tracer, Tl-201 and radioiodinated fatty acid, cardiomyopathy, 80
dynamic PET and, tracer arrival delay correction, cerebral blood flow, 1069
estimation of LDL catabolic sites, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
[I-123]- and [I-125]-3-iodo-MK-801, NMDA receptor-ion channel complex, 923ab(5)
influence of antibody protein dose, antibody distribution, human tumor xenografts, 759ab(5)
L6 binding sites, 1754ab(10)
oxygen-15, realtime correction for deadtime, PET, 878ab(5)
quantitative lesion to normal bone uptake ratios, skeletal radiopharmaceuticals, 920ab(5)
radiolabeled proteins, In-111, 889ab(5), 1538
radiolabeled monoclonal antibodies, variations in absorbed dose, murine-human xenografts, 777ab(5)
rate of valine incorporation into proteins, brain tumor model, 913ab(5)
Tc-99m D,L-HM-PAO comparison, I-125 IMP, 938ab(5)
Tl-201, estimation, tumor and normal organ flow, 913ab(5)
tumor-associated antigens, malignant melanoma, 906ab(5)
Avidin
biotin conjugation to antibody, amplification, tumor targeting, 832ab(5)
rapid blood clearance, biotinylated IgG, 66
3'-Azido-2',3'-dideoxythymidine, reversal of brain metabolic abnormalities, treatment, AIDS dementia complex, 581

B

Basal ganglia, imaging, iodine-123 IBZM, 731ab(5)

Benzamides, iodine-substituted, high affinity, SPECT, 803ab(5)

Berson-Yalow Award, Robert C. Stadnik, excellence, radioassay, N994

Bile
 elimination, Tc-99m 1,1,1-tri(5-methylsalicylaldiminomethyl)ethane, 937ab(5)
 salts, evaluation, blind loop syndrome, 962ab(5)

Bile duct, portasystemic shunt fraction quantification, I-123 IMP, 1702

Biotin
 conjugation to antibody, amplification, tumor targeting, 832ab(5)
 streptavidin and
 monoclonal antibody radiolabeling, 832ab(5)
 radioimmunotargeting of tumor, 819ab(5)

Bismuth-212, labeled antibody, human cancer peritoneal xenografts, 778ab(5)

Bladder
 artifact correction, hip SPECT, 857ab(5)
 estimation of Bremsstrahlung radiation dose, 1373
 permeability to water, assessment, tritiated water, 2ab(4)
 radiation dose to wall, 2-[F-18]-fluoro-2-deoxy-D-glucose, 1747ab(10)

Blood
 automated sampler, high count rate, 745ab(5)
 levels of TI-201, reversible myocardial defects, 1172
 rapid clearance of biotinylated IgG, after avidin infusion, 66
 whole, cyclosporine concentrations, radioimmunoassays, 786ab(5)

Blood-brain barrier, integrity under MRI conditions, Gd-DTPA and In-DTPA-IgG brain uptake, 839ab(5)

Blood flow
 abnormal patterns in dementia, cerebral atrophy, Tc-99m HM-PAO SPECT, 896ab(5)
 accelerated glucose utilization, ischemic myocardium, quantitative PET, 867ab(5)

brain
 amino acid uptake, kinetic modeling approaches, 880ab(5)
 congenital dysphasia, Tc-99m HM-PAO SPECT, 1825
 realtime correction for deadtime, PET, 878ab(5)
 Tc-99m ECD, kinetics and biodistribution, 599
 Tc-99m *p*-halophenethyl diaminodithiol analogs, 939ab(5)
 central area of cerebral infarcts, Xe-133, I-123 isopropylodoamphetamine tomography, 781ab(5)

cerebral
 activation studies, I-123 iodoamphetamine, 811ab(5)
 acute ischemic stroke, SPECT, 781ab(5)
 Alzheimer's disease, multi-infarct dementia, 772ab(5)
 Alzheimer's disease, SPECT, 771ab(5)
 Alzheimer-type dementia, PET correlations, 895ab(5)
 arterial dispersion time constant, PET, 900ab(5)
 comparative study, PET, 157
 copper-labeled-PTSM, PET, 791ab(5)
 critical thresholds, SPECT, 337
 cytoarchitectural pattern, SQ 32097, 1751ab(10)
 drug abusers, SPECT, 1ab(11)
 dynamic SPECT, four-headed gamma camera, 792ab(5)
 I-123 IMP, normal subjects, 1753ab(10)

interictal and ictal SPECT, seizure focus localization, 751ab(5)
 O-15 and C-11 butanol, PET, 901ab(5)
 on-line plasma separation, PET, 791ab(5)
 Parkinson's disease, I-123 IMP SPECT, 830ab(5)
 post-ictal, diagnostic patterns, 751ab(5)
 Tc-99m ECD, microspheres, 792ab(5)
 tracer arrival delay correction,
 autoradiography and dynamic PET, 1069
 validity of microsphere model, I-123 IMP, 878ab(5)
 volume comparison, capillary transit time, 792ab(5)
 Xe-133 SPECT and Tc-99m HMPAO uptake, dedicated brain imaging device, 1752ab(10)
 cerebral perfusion imaging with Tc-99m HM-PAO, brain death, central nervous system injury, 1627
 cerebral perfusion studies, Tc-99m D,L-CB-PAO, 831ab(5)
 combined CBF/CBV SPECT study, recent and old strokes, 897ab(5)
 corpora cavernosa, radioisotope penile plethysmography, early tumescence, 466
 effects of anti-anginal agents, PET, 866ab(5)
 evaluation of cerebral perfusion, violent sexual aggression, 812ab(5)
 focal cerebral ischemia, Tc-99m HM-PAO, 781ab(5)
 following radiation, lung vascular permeability, 852ab(5)
 forearm, Tc-99m human serum albumin, after brachial arteriotomy, 45
 head trauma, panic attacks, Tc-99m D,L-HM-PAO, 965ab(5)
 hepatic, nutrients, age-related reduction, 1748ab(10)
 improved routine synthesis, O-15 butanol, PET, 927ab(5)
 intrarenal, essential hypertension, angiotensin converting enzyme, 6ab(4)
 kinetics of copper-PTSM in heart, 1843
 localization of seizure foci, Tc-99m HM-PAO, interictal and immediate postictal SPECT, 831ab(5)
 measurement of capillary permeability, small solutes, 842ab(5)
 measurement of functional hepatic mass, Tc-99m galactosyl neoglycoalbumin, 814ab(5)
 method to outline myocardium, single diffusible tracer, 775ab(5)
 microsphere-like retention in heart, copper-PTSM, PET, 768ab(5)
 microspheres, Cu(PTSM) localization, dog heart and kidney, 848ab(5)
 myocardial
 accuracy of quantitative measurements, rubidium-82 and PET, 807ab(5)
 DMIP uptake, reperfused myocardium, 797ab(5)
 isosorbide dinitrate, dynamic PET, 866ab(5)
 myocardial infarction, dynamic PET, 945ab(5)
 new quantitation method, 808ab(5)
 O-15 water, novel mathematical approach, 825ab(5)
 O-15 water, PET, 807ab(5)
 penile
 male impotence, non-invasive technique, 784ab(5)
 radioisotope plethysmography, 784ab(5)
 primate brain, single-pass extraction, I-123 amines, 901ab(5)
 regional, copper-PTSM and PET measurements, 807ab(5)
 regional cerebral, preliminary kinetics, SQ32097, 792ab(5)
 regional pulmonary perfusion, heart-lung transplantation, 1297
 renal
 captopril, angioplasty in renal artery stenosis, 841ab(5)
 hypertension, extracorporeal shock wave lithotripsy, 4ab(11)
 hypertension, lithotripsy complications, 842ab(5)
 oxygen-15 water, PET, 824ab(5)
 renovascular hypertension, captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
 right-to-left shunting, left superior vena cava, perfusion lung scintigraphy, 412
 shunt size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
 subcutaneous, dialysate sodium concentration, skeletal muscle, 4ab(4)
 temporal lobe epilepsy, presurgical evaluation, Xe-133 SPECT and Tc-99m HM-PAO, 896ab(5)
 tumor and normal organ, estimation, TI-201 autoradiography, 913ab(5)
 uptake of Tc-99m MIBI, coronary occlusion, reperfusion, 756ab(5)
 visualization of pulsatile lung circulation, ECG gated acquisition, 744ab(5)

Blood-pool imaging
 antibody and chelate, diester linkage, radioimmunodetection of tumor, 1693
 blood-pool radionuclide angiography, functional assessment, total artificial heart, 1405
 blood-pool subtraction, cardiac In-111 platelets, 1445
 evaluation of ventricular function, coronary artery disease, 1149
 gated cardiac, three-dimensional display, 2036
 left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
 left ventricular function, assisted circulation, artificial heart, 780ab(5)
 novel functionalized diphosphine complexes, Tc-99m, myocardial imaging, 818ab(5)
 radionuclide blood pool venography, deep vein thrombosis, 1744ab(10)
 scintigraphic LV volume calculations, technical aspects, 869ab(5)
 Tc-99m red blood cell scanning
 diagnosis, hepatic hemangioma, 815ab(5)
 labeling interference, chronic renal failure, 869ab(5)
 labeling kit, first human studies, 811ab(5)
 soft-tissue hemangioma, vascular malformation, 799ab(5)

Bone
 appearance of Paget's disease, In-111 leukocyte images, 754ab(5)
 brown tumor, false-positive TI-201 localization, 1264
 cancer radiopharmaceutical, evolution, Sm-153 EDTMP, 966ab(5)
 chronic complicated osteomyelitis, In-111 white blood cells, MRI, 754ab(5)
 correlative pediatric imaging, 15
 dental, orthopan-tomoscintigram, 835ab(5)
 detection of infected orthopedic implants, Tc-99m MDP and WBC, Ga-67 scans, 754ab(5)
 diagnostic accuracy of skeletal infection, blood-pool sign, gallium scintiscan, 774ab(5)

- dual-energy radiography, comparison, quantitative computed tomography, 774ab(5)
- extended x-ray absorption fine structure, technetium and rhenium diphosphonates, 732ab(5)
- imaging agents, Tc-99m label, radiation absorbed dose, 1117
- infectious complications in orthopedic surgery, Tc-99m HM-PAO-labeled leukocytes, 804ab(5)
- inflammation imaging, HM-PAO labeled leukocytes, anti-granulocyte-antibody, 805ab(5)
- In-111 white blood cell scintigraphy, three-phase bone scintigraphy, pedal osteomyelitis in diabetics, 753ab(5)
- joint diseases and, Tc-99m granulocytes, 1743ab(10)
- lesion to normal bone uptake ratios, skeletal radiopharmaceuticals, QARG, 920ab(5)
- mandibular grafts, utility of SPECT, 843ab(5)
- marrow doses, delivery in radioimmunotherapy, 778ab(5)
- marrow imaging, Tc-99m sulfur colloid, GM-CSF, 738ab(5)
- marrow imaging vs. blind biopsy, Hodgkin's and non-Hodgkin's lymphoma, 843ab(5)
- marrow scintigraphy, Tc-99m NCA-antibodies, breast carcinoma and malignant lymphomas, 819ab(5)
- marrow uptake and clearance, I-131 labeled antibody, 826ab(5)
- mestastases, nuclear medicine in monitoring, response to cancer treatment, 1731
- mineral content
- disease versus etiology, 1273
 - lumbar spine vertebrae, uremic patients, 774ab(5)
- precision, whole-body scanning, 775ab(5)
- scintigraphic findings, Paget's disease, 855ab(5)
- single and multi-site measurements, spine fracture probability, 1166
- mineral densitometry, HCFA's intention to deny Medicare coverage, N139
- mineral density
- non-hormonal cyclic therapy, postmenopausal osteoporosis, 774ab(5)
 - precision, total body scans, 2ab(2)
 - x-ray analyzer, reproducibility, 1750ab(10)
- mineral distribution, spinal cord injury, five years later, 857ab(5)
- marrow, effect of Sn-117mDTPA, 1754ab(10)
- nuclear magnetic imaging, systemic mastocytosis, 2046
- painful metastases
- action of 186-Re(Sn)-HEDP, 732ab(5), 837ab(5)
 - palliation, strontium-89, 2ab(2)
- pain treatment, N1293
- photopenia, clinical significance, In-111 leukocyte scintigraphy, 1749ab(10)
- prediction of osteomyelitis cure, three-phase bone and Ga-67 scans, 754ab(5)
- radionuclide scan
- detection, noncalcified splenic hemangioma, 1111
 - early detection, hip fractures, 843ab(5)
 - HIV-associated myositis, 556
 - routine imaging, occult metastases, advanced melanoma, 1ab(2)
 - scan
 - acute myelofibrosis, 251
- asymptomatic cementless hip arthroplasty, 858ab(5)
- chemotherapy, hot skull, 858ab(5)
- "cold" spot, subperiosteal abscess, 857ab(5)
- hot kidney, cancer patients, 858ab(5)
- prostate specific antigen, prostate cancer follow-up, 9ab(4)
- significance of abnormalities, no underlying malignancy, 856ab(5)
- scintigraphy
- diagnosis, sacral fractures, 959ab(5)
 - MR and, early stage of Legg-Calve-Perthes disease, 1755ab(10)
 - MRI and radiography, sacroiliitis, 842ab(5)
 - non-ossaceous subtalar coalition, 799ab(5)
 - reflex sympathetic dystrophy, lower extremities, 856ab(5)
 - serum alkaline phosphatase, stress fractures, 3ab(2)
 - serum osteocalcin, PSA and/or PAP, 918ab(5)
 - serum osteocalcin levels, 1748ab(10)
 - SPECT, 240
- secondaries in breast cancer, 1318
- seeking radiotherapeutic agent, yttrium-90 EDTMP, 843ab(5)
- sickle cell-related infarction, nonspecificity, gallium citrate localization, 855ab(5)
- single photon absorptiometry, reproducibility, clinical setting, 775ab(5)
- SPECT
- back pain, lumbar spine surgery, 490
 - persistent back pain, lumbar spinal fusion, 1739(ab)
 - septic arthritis, lumbar facet joint, 1408
 - Tc-99m phosphonate, detection, infected hip prosthesis, 562(ab)
- three-phase scan
- indium white blood cell scintigraphy, porous coated hip arthroplasty, 1321
 - Klebsiella pneumoniae*, 1412
- tumor response to chemotherapy, ³¹P magnetic resonance spectroscopy, 813ab(5)
- Book reviews**
- An Atlas of Clinical Nuclear Medicine*, 1577
 - An Atlas of Planar and SPECT Bone Scans*, 1424
 - Anatomy and MRI of the Joints: A Multiplanar Atlas*, 1136
 - Avulsion and Stress Injuries of the Musculoskeletal System*, 2064
 - Bone Mineral Measurements by Photon Absorptiometry: Methodological Problems*, 1281
 - Cardiovascular Nuclear Medicine*, 422
 - Clinical Radioimmunomaging*, 130
 - Computed Tomography*, 130
 - Computed Tomography of the Head and Neck: Neuroradiology, Volume 3*, 1424
 - Coronary Angioplasty*, 1281
 - Correlative Imaging: Nuclear Medicine, Magnetic Resonance, Computed Tomography, Ultrasound*, 1919
 - Data for Use in Protection against External Radiation, ICRP Publication 51*, 566
 - Gastrointestinal Nuclear Imaging*, 269
 - Handbooks in Radiology Vol 6: Nuclear Medicine*, 270
 - Health Physics Annotated Bibliography*, 1424
 - Imaging in Clinical Practice*, 2065
 - Intermediate Physics for Medicine and Biology*, 2nd Ed., 1136
 - Interventional Radiology*, 1577
 - Living with Radiation: the Risk, the Promise*, 566
- Magnetic Resonance Imaging: Atlas of the Head, Neck and Spine*, 725
- Magnetic Resonance Imaging: Basic Principles*, 422
- Magnetic Resonance Imaging in Diseases of the Nervous System-An Introduction*, 566
- Magnetic Resonance of Myelin, Myelination, and Myelin Disorders*, T26B
- Modern Imaging of the Liver. Applications of Computerized Tomography, Ultrasound, Nuclear Medicine, and Magnetic Resonance Imaging*, 1577
- NCRP Report No. 100, Exposure of the U.S. Population from Diagnostic Medical Radiation*, 1741
- NCRP Report No. 101, Exposure of the U.S. Population from Occupational Radiation*, 1918
- Normal Anatomy for Multiplanar Imaging: the Trunk and Extremities, Vol. 1. Normal Anatomy for Multiplanar Imaging: Head, Neck, and Spine, Vol. 2*, 725
- Nuclear Analytical Techniques in Medicine*, 1136
- Nuclear Medicine Annual 1988*, 2064
- Principles of Radiopharmacology*, 422
- Quantitative Methods in Bone Densitometry*, 1918
- Radiobiology for the Radiologist*, 269
- Radiochemistry of Carbon, Nitrogen and Oxygen*, 1741
- Radiologic-Pathologic Correlation of Musculoskeletal Lesions*, 423
- Radiopharmacy & Radiopharmacology Yearbook*, 1281
- Ultrasonic Bioinstrumentation*, 131
- Would the Insects Inherit the Earth? And Other Subjects of Concern to Those Who Worry about Nuclear War*, 725
- Brain**
- acute cerebral damage, Tc-99m glucarate, marker, 901ab(5)
 - acute injury, early and delayed SPECT, I-123 IMP, 1751ab(10)
 - acute stroke, clinical and metabolic correlates, 898ab(5)
 - amino acid uptake, kinetic modeling approaches, 880ab(5)
 - basal ganglia imaging, 731ab(5)
 - "beam" mapping, SPECT iofetamine scans, 966ab(5)
 - benzodiazepine receptor, radioiodinated diazepam derivative, SPECT studies, 803ab(5)
 - blood-brain barrier integrity, MRI conditions, Gd-DTPA and In-DTPA-IgG uptake, 839ab(5)
 - blood flow
 - congenital dysphasia, Tc-99m HM-PAO SPECT, 1825
 - realtime correction for deadtime, PET, 878ab(5) - Tc-99m p-halophenethyl diaminodithiol analogs, 939ab(5)
 - C-11 and F-18 labeled 4-fluorodeoxyglucose, functional monoamine oxidase, 821ab(5)
 - central area of cerebral infarcts, Xe-133, I-123 isopropylidodoamphetamine tomography, 781ab(5)
 - cerebral acetate and fluoroacetate uptake, glucose metabolic rate, 900ab(5)
 - cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)

- cerebral atrophy, abnormal blood flow patterns, Tc-99m HM-PAO SPECT, 896ab(5)
- cerebral blood flow
activation studies, emission tomography, 811ab(5)
acute ischemic stroke, SPECT, 781ab(5)
Alzheimer-type dementia, PET correlations, 895ab(5)
arterial dispersion time constant, PET, 900ab(5)
comparative study, PET, 157
critical thresholds, SPECT, 337
cytoarchitectural pattern, SQ 32097, 1751ab(10)
dynamic SPECT, four-headed gamma camera, 792ab(5)
I-123 IMP, normal subjects, 1753ab(10)
O-15 and C-11 butanol, PET, 901ab(5)
Parkinson's disease, I-123 IMP SPECT, 830ab(5)
preliminary kinetics, SQ32097, 792ab(5)
tracer arrival delay correction, autoradiography and dynamic PET, 1069
validity of microsphere model, I-123 IMP, 878ab(5)
volume comparison, capillary transit time, 792ab(5)
- cerebral dopamine D-1 receptors, non-carrier-added synthesis, F-18 fluoroethyl SCH-23390, 931ab(5)
- cerebral glucose metabolism
carbon monoxide poisoning, 802ab(5)
correlation of visual symptoms, Alzheimer's disease, 772ab(5)
F-18 FDG PET, Alzheimer's disease, 771ab(5)
normals, patients with optic nerve damage, 802ab(5)
quantitative comparison, two positron emission tomographs, 1386
stress effect, N1288
uptake, thirty vs. forty-five-minute period, 899ab(5)
- cerebral ischemia, filling out phenomenon, Tc-99m HM-PAO SPECT, 591
- cerebral metabolism of L-[2-F-18]fluorotyrosine, tracer of protein synthesis, 1367
- cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
- cerebral tissues, compartmental model, 6-[F-18] fluoro-L-dopa, 735ab(5)
- characterization of D-1 dopamine receptor ligand, I-123 FISCH, 830ab(5)
- chronic cerebral infarction, biodistribution, Tc-99m ethyl cysteinate dimer, 1018
- cocaine binding, carbon-11, human and baboon, 761ab(5)
- cocaine effect, iodoamphetamine uptake, dog, 830ab(5)
- combined CBF/CBV SPECT study, recent and old strokes, 897ab(5)
- comparison of SPECT images, stereographic projection, 875ab(5)
- complex partial seizures, pathologic findings, FDG-PET and MRI, 752ab(5)
- correlative pediatric imaging, 15
- cortical circumferential profiling, 816ab(5)
- corticosteroid receptors, F-18, 821ab(5)
- craniosynostosis, I-123 IMP SPECT, 916ab(5)
- customizable volume of interest atlas, three-dimensional PET data analysis, 839ab(5)
- cystic tumor, P-32 chromic phosphate colloid, distribution, 833ab(5)
- death, determination, Tc-99m HM-PAO, 1621,
- 1627
- decreased metabolism, alcohol intoxication, 801ab(5)
- development
plasticity, PET, 801ab(5)
preliminary results, high-resolution PET scanner, 892ab(5)
- dopamine D-2 receptors
I-123 IBZM biodistribution, dosimetry, 834ab(5)
I-123 IBZM evaluation, 88
I-123 iodolisuride imaging agent, SPECT, 731ab(5)
quantification, PET, 736ab(5)
uptake of C-11 YM-09151-2, 515
- dopamine neurons, quality control procedure, 6-[F-18]fluoro-L-DOPA, 1249
- dual-energy SPECT, methods and applications, 1750ab(10)
- enhanced tumor imaging with Gd-DTPA, T1 and T2 relaxation times, MRI, 902ab(5)
- evaluation of cerebral perfusion, violent sexual aggression, 812ab(5)
- focal cerebral ischemia, Tc-99m HM-PAO, 781ab(5)
- focal epilepsy, ictal Tc-99m HM-PAO SPECT, 751ab(5)
- F-18 pipamperone synthesis, PET studies, baboon, 932ab(5)
- glioma, intravascular streaming, intracarotid infusion, 839ab(5)
- glucose and deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)
- glucose metabolism, psychiatric patients, summer affective disorders, 1752ab(10)
- head trauma, panic attacks, Tc-99m D,L-HM-PAO, 965ab(5)
- high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
- histamine H1 receptor imaging, PET, baboon, 741ab(5)
- HIV-positive encephalopathy, I-123 IMP SPECT, 811ab(5)
- HPLC injection, radiopharmaceutical purification, 923ab(5)
- human neuroblastoma nude mouse xenograft, radiolabeled MIBG uptake, 884ab(5)
- Huntington's disease
glucos consumption, PET, 771ab(5)
striatal functional impairment, PET, 762ab(5)
- I-123 cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
- I-123 IMP SPECT, children, alternating hemiplegias, 965ab(5)
- I-123 6-iododopa, potential SPECT imaging agent, 924ab(5)
- imaging agent synthesis, 4-O-(E)-iodopropenyl glucose, 3ab(11)
- N-(ω -iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, SPECT, 925ab(5)
- ischemia, redistribution phenomenon, IMP metabolism, 897ab(5)
- least-squares optimization, reconstruction filters, high resolution PET, 745ab(5)
- localization of seizure foci, Tc-99m HM-PAO, SPECT, 831ab(5)
- mapping of cerebral sigma opiate receptors, no-carrier-added synthesis, F-18 fluoropropyl preclamol, 930ab(5)
- maturity, imaging in human, I-123 IMP SPECT, 1982
- measurement of post-synaptic dopamine receptors, cocaine abusers, 730ab(5)
- measurement of tissue perfusion, Cu-64 PTSM, 1756ab(10)
- mechanism of I-125 MHTP accumulation, dopaminergic radiotracer, 761ab(5)
- metabolic and electrophysiologic manifestations, recognition memory, 894ab(5)
- minor ischemic stroke, SPECT measurement, cerebral perfusion reserve, 897ab(5)
- model for outcome-prediction, comparison, CT and HM-PAO SPECT, 895ab(5)
- multiplanar PET, long-term performance, 1378
- neural crest tumors, therapeutic potential, I-131 MIBG, 769ab(5)
- neuroblastoma
I-125 MIBG uptake, children, 474
I-131 MIBG, therapeutic use, 903ab(5)
SPECT bone studies, extremities, 858ab(5)
- neurofibromatosis, re-evaluation of Tc-99m DTPA, 915ab(5)
- neutral amino acid uptake, C-11 L-methionine PET, 838ab(5)
- nicotine binding, PET, 742ab(5)
- noninvasive functional mapping, O-15 water, PET, 141
- novel Tc-N₂S₂ complex, synthesis, characterization, 773ab(5)
- pediatric imaging, Tc-99m HM-PAO and SPECT, 1917(lc)
- perfusion
I-123 IMP imaging, schizophrenia, 1616
Tc-99m L,L-ECD, humans, 1902
Tc-99m L,L-ECD, nonhuman primates, 1892
- positioning of cortical region of interest, SPECT images, isocontour method, 877ab(5)
- primate, single-pass extraction, I-123 amines, 901ab(5)
- principal axis transformation, image registration, 776ab(5)
- quantification of HM-PAO distribution, pediatric psychiatric patients, 812ab(5)
- quantitative pH mapping, acute stroke, C-11 carbon dioxide and PET, 782ab(5)
- rat glioma model, use of C1 vs. C2, C-11 glucose, 911ab(5)
- refractory complex partial seizures, surgery candidates, I-123 HIPDM SPECT, 751ab(5)
- regional cerebral distribution, microspheres, Tc-99m ECD, 792ab(5)
- regional cerebral localization, SQ 32097, SPECT, 1ab(11)
- regional cerebral metabolic rates, fixed dephosphorylation rate, 1483
- regional comparison of lumped constants, fluorodeoxyglucose, deoxyglucose, 900ab(5)
- regional dynamics, N-isopropyl-[I-123]-p-iodoamphetamine, 150
- regional ischemia, acetazolamide SPECT IMP imaging, 782ab(5)
- residual or recurrent tumor detection, F-18 FDG PET, Posicam 6.5 camera, 909ab(5), 966ab(5)
- reversal of metabolic abnormalities, AIDS dementia treatment, AZT, 581
- right hemisphere involvement, mescaline-induced psychosis, 812ab(5)
- seizure focus localization, interictal and ictal SPECT, cerebral blood flow, 751ab(5)
- serotonin S-2 receptors
mapping and SPECT, baboon, 741ab(5)
no-carrier-added synthesis, F-18 fluoroethylketanserin, 822ab(5)

- SPECT**
 3-[I-123]iodo- α -methyltyrosine, PET validation, 895ab(5)
 imaging characteristics, ASPECT, 796ab(5)
 neonates, 915ab(5)
 Tc-99m HM-PAO, congenital dysphasia, 798ab(5)
SPECT in neonates, 1337
stage IV neuroblastoma, Tc-99m and I-131 monoclonal antibody, 904ab(5)
states, metabolic characterization, partial sensory limitation, 899ab(5)
stereotactic method, anatomical mapping, PET, 961ab(5)
structure-activity relationships, metal-labeled perfusion tracers, 742ab(5)
subacute cerebral infarct, discordance, I-123 IMP and Tc-99m HM-PAO, 1752ab(10)
synthesis and biodistribution, F-18 DFPA, 928ab(5)
synthesis and biological evaluation, Tc-99m bis(aminoethanethiol), 939ab(5)
Tc-99m D,L-CB-PAO, new tracer, cerebral perfusion studies, 831ab(5)
Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, NMR techniques, 106
Tc-99m ECD
 metabolism in rat, 743ab(5)
 new imaging agent, kinetics and biodistribution, 599
Tc-99m HM-PAO SPECT
 children, 966ab(5)
 3D region of interest analysis, 961ab(5)
Tc-99m PAO, new cerebral perfusion agent, 742ab(5)
temporal changes in accumulation, *N*-isopropyl-p-iodoamphetamine, lung clearance, 1977
temporal lobe epilepsy
 diagnostic patterns, post-ictal cerebral blood flow, 751ab(5)
 presurgical evaluation, Xe-133 SPECT and Tc-99m HMPAO, 896ab(5)
theoretical effects of radioligand diffusional gradients, neuroreceptor distribution, 878ab(5)
three-dimensional imaging
 brain phantom, ECT applications, 851ab(5)
 high-resolution PET scanner, 765ab(5)
 I-123 IMP, CT and MRI comparisons, 961ab(5)
 MR image data, 902ab(5)
three-dimensional visualization, structure-function relationships, 1747ab(10)
tissue atrophy and parietal hypometabolism, Alzheimer's disease, PET studies, 895ab(5)
tomographic mapping of kinetic rate constants, I-123 IMP, dynamic SPECT, 805ab(5)
traumatic injury, visual cortex metabolism, affected arm movement, 965ab(5)
tumor model, valine incorporation into proteins, autoradiography, 913ab(5)
tumors
 dexamethasone effect, extracellular space, 899ab(5)
FDG-PET, 2ab(11)
I-123 iodo- α -methyl tyrosine, SPECT, 110
kinetic rate constants, F-18 fluorodeoxyglucose, 900ab(5)
monitoring of response to cancer treatment, 1731
neuropsychiatric disorders evaluation, PET, CT and MRI, 1589
protein synthesis, C-11 L-methionine, 910ab(5)
- Tl-201 and I-123 IMP SPECT, F-18 FDG**
 PET, 895ab(5)
Tl-201 SPECT, 913ab(5)
two-compartment Rb-82/PET model, 839ab(5)
volume, tomography of Tc-99m D,L-HMPAO, 1752ab(10)
whole-body multidetector SPECT, variable aperture, 796ab(5)
- Breast**
carcinoma: *see* Carcinoma, breast
bone metastases
 improved clinical response, strontium-89, 843ab(5)
 palliative therapy, strontium-89, 836ab(5)
cancer
 bone secondaries, solitary metastasis, 1318
 detection, imageable estradiol, 844ab(5)
 detection, In-111 GYK-DTPA-B7.2.3 monoclonal antibody, 819ab(5)
 detection, In-111 monoclonal antibody B7.2.3, 2ab(2)
 epirubicin application schemes, radionuclide ventriculography, 867ab(5)
 simplified lymphoscintigraphic technique, 1198, 904ab(5)
 milk, excretion of radioiodine, 124, 127(1e)
 16 α -substituted 21-[F-18]fluoro-(19-nor)-progesterones, receptor binding ligands, PET, 929ab(5)
Bremsstrahlung, radiation dose, measurement and estimation, 1373
Br ϕ HBED, improved bifunctional chelate, radiolabeling of antibodies, 763ab(5)
Bromine-76 bromolisuride, cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
Bromine-75 6-bromo-m-tyrosine, tracer for CNS dopamine, synthesis, evaluation, 924ab(5)
Bromine-80m halodeoxyuridines, Auger electron radiotherapy, intraperitoneal cancer, 833ab(5)
Bronchitis, pulmonary mucociliary transport, FDG powder inhalation, PET, 917ab(5)
Budinger, Thomas F., honors for outstanding contributions, basic science, N576
- C**
- CA 125**
 co-expression of sialyl SSEA-1 antigen, variability of expression, 919ab(5)
 radioimmunoassay, I-131 HMFG1 monoclonal antibody, ovarian cancer, 918ab(5)
 ultrasensitive assay for measuring serum values, monoclonal antibodies, different antigenic determinants, 785ab(5)
Caffeine, reduction, dipyridamole-induced myocardial ischemia, 1723, 861ab(5)
Calcium
 channel blocker, synthesis, [F-18]fluorocinnarizine, 753ab(5)
 ion sequestrants, inhibition, platelet thrombosis, 859ab(5)
 renal tubular reabsorption, primary hyperthyroidism, 2ab(4)
Cameras
 Anger, quantitative quality control program, SPECT, 851ab(5)
 single-crystal ring, imaging characteristics, brain SPECT, 796ab(5)
 Tc-99m DTPA images, quantitative calculations, GFR, 1747ab(10)
Cancer
 chemotherapy and hot skull, radionuclide bone
- scans, 858ab(5)
 imaging, F-18 FDG uptake, human tumor xenografts, 912ab(5)
 imaging in multicenter trial, fragments of CEA monoclonal antibodies, 748ab(5)
 intraperitoneal, I-123 and Br-80m halodeoxyuridines, Auger electron radiotherapy, 833ab(5)
 metastatic, human pharmacokinetics, Sm-153 EDTMP, 1814
 radiotherapy, radioiodinating reagent development, monoclonal antibodies, 216 treatment, nuclear medicine in monitoring response, 1731
- Capillary**
 permeability
 regional flows, heart, 798ab(5)
 small solutes, 842ab(5)
 transit time, cerebral blood flow, volume comparison, 792ab(5)
- Captopril**
 differing responses after Tc-99m GHA and Tc-99m DMSA, renovascular hypertension, 841ab(5)
 effect on glucoheptonate scintirenomogram, renal artery stenosis, 1759ab(10)
 -enhanced renal scintigraphy, hypertension evaluation, Tc-99m DTPA, 615
 renal blood flow change, angioplasty, renal artery stenosis, 841ab(5)
 renal scintigraphy, pitfall, bilateral renal artery stenosis, 2042
renography
 duplexonography, renovascular hypertension, 6ab(4)
 renal artery stenosis, Tc-99m DTPA, 6ab(4)
scintigraphy
 diagnosis, renovascular hypertension, 944ab(5)
 neonatal hypertension, 798ab(5)
 -stimulated renography, renal vein renins, hypertension, 5ab(4)
 test in hypertensive patients, renal artery stenosis detection, Gates' technique, 51
 test in screening hypertensive patients, 1422(1e)
Carbidopa, importance in 6-[F-18]fluoro-L-dopa PET studies, 761ab(5)
- Carbon-11**
 acetylcholinesterase inhibitor, simple preparation, 822ab(5)
 cocaine binding in human and baboon brain, 761ab(5)
 resin-supported methylation approach, phenols, amides and acidic precursors, 822ab(5)
- Carbon-11 acetate**
 kinetics, dietary state, human heart, 837ab(5)
PET
 myocardial oxidative metabolism, substrate utilization, 187
 myocardial oxidative metabolic reserve, 1489
 regional myocardial oxygen consumption, 1798
 quantification of myocardial metabolic reserve, PET, dobutamine, 837ab(5)
 regional myocardial oxidative metabolism, serial PET imaging, 867ab(5)
 tracer for myocardial metabolism, 1743ab(10)
- Carbon-11 amino acids**
 preparation, automated microprocessor-controlled reaction system, 4ab(11)
 preparation from C-11 nitroalkanes, 783ab(5)
- Carbon-11 ammonium cyanide**, method for routine production, C-11 D-glucose, 927ab(5)
- Carbon-11 benztrapine**, possible muscarinic

- cholinergic receptor ligand, PET, 741ab(5)
- Carbon-11 betamethylheptadecanoic acid**
myocardial fatty acid metabolism, 797ab(5)
synthesis and biodistribution in rats, 928ab(5)
- Carbon-11 butanol**, O-15 water and, cerebral blood flow, PET, 901ab(5)
- Carbon-11 carbon dioxide**
C-11 pyruvic acid synthesis, 928ab(5)
PET, quantitative brain pH mapping, acute stroke, 782ab(5)
- Carbon-11 carfentanil**, opiate receptor regulation, temporal lobe epilepsy, PET, 750ab(5)
- Carbon-11 citalopram**, facile synthesis, PET, serotonin uptake sites, 1757ab(10)
- Carbon-11 cocaine**, PET studies, kinetic analysis, baboon brain, 898ab(5)
- Carbon-11 diprenorphine**
opiate receptor density and ligand affinity, 740ab(5)
opiate receptor regulation, temporal lobe epilepsy, PET, 750ab(5)
- Carbon-11 fatty acids**, synthesis and biodistribution, C-11 betamethylheptadecanoic acid, 928ab(5)
- Carbon-11 4-fluorodeprenyl**, synthesis, probe, functional monoamine oxidase, 821ab(5)
- Carbon-11 D-glucose**
method for radiosynthesis, 1756ab(10)
method for routine production, C-11 ammonium cyanide, 927ab(5)
remote automated synthesis, PET, 928ab(5)
use of C1 vs. C2, rat glioma model, 911ab(5)
- Carbon-11 glycine**, preparation of C-11 amino acids, C-11 nitroalkanes, 783ab(5)
- Carbon-11 HECNU**, "no-carrier-added" synthesis, 783ab(5)
- Carbon-11 hydroxyephedrine**
alternative to 6-[F-18]fluorometaraminol, heart neuronal imaging, 767ab(5)
synthesis, neuronal cardiac imaging, 783ab(5)
- Carbon-11 methionine**
compared to F-18 fluorodeoxyglucose, differential diagnosis, lung tumor, 788ab(5)
PET, cerebral neutral amino acid uptake, 838ab(5)
protein synthesis in brain tumors, 910ab(5)
radiation effects on tumor, 739ab(5)
tumor uptake, response to irradiation, 2012
uptake in tumor, quantitative evaluation, PET, 1809
uptake with PET
histologic type, primary lung cancer, 33
prognosis, bronchogenic carcinoma, 1420(le)
- Carbon-11 methoxy-MK-801**, imaging of NMDA receptors by PET, 741ab(5)
- Carbon-11 8-methoxy-MK-801**, synthesis and preliminary evaluation, 930ab(5)
- Carbon-11 methyl acyclovir**, synthesis, 929ab(5)
- Carbon-11 methyl iodide**, simplified solid-phase synthesis, 927ab(5)
- Carbon-11 MK-329**, synthesis, cholecystokinin receptors, PET, 931ab(5)
- Carbon-11 MTRB**, pituitary imaging agent, 932ab(5)
- Carbon-11 nitroalkanes**, preparation of C-11 amino acids, 783ab(5)
- Carbon-11 N-Me-paroxetine**, central serotonin re-uptake sites, PET, 1753ab(10)
- Carbon-11 NMSP**, PET D-2 dopamine receptor quantification, schizophrenia, 731ab(5)
- Carbon-11 ornithine**, no-carrier-added synthesis, 782(ab), 783ab(5)
- Carbon-11 phorbol esters**, specific binding to protein kinase C, PET, 783ab(5)
- Carbon-11 pyruvic acid**, synthesis, 928ab(5)
- Carbon-11 thymidine**, liver regeneration measurement by PET, 929ab(5)
- Carbon-11 tropanyl benzoate methiodide**, synthesis and animal studies, promising ligand, peripheral muscarinic receptors, 930ab(5)
- Carbon-11 tyrosine**, effect of radiotherapy, tumor metabolism, PET, 789ab(5)
- Carbon-11 YM-09151-2**, brain uptake, D-2 dopamine receptor, 515
- Carbon-13**, nuclear magnetic resonance, cellular redox, 814ab(5)
- Carbon-14 cocaine**, whole body distribution and kinetics, 831ab(5)
- Carbon-14 deoxyglucose**
deposition, ischemia, reperfusion, 797ab(5)
fluorodeoxyglucose and, regional comparison, lumped constants, 900ab(5)
- Carbon-14 D-glucose**, cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)
- Carbon monoxide**, poisoning, regional cerebral glucose metabolism, 802ab(5)
- Carcinoembryonic antigen (CEA)**
anti-CEA imaging
I-123 Fab' and F(ab')2 fragments, 903ab(5)
pharmacokinetics and imaging, colorectal carcinoma, 908ab(5)
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, colorectal carcinoma, 809ab(5)
I-123 anti-CEA monoclonal antibody, evaluation, colorectal carcinoma, 890ab(5)
- I-131 anti-CEA/CA 19-9, immunoscintigraphy efficacy, colorectal cancer, 907ab(5)
- I-131 anti-colon specific antigen-p, monoclonal antibody, therapeutic efficacy, 826ab(5)
- In-111 monoclonal antibody
detection, recurrent colorectal carcinoma, 748ab(5)
metabolism, nude mouse tissues, 888ab(5)
- monoclonal antibody fragments, cancer imaging, multicenter trial, 748ab(5)
- monoclonal anti-CEA antigen I-123 F(ab')₂ fragments, pretherapy dosimetry, 962ab(5)
- new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
- preparation and characterization, Re-186 NR-CO-02 F(ab')₂, 793ab(5)
- role as metabolic indicator, bifunctional antibody system, colon carcinoma, 905ab(5)
- size-related diagnostic sensitivity, tumor radioimmunoscintigraphy, standard X-rays, 749ab(5)
- tumor localization of anti-CEA monoclonal antibodies, epitope specificity, 747ab(5)
- yttrium-labeled anti-CEA monoclonal antibodies, IgG and fragments, radioimmunotherapy, 848ab(5)
- Carcinoid tumor**, metastatic, I-131 MIBG treatment, 836ab(5)
- Carcinoma**, effects of interferon- α A, monoclonal antibody targeting, 809ab(5)
- Carcinoma, breast**
axillary metastasis and, TI-201 scintigraphy, 844ab(5)
bone marrow scintigraphy, Tc-99m NCA-antibodies, 819ab(5)
metastatic, 16- α -[F-18]fluoroestradiol uptake, PET, 788ab(5)
xenografts, localization, In-111 tumor necrosis factor, 819ab(5)
- Carcinoma, bronchial**, Tc-99m MIBI and TI-201 uptake, 845ab(5)
- Carcinoma, bronchogenic, C-11-L-methionine**
uptake with PET, predictor of prognosis, 1420(le)
- Carcinoma, colonic**
role of CEA as metabolic indicator, bifunctional antibody system, 905ab(5)
xenografts, comparative biodistribution, Yt- and In-labeled monoclonal antibody B72.3, 672
- Carcinoma, colorectal**
anti-CEA antibody, pharmacokinetics, imaging, 908ab(5)
biodistribution and tumor localization, In-111 monoclonal antibody, 747ab(5)
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, 809ab(5)
clinical value of immunoscintigraphy, 1646
differentiation from scar, PET, 789ab(5)
evaluation, early and delayed radioimmunoscinigrams, 890ab(5)
- HAMA responses**
intraperitoneal radioimmunotherapy infusions, 827ab(5)
patterns, In-111 ZCE 025 monoclonal antibody, 906ab(5)
- liver metastases**
immunoscinigraphy, Tc-99m monoclonal anti-CEA antibody, 748ab(5)
I-131 monoclonal antibody, 809ab(5)
perfusion and shunting, F-18 uracil, N-13 glutamate, 910ab(5)
recurrent, detection, In-111 monoclonal antibody, 748ab(5)
xenografts, radioimmunotherapy, Y-90 CO17-1A, 935ab(5)
- Carcinoma, hepatocellular**, diagnosis with Tc-99m DISIDA, adenoma, focal nodular hyperplasia, 1278(le)
- Carcinoma, lung**
Tc-99m α -D-glucose I-phosphate, compared to Ga-67 imaging, 913ab(5)
Tc-99m NR-LU-10 monoclonal antibody, lab(11)
- Carcinoma, mammary**, xenografts, curative radioimmunotherapy, I-131 monoclonal antibodies, 531
- Carcinoma, ovarian**
anti-CA 12.5 radioimmunodetection, 758ab(5)
human antimurine antibody responses, intraperitoneal radioimmunotherapy infusions, 827ab(5)
I-131 HMFG1 trial, 759ab(5)
I-131 HMKG1 monoclonal antibody, kinetics, nude mice and patients, 883ab(5)
immunoscinigraphy, In-111 monoclonal antibody, 758ab(5)
influence of antibody protein dose, antibody distribution, autoradiography, 759ab(5)
prospective immunoscintigraphic study, 758ab(5)
radioimmunoscintigraphy, monoclonal antibody SM3, 758ab(5)
- Carcinoma, prostatic**
bone scintigram, serum osteocalcin, PSA and/or PAP, 918ab(5)
prostatic acid phosphatase, prostatic specific antigen, 3ab(2)
- Carcinoma, renal cell**
xenografts
external beam irradiation, radioimmunotherapy, 826ab(5)
I-131 and In-111 monoclonal antibody, 906ab(5)
- Carcinoma, small cell**, F-18 deoxyglucose PET,

Carcinoma, squamous cell

- 1754ab(10)
- Carcinoma, squamous cell**
- head and neck, Tc-99m DMSA uptake, 174
 - lung
 - monoclonal antibody radioimmunoassay, 918ab(5)
 - serum TA-4 level, localization, 918ab(5)
 - radiolabeled anti-EGF receptor, phase I, imaging trial, 746ab(5)
 - Carcinoma, thyroid**
 - detection, cervical magnetic resonance imaging, 841ab(5)
 - differentiated, Tc-99m MIBI imaging, follow-up, 904ab(5)
 - improved determination, 24-hour I-131 uptake, 737ab(5)
 - medullary, Tc-99m DMSA scintigraphy, 1420(1e)
 - Tl-201 and I-131 scintigraphy comparison, follow-up, 914ab(5) - Carcinomatosis, intraperitoneal, lavage, improved monoclonal antibody uptake, 60**
 - Cardiolite:** *see* Technetium-99m HEXAMIBI
 - Cardiomyopathy**
 - damage delineated by In-111 monoclonal anti-myosin, 779ab(5)
 - dual-tracer autoradiography, Tl-201, radioiodinated fatty acid, 80
 - hypertrophic, left ventricular diastolic filling patterns, 868ab(5)
 - idiopathic congestive, I-123 MIBG imaging, 1182
 - primary hypertrophic, I-123 MIBG myocardial uptake, 810ab(5)
 - visual analysis of PET images, reproducibility, reliability, 846ab(5) - Cardiopulmonary resuscitation, back-flow testing of CPR airway valves, radioactive gas, 1755ab(10)**
 - Cardiovascular system, European Association of Nuclear Medicine Congress, 1989, N1921**
 - Carotid artery, extraction and kinetics, Tc-99m ECD and HM-PAO, 742ab(5)**
 - Catecholamines**
 - analog behavior, compartmental analysis, myocardial tissue, 735ab(5)
 - depletion of myocardial stores, detection with I-123 MIBG, acute myocardial infarction, 810ab(5)
 - dopamine infusion, myocardial glucose uptake, regional ischemia, 859ab(5) - Catheter**
 - indwelling, radionuclide evaluation, chemotherapy, 845ab(5)
 - therapeutic transcatheter embolization, improved radiolabeling technique, ivalon, 1399 - Cations, complexes of technetium, myocardial imaging, 1415**
 - Caudate nucleus, quantification of dopamine D-2 receptor, PET, 736ab(5)**
 - Central nervous system**
 - brain death, cerebral perfusion imaging, Tc-99m HM-PAO, 1627
 - correlative pediatric imaging, 15 - Cerebrospinal fluid, fistulae, diagnosis, radionuclide cisternography, 120**
 - CGP 12177, β -adrenergic receptors, PET, 766ab(5), 825ab(5)**
 - Chelate, antibody and, diester linkage, radioimmunodetection of tumor, 1693**
 - Chelating agents**
 - antibody-bifunctional chelator conjugates, ester-linker Tc-99m, whole-body clearance, 934ab(5)
 - Br β HBED, radiolabeling of antibodies, 763ab(5)
 - chemical modification, Tc-99m antibody, accelerated background clearance, 940ab(5)
 - comparison of five techniques for radiolabeling, monoclonal antibody with Y-90, 763ab(5)
 - endotoxin testing, limulus amoebocyte lysate, radiopharmaceuticals, 921ab(5)
 - hexadentate bifunctional, radiolabeling of antibodies, 1758ab(10)
 - macrocyclic bifunctional, Y-90 monoclonal antibodies, 763ab(5)
 - N,S, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, 933ab(5)
 - porphyrin bifunctional chelator, monoclonal antibody labeling, radioactive manganese, 935ab(5)
 - preparation of new agents, immunoscintigraphy, 936ab(5)
 - radiolabeled antibody imaging, gastrointestinal cancer, 909ab(5)
 - Tc-99m-labeled antibody-bifunctional chelator conjugates, 793ab(5)
 - Tc-99m tetradeinate amine-phenols, radiopharmaceutical cell labeling, 938ab(5) - Chemodectoma, I-123 MIBG uptake, 769ab(5)**
 - Chemotaxis, neutrophil function, after monoclonal antibody interaction, 747ab(5)**
 - Chemotherapy**
 - bone and soft tissue response, ^{31}P magnetic resonance spectroscopy, 813ab(5)
 - F-18 uracil uptake, changes in tumor volume, colorectal carcinoma, 911ab(5)
 - hot kidney or skull on radionuclide bone scans, cancer patients, 858ab(5)
 - radionuclide evaluation, indwelling catheters, 845ab(5)
 - synthesis of "no-carrier-added,cQ C-11 HECNU, 783ab(5) - Chernobyl, Swedish thyroid cancer risk, 721(1e)**
 - Chervu, Lakshman Rao, In Memoriam, 723**
 - Chervu, Shanta, In Memoriam, 723**
 - Chest**
 - correlative pediatric imaging, 15
 - three-dimensional attenuation coefficients, distribution for SPECT, 128(1e) - Child abuse, unusual and subtle scintigraphic findings, 967ab(5)**
 - evaluation, 4ab(2) - Cholecystokinin, receptor localization, MK 329, 849ab(5)**
 - Cholescintigraphy**
 - morphine-augmented, 8ab(4), 850ab(5)
 - reflux sign, administration, gallbladder contracting agent, 1192
 - sensitivity, sonography, gallbladder perforation, 850ab(5) - Cholesterol, lowering, coronary artery stenosis reversal, PET, 845ab(5)**
 - Chromatography**
 - HPLC
 - injection, radiopharmaceutical purification, 923ab(5)
 - Tc-99m radiopharmaceuticals, quality control, 940ab(5)
 - Tc-99m radiopharmaceuticals, structural identification, 1240
 - internal surface-reverse phase, plasma metabolite analysis, radiopharmaceuticals, 920ab(5) - Cirrhosis, portasystemic shunt fraction quantification, I-123 IMP, 1702**
 - Cisplatin, -induced tubular toxicity, comparison, radioactive renal agents, 659**
 - Cisternography, radionuclide, diagnosis, pleural cerebrospinal fluid fistulae, 120**
 - Clonidine, pre-treatment for early detection, mechanical-overload heart failure, I-123 MIBG SPECT, 810ab(5)**
 - Cobalt-55, development as an antibody label, PET imaging studies, 923ab(5)**
 - Cobalt-57 cyanobalamin, content uniformity of capsules, 265(1e)**
 - Cocaine**
 - abusers, measurement, post-synaptic dopamine receptors, 730ab(5)
 - carbon-11, binding, human and baboon brain, 761ab(5)
 - effect on brain uptake, iodoamphetamine, dog, 830ab(5)
 - imaging *in vivo* chemistry, N1285
 - whole-body distribution and kinetics, 831ab(5) - Colchicine, -induced thyroidal radioiodide retention, iodine-deficient male rats, 737ab(5)**
 - Collimator**
 - angulation error, effect on SPECT, 852ab(5)
 - diverging, glomerular filtration rate inaccuracies, 941ab(5)
 - electronically collimated SPECT, first experimental study, 851ab(5)
 - influence on SPECT center of rotation, measurements, 265(1e)
 - performance
 - penetration effects, 891ab(5)
 - use, hotelling trace, 892ab(5)
 - restoration filter and, quantitative imaging, I-131 antibody, 876ab(5)
 - rotating slanthole, SPECT, 1737(1e)
 - scatter, novel Monte Carlo simulation, 806ab(5)
 - technique for evaluation of anisotropy, SPECT, 894ab(5) - Colon**
 - cancer, In-111 monoclonal antibodies, 905ab(5)
 - carcinoma: *see* Carcinoma, colonic
 - coverage by mesalamine enema, active distal ulcerative colitis, 764ab(5)
 - scintigraphy, chronic constipation, 887ab(5)
 - transit
 - clinical assessment, In-111 DTPA, 887ab(5)
 - development, noninvasive test, 764ab(5)
 - non-invasive radionuclide assessment, 746ab(5)
 - oral I-131 cellulose, health and constipation, 764ab(5) - Colony-stimulating factor, granulocyte-macrophage, bone marrow imaging, Tc-99 sulfur colloid, 738ab(5)**
 - Colorectal cancer**
 - cold antibody administration, In-111 monoclonal antibody, 809ab(5)
 - diagnostic efficacy of immunoscintigraphy, SPECT and I-131 anti-CEA/CA 19-9, 907ab(5)
 - epithelial membrane antigen, target antigen, radiolabeled monoclonal antibody, 808ab(5)
 - F-18 uracil uptake, changes in tumor volume, chemotherapy, 911ab(5)
 - In-111 and I-131 monoclonal antibody, B72.3, 320
 - inflammation-related mAb localization, 3ab(11)
 - intra-operative localization, metastases, radiation detection probe, 908ab(5)
 - metastatic, F-18 uracil and O-15 water, 910ab(5)
 - radioimmunoscintigraphy, Tc-99m monoclonal

- antibody, 748ab(5)
Complex, formation and biodistribution, mouse antitumor monoclonal antibody, cancer patients, 1311
Computed tomography
 constraining SPECT reconstruction to body volume, 835ab(5)
 correlative pediatric imaging, 15
 3D brain imaging, I-123 IMP, 961ab(5)
 effect of radioiodination, protein charge, electrophoretic mobility, 933ab(5)
 Ga-67 SPECT, evaluation, recurrent lymphoma, 874ab(5)
 HM-PAO SPECT comparison, model for outcome-prediction, after stroke, 895ab(5)
 localization of pheochromocytoma, correlation with MIBG and MRI, 328
 longitudinal PET and, normal aging, Alzheimer's disease, 772ab(5)
 metabolic PET correlates, anatomic lesions, head trauma, 802ab(5)
 MR and PET, Alzheimer's dementia, normal aging, 1607
 MRI and PET, evaluation, neuropsychiatric disorders, 1589
quantitative
 comparison, dual energy radiography, 774ab(5)
 image registration system, 894ab(5)
 transmission computerized tomography, utility of Ga-67, lymphoma, 914ab(5)
Computers
 all-digital nuclear medicine department, display stations, 874ab(5)
 identifiability analysis, ligand-receptor model influence, injection protocol, 877ab(5)
 implementation of nuclear medicine computer hardware, software quality control program, 874ab(5)
 Macintosh, PET data analysis, 873ab(5)
 microcomputer-based molecular modeling, radiopharmaceuticals, structure/activity relationships, 877ab(5)
 ultra-high speed nuclear medicine image telecommunications, ISDN, 874ab(5)
Computers, software
 analysis of cardiac perfusion tomography, 871ab(5)
 analysis of scatter and quantum noise, camera non-uniformity, holospectral imaging, 807ab(5)
 application of machine intelligence, diagnosis, coronary stenosis, 816ab(5)
 automatic program for long axis, left ventricular myocardium, TI-201, 806ab(5)
 automatic superposition of cardiac SPECT images, 871ab(5)
 composite gallium SPECT-CT images, evaluation, recurrent lymphoma, 874ab(5)
 computer-aided radiopharmaceutical design, 732ab(5)
 correction of bladder artifact, hip SPECT, 857ab(5)
 cortical circumferential profiling, emission tomography, 816ab(5)
 dental bone scans, orthopan-tomosintigram, 835ab(5)
 development of image display, analysis workstation, 873ab(5)
 development of treatment planning program, radioimmunotherapy, 884ab(5)
 3D non-stationary simulation of SPECT imaging, 881ab(5)
 effect of attenuation weighted backprojection, 3D MTF, SPECT, 816ab(5)
 effect of differential washout, reconstructed SPECT images, 870ab(5)
 efficient attenuated reprojection algorithm, SPECT, 817ab(5)
 elimination of K_1 from least squares optimization, rate parameters, three-compartment model, 879ab(5)
 experimental information directory, international computer network, 815ab(5)
 gamma camera image restoration and applications, 876ab(5)
 I-123 MIBG uptake by chemodectomas, 769ab(5)
 maximum likelihood image reconstruction, PET, 776ab(5)
 miniature scintillation detector system, 891ab(5)
 model for fluoromisonidazole retention, PET image interpretation, 735ab(5)
 Monte Carlo simulation, collimator scatter, 806ab(5)
 new reconstruction algorithm, radial long-axis tomography, TI-201 SPECT, 881ab(5)
 operation, picture archiving and communication system, 873ab(5)
 optimal experimental design for tissue data, fluorodeoxyglucose, 879ab(5)
 practical use of full relational model, dynamic management, nuclear and cardiological data, 873ab(5)
 quality control program, implementation, nuclear medicine computer hardware, 874ab(5)
 quantification of amplitude images, gated radionuclide heart studies, 1393
 quantification of myocardial perfusion and thickness, tomographic phantom studies, 871ab(5)
 quantitative difference mapping, dual isotope autoradiography, 874ab(5)
 quantitative measurement, In-111 anti-melanoma monoclonal antibody, 885ab(5)
 robustness of dynamic D-2 receptor models, 736ab(5)
 scintigraphic display and processing software, personal computer, 969ab(5)
 simple positron imaging, time-of-flight, iterative deblurring, 746ab(5)
 simplified analysis of gastric emptying, PC-based system, weighted-least-squares regression, 794ab(5)
 simulation of scintigrams, 879ab(5)
 synthetic classification images, cardiac RWMA, 816ab(5)
 three-dimensional display cardiac metabolism, PET, 808ab(5)
 SPECT images, 834ab(5)
 validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
 validity of microsphere model, cerebral blood flow, I-123 IMP, 878ab(5)
Constipation, chronic, colonic scintigraphy, 887ab(5)
Copper
 metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
 positron-emitting, potential agent, leukocyte labeling, 920ab(5)
Copper-18, monoclonal antibody conjugation, desferrioxamine In-111, oligosaccharide moiety, 936ab(5)
Copper-62, Zn-62 Cu-62 generator, PET radiopharmaceuticals, 1838
Copper-64, *p-* carboxyalkylphenyldithiocarbazones, antibody labeling, 848ab(5)
Copper-64 PTSM, measurement of tissue perfusion, 1756ab(10)
Copper-67, improved separation procedure, radiotherapy, 921ab(5)
Copper-67 beta dose point kernels, potential use in radioimmunotherapy, 1036
Copper-PTSM
 cerebral blood flow, PET, 791ab(5)
 correlation of localization, microsphere blood flow, dog heart and kidney, 848ab(5)
 kinetics in heart, PET, 1843
 measurement of regional blood flow, PET, 807ab(5)
 microsphere-like retention in heart, blood flow, PET, 768ab(5)
 subcellular distribution, tissue radiocopper, 920ab(5)
Coronary artery
 flow and distribution, response to stress, 818ab(5)
 normal, causes, abnormal stress TI-201 SPECT, 750ab(5)
Coronary artery disease (CAD)
 automatic superposition of cardiac SPECT images, 871ab(5)
 bicycle exercise first-pass radionuclide angiography, frequency, silent myocardial ischemia, 868ab(5)
 cardiac transplant patients, 3ab(2)
 comparison of severity, PET, arteriography, 846ab(5)
 comparison of SPECT and TI-201, I-123 fatty acids, 739ab(5)
 continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
 detection of area at risk, angioplasty, Tc-99m RP-30, 791ab(5)
 diagnosis by radionuclide angiography, left ventricular function, 1966
 diagnosis with PET, correlation, coronary angioplasty, 845ab(5)
 diagnostic utility of Tc-99m SQ 30217, rapid imaging protocol, 730ab(5)
 differences, TI-201, Tc-99m MIBI, 865ab(5)
 dipyridamole effects, cardiac MRI, 840ab(5)
 dipyridamole-thallium imaging, lazy man's stress test, 281
 effects of anti-anginal agents, PET, 866ab(5)
 evaluation of ventricular function, 1149
 identification of high-risk patients, oral dipyridamole TI-201 SPECT, 862ab(5)
 In-111 neutrophils, myocardial infarction, reperfusion injury, 859ab(5)
 I-123 phenylpentadecanoic acid tomography, dipyridamole infusion, 760ab(5)
 left ventricular dilation, exercise SPECT thallium imaging, three-vessel disease, 749ab(5)
 low risk patients, quantitative TI-201 SPECT, 863ab(5)
 myocardial fatty acid utilization, tomographic assessment, recurrent chest pain, 828ab(5)
 myocardial perfusion and Tc-99m RP-30A, coronary arteriography, exercise TI-201 SPECT, 820ab(5)
 myocardial perfusion abnormality, exercise, TI-201 SPECT, 749ab(5)
 myocardial perfusion imaging, Tc-99m HEXAMIBI, TI-201, 301
 myocardial scintigraphy, I-123 phenylpentadecanoic acid, 829ab(5)
 optimal specificity of TI-201 SPECT,

recognition, imaging artifacts, 441
radionuclide angiography and Tl-201 perfusion, during exercise, 818ab(5)
redistribution after thallium reinjection, relationship, coronary anatomy and regional wall motion, 740ab(5)
regional left ventricular filling, diastolic abnormalities, myocardium, 165
regional wall motion, gated myocardial PET, 1775
right ventricular uptake, Tc-99m MIBI and Tl-201, 820ab(5)
rubidium-82 and Tl-201 myocardial perfusion imaging, coronary artery disease, 759ab(5)
rubidium-82 PET and Tl-201 SPECT, comparisons, 829ab(5)
Tc-99m HEXAMIBI and Tl-201 SPECT, diagnosis, 4ab(2)
Tc-99m monoclonal antibody, after balloon arterial injury, atherosclerotic model, 787ab(5)
three-dimensional cardiac PET, automated quantitation, routine clinical use, 1787
three-dimensional SPECT Tl-201 images, accuracy of detection, 834ab(5)
Tl-201 myocardial tomography, analysis, polar probability map, 871ab(5)
Tl-201 scintigraphy, maximal coronary vasodilation, adenosine, 760ab(5)
Tl-201 SPECT myocardial imaging, prone position, 750ab(5)
left bundle branch block, 419(ie)
treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, Tc-99m MIBI, 759ab(5)
ventricular function and perfusion, myocardial infarction, Tc-99m MIBI, 801ab(5)

Corrections, table correction, 268

Creatinine, measurement of renal function, radionuclides, 2054

Crohn's transit, gallbladder and gastrointestinal transit, 764ab(5)

Cryptand 2,2,2, tritiated, synthesis and biodistribution, 1756ab(10)

CsI-photodiode detector, patient-borne, left ventricular function, ST segment, 868ab(5)

Cyclohexylpolyaminocarboxylates, improved In-111 immunoconjugates, tumor imaging, 934ab(5)

Cyclosporine comparison of INCSTAR CYCLOTRAC and SANDOZ SANDIMMUNE, whole blood assays, 3ab(2)
concentrations in whole blood, H-3 and I-125 radioimmunoassays, monoclonal antibody, 786ab(5)
nephrotoxicity, pathophysiology, 784ab(5)

Cyclosporine A, toxicity, hepatobiliary dysfunction, Tc-99m EHIDA, 921ab(5)

Cyclotron essentials of design and operation, corrections to lecture notes, 129(ie)
first products, nuclear medicine history, St. Louis, N569
-produced radiopharmaceuticals, IAEA report, N1443
proton only, automated radiopharmaceutical production, 965ab(5)
small proton, electrophilic F-18, 927ab(5)
solution to current radioisotope shortage, N438

Cyst, choledochal, scintigraphic features, 622

Cystic fibrosis, pulmonary function testing, Tc-99m DTPA aerosol ventilation studies, 967ab(5)

Cystography

nuclear, Tc-99m pertechnetate absorption, bladder augmentation, 2ab(2)
radionuclide, two-stage, early results, 10ab(4)
radionuclide voiding, vesico-ureteral reflux, expert system, 5ab(2)

D**Dehdashti, Farrokh, Mallinckrodt Fellowship, N1444**

Dementia abnormal blood flow patterns, cerebral atrophy, Tc-99m HM-PAO SPECT, 896ab(5)

AIDS, reversal, brain metabolic abnormalities, 581

Alzheimer's CT, MR and PET, 1607
one year follow-up, rCBF/PET correlations, 895ab(5)

Alzheimer's disease, regional cerebral blood flow, SPECT, 771ab(5)

brain tumor and, kinetic rate constants, F-18 fluorodeoxyglucose, 900ab(5)

evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589

F-18 deoxyglucose PET and I-123 QNB SPECT, 896ab(5)

HIV-positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)

multi-infarct, Alzheimer's disease and, cerebral blood flow, 772ab(5)

Deoxyglucose, glucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)

Department of Energy (DOE)

isotope production and distribution office, N1933

nuclear medicine research grants, N1148
SNM/ACNP testimony on 1990 budget, N1148 suspension of enriched uranium shipments, jeopardized Mo-99/Tc-99m supply, N1139

Dermatomyositis, P-31 MR spectroscopy and MRI, 5ab(11)

Desferrioxamine, In-111, MoAb-CU-18 conjugation, oligosaccharide moiety, 936ab(5)

Dexamethasone, effect on extracellular space, influx and plasma volume, human brain tumors, 899ab(5)

Diabetes, *Klebsiella pneumoniae* osteomyelitis, three-phase radionuclide bone imaging, 1412

Diabetes mellitus nephropathy, early detection, Tc-99m DTPA and I-131 hippuran, 941ab(5)

pedal osteomyelitis, three-phase bone scintigraphy, In-111 leukocytes, 753ab(5)

type 1, modulation of gastric emptying, blood glucose concentrations, 795ab(5)

type 2, esophageal and gastric emptying, 795ab(5)

Dialysate sodium, concentration, skeletal muscle and subcutaneous blood flow, 4ab(4)

Diazepam, radioiodinated derivative, SPECT studies, benzodiazepine receptor, 803ab(5)

Diet nutrient hepatic blood flow, age-related reduction, 1748ab(10)

protein, radionuclide assessment, glomerular filtration rate, 785ab(5)

Diethylenetriamine, labeling of human IgG, Rh-105 complexes, 832ab(5)

Digoxin, radioiodinated derivative, Na,K-ATPase binding, myocardial imaging agent,

923ab(5)

3,3-Dimethyl(p-I-123 phenyl-)pentadecanoic acid, uptake in excess to rMBF, reperfused myocardium, 797ab(5)

Dipyridamole

effects on cardiac MRI, coronary artery disease, 840ab(5)

-induced myocardial ischemia, reduction by caffeine, 861ab(5), 1723

infusion for CAD detection, I-123 phenylpentadecanoic acid tomography, 760ab(5)

Rb-82 PET and Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)

-redistribution Tl-201 ECT, children, Kawasaki disease, 760ab(5)

"stress", dynamic exercise, ambulatory ST changes and perfusion, 861ab(5)

Tl-201 imaging comparative efficacy, adenosine infusion, 730ab(5)

lazy man's stress test, 281

transient mitral regurgitation, myocardial ischemia, 1271

Tl-201 SPECT

left bundle branch block, 2ab(11)

compared to exercise RNV, jeopardized myocardium detection, 862ab(5)

future cardiac events, angina pectoris, 861ab(5)

high-risk patient identification, coronary artery disease, 862ab(5)

Distinguished Scientist Award, David A. Goodwin, N14

DMSA, studies in infants under one year old, 5ab(4)

Dobutamine, quantification of myocardial metabolic reserve, C-11 acetate, PET, 837ab(5)

Dopamine

asymmetric synthesis, 6-[F-18]fluoro-L-dopa, NCA nucleophilic fluorination, 752ab(5)

Br-75 6-bromo-m-tyrosine as tracer, synthesis, evaluation, 924ab(5)

central norepinephrine protracer, synthesis, F-19/F-18 MOPS, 929ab(5)

D-2 imaging agent, I-123 IBF, 762ab(5)

dopaminergic radiotracer, I-125 MHTP, mechanism of accumulation, 761ab(5)

imaging of *in vivo* chemistry, N1287

infusion, myocardial glucose uptake, regional ischemia, 859ab(5)

neurons, quality control procedure, 6-[F-18] fluoro-L-DOPA, 1249

presynaptic dopaminergic function, probe, 4[F-18]fluoro-L-m-tyrosine, 752ab(5)

protractors for neuron mapping, [H-3]-L-m-tyrosine, [H-3] α-methyl-L-m-tyrosine, 752ab(5)

receptors: see Receptors

Dosimetry

conventional internal, limitations, cellular levels, 826ab(5)

distributions for alpha and beta particle emitters, intraperitoneal radioimmunotherapy, 777ab(5)

EGS4 Monte Carlo determination, beta dose kernel in water, 883ab(5)

encapsulated nondigestible In-111 source, human gastrointestinal tract, 882ab(5)

estimation of bone marrow doses, delivery, radioimmunotherapy, 778ab(5)

gastrointestinal cancer radioimmunotherapy, administration, monoclonal antibodies,

- 779ab(5)
heterogeneity of monoclonal antibody uptake, human tumor xenografts, Sprint tomographic scanner, 777ab(5)
- human radioimmunotherapy estimates, mouse data basis, antibody carrier/radionuclide combinations, 777ab(5)
- hyperthyroidism radioiodine treatment, extrathyroidal absorbed doses, 833ab(5)
- I-123 IBZM biodistribution, 834ab(5)
- I-125 seed implants using SPECT, 1748ab(10)
- I-131 anti-idiotype monoclonal antibody, B cell lymphoma, 826ab(5)
- I-131 HMFG1 monoclonal antibody, whole body profile scanning, 884ab(5)
- inhomogenous deposition of radiopharmaceuticals, cellular level, 883ab(5)
- internal, model, peritoneal cavity, 2002
iodoantipyrine labeled with radioactive iodine, 1ab(2)
- kinetics of radiolabeled antibody penetration, micrometastatic cell clusters, 777ab(5)
- new coated-bead dosage form, I-131 sodium iodide, 886ab(5)
- pretherapy, monoclonal anti-CEA antigen I-123 F(ab')₂ fragments, 962ab(5)
- Radiation**
exposure and risk, performance of radiologic studies, 884ab(5)
- In-111 antimyosin pharmacokinetics, 833ab(5)
- radionuclide hysterosalpingography, Tc-99m, 415(l)e
- splenectomy, intraarterial P-32 chromic phosphate, 884ab(5)
- radiobiological efficacy, clinical
radioimmunotherapy, 827ab(5)
- "S" factors for self-dose to large tumors, selected therapeutic radionuclides, 883ab(5)
- Tc-99m ethyl cysteinate dimer, biodistribution, chronic cerebral infarction, 1018
- variations in absorbed dose, radiolabeled monoclonal antibodies, murine-human xenografts, 777ab(5)
- Drug abusers**, regional cerebral blood flow, SPECT, 1ab(11)
- Drug targeting**, F-19 nuclear magnetic resonance, animal tumor models, 814ab(5)
- Dual-photon absorptiometry (DPA)**
bone mineral content, lumbar spine vertebrae, uremic patients, 774ab(5)
- bone mineral density response, non-hormonal cyclic therapy, postmenopausal osteoporosis, 774ab(5)
- nuclear magnetic imaging, systemic mastocytosis, 2046
- scintigraphic findings and bone mineral content, Paget's disease, 855ab(5)
- Duplexsonography**, captopril renography and, renovascular hypertension, 6ab(4)
- DuPont Nuclear Medicine Technologist Advisory Board**, Professional Development Program, N1588
- Dyslexia**, PET studies, 802ab(5)
- Dysphasia**
congenital, brain blood flow, Tc-99m HM-PAO SPECT, 798ab(5), 1825
- developmental, abnormal regional response, SPECT and xenon-133, 812ab(5)
- E**
- Echocardiography**, radial shortening and myocardial thickening, Tc-99m MIBI, 821ab(5)
- Editorials**
Cardiovascular nuclear medicine: the next step, 1123
- Disease versus etiology, 1273
- Excretion of radioiodine in breast milk, 124
- Education and Research Foundation (E&R)**, student fellowships, N1441
- EHPG complexes**, behavior with metal ions, 848ab(5)
- Ejection fraction**
continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
- evaluation of ventricular function, coronary artery disease, 1149
- first pass left ventricular, iridium-191m, new generator system, 817ab(5)
- left ventricular diastolic filling, left ventricular systolic dysfunction, 868ab(5)
- nature of background, radionuclide ventriculography, 872ab(5)
- patient-borne CsI-photodiode detector, left ventricular function, ST segment, 868ab(5)
- percutaneous aortic balloon valvuloplasty, radionuclide ventriculography, 867ab(5)
- pulmonary uptake of thallium-201, exercise, 788ab(5)
- Electrocardiogram (ECG) gating**
Tl-201 myocardial SPECT, clinical evaluation, 864ab(5)
- whole body multidetector SPECT, variable aperture, 796ab(5)
- Electrocorticography**, PET and, epilepsy surgery, children, 896ab(5)
- Embolization**, therapeutic transcatheter, improved radiolabeling technique, ivalon, 1399
- Emission computed tomography**
analysis of cardiac perfusion tomography, new quantitative method, 871ab(5)
- commercially available SPECT systems assessment, 893ab(5)
- assessment, progress report, 963ab(5)
- cortical circumferential profiling, 816ab(5)
- 3-D brain phantom, 851ab(5)
- dipyridamole-redistribution Tl-201, children, Kawasaki disease, 760ab(5)
- high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
- image reconstruction, Bayesian methods, planar image processing, 880ab(5)
- interpolating shape and intensity, 960ab(5)
- new Genesys center of rotation, radius of orbit, 893ab(5)
- quantitative cerebral blood flow activation, I-123 iodoamphetamine, 811ab(5)
- validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
- Emphysema**, comparison of V/Q and CT, *alpha*-1 antitrypsin deficiency, 1755ab(10)
- Encephalopathy**, HIV-positive, I-123 IMP SPECT brain scanning, 811ab(5)
- Endotoxemia**, pulmonary localization, In-111 neutrophils, monoclonal antibodies, 852ab(5)
- Endotoxins**, testing with limulus amoebocyte lysate, radiopharmaceuticals, chelating agents, 921ab(5)
- Enema**, mesalamine, colonic coverage, ulcerative coverage, 764ab(5)
- Environmental Protection Agency (EPA)**
continuing debate over radon, N987
- med-waste regulations, N1431
- radionuclide emission standards, N1435
- Epilepsy**
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
- focal, ictal Tc-99m HM-PAO SPECT, 751ab(5)
- localization of epileptogenic foci, PET, 2ab(11)
- postictal studies and SPECT, N1289
- seizure focus localization, interictal and ictal SPECT, cerebral blood flow, 751ab(5)
- surgery in children, PET, intraoperative electrocorticography, 896ab(5)
- temporal lobe**
diagnostic patterns, post-ictal cerebral blood flow, 751ab(5)
- opiate receptor regulation, C-11 diprenorphine and PET, 750ab(5)
- presurgical evaluation, Xe-133 SPECT and Tc-99m HM-PAO, 896ab(5)
- Epirubicin**, different application schemes, radionuclide ventriculography, breast cancer, 867ab(5)
- Epithelial membrane antigen**, radiolabeled monoclonal antibody as target antigen, colorectal cancer, 808ab(5)
- Erythromycin**, abolition of gastric emptying discrimination, solids and liquids, 795ab(5)
- Erythropoietin**, radioimmunoassay, recombinant human erythropoietin, 918ab(5)
- Escherichia coli**, short-term ethanol consumption, R-E cell function of liver, Tc-99m sulfur colloid, 1ab(2), 815ab(5)
- Esophagus**
dilatation, assessment and follow-up, achalasia, 851ab(5)
- gastric emptying and, type 2 diabetes mellitus, 795ab(5)
- transit scintigraphy, effect of projection, 850ab(5)
- Ethanol**, short-term consumption, R-E cell function of liver, Tc-99m sulfur colloid, 1ab(2), 815ab(5)
- European Association of Nuclear Medicine Congress**, 1989, N1921
- European Economic Community**, symposium, N1588
- Europium-153**, dual radionuclide SPECT, flood radionuclide choice, Tc-99m base, 872ab(5)
- EXAFS spectroscopy**, structural studies on technetium, rhenium diphosphonates, 732ab(5)
- Exercise**
bicycle, silent myocardial ischemia, first pass radionuclide angiography, 868ab(5)
- dynamic, ambulatory ST changes and perfusion, dipyridamole "stress", 861ab(5)
- effects on myocardial kinetics, I-123 phenylpentadecanoic acid, 829ab(5)
- induced myocardial ischemia, iodine-123 fatty acid, compared to thallium-201, 729ab(5)
- one and two day rest and treadmill tests, comparison, Tc-99m HEXAMIBI, 790ab(5)
- peak, anaerobic threshold, left ventricular function, 1744ab(10)
- pulmonary uptake of thallium-201, 788ab(5)
- right ventricular uptake, Tc-99m MIBI and Tl-201, 820ab(5)
- RNV, compared to dipyridamole Tl-201 SPECT, jeopardized myocardium detection, 862ab(5)
- Tl-201 SPECT**
false positive, men, 749ab(5)
- myocardial perfusion abnormality, 749ab(5)
- treadmill, first-pass radionuclide angiography, 770ab(5)

Fab fragments

vigorous response, splenic platelet pool, 738ab(5)

F

Fab fragments

diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)

monoclonal antibodies, biodistribution, anti-mouse antibody effects, 847ab(5)
non-specific lymph node background, monoclonal antibody lymphoscintigraphy, 847ab(5)

radiolabeled monovalent and divalent haptens, dual specificity monoclonal antibody conjugates, 1358

Tc-99m labeled antibody-bifunctional chelator conjugates, 793ab(5)

Tc-99m monoclonal antibody, small cell lung carcinoma, 819ab(5)

Fat, Xe-133 hepatic retention ratio, 1708

Fatty acids

altered myocardial perfusion, small-vessel disease, 829ab(5)

characterization of carrier, human myocardium, 798ab(5)

I-123 phenylpentadecanoic acid, myocardial scintigraphy, 829ab(5)

myocardial metabolism, I-[C-11] betamethylheptadecanoic acid, 797ab(5)

radioiodinated, dual tracer autoradiography, cardiomyopathy, 80

radioiodinated IPPA and BMIPP, HPLC analysis, 923ab(5)

Feet, scintigraphic evaluation, 959ab(5)

Ferritin, transfer of In-111 and Ga-67, transferrin, phosphate-containing compounds, 70

Fibrin, -specific monoclonal antibodies, thrombus imaging, 747ab(5)

Fibrinopeptide, urinary, evaluation, pulmonary embolism, 733ab(5)

Filters

finite spatial, scintigraphic images, energy weighted acquisition, 2029

restoration, collimator, quantitative imaging with I-131 antibody, 876ab(5)

Wiener, combined conjugate views in SPECT, 756ab(5)

improved SPECT quantification, myocardial ischemia, 755ab(5)

Fistulae

hemodialysis, In-111 WBC enhancement, Tc-99m RBC subtraction, 10ab(4)

pleural cerebrospinal fluid, diagnosis, radionuclide cisternography, 120

tracheoesophageal, gastrointestinal visualization, Xe-133 ventilation study, 258

Fluorine, -substituted progestins, uptake selectivity, 928ab(5)

Fluorine-15, modified diuresis renography, uses and interpretation, 3ab(4)

Fluorine-18

automated blood sampler, high count rate, 745ab(5)

brain corticosteroid receptors, 821ab(5)
electrophilic, small proton cyclotron, 927ab(5)

fluorinated U-50488 analogs, characterization, PET studies, 931ab(5)

high-resolution positron emission tomography, clinical efficacy, 765ab(5)

least-squares optimization, reconstruction filters, high resolution PET, 745ab(5)
NO₂ aromatic nucleophilic substitution

reactions, no-carrier-added, nitrocinnamic acid derivatives, 1757ab(10)

PET and SPECT detection of residual viable tissue, myocardial infarctions, different ages, 869ab(5)

progesterone receptor binding ligands, PET, 929ab(5)

receptor imaging agents, direct analysis, binding assays, 931ab(5)

Fluorine-18 aromatic compounds, nucleophilic aromatic substitution, electron-rich aromatic rings, 753ab(5)

Fluorine-18 benzamide analogs, potential ligands, imaging dopamine D-2 receptors, PET, 899ab(5)

Fluorine-18 2-deoxy-2-fluoro-D-glucose, evaluation as imaging agent, malignant melanoma, 738ab(5)

PET, therapeutic effect, malignant lymphoma, 910ab(5)

Fluorine-18 deoxyglucose

cortical and thalamic glucose consumption, Huntington's disease, PET, 771ab(5)

PET

I-123 QNB SPECT, dementia, 896ab(5)
myocardial glucose utilization, 359
radiotherapy effect, tumor metabolism, 789ab(5)

relief of chronic ischemia, recovery of myocardial metabolism, 838ab(5)

visual analysis of PET images, reproducibility, reliability, 846ab(5)

Fluorine-18 DFPA, synthesis and biodistribution studies, 928ab(5)

Fluorine-18 estrogens, 17 α -ethynodiol-11 β -substituted, improved PET imaging agent, 753ab(5)

Fluorine-18 FES, estrogen receptor concentration, tamoxifen, 910ab(5)

Fluorine-18 fluoride

extraction from O-18 water, fibrous ion exchange resin, 926ab(5)

fluorination of heteroaromatic compounds, nucleophilic displacement, halide, 925ab(5)

new radiotracer for PET, dopamine D2 receptors, 1757ab(10)

Fluorine-18 fluorocinnarizine, synthesis, calcium channel blocker, 753ab(5)

Fluorine-18 fluorodeoxyglucose

automated radiopharmaceutical production, proton only cyclotron, 965ab(5)

automated synthesis, 2ab(11)

cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)

cerebral glucose metabolism, PET, Alzheimer's disease, 771ab(5)

compared to C-11 methionine, differential diagnosis, lung tumor, 788ab(5)

deoxyglucose and, regional comparison, lumped constants, 900ab(5)

"first session" effects in PET studies, 899ab(5)

kinetic rate constants, brain tumor and dementia, 900ab(5)

O-15 water PET, colorectal carcinoma, radiation therapy, 909ab(5)

PET, detection, residual or recurrent brain and liver tumors, 909ab(5), 966ab(5)

pancreas cancer, chronic pancreatitis differentiation, 887ab(5)

powder inhalation, pulmonary mucociliary transport, 917ab(5)

Tl-201 and I-123 IMP SPECT, brain tumor, 895ab(5)

two behavioral states, single procedure, 93

production, computer-controlled synthesis unit, 968ab(5)

radiation dose to bladder wall, dynamic bladder model, 1747ab(10)

radiotherapy, imaging of noncerebral tumors, 912ab(5)

regional cerebral metabolic rates, fixed

dephosphorylation rate, 1483

reversal of brain metabolic abnormalities, AIDS dementia treatment, AZT, 581

routine production, direct nucleophilic

exchange, quaternary ammonium resin, 1758ab(10)

uptake in benign and malignant musculoskeletal tumors, 1753ab(10)

uptake in human tumor xenografts, feasibility studies, cancer imaging, 912ab(5)

Fluorine-18 4-fluorodeprendyl, synthesis, probe, functional monoamine oxidase, 821ab(5)

Fluorine-18 fluoro-L-dopa

asymmetric synthesis, NCA nucleophilic fluorination, 752ab(5)

compartmental model, kinetics, cerebral tissues, 735ab(5)

importance of carbidopa, PET studies, 761ab(5)

pharmacokinetics, 1757ab(10)

presynaptic nigrostriatal function, Parkinson's disease, 761ab(5)

quality control procedure, brain dopamine neurons, 1249

Fluorine-18 fluoroestradiol, PET assessment of uptake, metastatic breast carcinoma, 788ab(5)

Fluorine-18 fluoroethylketanserin, no-carrier-added synthesis, cerebral serotonin S-2 binding ligand, 822ab(5)

Fluorine-18 fluoroethyl SCH-23390, no-carrier-added synthesis, mapping, cerebral dopamine D-1 receptors, 931ab(5)

Fluorine-18 fluorometaraminol, C-11 hydroxyephedrine alternative, heart neuronal imaging, 767ab(5)

Fluorine-18 fluoromisonidazole

detection of viable hypoxic myocardium, PET, 846ab(5)

enhanced extraction in jeopardized myocardium, PET assessment, 730ab(5)

hypoxia imaging of tumors, 789ab(5)

radiosynthesis, 343
retention, model, PET image interpretation, 735ab(5)

Fluorine-18 fluorotyrosine, cerebral metabolism, PET tracer of protein synthesis, 1367

Fluorine-18 fluoro-L-m-tyrosine, probe, presynaptic dopaminergic function, 752ab(5)

Fluorine-18 fluoro-D,L-m-tyrosine, tracer for dopamine neuron mapping, 752ab(5)

Fluorine-18 fluoropropyl prelamol, no-carrier-added synthesis, mapping, cerebral sigma opiate receptors, 930ab(5)

Fluorine-18 fluoropropylputrescine, potential PET imaging agent, prostate and prostate-derived tumors, 1205

Fluorine-18 haloperidol, binding in baboon and human brain, kinetic analysis, 898ab(5)

Fluorine-18 m-hydroxyphenylserine, synthesis, central norepinephrine tracer, 929ab(5)

Fluorine-18 misonidazole, myocardial kinetics, marker of hypoxia, 351

Fluorine-18 N-3-propyl diprenorphine, sex-dependent differences, distribution and metabolism, 732ab(5)

Fluorine-18 pipamperone, synthesis and PET studies, baboon, 932ab(5)

Fluorine-18 uracil changes in tumor volume, chemotherapy, colorectal carcinoma, 911ab(5)

N-13 glutamate and, perfusion and shunting, colorectal carcinoma, 910ab(5)

O-15 water and, PET, regional chemotherapy of liver metastases, 1754ab(10)

PET, metastatic colorectal cancer, 910ab(5)

Fluorine-19 magnetic resonance spectroscopy, 5-fluorouracil pharmacokinetics, 813ab(5)

nuclear magnetic resonance drug targeting, animal tumor models, 814ab(5)

5-fluorouracil trapping, therapeutic effectiveness, 813ab(5)

Fluoroacetate, acetate uptake and, glucose metabolic rate, 900ab(5)

Fluoroalkyl amphetamine analogs, synthesis and evaluation, serotonin 5-HT2 agonists, PET, 822ab(5)

Fluorodeoxyglucose causes of variability in studies, N1288 imaging and TI-201 redistribution, value of quantitative TI-201 SPECT, 863ab(5)

kinetic determination of model parameters, high-resolution PET, 879ab(5)

optimal experimental design, tissue data, 879ab(5)

parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)

-PET, evaluation of seizures, primary brain tumors, 2ab(11)

PET and MRI, pathologic findings, complex partial seizures, 752 ab(5)

relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)

whole body imaging technique for PET, 1750ab(10)

5-Fluorouracil pharmacokinetics, F-19 magnetic resonance spectroscopy, 813ab(5)

therapeutic effectiveness, F-19 nuclear magnetic resonance, 813ab(5)

Follicle-stimulating hormone, specificity of radioimmunoassay, polyclonal and monoclonal antibodies, 919ab(5)

Food and Drug Administration (FDA), pilot drug review division, N1147

Furosemide diuretic renography, 841ab(5)

serial renography, asymptomatic hydronephrosis, ultrasound, 4ab(4)

standard method vs. direct intrapelvic infusion, diuretic renography, 7ab(4)

G

Gadolinium, -labeled microspheres and liposomes, MRI, lung parenchyma, 901ab(5)

Gadolinium-153 clearance and organ distribution, MRI contrast agent, 840ab(5)

simultaneous transmission/emission SPECT, moving line source, 964ab(5)

Gadolinium-155, dual radionuclide SPECT, flood radionuclide choice, Tc-99m base, 872ab(5)

Gadolinium-DTPA brain uptake, blood-brain barrier integrity, MRI conditions, 839ab(5)

enhanced brain tumor imaging, T1 and T2 relaxation times, MRI, 902ab(5)

evaluation of musculoskeletal sarcomas, 901ab(5)

Gallbladder administration of contracting agent, reflux sign, cholescintigraphy, 1192

gastrointestinal transit, Crohn's disease, 764ab(5)

morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)

perforation, sensitivity, cholescintigraphy and sonography, 850ab(5)

Gallium, new amino-thiol ligand, radiopharmaceutical use, 922ab(5)

Gallium-67 apical pattern of lung uptake, AIDS, aerosolized pentamidine, 744ab(5)

"delayed" localization, clinical significance, 969ab(5)

detection of infected orthopedic implants, 754ab(5)

diagnostic accuracy of skeletal infection, blood pool sign, 774ab(5)

labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)

new generation scintillation camera system, 855ab(5)

radionuclide evaluation, acute pulmonary emboli, right ventricular function, 853ab(5)

relationship, TI-201 scintigraphy, lymphoma, 915ab(5)

SPECT, evaluation, recurrent lymphoma, 874ab(5)

Tc-99m DTPA lung clearance, HIV-related lymphocytic alveolitis, 746ab(5)

Tc-99m α -D-glucose 1-phosphate, lung carcinoma imaging, 913ab(5)

three-phase bone scans and, prediction, osteomyelitis cure, 754ab(5)

transfer from transferrin to ferritin, phosphate-containing compounds, 70

tumor accumulation, lysosomal role, dual-tracer studies, 921ab(5)

uptake rejecting and nonrejecting cardiac implants, 1464

tumors, whole body irradiated mice, 913ab(5)

utility 24-hour images in acute pulmonary processes, AIDS, 888ab(5)

transmission computerized tomography, lymphoma, 914ab(5)

Gallium-67 citrate detection of focal inflammation, scintigraphy, 385

detection of inflammatory lesions, Tc-99m HM-PAO leukocytes, 1332

diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935

nonspecificity of localization, sickle cell-related marrow infarction, 855ab(5)

scintigraphy, salmonella-infected thrombus, left ventricular aneurysm, 1277(le)

Tc-99m albumin comparison, lung scanning, HIV-positive patients, 917ab(5)

Gallium-67 DAS-DFO-fibrinogen, pitfalls in detection of thrombi, transplanted grafts, 914ab(5)

Gallium-67 deferoxamine, labeled antibody, spacer, maleimidioethyl succinimyl succinate, 832ab(5)

Gallium-67 MDP, distribution in rats, 857ab(5)

Gallium-67 monoclonal antibody, development of antibody cocktail, radioimmunodetection, adenocarcinoma, 935ab(5)

Gallium-68, labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)

Gallium-68 DTPA-VLDL, PET quantification, tissue low-density lipoprotein receptor activity, 763ab(5)

Gallium-69 transferrin, iron-59 and In-111, vascular permeability, transferrin receptor, 1676

Gamma cameras camera- and well-counting techniques, portal systemic shunting, 890ab(5)

commercially available SPECT systems assessment, 893ab(5)

assessment, progress report, 963ab(5)

four-headed, dynamic SPECT, regional cerebral blood flow, 792ab(5)

glomerular filtration rate inaccuracies, diverging collimator, 941ab(5)

high spatial resolution SPECT, small-animal resolution, 796ab(5)

image restoration and applications, 876ab(5)

line resolution pattern, new intrinsic resolution test pattern, 1134(le)

modern, comparison, imaging parameters, 3ab(2)

multiple-energy, dynamic transport studies, 852ab(5)

phantom feet on digital radionuclide images, 1559

renography, renal vein renin vs. peripheral plasma renin, renovascular hypertension, 6ab(4)

surgical imaging probe for tumor detection, 891ab(5)

technique for evaluation of anisotropy, collimators used for SPECT, 894ab(5)

Gangliosides, antigenic, radioimmunoassay, monoclonal antibodies, 919ab(5)

Gastric emptying abolition of discrimination between solids and liquids, erythromycin, 795ab(5)

esophageal and, type 2 diabetes mellitus, 795ab(5)

Garren-Edwards gastric bubble effect, 692

improved analytical method, 794ab(5)

influence of stress, 794ab(5)

left anterior oblique projection, peak-to-scatter ratio, attenuation compensation, 233

meal energy content effect, 1106

metoclopramide-induced patient restlessness, radionuclide imaging, 3ab(11)

modulation by blood glucose concentrations, type 1 diabetes mellitus, 795ab(5)

regulation of PET radiopharmaceuticals, N137 simplified analysis with PC-based system, weighted-least-squares regression, 794ab(5)

solid and caloric liquid meals, relationships, 887ab(5)

solid phase, reduced acquisition time, 1749ab(10)

Gastric function colonic scintigraphy, chronic constipation, 887ab(5)

gastroesophageal scintigraphy and barium exams, pH probe studies, pediatric patients, 2ab(2)

Gastrointestinal tract cancer radioimmunotherapy, monoclonal antibody administration, 779ab(5)

radiolabeled antibody imaging, chelating agents, 909ab(5)

Gated blood-pool studies

- two probe systems, In-111 monoclonal antibody, 891ab(5)
complete duodenogastric reflux, scintigraphic sign, 1568
correlative pediatric imaging, 15
dosimetric calculations, encapsulated nondigestible In-111 source, 882ab(5)
evaluation of blind loop syndrome, bile salts, 962ab(5)
functional disturbances, after abdominal irradiation, 765ab(5)
gallbladder and, Crohn's transit, 764ab(5)
inflammatory bowel disease autologous labeled In-111 leukocytes, 1ab(2)
In-111 white blood cells, 963ab(5)
transit, Tc-99m cellulose fiber, In-111 plastic particles, 402
visualization during Xe-133 ventilation study, tracheoesophageal fistula, 258
- Gated blood-pool studies**
- equilibrium gated radionuclide ventriculography, post extra systolic potentiation, 870ab(5)
 - evaluation of ventricular function parameters, sampling requirements, corrections, 872ab(5)
 - Fourier-gated PET, wall motion analysis, 771ab(5)
 - gated SPECT, aortic and mitral valve regurgitation, 870ab(5)
 - left ventricular function, assisted circulation, artificial heart, 780ab(5)
 - myocardial perfusion and regional wall motion, coronary anatomy, anterior infarction, 739ab(5)
 - regional ejection fraction, definition, normal limits, 769ab(5)
 - Tc-99m RBC labeling interference, chronic renal failure patients, 869ab(5)
 - three dimensional cinematic display, SPECT, 770ab(5)
 - visualization of pulsatile lung circulation, 744ab(5)
- Gated heart studies**
- detection of subendocardial ischemia, gated positron tomography, left ventricular hypertrophy, 866ab(5)
 - evaluation of ventricular function, coronary artery disease, 1149
 - quantification of amplitude images, 1393
 - quantification of 3D left ventricular segmental wall motion, radionuclide ventriculograms, 638
 - radial shortening and myocardial thickening, Tc-99m MIBI, echocardiography, 821ab(5)
 - realistic dynamic cardiac phantom, evaluation, radionuclide ventriculography, 542
- Gates' technique**
- glomerular filtration rate, factors affecting measurement, 842ab(5)
 - renal artery stenosis detection, captopril test, hypertensives, 51
 - validation in children, 2ab(2)
- Generators, isotope**
- carbon-based system, ultrashort-lived Ir-191m, left ventricular function, 1025
 - development, tellurium-118/antimony-118, 849ab(5)
 - iridium-99m left ventricular first pass angiography, exercise, coronary artery disease, 818ab(5)
 - Krypton-81m gas, long-lived radioactive contaminant, 1574(1e)
 - zirconium-tungsten gel, 849ab(5)

Glioma

- antibody guided diagnosis, epidermal growth factor receptor, placental alkaline phosphatase, 1636
 - glucose and deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)
 - intracarotid infusion, intravascular streaming, PET, 839ab(5)
 - rat model, use of C1 vs. C2, C-11 glucose, 911ab(5)
- Glomerular filtration rate (GFR)**
- Gates methodology, children, 1755ab(10)
 - quantitative calculations, Tc-99m DTPA camera images, 1747ab(10)
 - tubular secretion of MAG-3 and, rat kidney, 1986

Glucuheptone

- increased uptake, renovascular hypertension, 5ab(4)
- scintrenogram, captopril effect, renal artery stenosis, 1759ab(10)

Glucose

- cerebral metabolism Alzheimer's disease, correlation of visual symptoms, 772ab(5)
- Alzheimer's disease, disease severity, 965ab(5)
- carbox monoxide poisoning, 802ab(5)
- imaging of *in vivo* chemistry, N1288
- normals, patients with optic nerve damage, 802ab(5)
- quantitative comparison, two positron emission tomographs, 1386
- thirty vs. forty-five-minute period, 899ab(5)
- deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)

metabolism

- cerebral acetate, fluoroacetate uptake, 900ab(5)
- IBG as potential tracer, 921ab(5)
- psychiatric patients, summer affective disorders, 1752ab(10)
- modulation of gastric emptying, blood concentrations, type I diabetes mellitus, 795ab(5)
- myocardial uptake, dopamine infusion, regional ischemia, 859ab(5)
- myocardial utilization, PET, F-18 deoxyglucose, 359
- regional cerebral metabolic rates, fixed dephosphorylation rate, 1483
- three-dimensional visualization of brain, structure-function relationships, 1747ab(10)

Goodwin, David A., Distinguished Scientist Award, N14

- Granulocytes**, evaluation of labeling, Tc-99m D,L-HM-PAO, 2022
- Grave's disease**, anti-thyroid medications, thyroid scan, 1748ab(10)

H

- Halide**, nucleophilic displacement, fluorination, heteroaromatic compounds, 925ab(5)
- HAMA response**: *see* Antibodies, human anti-murine
- Haptens**, radiolabeled monovalent and divalent, dual specificity monoclonal antibody conjugates, 1358
- Haynie, Thomas P.**, "Last Thoughts from the Editor to a Future Trust", T21

Head

- irradiation for Hodgkin's disease, hyperthyroidism, low radioiodine uptake, 255

- trauma, metabolic PET correlates, anatomic lesions, 802ab(5)

Health Care Financing Administration (HCFA)

- ACR RVS close to implementation, Harvard study, second phase, N271
- implementation of ICD-9-CM codes, N580
- intention to deny Medicare coverage, bone mineral densitometry, N139
- PET coverage, N580

Heart

- acute coronary occlusion, critically ischemic myocardial mass, PET, 866ab(5)
- 180° and 360° reconstructions, TI-201 and Tc-99m SPECT, 756ab(5)
- angina pectoris, sympathetic nervous function, I-123 MIBG SPECT, 811ab(5)
- aortic and mitral valve regurgitation, gated SPECT, 870ab(5)
- artificial, left ventricular function, assisted circulation, 780ab(5)
- blood-pool scintigraphy, Tc-99m DTPA-HSA, 1713
- canine, myocardial retention, Tc-99m SQ30217, 860ab(5)
- cardiac MRI, dipyridamole effects, coronary artery disease, 840ab(5)
- cardiac RWMA, synthetic classification images, 816ab(5)
- cardiac wall motion abnormalities, automated detection, 961ab(5)
- cardiovascular nuclear medicine European Association of Nuclear Medicine Congress, N1921
- new Young Investigator Award, N14
- the next step, 1123
- characterization of *beta*-adrenergic receptors, CGP-12177, PET, 766ab(5)
- competition between palmitate and ketone bodies, fuels, 797ab(5)
- computer subtracted thallium cardiac images, 4ab(2)
- coronary bypass surgery, In-111 anti-myocin scintigraphy, 780ab(5)
- coronary insufficiency, cardiac events predictor, exercise radionuclide ventriculography, 1745ab(10)
- correlative pediatric imaging, 15
- cultured cardiac cells, TI-201 and Tc-99m MIBI uptake, 860ab(5)
- Cu(PTSM) localization, microsphere blood flow, 848ab(5)
- detection of acute cardiac injury, Tc-99m glucaric acid, 1743ab(10)
- detection of myocardial abscess, In-111 leukocyte scintigraphy, endocarditis, 703
- diagnosis of coronary stenosis, application, machine intelligence, 816ab(5)
- dynamic management of cardiological data, practical use, full relational model, 873ab(5)
- early detection of mechanical-overload failure, clonidine pre-treatment, I-123 MIBG SPECT, 810ab(5)
- economic analysis of clinical PET, Rb-82, 707
- effect of stereochemistry, Tc-99m isonitrile, 773ab(5)
- evaluation, renal imaging, thallium-201, 2ab(4)
- gated cardiac blood-pool studies, three-dimensional display, 2036
- high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
- human organ transplants, evaluation of viability, magnetic resonance spectroscopy,

- 813ab(5)
imaging agent synthesis, 4-O-(E)-iodopropenyl glucose, 3ab(11)
I-125 MIBG imaging, idiopathic congestive cardiomyopathy, cardiac transplants, 1182
impaired diastolic function, hypertensive patients, no left ventricular hypertrophy, 780ab(5)
importance of timing, Rb-82 PET, 871ab(5)
In-111 antimyosin pharmacokinetics, radiation dosimetry, 833ab(5)
independence of C-11 acetate kinetics, dietary state, 837ab(5)
ischemic disease, adenosine infusion, TI-201 SPECT, 1745ab(10)
kinetics of copper-PTSM, PET, 1843
left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
-lung transplantation, regional pulmonary perfusion, 1297
microsphere-like retention, copper-PTSM, blood flow and PET, 768ab(5)
myocardial imaging agents, synthesis, technetium-nitride cations, 773ab(5)
myocardial kinetics and exercise, I-123 phenylpentadecanoic acid, 829ab(5)
myocardial perfusion imaging percholate, failure to inhibit Tc-99m isonitrile thyroid binding, 885ab(5)
simultaneous Tc-99m MIBI angiography, 38
neuronal imaging
 C-11 hydroxyephedrine, 6-[F-18] fluorometaraminol, 767ab(5)
 C-11 m-hydroxyephedrine synthesis, 783ab(5)
neuronal markers, H-3 phenylephrine, H-3 epinephrine, 733ab(5)
neutral and cationic myocardial perfusion agents, mechanistic comparison, 757ab(5)
no-carrier-added I-123 iodocyanopindolol, rapid high yield synthesis, 859ab(5)
noninvasive detection of left-to-right shunts, carbon-15 oxygen, cardiac PET study, 865ab(5)
non-uniform attenuation correction, SPECT, iterated radial post correction method, 870ab(5)
novel Tc-N₂S₂ complex, synthesis, characterization, 773ab(5)
parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)
percutaneous aortic balloon valvuloplasty, radionuclide ventriculography, 867ab(5)
percutaneous transluminal coronary angioplasty, scintigraphy, myocardial reperfusion, 821ab(5)
perfusion imaging, Tc-99m MIBI, 790ab(5)
PET scans, partial volume and spillover correction, 824ab(5)
PET studies, N1289
postexercise lung TI-201 uptake, SPECT, 288
pulse sequence of cine NMR imaging, 4ab(2)
radioiodinated IPPA and BMIPP fatty acid, HPLC analysis, 923ab(5)
rate, myocardial TI-201 uptake and clearance, 1972
realistic dynamic cardiac phantom, radionuclide ventriculography, 542
reconstruction of truncated fan beam data, 755ab(5)
regional flows, capillary permeability, 798ab(5)
regional myocardial oxygen consumption, C-11 acetate PET, 1798
shunt size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
SPECT imaging, correction, nonuniform attenuation, 497
synthesis of aqueous N-13 ammonia, proton irradiation of water, hydrogen pressure, 926ab(5)
Tc-99m complexes with ester analogues, biological characteristics, 937ab(5)
three-dimensional cardiac PET, automated quantitation, routine clinical use, 775ab(5)
three-dimensional characterization of metabolism, PET, 808ab(5)
three-dimensional PET, automated quantitation, routine clinical use, 1787
total artificial, functional assessment, blood-pool radionuclide angiography, 1405
transplantation
 clinical utility, radionuclide ventriculography, 781ab(5)
 noninvasive follow-up, In-111 antimyosin scintigraphy, 862ab(5)
transplant rejection, diagnosis, In-111 antimyosin Fab mAb imaging, 847ab(5)
"upward creep", false-positive reversible defects, TI-201 stress-redistribution SPECT, 1718
use of mercury-thiol resin, preparation, I-123 IPPA, 925ab(5)
value of blood-pool subtraction, In-111 platelets, 1445
whole body distribution and kinetics, cocaine, 831ab(5)
Hemangioma
hepatic, early blood pool phases, Tc-99m red blood cells, 815ab(5)
liver, scintigraphic and ultrasound features, 181
noncalcified splenic, detection, radionuclide bone scan, 1111
soft tissue, Tc-99m RBC scanning, 799ab(5)
Hemodialysis
access site infection, radionuclide diagnosis, 804ab(5)
fistulas, In-111 WBC enhancement, Tc-99m RBC subtraction, 10ab(4)
Heparin, -protamine reaction, In-111 protamine scanning, sheep, 917ab(5)
Hepatobiliary imaging
cholescintigraphy and sonography, sensitivity, gallbladder perforation, 850ab(5)
deconvolutional analysis of scans, jaundiced infant, 9ab(4)
early tumor response to therapy, PET, 789ab(5)
hepatobiliary dysfunction, cyclosporine A toxicity, Tc-99m EHIDA, 921ab(5)
morphine-augmented cholescintigraphy, 850ab(5)
scintigraphic features, choledochal cyst, 622
scintigraphy, morphine, potential pitfalls, 850ab(5)
semiquantitative scintigraphy, functional parameters, orthotopic liver transplant, 888ab(5)
Hevesy Nuclear Medicine Pioneer Award, John G. McAfee, N577
Hexadentate, bifunctional chelating agents, radiolabeling of antibodies, 1758ab(10)
Hexokinase, Michaelis-Menten kinetics, glucose and deoxyglucose phosphorylation ratio, brain and gliomas, 838ab(5)
Hip
arthroplasty, three-phase bone scan, indium white blood cell scintigraphy, 1321
asymptomatic cementless arthroplasty, bone scanning, femoral component, 858ab(5)
detection of infected prosthesis, Tc-99m phosphonate bone and In-111 leukocyte scanning, 562(ab)
fractures, radionuclide bone imaging, early detection, 843ab(5)
SPECT, correction, bladder artifact, 857ab(5)
Hippurate, post-transplant renograms, long-term graft development, 784ab(5)
Hodgkin's disease, hyperthyroidism with low radioiodine uptake, head and neck irradiation, 255
Holmium-165, activation in biodegradable microspheres, 836ab(5)
Holmium-166 FHMA, new agent for radiation synovectomy, 856ab(5)
Holospectral imaging, analysis of scatter, quantum noise, camera non-uniformity, 807ab(5)
Human immunodeficiency virus (HIV)
 -associated myositis, detection, radionuclide bone scanning, 556
 -positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)
 -positive patients, Tc-99m albumin and Ga-67 citrate, lung scanning, 917ab(5)
 -related lymphocytic alveolitis, Tc-99m DTPA lung clearance, gallium scans, 746ab(5)
Huntington's disease
 cortical and thalamic glucose consumption, reduction, PET, 771ab(5)
 detection of striatal functional impairment, primate model, PET, 762ab(5)
 evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
Hydrogen-3, radioimmunoassay, cyclosporine concentrations, whole blood, 786ab(5)
Hydrogen-3 epinephrine, neuronal marker for heart, 733ab(5)
Hydrogen-3 fluoromisonidazole, binding of hypoxic cell marker, ischemic myocardium, 194
Hydrogen-3 α-methyl-L-m-tyrosine, tracer for dopamine neuron mapping, 752ab(5)
Hydrogen-3 m-hydroxyephedrine, neuronal marker for heart, 733ab(5)
Hydrogen-3 MK 329, cholecystokinin receptor localization, 849ab(5)
Hydrogen-3 L-m-tyrosine, tracer for dopamine neuron mapping, 752ab(5)
Hydrogen-3 phenylephrine, neuronal marker for heart, 733ab(5)
Hydronephrosis
 antenatal, diuretic renography, 799ab(5)
 asymptomatic, serial furosemide renography, ultrasound, 4ab(4)
 lasix renal scintigraphy, pressure-perfusion test, 944ab(5)
 renal parenchymal transit time of Tc-99m MAG₃, factor analysis, ROI selection, 3ab(4)
Hyperemia, forearm blood flow measurements, Tc-99m serum albumin, after brachial arteriotomy, 45
Hyperplasia, focal nodular, hepatocellular carcinoma diagnosis, Tc-99m DISIDA, 1278(ab)
Hypertension
 captopril-enhanced renal scintigraphy, Tc-99m DTPA, 615
 captopril test, 1422(ab)
 decreased renal blood flow, extracorporeal shock wave lithotripsy, 4ab(11)
 essential, intrarenal plasma flow, angiotensin converting enzyme, 6ab(4)
 glomerular filtration rate, atrial natriuretic peptide, 941ab(5)

- impaired diastolic function, without left ventricular hypertrophy, 780ab(5)
- neonatal**, captopril scintigraphy, 798ab(5)
- renal artery stenosis detection, Gates' technique, captopril test, 51
- renovascular**
- captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
 - captopril renography, duplexsonography, 6ab(4)
 - diagnosis, captopril scintigraphy, 944ab(5)
 - increased glucoheptonate uptake, 5ab(4)
 - parametric imaging, renal function, 5ab(4)
 - primary parenchymal disease vs. secondary disease, 942ab(5)
 - renal vein renin vs. peripheral plasma renin, gamma camera renography, 6ab(4)
 - Tc-99m MAG, clearances, captopril, 666
 - two-kidney/two-clip, captopril-stimulated renography, renal vein renins, 5ab(4)
- Hyperthermia**, malignant, Tc-99m pyrophosphate scintigraphy, 718(1e)
- Hyperthyroidism**
- head and neck irradiation, 2063(1e)
 - low radioiodine uptake, head and neck irradiation, Hodgkin's disease, 255
 - nonimmunogenic, radioiodine, surgical treatment, 1960
 - primary, renal tubular reabsorption, 2ab(4)
 - TSH-receptor antibody measurements, clinical significance, 786ab(5)
- Hypoxia**
- F-18 fluoromisonidazole tumor imaging, 789ab(5)
 - marker, myocardial kinetics, F-18 misonidazole, 351
 - myocardial extraction of Tc-99m sestamibi, flow effects, thallium-201, 756ab(5)
 - ouabain and, myocardial uptake kinetics, Tc-99m HEXAMIBI and Tl-201, 1500
 - regions of low myocardial flow, 808ab(5)
- Hysterosalpingography**, radionuclide, radiation dosimetry, Tc-99m, 415(1e)
- I**
- Ibuprofen**, In-111 neutrophils, myocardial infarction, reperfusion injury, 859ab(5)
- Image processing**
- image restoration and, gamma camera, 876ab(5)
 - planar, Bayesian methods, ECT image reconstruction, 880ab(5)
 - principal axis transformation, image registration, 776ab(5)
- Image reconstruction**
- accuracy of contour detection, small objects, scintigraphic images, 806ab(5)
 - maximum likelihood, PET, 776ab(5)
- Immune complexes**, Tc-99m metallothionein-conjugated mouse mAb B72.3, pharmacokinetic evaluation, monkeys, 1351
- Immunogens**, synthetic peptide, cardiac myosin light chain 1 mAb, radioimmunoassay, 785ab(5)
- Immunoglobulin**
- complex formation, murine monoclonal antibodies, 10ab(4), 888ab(5)
 - detection of focal inflammation, scintigraphy, Ga-67 citrate and Tc-99m albumin, 385
- Immunoglobulin G**
- antibody labeling, rapid and efficient method, Tc-99m, 793ab(5)
 - biotinylated, rapid blood clearance, avidin infusion, 66
- conjugation of MoAb-CU-18, desferrioxamine In-111, oligosaccharide moiety, 936ab(5)
- In-111-labeled, monitoring response, antimicrobial therapy, 890ab(5)
- In-111 radiolabeled proteins, autoradiographic method, quantitation, 889ab(5)
- labeling with Rh-105 complexes, diethylenetriamine derivatives, 832ab(5)
- polyclonal, radionuclide imaging, atherosclerosis, 1095
- radioimmunotherapy of colorectal carcinoma xenografts, Y-90 CO17-1A, 935ab(5)
- Tc-99m-labeled, imaging, inflammatory arthritis, 2017
- yttrium-labeled anti-CEA monoclonal antibodies, radioimmunotherapy, 848ab(5)
- Immunoglobulin M**, monoclonal antibodies, pharmacokinetics, 909ab(5)
- Immunoreactivity**
- higher immunoreactive fraction, antigen-binding site protection, radiolabeling, 932ab(5)
 - monoclonal antibody, Lindmo double reciprocal analysis, 903ab(5)
- Immunoscintigraphy**
- charge modification of monoclonal antibodies, enhanced target localization, 762ab(5)
 - colorectal carcinoma, clinical value, 1646
 - diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
 - diagnostic efficacy, SPECT and I-131 anti-CEA/CA 19-9, colorectal cancer, 907ab(5)
 - effect of human anti-mouse antibodies, 786ab(5)
 - follow-up of cutaneous melanoma, 907ab(5)
 - human leukemia xenografts, radiolabel and antigen modulation, 889ab(5)
 - improved tumor uptake, In-111, Ga-67 and Ga-68, 762ab(5)
 - In-111 monoclonal antibody, ovarian carcinoma, 758ab(5)
 - liver metastases, Tc-99m monoclonal anti-CEA antibody, colorectal carcinoma, 748ab(5)
 - melanoma targeting, monoclonal antibody cocktail, human HMW-MAA, 390
 - preparation of new agents, 936ab(5)
 - prospective study, ovarian carcinoma, 758ab(5)
 - Tc-99m and I-131 monoclonal antibody, stage IV neuroblastoma, 904ab(5)
 - Tc-99m genetically engineered chimeric metallothionein antibody, 794ab(5)
- Immunospheres**, Tc-99m albumin, intravascular targeting, 934ab(5)
- Immunosuppression**
- Ga-67 uptake in tumors, whole body irradiated mice, 913ab(5)
 - local lymphoid irradiation, palladium-190, 890ab(5)
- Impotence**
- male
 - non-invasive technique, 784ab(5)
 - radioisotope penile plethysmography, 784ab(5)
- Indium-111**
- accumulation in liver, administration, B72.3 antibody, 1575(1e)
 - anti-EGF receptor monoclonal antibody, phase I, imaging trial, 746ab(5)
 - clinically practical quantitative SPECT, 881ab(5)
 - desferrioxamine, MoAb-CU-18 conjugation, oligosaccharide moiety, 936ab(5)
 - development of noninvasive test, colonic transit in man, 764ab(5)
 - encapsulated nondigestible source, dosimetry, human gastrointestinal tract, 882ab(5)
 - GYK-DTPA-B72.3 monoclonal antibody, breast cancer detection, 819ab(5)
 - inhibition of platelet thrombosis, biomaterials, calcium ion sequestrants, 859ab(5)
 - iron-59 and Ga-69 transferrin, vascular permeability, transferrin receptor, 1676
 - labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)
 - new amino-thiol ligand, radiopharmaceutical use, 922ab(5)
 - non-invasive radionuclide assessment, colonic transit, 764ab(5)
 - preparation of new agents, immunoscintigraphy, 936ab(5)
 - radiolabeled proteins in tissues, autoradiographic method, quantitation, 889ab(5), 1538
 - stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
 - thrombus imaging, fibrin-specific monoclonal antibodies, 747ab(5)
 - transfer from transferrin to ferritin, phosphate-containing compounds, 70
- Indium-111 antibodies**
- anti-CEA antibody, colorectal carcinoma, 908ab(5)
 - I-125 antibody and, dual isotope study, athymic mice, 374
- Indium-111 antimelanoma monoclonal antibody**, ZME-018, quantitative measurement, 885ab(5)
- Indium-111 antimyosin**
- delineation of myocardial damage, cardiomyopathy, 779ab(5)
 - pharmacokinetics, radiation dosimetry, 833ab(5)
 - scintigraphy, noninvasive follow-up, heart transplant, 862ab(5)
 - scintigraphy after coronary bypass surgery, 780ab(5)
 - Tc-99m MIBI and, post-infarction myocardial viability, 800ab(5)
 - Tc-99m pyrophosphate and, detection of different stages, myocardial infarction, 862ab(5)
- Indium-111 antimyosin Fab**
- monoclonal antibody imaging, diagnosis, acute heart transplant rejection, 847ab(5)
 - Tc-99m for anatomical landmarking, myocardial infarction, 800ab(5)
 - Tc-99m MIBI and, myocardial infarction, reperfusion, 757ab(5)
- Indium-111 chemotactic peptide**, rapid detection, focal sites of infection, 805ab(5)
- Indium-111 chloride**, joint imaging, rheumatoid arthritis, 855ab(5)
- Indium-111 DTPA**
- clinical assessment of colon transit, 887ab(5)
 - low-density lipoprotein imaging, receptor activity, 768ab(5)
 - molecular structure, 1235
 - plasma clearance in liver and kidney transplants, measurement, glomerular filtration rate, 942ab(5)
- Indium-111 DTPA-IgG**, brain uptake, blood-brain barrier integrity, MRI conditions, 839ab(5)
- Indium-111 granulocytes**, sequestration in lungs, 1531
- Indium-111 IgG**
- antimicrobial therapy, monitoring response,

- 890ab(5)
imaging of atherosomatous lesions, iliac and femoral vessels, 817ab(5)
- Indium-111 immunoconjugates**, improved tumor imaging, cyclohexylpolyaminocarboxylates, 934ab(5)
- Indium-111 leukocytes**
appearance of Paget's disease, 754ab(5)
autologous label, inflammatory bowel disease, 1ab(2)
compared to three-phase bone scintigraphy, pedal osteomyelitis, diabetics, 753ab(5)
hemodialysis site infection, radionuclide diagnosis, 804ab(5)
scintigraphy, bone photopenia, clinical significance, 1749ab(10)
 Tc-99m MDP images, false-positive, noninfected Charcot joints, 754ab(5)
 $\text{Tc-99m phosphonate}$ bone scanning, detection, infected hip prosthesis, 562(1e)
urinary tract activity, 889ab(5)
- Indium-111 low-density lipoproteins**, imaging of atherosclerotic lesions, 787ab(5), 788ab(5)
- Indium-111 metalloporphyrin**, tumor imaging, 738ab(5)
- Indium-111 monoclonal antibody**
anti-laminin, detection, irradiation lung injury, 916ab(5)
B72.3
breast cancer detection, 2ab(2)
colorectal cancer, 320
biodistribution and tumor localization, colorectal carcinoma, 747ab(5)
cold antibody administration, colorectal cancer, 809ab(5)
colon cancer, 905ab(5)
compared to Y-88 monoclonal antibody, biodistribution, colon carcinoma xenografts, 672
detection of recurrent colorectal carcinoma, 748ab(5)
development of antibody cocktail, radioimmunodetection, adenocarcinoma, 935ab(5)
epithelial membrane antigen, target antigen, colorectal cancer, 808ab(5)
evaluation of two probe systems, gastrointestinal cancer, 891ab(5)
I-131 and, renal cell carcinoma xenografts, 906ab(5)
immunoscintigraphy, ovarian carcinoma, 758ab(5)
metabolism in nude mouse tissues, 888ab(5)
subcellular kinetics, liver and tumor, 907ab(5)
TAG-72 and, tumor expression, relationship, 908ab(5)
ZCE 025
concentration, primary lung cancer, 905ab(5)
HAMA development patterns, colorectal carcinoma, 906ab(5)
- Indium-111 neutrophils**
myocardial infarction, reperfusion injury, 859ab(5)
pulmonary localization, endotoxemia, monoclonal antibodies, 852ab(5)
- Indium-111 oxine**
distribution of cell-bound activity, human leukocytes, 804ab(5)
-labeled peripheral blood mononuclear cells, lymphatic malignancies, 1005
platelet scintigraphy, thrombocytopenia, children, 1819
- Indium-111 plastic particles**, gastrointestinal transit, 402
- Indium-111 platelets**
human pancreatic transplants, 1470
scintigraphy, false-positive, 267(1e)
splenic dynamics, idiopathic thrombocytopenic purpura, 1546
value of blood-pool subtraction, cardiac imaging, 1445
- Indium-111 protamine**, scanning during heparin-protamine reaction, sheep, 917ab(5)
- Indium-111 TE-BAT**, new myocardial imaging agent, 367
- Indium-111 tropolone**, whole body and depth-independent build-up factor, platelet uptake, liver and spleen, 914ab(5)
- Indium-111 tumor necrosis factor**, breast carcinoma xenografts, 819ab(5)
- Indium-111 white blood cells**
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
enhancement of hemodialysis fistulas, Tc-99m RBC subtraction, 10ab(4)
evaluation of granulocyte labeling, Tc-99m D,L-HM-PAO , 2022
inflammatory bowel disease, 963ab(5)
vs. MRI, chronic complicated osteomyelitis, 754ab(5)
- Inflammation**, detection of lesions with Tc-99m HM-PAO leukocytes, compared to Ga-67 citrate, 1332
- Inflammatory diseases**, vertebral column, new scintigraphic technique, 856ab(5)
- In Memoriam**
Lakshman Rao Chervu, 723
Shanta Chervu, 723
William Graydon Myers, 1129
- Interferon**, response to therapy, hairy-cell leukemia, $\text{Tc-99m colloid liver/spleen scans}$, 2ab(2)
- Interferon- α A**, effect on monoclonal antibody targeting, carcinoma, 809ab(5)
- Iodine**
antigen-binding site protection, radiolabeling, higher immunoreactive fraction, 932ab(5)
-substituted benzamides, high affinity, SPECT, 803ab(5)
- Iodine-123**
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, colorectal carcinoma, 809ab(5)
diagnostic imaging of amyloidosis, 847ab(5)
diazepam derivative, benzodiazepine receptor, SPECT studies, 803ab(5)
N-(ω -iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, SPECT, 925ab(5)
3-iodo-MK-801, NMDA receptor-ion channel complex, SPECT, 923ab(5)
iodovinylestrogens, steroid and triphenylethylene-based, 924ab(5)
labeled SPECT cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
octreotide, metabolism, clinical applications, 768ab(5)
radioiodinated digoxin derivative, myocardial imaging agent, Na,K-ATPase binding, 923ab(5)
radionuclide evaluation, acute pulmonary emboli, right ventricular function, 853ab(5)
scintigraphy of adrenergic receptors and neurons, myocardial infarcts, 767ab(5)
thyroid uptake, techniques for measurement, 886ab(5)
- Iodine-123 amines**
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
single-pass extraction, primate brain, 901ab(5)
- Iodine-123 anti-CEA monoclonal antibody**, early and delayed radioimmunoscinigrams, evaluation, colorectal carcinoma, 890ab(5)
- Iodine-123 estradiol**, breast cancer detection, 844ab(5)
- Iodine-123 Fab fragments**
anti-CEA imaging, 903ab(5)
monoclonal anti-CEA antigen, pretherapy dosimetry, 962ab(5)
- Iodine-123 fatty acid**
compared to thallium-201, exercise-induced myocardial ischemia, 729ab(5)
comparison of SPECT and TI-201, coronary artery disease, 739ab(5)
- Iodine-123 FISCH**, characterization, D-1 dopamine receptor imaging ligand, 830ab(5)
- Iodine-123 fragment E1**, imaging thrombi with improved formulation, 817ab(5)
- Iodine-123 halodeoxyuridines**, Auger electron radiotherapy, intraperitoneal cancer, 833ab(5)
- Iodine-123 HEAT**, use of carrier, 1916(1e)
- Iodine-123 HIPDM**
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
SPECT, surgery candidates, refractory complex partial seizures, 751ab(5)
- Iodine-123 hippuran**, renal allograft evaluation, radionuclide scintigraphy, aspiration biopsy, 785ab(5)
- Iodine-123 hippurate**, Tc-99m MAG , clearance and, renal scintigraphy, 2ab(4)
- Iodine-123 IBF**, potential CNS D-2 dopamine imaging agent, 762ab(5)
- Iodine-123 IBHPE**, biodistribution studies, novel non-steroidal estrogen, 883ab(5)
- Iodine-123 IBZ**, potential D-2 dopamine receptor imaging agent, 88
- Iodine-123 IBZM**
D2 receptor agent, biodistribution, dosimetry, 834ab(5)
imaging of basal ganglia, 731ab(5)
preparation, peracetil acid, superior oxidant, 926ab(5)
- Iodine-123 IMP**
aerosol, assessment, inhalation lung imaging, 853ab(5)
brain perfusion imaging, schizophrenia, 1616
brain SPECT in neonates, 1337
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
3D brain imaging, CT and MRI comparisons, 961ab(5)
dynamic SPECT and, tomographic mapping, kinetic rate constants, 805ab(5)
dynamic SPECT with Tc-99m HM-PAO , meningiomas, 1101
early and delayed SPECT, acute brain injury, 1751ab(10)
effect on brain uptake, iodoamphetamine, 830ab(5)
local cerebral blood flow, Parkinson's disease, 830ab(5)
PET, regional cerebral blood flow, 157
portasystemic shunt fraction quantification, 1702
quantitative cerebral blood flow activation, emission tomography, 811ab(5)
redistribution and metabolism, brain ischemia, 897ab(5)
regional cerebral blood flow, normal subjects,

Iodine-123 *N*-iodoallylpiperone

1753ab(10)
regional dynamics in human brain, 150
SPECT
brain tumor usefulness, F-18 FDG PET, 895ab(5)
children, alternating hemiplegias, 965ab(5)
craniosynostosis, 916ab(5)
critical cerebral blood flow thresholds, 337
functional imaging, brain maturation, 1982
HIV-positive encephalopathy, 811ab(5)
Tc-99m HM-PAO and, discordance, subacute cerebral infarct, 1752ab(10)
temporal changes in brain accumulation, lung clearance, 1977
validity of microsphere model, cerebral blood flow, 878ab(5)

Iodine-123 *N*-iodoallylpiperone, synthesis, dopamine D-2 receptor studies, 803ab(5)

Iodine-123 iodobenzamide, dopamine D2 receptor imaging, SPECT, 731ab(5)

Iodine-123 iodocyanopindolol, no-carrier-added, rapid high yield synthesis, 859ab(5)

Iodine-123 iodo-2'-deoxyuridine, early ascites tumor model, 882ab(5)

Iodine-123 6-iodydopa, potential SPECT brain imaging agent, 924ab(5)

Iodine-123 iodoestradiol, interaction with estrogen receptor, 209

Iodine-123 iodoluride, new SPECT imaging agent, brain dopamine D-2 receptors, 731ab(5)

Iodine-123 iodo- α -methyltyrosine
brain SPECT, validation with PET, 895ab(5)
brain tumor imaging, SPECT, 110

Iodine-123 IPPA, use of mercury-thiol resin for preparation, 925ab(5)

Iodine-123 isopropyliodoamphetamine, central area of cerebral infarcts, spontaneous evolution, 781ab(5)

Iodine-123 low-density lipoprotein, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)

Iodine-123 MIBG
detection of depleted myocardial catecholamine stores, acute myocardial infarction, 810ab(5)
early detection of mechanical-overload heart failure, clonidine pre-treatment, SPECT, 810ab(5)
first pass extraction fraction, swine heart, 767ab(5)
myocardial sympathetic nervous function, angina pectoris, SPECT, 811ab(5)
scintigraphy
children with neuroblastoma, 799ab(5)
myocardial sympathetic nerve development, 810ab(5)
uptake by chemodectomas, 769ab(5)

Iodine-123 phenylpentadecanoic acid
exercise effects, myocardial kinetics, 829ab(5)
myocardial fatty acid utilization, recurrent chest pain, SPECT, 828ab(5)
tomography, CAD detection, dipyridamole infusion, 760ab(5)

Iodine-123 QNB, SPECT, F-18 deoxyglucose PET, dementia, 896ab(5)

Iodine-123 SCH-23982, D-1 receptor-based SPECT studies, 804ab(5)

Iodine-123 spiperone, tracer for D-2 receptor studies, SPECT, 926ab(5)

Iodine-123 tyramine-cellulose, low-density lipoprotein estimation, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)

Iodine-124, PET applications, immunotherapeutic radiopharmaceuticals, 922ab(5)

Iodine-124 2-idoisonicotinic acid hydrazide, radiotracer for tuberculoma, 1756ab(10)

Iodine-125
effects of interferon- α A, monoclonal antibody targeting, carcinoma, 809ab(5)
full retention of immunoreactivity, antibody labeling, site-specific methods, 831ab(5)
high spatial resolution SPECT, small-animal resolution, 796ab(5)
3-iodo-MK-801, NMDA receptor-ion channel complex, SPECT, 923ab(5)
iodovinylestrogens, steroid and triphenylethylene-based, 924ab(5)
new radioimmunoassay, simultaneous measurement, serum T3 and T4, 919ab(5)
non-specific lymph node background, monoclonal antibody lymphoscintigraphy, 847ab(5)
plasma turnover studies, serum amyloid P component, 847ab(5)
radioimmunoassay, cyclosporine concentrations, whole blood, 786ab(5)
seed implants, dosimetry, SPECT, 1748ab(10)
serum osteocalcin, bone scintigram, prostate carcinoma, 918ab(5)
specificity of radioimmunoassay for LH and FSH, monoclonal and polyclonal antibodies, 919ab(5)

Iodine-125 antibody, In-111 antibody and, dual isotope study, athymic mice, 374

Iodine-125 cholesterol iopanoate, uptake into steroid hormone-secreting tissues, enhancement, lipoprotein, 1088

Iodine-125 cyclosporine, comparison of INCSTAR CYCLOTAC and SANDOZ SANDIMMUNE, whole blood assays, 3ab(2)

Iodine-125 FISCH, improved imaging ligand, dopamine D-1 receptors, 803ab(5)

Iodine-125 IMP, compared to Tc-99m D,L-HM-PAO, autoradiographic analysis, 938ab(5)

Iodine-125 iodophenyl-6-selenapentadecanoic acid, preparation and evaluation, 968ab(5)

Iodine-125 iothalamate
I-131 OIH and Tc-99m MAG₃, comparisons, renal ischemia, 1ab(4)
renal ischemia, 823ab(5)

Iodine-125 IPPA, myocardial kinetics, quantitative analysis, 1211

Iodine-125 low-density lipoprotein, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)

Iodine-125 MHTP, mechanism of accumulation, dopaminergic radiotracer, 761ab(5)

Iodine-125 MIBG
denervated but viable canine myocardium, acute myocardial infarction, thallium SPECT, 767ab(5)
heart imaging, idiopathic congestive cardiomyopathy, cardiac transplants, 1182
uptake, human neuroblastoma nude mode xenograft, 884ab(5)
uptake and histopathology, neuroblastoma, 836ab(5)
uptake in children, neuroblastoma, tumor histopathology, 474

Iodine-125 monoclonal antibody, isotype switch variant anti-idiotype mAb, comparative radiolabeling, 227

Iodine-125 *N*-iodoallylpiperone, synthesis, dopamine D2 receptor studies, 803ab(5)

Iodine-125 phospholipid ether, tumor imaging agents, 849ab(5)

Iodine-125 3-(R)-quinuclidinyl (S)-4-iodobenzilate, *in vitro* and *in vivo* characteristics, 1079

Iodine-125 tyramine-cellulose, low-density lipoprotein estimation, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)

Iodine-131
anti-CA 12.5 radioimmunodetection, follow-up ovarian carcinoma, 758ab(5)
anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
anti-pan-B cell antibodies, radioimmunotherapy, non-Hodgkin's lymphoma, 828ab(5)
diffuse hepatic uptake, total body scans, thyroid cancer, 4ab(2)
effectiveness of radionuclide treatment, differentiated thyroid cancer, 737ab(5)
excretion in breast milk, 124, 127(le)
heavy activity radioiodination, monoclonal antibodies, iodogen particle suspensions, 933ab(5)
hyperthyroidism treatment, extra-thyroidal absorbed doses, 833ab(5)
improved determination of uptake, metastatic thyroid carcinoma, 737ab(5)
new generation scintillation camera system, 855ab(5)
new radioimmunoassay, simultaneous measurement, serum T3 and T4, 919ab(5)
para-iodophenyl conjugates of antibodies, synthesis, radioiodination, 924ab(5)
prospective immunoscintigraphic study, ovarian carcinoma, 758ab(5)
quantitation of therapeutic concentration, SPECT, 737ab(5)
radiolabeled conjugates of monoclonal antibodies, fragments, urinary metabolites, 793ab(5)
scintigraphy, Tl-201 comparison, thyroid carcinoma follow-up, 914ab(5)
solitary autonomous thyroid nodules, long-term follow-up, 736ab(5)
toluidine blue, mediastinal parathyroid adenoma, 768ab(5)

Iodine-131 antibody
importance of collimator and restoration filter, quantitative imaging, 876ab(5)
uptake and clearance, bone marrow, 826ab(5)

Iodine-131 anti-CEA/CA 19-9, diagnostic efficacy of immunoscintigraphy, colorectal cancer, 907ab(5)

Iodine-131 anti-idiotype monoclonal antibody, B cell lymphoma therapy, external beam irradiation, 826ab(5)

Iodine-131 beta dose point kernels, potential use in radioimmunotherapy, 1036

Iodine-131 cellulose, oral, colonic transit, health and constipation, 764ab(5)

Iodine-131 hippuran
Tc-99m DTPA and, early detection, diabetic nephropathy, 941ab(5)
Tc-99m MAG₃ and, clearances, renal plasma flow, 823ab(5)

Iodine-131 HMFG1, trial diagnostic distribution and dose-controlled therapy, otherwise incurable ovarian carcinoma, 759ab(5)

Iodine-131 immunoglobulin G, pretherapy dosimetry, comparison, I-123 Fab fragments, 962ab(5)

Iodine-131 lym-1, chronic lymphocytic leukemia, 827ab(5)

Iodine-131 MIBG

- alterations of biodistribution, impaired renal function, 6ab(4)
- biodistribution alterations, anephritic patient, 1476
- localization of pheochromocytoma, correlation with CT and MRI, 328
- reduction of uptake by betalol, pheochromocytoma, normal tissues, 481
- scintigraphy, occult lung metastasis, pheochromocytoma, 885ab(5)
- therapeutic use
- neural crest tumors, 769ab(5)
 - treatment, resistant neuroblastoma, 903ab(5)
- treatment of metastatic carcinoid tumor, 836ab(5)
- uptake, human neuroblastoma nude mouse xenograft, 884ab(5)
- Iodine-131 monoclonal antibody**
- B72.3, colorectal cancer, 320
- curative radioimmunotherapy, mammary carcinoma xenografts, 531
- estimating dosimetry, whole body profile scanning, 884ab(5)
- HMFG1, CA 125 RIA, ovarian cancer, 918ab(5)
- imaging of hepatic metastases, colorectal carcinoma, 809ab(5)
- In-111 and, renal cell carcinoma xenografts, 906ab(5)
- ovarian cancer, kinetics, nude mice and patients, 883ab(5)
- stage IV neuroblastoma, 904ab(5)
- successful serial radioimmunotherapy, HAMA response, 827ab(5)
- Iodine-131 OC 125**, intraperitoneal, advanced ovarian cancer, 904ab(5)
- Iodine-131 OIH**
- renal ischemia, 823ab(5)
- Tc-99m MAG₃ clearances
- captopril, renovascular hypertension, 666
 - iotalamate comparisons, renal ischemia, lab(4)
- renal plasma flow, 823ab(5)
- renal plasma flow, renal artery stenosis, lab(4)
- Tc-99m DTPA comparison, follow-up renal transplants, 4ab(4)
- Iodine-131 ortho iodo hippurate**, renal transplant and lymphoceles, 3ab(11)
- Iodine-131 sodium iodide**, new coated-bead dosage form, 886ab(5)
- Iodine-137 MIBG**, myocardial uptake, primary hypertrophic cardiomyopathy, 810ab(5)
- Iodoantipyrine**, labeled with radioactive iodine, dosimetry, lab(2)
- Iodobenzamide**, new analogs, potential D-2 dopamine imaging agents, 803ab(5)
- para-Iodo-benzyl alcohol ester**, antibody conjugate, synthesis, radioiodination, 924ab(5)
- Iodophenyl pentadecanoic acid**, noninvasive testing, hypoxic myocyte metabolism, 860ab(5)
- 4-O-(E)-Iodopropenyl glucose**, synthesis, brain and heart imaging agent, 3ab(11)
- Iodovinylestrogens**, steroid and triphenylethylene-based, biodistribution, metabolism, 924ab(5)
- Iofetamine**, SPECT, child psychiatry, "beam" brain mapping, 966ab(5)
- Iridium-191m**
- clinical usefulness, carbon-based generator system, left ventricular function, 1025
 - first pass left ventricular ejection fraction, 817ab(5)
- left ventricular first pass angiography, Tl-201 perfusion during exercise, coronary artery disease, 818ab(5)
- Os-191 generator based on silica gel, impregnation, tridodecylmethylammonium chloride, 538
- radionuclide angiography, evaluation, ventricular function, 450
- Iron-59**, In-111 and Ga-69 transferrin, vascular permeability, transferrin receptor, 1676
- Irradiation**
- abdominal, gastrointestinal functional disturbances, 765ab(5)
 - external beam
- combined with radioimmunotherapy, renal cell carcinoma xenografts, 826ab(5)
 - I-131 anti-idiotype mAb, B cell lymphoma, 826ab(5)
- head and neck, hyperthyroidism, 2063(ie)
- rapid and sensitive response, carbon-11-L-methionine tumor uptake, 2012
- volunteers in nuclear medicine, 260, 2062(ie)
- Ischemia**, preoperative prediction of reversible asynergy, rest-stress myocardial positron tomography, 1302
- Isotopes**, production and distribution office, DOE, N1933
- Ivalon**, improved radiolabeling technique, monitoring, therapeutic transcatheter embolization, 1399
- J**
- Jaudice**, infant, deconvolutional analysis, hepatobiliary scans, 9ab(4)
- Joint**
- bone diseases and, Tc-99m granulocytes, 1743ab(10)
 - Charcot, false-positive, In-111 leukocyte/Tc-99m MDP images, 754ab(5)
 - In-111 chloride imaging, rheumatoid arthritis, 855ab(5)
 - radiation synovectomy, radiopharmaceuticals, Y-90 particulate agents, 1047
 - reflex sympathetic dystrophy, lower extremities, bone scintigraphy, 856ab(5)
 - sacroiliitis, MRI and radiography, bone scintigraphy, 842ab(5)
 - scintigraphy, Tc-99m IgG, inflammation, 889ab(5)
 - subtalar, non-osseous coalitions, bone scintigraphy, 799ab(5)
- K**
- Kawasaki disease**, dipyridamole-redistribution Tl-201 ECT, children, 760ab(5)
- Ketone bodies**, palmitate and, competition as fuels, heart, 797ab(5)
- Kidney**
- abnormal mobility, radionuclide features, clinical relevance, 3ab(4)
 - anephritic patient, alterations, I-131 MIBG, 1476
 - antenatally diagnosed pelviureteric junction obstruction, conservative management, 5ab(4)
 - atherosclerotic renal artery stenosis, outcome of treatment, quantitative renography, 1946
 - bilateral renal artery stenosis, pitfall, captopril renal scintigraphy, 2042
 - blood flow, captopril, angioplasty in renal artery stenosis, 841ab(5)
 - captopril-enhanced renal scintigraphy, hypertension evaluation, Tc-99m DTPA, 615
 - captopril-stimulated renography, renal vein renins, hypertension, 5ab(4)
 - chronic renal failure patients, Tc-99m RBC labeling interference, 869ab(5)
 - clearance of Tc-99m MAG₃, simplified methods, 943ab(5)
 - comparison of radioactive agents, cisplatin-induced tubular toxicity, 659
 - correlative pediatric imaging, 15
 - cyclosporine nephrotoxicity, pathophysiology, 784ab(5)
 - decreased blood flow and hypertension, complications, renal lithotripsy, 842ab(5)
 - "delayed" Ga-67 localization, clinical significance, 969ab(5)
 - depth, radionuclide renal studies, 1745ab(10)
 - diuretic renography
 - antenatal hydronephrosis, 799ab(5)
 - standard furosemide method, direct infusion comparison, 7ab(4) - DMSA studies, infants under one year of age, 5ab(4)
 - estimated differential renal clearance, dynamic Tc-99m DTPA imaging, compartmental model analysis, 877ab(5)
 - evaluation of MAG₃-like compounds, 937ab(5)
 - factors affecting Gates' GFR measurement, 842ab(5)
 - functional changes, extra-corporeal piezoelectric lithotripsy, 943ab(5)
 - functional renal imaging post lithotripsy, 942ab(5)
 - glomerular filtration rate
 - atrial natriuretic peptide, essential hypertension, 941ab(5)
 - diverging collimator, SFOV gamma camera, 941ab(5) - In-111 DTPA plasma clearance, liver and kidney transplants, 942ab(5)
 - partial obstruction, long-term follow-up, 4ab(4)
 - radionuclide assessment, protein diet, 785ab(5)
 - tubular secretion of MAG-3, 1986
 - handling of Tc-99m and Re-186 CO₂DADS, pair applications, 743ab(5)
 - handling of Tc-99m DMSA, glomerular filtration, peritubular uptake, 1219
 - handling of Tc-99m MAG₃, 1ab(4)
 - high-resolution Tc-99m DMSA SPECT imaging, 1759ab(10)
 - hot, radionuclide bone scans, cancer patients, 858ab(5)
 - imaging of Tl-201, cardiac thallium evaluation, 2ab(4)
 - impaired renal function, alterations, I-131 MIBG biodistribution, 6ab(4)
 - importance of Tc-99m glucoheptonate scintigraphy, first UTI, infants, 915ab(5)
 - ischemia, I-131 OIH, Tc-99m MAG₃ and I-125 iotalamate, lab(4), 823ab(5)
 - lasix renal scintigraphy, hydronephrosis, pressure-perfusion test, 944ab(5)
 - measurement of renal function, radionuclides, 2054
 - microsphere blood flow, Cu(PTSM) localization, 848ab(5)
 - modified diuresis renography, uses and interpretation, 3ab(4)
 - neonatal hypertension, captopril scintigraphy, 798ab(5)
 - obstructive renal disease, scintigraphy, sonography, 944ab(5)

- parametric imaging of function, renovascular hypertension, 5ab(4)
- parenchymal transit time of Tc-99m MAG₃, factor analysis, hydronephrosis, 3ab(4)
- percutaneous nephroureterolithotomy, therapeutic effect, Tc-99m DTPA renal scintigraphy, 942ab(5)
- plasma flow clearances, Tc-99m MAG₃ and I-131 OIH, 823ab(5) errors, single plasma sample-based values, 944ab(5) oxygen-15 water, PET, 824ab(5)
- plasma flow and renal artery stenosis, I-131 OIH and Tc-99m MAG₃ clearances, 1ab(4)
- primary parenchymal disease vs. secondary disease, renovascular hypertension, 942ab(5)
- prototype total performance kinetic phantom, 1750ab(10)
- quantitation of renal uptake, Tc-99m DMSA, SPECT, 246
- radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)
- radioisotopic evaluation, spinal cord injury, 944ab(5)
- radiopharmaceutical evaluation, 823ab(5)
- relative renal function estimation, early and delay Tc-99m MDP scintigraphy, 941ab(5)
- renal artery stenosis captopril effect, glucoheptonate scintrenogram, 1759ab(10) diagnostic use, angiotensin converting enzyme inhibitor, 605 Gates' technique, captopril test, 51
- renal cell carcinoma external beam irradiation, radioimmunotherapy, 826ab(5)
- xenografts, I-131 and In-111 monoclonal antibody, 906ab(5)
- renal transplant and lymphoceles, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)
- renovascular hypertension captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
- captopril, Tc-99m MAG₃ clearance, 656 increased glucoheptonate uptake, 5ab(4)
- scintigraphy special chair, upright position, 963ab(5) Tc-99m MAG₃ and I-123 hippurate clearances, 2ab(4)
- Tc-99m MAG₃, 1ab(4)
- Tc-99m MDP scintigraphy, functional assessment, 945ab(5)
- Tc-99m methylene diphosphate uptake, therapeutic radiation, vertebral metastases, 1113
- Tc-99m MSG and Tc-99m MAG₃, comparative pharmacokinetics, dogs, 937ab(5)
- thallium distribution, stress/delayed renal scintigraphy, 824ab(5)
- transplants allograft evaluation, radionuclide scintigraphy and aspiration biopsy, 785ab(5) bone mineral content, lumbar spine vertebrae, 774ab(5) evaluation, radionuclide monitoring, 3ab(4) evaluation, Tc-99m MAG₃, 823ab(5) evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
- hippurate renograms, long-term graft development, 784ab(5) measurements, Tc-99m MAG₃ uptake, 3ab(4) Tc-99m MAG₃, I-131 OIH and Tc-99m
- DTPA comparisons, 4ab(4) tubular reabsorption of calcium, primary hyperthyroidism, 2ab(4)
- tumor cells, transport mechanism, Tc-99m glucoheptonate, 912ab(5)
- validation of Gates GFR methodology, 1755ab(10) children, 2ab(2)
- Krypton-81m** gas generator, long-lived radioactive contaminant, 1574(le)
- reservoir administration systems, evaluation methods, 650
- Kuhl, David E.**, ACP award, N1148
- L**
- Labetalol**, reduction of I-131 MIBG uptake, pheochromocytoma, normal tissues, 481
- Lead-203 immunoconjugates**, tumor imaging agents, 935ab(5)
- Left bundle branch block**, dipyridamole-thallium 201 SPECT, 2ab(11)
- Leg**, muscle perfusion, quantification, TI-201 SPECT, 458
- Legg-Calve-Perthes disease**, early stage, bone scintigraphy and MR, 1755ab(10)
- Leukemia** chronic lymphocytic, I-131 lym-1, 827ab(5) diffuse nonuniformity on SPECT, liver studies, 905ab(5) hairy-cell, interferon therapy, Tc-99m colloid liver/spleen scans, 2ab(2) phase I of cancer cluster study, N1147 SPECT liver/spleen scans, 3ab(2) xenografts, immunoscintigraphy, radiolabel and antigen modulation, 889ab(5)
- Leukocytes** chemotactic peptide labeled with In-111, rapid detection, focal infection sites, 805ab(5) labeled with In-111 oxine and Tc-99m HM-PAO, 804ab(5) potential agent for labeling, positron-emitting copper, 920ab(5)
- Tc-99m HM-PAO-labeled detection of inflammatory lesions, 1332 infectious complications, orthopedic surgery, 804ab(5)
- Tc-99m-SnF₂ colloid kit, preparation, evaluation, 1257
- Levothyroxine** triiodothyroacetic acid and, TSH suppressive treatment, thyroid cancer, 886ab(5)
- Ligands** bifunctional, Tc-99m complex, protein labeling, 940ab(5) C-11 tropanyl benzilate methiodide, peripheral muscarinic receptors, 930ab(5) exchange, Tc-99m glucoheptonate, BPA-BAT, 939ab(5) hexadentate Schiff base, preparation, Tc-99m, 773ab(5) mixed, technetium(III/II) complexes, inorganic chemistry, 936ab(5) new amino-thiol, use with indium and gallium, 922ab(5) -receptor model influence, injection protocol, identifiability analysis, 877ab(5) substitution, comparative rates, technetium(V) and rhenium(V), 743
- Limb**, forearm blood flow measurements, Tc-99m serum albumin, after brachial arteriotomy, 45
- Lipids**, -soluble Sn(II)MPO, platelet labeling, Tc-99m pertechnetate, 922ab(5)
- Lipoproteins** low density estimation of catabolic sites, hypercholesterolemia, 932ab(5)
- In-111 imaging, atherosclerotic lesions, 787ab(5)
- paramagnetic label, localization in tumor model, 902ab(5)
- receptor activity, Ga-68 DTPA-VLDL, 763ab(5)
- radioiodinated cholesterol ester uptake, steroid hormone-secreting tissues, 1088
- Lithotripsy** extracorporeal piezoelectric, renal functional changes, 943ab(5)
- extracorporeal shock wave, decreased renal blood flow, hypertension, 4ab(11) functional renal imaging, 942ab(5) long-term complications, renal blood flow, hypertension, 842ab(5)
- Liver** correlative pediatric imaging, 15 diffuse hepatic uptake of I-131, total body scans, thyroid cancer, 4ab(2) diffuse nonuniformity on SPECT, leukemia, 905ab(5) giant hemangiomas, scintigraphic and ultrasound features, 181 hepatic retention ratio, Xe-133, 1708 human organ transplants, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
- immunosciintigraphy, Tc-99m monoclonal anti-CEA antibody, colorectal carcinoma, 748ab(5)
- In-111 accumulation, administration, B72.3 antibody, 1575(le)
- magnetic particles as MR contrast agent, 840ab(5)
- measurement of functional hepatic mass, Tc-99m galactosyl neoglycoalbin, 814ab(5)
- metastases detection, hepatic arterial perfusion scintigraphy, 4ab(11) I-131 monoclonal antibody, colorectal carcinoma, 809ab(5)
- metastases from colorectal cancer, F-18 uracil uptake and tumor volume changes, chemotherapy, 911ab(5)
- morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)
- orthotopic transplant, semiquantitative hepatobiliary scintigraphy, 888ab(5)
- perfusion system, R-E cell function, Tc-99m sulfur colloid, 4ab(2)
- peritoneo-pleural fluid communication, mediastinal lymph nodes, Tc-99m albumin colloid, 559(ab)
- planar scintigraphy, worth of SPECT, 57 platelet uptake, whole body, depth-independent build-up factor, 914ab(5)
- portal systemic shunting portal hypertensive rats, 887ab(5) portal hypertensive rats, portal vein stenosis, 814ab(5)
- radioparticle uptake, discrepant sulfur colloid, superior vena cava obstruction, 113 radiopharmaceutical receptor binding, discriminant analysis, Tc-99m NGA, 879ab(5)
- R-E cell function, short-term ethanol consumption, Tc-99m sulfur colloid, 1ab(2)
- regeneration, determination, radiothymidine labeled in carbon 2 position, 815ab(5)

regeneration measurement by PET, C-11 thymidine, 929ab(5)
 residual or recurrent tumor detection, F-18 FDG PET, posicam 6.5 camera, 909ab(5), 966ab(5)
 routine imaging, occult metastases, advanced melanoma, lab(2)
 short-term ethanol consumption, R-E cell function, liver, 815ab(5)
SPECT
 automated body contour, 266(le)
 leukemia, 3ab(2)
 splenic uptake and, monoclonal antibody study, Sab(11)
 subcellular kinetics, In-111 monoclonal antibody, 907ab(5)
Tc-99m colloid, interferon therapy, hairy-cell leukemia, 2ab(2)
Tc-99m complexes with ester analogues, biological characteristics, 937ab(5)
Tc-99m ECD metabolism in rat, 743ab(5)
 therapeutically embolized, variable perfusion patterns, Tc-99m MAA, 1012
 tracer kinetic modeling approaches, quantification, Tc-99m DISIDA and scintigraphy, 1507
transplant, In-111 DTPA plasma clearance, glomerular filtration rate, 942ab(5)
 tumor, metabolic PET images, 878ab(5)

Lung
 acute pulmonary emboli, radionuclide evaluation, right ventricular function, 853ab(5)
 acute pulmonary processes, 24-hour gallium images, AIDS, 888ab(5)
 aminodarone pneumonitis, Tc-99m DTPA aerosol washout rates, 916ab(5)
 ammonia-13 kinetics, positron emission computed tomography, smokers and nonsmokers, 866ab(5)
 assessment of inhalation imaging, I-123 IMP aerosol, 853ab(5)
 biventricular forward and regurgitant flows, radioangiography, 560(le)
 cancer
 In-111 anti-CEA ZCE 025 monoclonal antibody, 905ab(5)
 radon, information for practicing physician, 961ab(5)
 radon debate, N987
 central pulmonary emboli, perfusion distribution patterns, 734ab(5)
 characterization of *beta*-adrenergic receptors, CGP-12177, PET, 766ab(5)
 clearance of I-123 IMP, temporal changes, brain accumulation, 1977
 clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
 correlative pediatric imaging, 15
 decreased clearance of Tc-99m imidodiphosphate, Tc-99m DTPA, 853ab(5)
 detection of irradiation injury, In-111 monoclonal anti-laminin antibody, 916ab(5)
 detection of pulmonary aspiration in children, radionuclide "salivagram", 697
 diffuse uptake of Tc-99m sulfur colloid, malaria, 117
 disease, N1292
Ga-67 uptake, AIDS, aerosolized pentamidine, 744ab(5)
 -heart transplantation, regional pulmonary perfusion, 1297

inhalation scintigraphy in newborns, 744ab(5)
 krypton-81m reservoir administration systems, evaluation methods, 650
 localization of In-111 neutrophils, endotoxemia, monoclonal antibodies, 852ab(5)
 malignant lesion differentiation, SPECT, 844ab(5)
 mucociliary transport, FDG powder inhalation, PET, 917ab(5)
 myocardial-to-lung ratio, perfusion tracers and techniques, comparison, 959ab(5)
 non-thromboembolic disease, reversed mismatch, ventilation-perfusion ratio, 734ab(5)
 obstructive pulmonary disease, Xe-133, dynamic SPECT, 916ab(5)
 occult metastasis of pheochromocytoma, I-131 MIBG scintigraphy, 885ab(5)
 parenchyma, gadolinium-labeled microspheres, MRI, 901ab(5)
 perfusion scans, hot spots, 734ab(5)
 perfusion scintigraphy, right-to-left shunting, persistent left superior vena cava, 412
 postexercise TI-201 uptake, SPECT, 288
 pre-operative ventilation and perfusion scans, pulmonary embolism assessment, 733ab(5)
 primary cancer, histologic type, C-11 L-methionine uptake with PET, 33
 pulmonary aspiration, scintigraphy, videofluoroscopy, 967ab(5)
 pulmonary function testing, Tc-99m DTPA aerosol ventilation studies, cystic fibrosis, 967ab(5)
 pulsatile, visualization of circulation, ECG gated acquisition, 744ab(5)
 reversed V/Q mismatch, clinical significance, 734ab(5)
 reversible uptake, pulmonary osteoarthropathic distribution, Tc-99m methylene diphosphonate, 1563
 scans and pulmonary arteriography, PIOPED study, N279
 sequestration of In-111 granulocytes, organ specificity, 1531
 small cell carcinoma
 Tc-99m monoclonal antibody Fab fragment, 819ab(5)
 Tc-99m monoclonal antibody, 818ab(5)
 squamous cell carcinoma, serum TA-4 level, localization, 918ab(5)
 suspected cancer, evaluation, TI-201 SPECT, 997
 Tc-99m aerosol scans, performance, ventilator patients, 9ab(4)
 Tc-99m albumin and Ga-67 citrate, HIV-positive patients, 917ab(5)
 Tc-99m HEXAMIBI isonitrile uptake, discordant hemodynamic disturbances, 860ab(5)
 tumor
 C-11 methionine, F-18 fluorodeoxyglucose, 788ab(5)
 small cell, Tc-99m NR-Lu-10 monoclonal antibody, 1749ab(10)
 transport mechanism, Tc-99m glucoheptonate, 912ab(5)
 uptake of TI-201 during exercise, 788ab(5)
 vascular permeability, blood flow following radiation, 852ab(5)
 ventilation/perfusion mismatch, positive pressure ventilatory support, 1268
 ventilation scintigraphy, Tc-99m Technegas, 744ab(5)
 vessels, radioimmunoimaging, 1686

Luteinizing hormone, specificity of radioimmunoassay, polyclonal and monoclonal antibodies, 919ab(5)
Lymph node
 contralateral metastasis, melanoma, lower extremity, 912ab(5)
 malignancies, tracing, In-111 oxine-labeled mononuclear cells, 1005
 mediastinal, peritoneo-pleural fluid communication, 559(le)
 non-specific background, monoclonal antibody lymphoscintigraphy, Fab fragments, 847ab(5)
 uptake, Tc-99m hydroxyethyl starch, 969ab(5)
Lymphoceles, renal transplant and, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)

Lymphoma
 Hodgkin's and non-Hodgkin's, bone marrow imaging, blind biopsy, 843ab(5)
 malignant
 bone marrow scintigraphy, Tc-99m NCA-antibodies, 819ab(5)
 therapeutic effect, F-18 FDG PET, 910ab(5)
 non-Hodgkin's
 radioimmunotherapy, I-131 anti-pan-B cell antibodies, 828ab(5)
 Y-90 anti-idiotype monoclonal antibody, 778ab(5)
 nuclear medicine in monitoring, response to cancer treatment, 1731
 recurrent, composite gallium SPECT-CT images, 874ab(5)
 TI-201 scintigraphy, relationship, Ga-67, 915ab(5)
 utility of Ga-67, transmission computerized tomography, 914ab(5)

Lymphoma, B cell
 I-131 anti-idiotype monoclonal antibody, external beam irradiation, 826ab(5)
 radioimmunodetection and radioimmunotherapy, monoclonal antibody, 828ab(5)
Lymphoscintigraphy
 contralateral lymph node metastasis, melanoma, lower extremity, 912ab(5)
 simplified technique, breast cancer, 904ab(5), 1198
 surgical management, truncal melanoma, Tc-99m sulfur colloid and serum albumin, 844ab(5)
Lysosomes, role in tumor accumulation, Ga-67, dual-tracer studies, 921ab(5)

M

Magnetic resonance imaging: see Nuclear magnetic resonance
Magnetic particles, MR contrast agent for liver, 840ab(5)
Malaria, diffuse lung uptake, Tc-99m sulfur colloid, 117
Maleimidioethyl succinimyl succinate, spacer for Ga-67 deferoxamine labeled antibody, 832ab(5)
Malformation
 therapeutic transcather embolization, improved radiolabeling technique, ivalon, 1399
 vascular, Tc-99m RBC scanning, 799ab(5)
Mallinckrodt Fellowship
 applications, N1933
 award to Farrokh Dehdashti, N1444
Manganese, radioactive, monoclonal antibody labeling, porphyrin bifunctional chelator, 935ab(5)
Mastocytosis, systemic, nuclear medicine imaging,

- 2046
- McAfee, John G., SNM Hevesy Nuclear Medicine Pioneer Award, N577**
- Medicare**
Catastrophic Coverage Act of 1988,
implementation of ICD-9-CM codes, N580
radiology fee schedule, effect on a practice,
N1143
- Melanoma**
affinity enhanced targeting, radiolabeled
divalent haptens, mice, 907ab(5)
cutaneous, follow-up, immunoscintigraphy,
907ab(5)
heterotransplanted nude rats, biokinetics,
radiolabeled monoclonal antibodies, 1224
lower extremity, contralateral lymph node
metastasis, 912ab(5)
malignant
evaluation, F-18 2-deoxy-2-fluoro-D-glucose,
738ab(5)
successful imaging, Tc-99m monoclonal
antibodies, 25
tumor-associated antigens, autoradiography,
906ab(5)
mouse antitumor monoclonal antibody,
complex formation and biodistribution,
cancer patients, 1311
radioimmunoscintigraphy vs. X-rays, size-
related diagnostic sensitivity, 749ab(5)
routine bone and liver imaging, occult
metastases, 1ab(2)
targeting, monoclonal antibody cocktail, human
HMW-MAA, 390
truncal, lymphoscintigraphy, Tc-99m sulfur
colloid and serum albumin, 844ab(5)
- Memory**, recognition, metabolic and
electrophysiologic manifestations, 894ab(5)
- Mesalamine**, enema, colonic coverage, active
distal ulcerative colitis, 764ab(5)
- Mescaline**, -induced psychosis, right hemisphere
involvement, 812ab(5)
- Metabolite**, analysis, internal surface-reverse phase
chromatography, 920ab(5)
- Metaiodobenzylguanidine**, use in neurocardiology,
N1291
- Metal**, -labeled perfusion tracers, structure-activity
relationships, 742ab(5)
- Metallothionein**, genetically engineered chimeric
antibody, Tc-99m, 794ab(5)
- Metastasis**
axillary, primary breast carcinoma, Ti-201
scintigraphy, 844ab(5)
bone
nuclear medicine in monitoring, response to
cancer treatment, 1731
palliation, strontium-89, 2ab(2), 836ab(5)
bone scintigram, serum osteocalcin, PSA and/or
PAP, 918ab(5)
contralateral lymph node, melanoma, lower
extremity, 912ab(5)
hepatic
detection, hepatic arterial perfusion
scintigraphy, 4ab(11)
I-131 monoclonal antibody, colorectal
carcinoma, 809ab(5)
intra-operative localization, radiation detection
probe, colorectal cancer, 908ab(5)
lung, pheochromocytoma, I-131 MIBG
scintigraphy, 885ab(5)
micrometastatic cell clusters, kinetics,
radiolabeled antibody penetration, 777ab(5)
occult, routine bone and liver imaging,
melanoma, 1ab(2)
skeletal, action of 186-Re(Sn)-HEDP, 732ab(5)
- solitary, bone secondaries, breast cancer, 1318
spinal, malignant struma ovarii, 407
vertebral, renal uptake, Tc-99m methylene
diphosphate, 1113
- Methylene diphosphate**, Ga-67 distribution,
857ab(5)
- Methyl iodide**, carbon-11, simplified solid-phase
synthesis, 927ab(5)
- Metoclopramide**, -induced patient restlessness,
radionuclide gastric emptying imaging,
3ab(11)
- Michaelis-Menten kinetics**, hexokinase, glucose
and deoxyglucose phosphorylation ratio,
brain and gliomas, 838ab(5)
- Microspheres**
biodegradeable, Ho-165 activation, 836ab(5)
blood flow, Cu(PTSM) localization, dog heart
and kidney, 848ab(5)
gadolinium-labeled, MRI, lung parenchyma,
901ab(5)
-like retention in heart, copper-PTSM, blood
flow and PET, 768ab(5)
regional cerebral distribution, Tc-99m ECD,
non-human primates, 792ab(5)
validity of model in cerebral blood flow, I-123
IMP, 878ab(5)
yttrium-90, therapy, hepatic metastasis,
836ab(5)
- Mintun, Mark A.**, Tetralman Memorial Award,
N1141
- MIRD "S" factor**, disparity in organ masses,
416(lc)
- MK 329**, cholecystokinin receptor localization,
849ab(5)
- Molybdenum-99**, suspension of uranium
shipments, Department of Energy, N1139
- Monoamine oxidase**, probes, C-11 and F-18
labeled 4-fluorodoprenyl, 821ab(5)
- Monoclonal antibodies**
anti-CEA, epitope specificity, tumor
localization, 747ab(5)
anti-fibrin T2G1S, thrombus imaging, 963ab(5)
anti-idiotype, I-131, B cell lymphoma, 826ab(5)
anti-melanoma, variation in labeling efficiency,
different Tc-99m generators, 1759ab(10)
astatin-211 labeled F(ab')₂ fragment,
immunoreactivity, tumor uptake, 778ab(5)
B72.3, accumulation of In-111, liver, 1575(lc)
cardiac myosin light chain 1, synthetic peptide
immunogens, radioimmunoassay, 785ab(5)
charge modification, enhanced target
localization, 762ab(5)
chelate and, diester linkage,
radioimmundetection of tumor, 1693
clinical value of immunoscintigraphy, colorectal
carcinoma, 1646
cocktails
localization, tumor xenografts, 747ab(5)
melanoma targeting, human HMW-MAA,
390
copper-18 conjugation, desferrioxamine In-111,
oligosaccharide moiety, 936ab(5)
detection of human anti-murine antibody
response, 908ab(5)
diagnosis of acute heart transplant rejection, In-
111 antimyosin Fab mAb imaging,
847ab(5)
differential intratumor localization, mice
bearing transplantable human tumors,
autoradiography, 1758ab(10)
dual specificity conjugates, radiolabeled
monovalent and divalent haptens, 1358
effect of interferon- α A on targeting, carcinoma,
809ab(5)
- enhanced regional delivery, peritoneal cavity,
transdiaphragmatic blockade, 815ab(5)
- epidermal growth factor receptor, placental
alkaline phosphatase, glioma, 1636
- estimate of immunoreactive fraction, curve
fitting method, 915ab(5)
- fibrin-specific, thrombus imaging, 747ab(5)
- fragments of CEA, cancer imaging, multicenter
trial, 748ab(5)
- heterogeneity of uptake, human tumor
xenografts, Sprint tomographic scanner,
777ab(5)
- high activity radioiodination, iodogen particle
suspensions, 933ab(5)
- human anti-mouse, immunoscintigraphy effect,
786ab(5)
- human antimurine antibody responses,
intraperitoneal radioimmunotherapy
infusions, 827ab(5)
- I-131 and Re-186 radiolabeled conjugates,
urinary metabolites, 793ab(5)
- I-131 HMFG1, ovarian cancer, nude mice and
patients, 883ab(5)
- immunoglobulin complex formation, 10ab(4),
888ab(5)
- immunoglobulin M, pharmacokinetics,
909ab(5)
- immunoreactivity, Lindmo double reciprocal
analysis, 903ab(5)
- improved labeling with Br ϕ HBED, bifunctional
chelate, 763ab(5)
- improved uptake, lavage, intraperitoneal
carcinomatosis, 60
- inflammation-related localization, colorectal
cancer, 3ab(11)
- influence of antibody protein dose, antibody
distribution, human tumor xenografts,
759ab(5)
- In-111 GYK-DTPA-B72.3, breast cancer
detection, 819ab(5)
- In-111-labeled, two probe systems,
gastrointestinal cancer, 891ab(5)
- intact and Fab fragments, biodistribution, anti-
mouse antibody effects, 847ab(5)
- interaction, evaluation, neutrophil function,
747ab(5)
- isotype switch variant anti-idiotype,
comparative radiolabeling, 227
- L-6, dose-dependent human biokinetics,
907ab(5)
- labeling, combined radioimmunoscintigraphy,
radioimmunotherapy, 683
- labeling with radioactive manganese, porphyrin
bifunctional chelator, 935ab(5)
- liver and splenic uptake, comparative analysis,
5ab(11)
- localization of atherosclerotic lesions, 859ab(5)
- lymphoscintigraphy, non-specific lymph node
background, Fab fragments, 847ab(5)
- mouse antitumor, complex formation and
biodistribution, cancer patients, 1311
- mouse B72.3, conjugated to Tc-99m
metallothionein, Rhesus monkeys, 1351
- patients not injected with murine mAb,
characterization, human anti-murine
antibody, 1749ab(10)
- percolation through tumors, modeling analysis,
903ab(5)
- preparation of new agents, immunoscintigraphy,
936ab(5)
- pulmonary localization of In-111 neutrophils,
endotoxemia, 852ab(5)
- quo vadis radioimmune imaging, 1911
- radioimmunoassay, diagnosis, squamous cell

- carcinoma of lung, 918ab(5)
radioimmunoimaging of lung vessels, 1686
radioimmunotherapy of colorectal carcinoma
 xenografts, Y-90 CO17-1A, mouse IgG
 coinjection, 935ab(5)
radioiodinated and yttrium-labeled anti-CEA,
 IgG and fragments, radioimmunotherapy,
 848ab(5)
radiolabeled
 epithelial membrane antigen, colorectal
 cancer target antigen, 808ab(5)
 heterotransplanted nude rats, biokinetics,
 1224
 variations in absorbed dose, murine-human
 tumor xenograft, 777ab(5)
radiolabeled anti-EGF receptor, phase I,
 imaging trial, 746ab(5)
radiolabeling, hexadentate bifunctional
 chelating agents, 1758ab(10)
radiolabeling with Y-90, comparison, five
 bifunctional chelate techniques, 763ab(5)
SM3, radioimmunoscintigraphy, ovarian
 tumors, 758ab(5)
specificity of radioimmunoassay for LH and
 FSH, compared to polyclonal antibodies,
 919ab(5)
stable radioiodinating reagent development,
 cancer radiotherapy, 216
sulphydryl site-specific radiolabeling, biotin/
 streptavidin methodology, 832ab(5)
systemic and locoregional administration,
 gastrointestinal cancer
 radioimmunotherapy, 779ab(5)
Tc-99m, successful imaging, malignant
 melanoma, 25
Tc-99m and platelet activation, after balloon
 arterial injury, arterosclerotic model,
 787ab(5)
ultrasensitive assay for measuring serum CA125
 values, different antigenic determinants,
 785ab(5)
use in cancer, N1293
Y-90
 effect of carrier IGG, biodistribution, 4ab(11)
 macrocyclic bifunctional chelating agents,
 763ab(5)
Mononuclear cells, In-111 oxine-labeled, tracing,
 lymphatic malignancies, 1005
Morphine
 augmented cholescintigraphy, 8ab(4), 850ab(5)
 hepatobiliary scintigraphy, potential pitfalls,
 850ab(5)
Muscle
 perfusion in leg, quantification, TI-201 SPECT,
 458
 skeletal, dialysate sodium concentration,
 subcutaneous blood flow, 4ab(4)
Musculoskeletal neoplasms, benign and
 malignant, F-18 FDG uptake, 1753ab(10)
Myelofibrosis, acute, correlation of findings, 251
Myers, William Graydon, In Memoriam, 1129
Myocardial, uptake kinetics, hypoxia and ouabain
 effects, Tc-99m HEXAMIBI and TI-201,
 1500
Myocardial infarction
 analysis of cardiac perfusion tomography, new
 quantitative method, 871ab(5)
 assessment of myocardial salvage, Tc-99m
 MIBI, 801ab(5)
 assessment of ventricular topography, gated
 tomographic radionuclide ventriculography,
 770ab(5)
 denervated but viable canine myocardium, I-
 123 MIBG, thallium SPECT, 767ab(5)
 depletion of myocardial catecholamine stores,
 detection with I-123 MIBG, 810ab(5)
 detection of different stages, In-111 antimyosin,
 Tc-99m pyrophosphate, 862ab(5)
 detection of residual viable tissue, PET and
 SPECT, different ages, 869ab(5)
 development of cardiac myosin light chain 1
 mAb, synthetic peptide immunogens,
 radioimmunoassay, 785ab(5)
 dipyridamole TI-201 SPECT, compared to
 exercise RNV, jeopardized myocardium
 detection, 862ab(5)
 enhanced F-18 fluoromisonidazole extraction,
 PET assessment, 730ab(5)
 evaluation of ventricular function, coronary
 artery disease, 1149
 flow and distribution response to stress, normal
 coronary arteries, 818ab(5)
 identification of viable myocardium, automated
 3D cardiac PET, RB-82, 865ab(5)
In-111 antimyosin Fab and Tc-99m MIBI,
 reperfusion, 757ab(5)
myocardial viability, rest-redistribution thallium
 scintigraphy, early post-thrombosis,
 729ab(5)
neuronal markers, H-3 phenylephrine, H-3
 epinephrine, 733ab(5)
pre- and post-thrombolysis, Tc-99m MIBI
 SPECT, 820ab(5)
quantitative stress-redistribution TI-201 SPECT,
 780ab(5)
regional wall motion and coronary anatomy,
 myocardial perfusion relationship, 739ab(5)
reperfusion injury, In-111 neutrophils, 859ab(5)
scintigraphy of adrenergic receptors and
 neurons, 767ab(5)
serial Tc-99m MIBI myocardial SPECT studies,
 reperfusion, 800ab(5)
silent myocardial ischemia, evaluation, exercise
 TI-201 SPECT, 864ab(5)
stress myocardial perfusion, left ventricular wall
 motion, Tc-99m MIBI, 864ab(5)
Tc-99m MIBI for anatomical landmarking, In-
 111 antimyosin Fab, 800ab(5)
Tc-99m MIBI uptake, coronary occlusion,
 reperfusion, 756ab(5)
variability of response to reperfusion,
 thrombolysis, MIBI-SPECT, 820ab(5)
ventricular function and perfusion, gated
 tomographic imaging, Tc-99m MIBI,
 801ab(5)
Myocardial ischemia
 accelerated glucose utilization, quantitative
 PET, 867ab(5)
 ambulatory ST changes and perfusion imaging,
 dynamic exercise, dipyridamole "stress",
 861ab(5)
 binding of hypoxic cell marker, H-3
 fluoromisonidazole, 194
C-14 deoxyglucose deposition, reperfusion,
 797ab(5)
cultured cardiac cells, TI-201 and Tc-99m MIBI
 uptake, 860ab(5)
detection of area at risk, coronary angioplasty,
 Tc-99m RP-30, 791ab(5)
detection of subendocardial ischemia, gated
 positron tomography, left ventricular
 hypertrophy, 866ab(5)
diagnosis of coronary artery disease, coronary
 angioplasty, PET, 845ab(5)
diagnosis of coronary stenosis, application,
 machine intelligence, 816ab(5)
dipyridamole-induced, reduction by caffeine,
 1723, 861ab(5)
 enhanced F-18 fluoromisonidazole extraction,
 PET assessment, 730ab(5)
 exercise-induced, iodine-123 fatty acid.
 compared to thallium-201, 729ab(5)
 exercise/rest Tc-99m MIBI-SPECT, regional
 quantitation, coronary heart disease,
 791ab(5)
 fatty acid utilization, tomographic assessment,
 recurrent chest pain, 828ab(5)
 improved Tc-99m isonitrile uptake, myocardial
 salvage, compared to TI-201, 800ab(5)
 left ventricular dilation, exercise SPECT
 thallium imaging, three-vessel disease,
 749ab(5)
 mechanisms of RP-30 redistribution, post-
 ischemia, 757ab(5)
 myocardial glucose uptake, dopamine infusion,
 PET, 859ab(5)
 planar TI-201 perfusion defects, 863ab(5)
 quantitation of mass, acute coronary occlusion,
 PET, 866ab(5)
 Rb-82 PET and TI-201 SPECT disparities,
 dipyridamole stress, 861ab(5)
 redistribution after thallium reinjection,
 relationship, coronary anatomy and
 regional wall motion, 740ab(5)
 relief by PTCA, recovery, myocardial
 metabolism, 838ab(5)
 reversible, dipyridamole perfusion PET,
 760ab(5)
 scintigraphic assessment of myocardial
 reperfusion, percutaneous transluminal
 coronary angioplasty, 821ab(5)
 significance of absence or presence of angina,
 positive thallium TI-201 stress test,
 863ab(5)
 silent
 after myocardial infarction, exercise TI-201
 SPECT, 864ab(5)
 bicycle exercise, first pass radionuclide
 angiography, 868ab(5)
 three-dimensional cardiac PET, automated
 quantitation, routine clinical use, 1787
 TI-201 imaging and FDG imaging,
 redistribution, metabolic activity, 863ab(5)
 transient mitral regurgitation, dipyridamole-
 thallium imaging, 1271
 treadmill stress test and intravenous
 dipyridamole, myocardial perfusion
 imaging, Tc-99m MIBI, 759ab(5)
 unstable angina patients, coronary stenosis,
 resting/redistribution TI-201, 740ab(5)
 whole body multidetector SPECT, variable
 aperture, 796ab(5)
 Wiener filtering, SPECT quantification,
 755ab(5)
Myocardium
 altered perfusion, free fatty acid utilization,
 small-vessel disease, 829ab(5)
 behavior of catecholamine analogs,
 compartimental analysis, 735ab(5)
 blood flow
 isosorbide dinitrate, dynamic PET, 866ab(5)
 myocardial infarction, dynamic PET,
 945ab(5)
 O-15 water, novel mathematical approach,
 825ab(5)
 O-15 water, PET, 807ab(5)
 quantitative measurements, rubidium-82 and
 PET, 807ab(5)
 cationic complexes of technetium for imaging,
 1415
 characterization of fatty acid carrier, 798ab(5)
 delineation of damage, In-111 monoclonal anti-

Myocytes

myosin, cardiomyopathy, 779ab(5)
differentiation of viable from scarred, delayed SPECT TI-201 images, 864ab(5)
3,3-dimethyl(*p*-I-123 phenyl)-pentadecanoic acid uptake, reperfusion, 797ab(5)
3D quantification of defects, axial sampling and motion, PET, 892ab(5)
extraction of Tc-99m sestamibi, flow effects, thallium-201, 756ab(5)
false positive exercise TI-201 SPECT in men, 749ab(5)
fatty acid metabolism, I-[C-11] betamethylheptadecanoic acid, 797ab(5)
glucose utilization, PET, F-18 deoxyglucose, 359
human, thallium kinetics, 863ab(5)
imaging, neutral Tc-99m complex, 1830
I-123 MIBG uptake, primary hypertrophic cardiomyopathy, 810ab(5)
I-123 phenylpentadecanoic acid tomography, dipyridamole infusion, CAD detection, 760ab(5)
jeopardized, dipyridamole TI-201 SPECT, exercise RNV, 862ab(5)
kinetics and exercise, I-123 phenylpentadecanoic acid, 829ab(5)
kinetics of F-18 misonidazole, marker of hypoxia, 351
kinetics of 15-*p*-[I-125]iodophenylpentadecanoic acid, quantitative analysis, 1211
left ventricular, automatic program for long axis, TI-201, 806ab(5)
measurement of regional blood flow, copper-PTSM, PET, 807ab(5)
metabolic and functional abnormalities, coronary thrombolysis, 837ab(5)
metabolism tracer, C-11 acetate, 1743ab(10)
method to outline, single diffusible tracer, 775ab(5)
neuronal markers, H-3 phenylephrine, H-3 epinephrine, 733ab(5)
neutral and cationic perfusion agents, mechanistic comparison, 757ab(5)
new imaging agent, In-111 TE-BAT, 367
noninvasive assessment of performance, radionuclide ventriculography, aorta pressure change, 1657
novel functionalized diphosphine complexes, Tc-99m, 818ab(5)
optimal specificity of TI-201 SPECT, recognition, imaging artifacts, 441
optimization of Tc-99m MIBG SPECT acquisition, processing parameters, 757ab(5)
oxidative metabolic reserve, PET, C-11 acetate, 1489
oxidative metabolism, C-11 acetate and PET, substrate utilization, 187
percent hypoperfused, algorithm, TI-201 SPECT, 750ab(5)
perfusion abnormality, exercise, TI-201 SPECT, 749ab(5)
perfusion agent Tc-99m SQ 30217, diagnostic utility, rapid imaging protocol, 730ab(5)
perfusion images from SPECT, model based quantification, 1992
perfusion imaging functionalized diphosphine complexes, Tc-99m, 773ab(5)
simultaneous Tc-99m MIBI angiography, 38
Tc-99m HEXAMIBI, TI-201, 301
Tc-99m SQ30217, TI-201, 312
perfusion safety and efficacy, Tc-99m CDO-MEB, 959ab(5)

perfusion scans, limitations in LV wall thickness, SPECT, 796ab(5)
perfusion tomography, quantitative algorithm, 1746ab(10)
perfusion tracers and techniques, comparison, myocardial-to-lung ratio, 959ab(5)
PET compared to arteriography, coronary artery disease severity, 846ab(5)
post-infarction viability, In-111 antimyosin antibodies, Tc-99m MIBI, 800ab(5)
quantification of metabolic reserve, C-11 acetate, PET, 837ab(5)
quantitative standards for HEXAMIBI, 790ab(5)
radial shortening and myocardial thickening, Tc-99m MIBI, echocardiography, 821ab(5)
radioiodinated digoxin derivative, Na,K-ATPase binding, 923ab(5)
radioiodinated IPPA and BMIPP fatty acid, HPLC analysis, 923ab(5)
regional blood flow, new quantitation method, 808ab(5)
regional left ventricular filling, diastolic abnormalities, contiguous areas, 165
regional oxidative metabolism, C-11 acetate, serial PET imaging, 867ab(5)
regional perfusion, Tc-99m teboroxime, dynamic SPECT, 1744ab(10), lab(11)
regions of low flow, not necessarily hypoxic, 808ab(5)
rejecting and nonrejecting cardiac implants, imaging agent uptake, 1464
retention and clearance of Tc-99m SQ30217, dog, 860ab(5)
reversible defects, TI-201 blood levels, 1172
rubidium-82 and TI-201 perfusion imaging, coronary artery disease, 759ab(5)
scintigraphy, I-123 phenylpentadecanoic acid, 829ab(5)
simultaneous transmission/emission SPECT, moving line source, 964ab(5)
SPECT color-coded surface image display, 872ab(5)
sectional images, rotating patient chair, lab(2)
swine, first pass extraction fraction, 767ab(5)
sympathetic nerve development, scintigraphic assessment, MIBG, 810ab(5)
sympathetic nervous function, angina pectoris, I-123 MIBG SPECT, 811ab(5)
synthesis and biodistribution, C-11 betamethylheptadecanoic acid, 928ab(5)
Tc-99m cardiac phantom, attenuation correction, SPECT quantitation, 894ab(5)
Tc-MIBI SPECT acquisition parameters, 795ab(5)
Tc-99m MIBI SPECT, 180° and 360° data collection, 295
TI-201 ECG-gated myocardial SPECT, clinical evaluation, 864ab(5)
TI-201 SPECT, prone vs. supine, 548
TI-201 tomography analysis, polar probability map, 871ab(5)
solution, inferior wall attenuation, 398
TI-201 uptake and clearance, effects of heart rate, 1972
value of rest-stress positron tomography, nitrogen-13 ammonia, reversible asynergy, 1302
viable hypoxic, detection by PET, F-18 fluoromisonidazole, 846ab(5)
viable vs. infarcted, automated 3D cardiac PET, Rb-82, 865ab(5)

Myocytes, hypoxic metabolism, noninvasive testing, iodophenyl pentadecanoic acid,

860ab(5)
Myositis, HIV-associated, radionuclide bone scanning, 556
N
Nanocolloid, inflammation imaging, HM-PAO labeled leukocytes, 805ab(5)
National Cancer Institute (NCI), Canadian energy agency release, phase I, cancer cluster study, N1147
NCRP, Radiation Protection Award, N1934
Neck, irradiation for Hodgkin's disease, hyperthyroidism, low radioiodine uptake, 255
Neonates brain SPECT, 915ab(5), 1337
effect on PEEP on regional ventilation, mechanically ventilated preterm lamb, 1342
importance of Tc-99m glucoheptonate scintigraphy, first UTI, 915ab(5)
Nephropathy, diabetic, early detection, Tc-99m DTPA and I-131 hippuran, 941ab(5)
Nephrotoxicity cisplatin-induced tubular toxicity, comparison, radioactive renal agents, 659
cyclosporine nephrotoxicity, pathophysiology, 784ab(5)
Nephroureterolithotomy, percutaneous, therapeutic effect, Tc-99m DTPA renal scintigraphy, 942ab(5)
Neural crest tumors, therapeutic potential, I-131 MIBG, 769ab(5)
Neuroblastoma children, I-123 metaiodobenzylguanidine scintigraphy, 799ab(5)
I-125 MIBG uptake correlation, tumor histopathology, 474 histopathology, 836ab(5)
nude mouse xenograft, radiolabeled MIBG uptake, 884ab(5)
resistant, therapeutic use, I-131 MIBG, 903ab(5)
SPECT bone studies of extremities, 858ab(5)
stage IV, Tc-99m and I-131 monoclonal antibody, 904ab(5)
Neurocardiology, use of MIBG, N1291
Neurofibromatosis, re-evaluation of Tc-99m DTPA, tumor-seeking agent, 915ab(5)
Neuropsychiatric disorders D-2 dopamine receptor densities, PET, 731ab(5) evaluation, PET, CT and MRI, 1589
Neuroreceptors imaging histamine H1 receptors, PET, baboon brain, 741ab(5)
imaging *in vivo* chemistry, N1283 theoretical effects, radioligand diffusional gradients, kinetic studies, 878ab(5)
Neutrophils, function, after monoclonal antibody interaction, 747ab(5)
Newline addendum, Pennsylvania certification, N14
Commentary developments in RVSs/10CFR35/PET, N992 lines from the President, N1440, N1931 magnitude estimation, N1294 NRC workshop participants, N1584 nuclear medicine, procedural and cognitive, N276
radioimmunoassay, N12 RVSs and PET reimbursement, budget, N277 solution, radioisotope shortage, N438 radwaste revisited-1989, N133 survey of nuclear medicine physicians, scientists, facilities, N1
Nicotine, binding in brain, PET, 742ab(5)
Nifedipine, effects with PET, 866ab(5)

- Nitride, -technetium cations, synthesis, myocardial imaging agents, 773ab(5)**
- Nitrocinnamic acid, no-carrier-added F-18-for-NO₂ aromatic nucleophilic substitution, 1757ab(10)**
- Nitrogen-13**
 - ammonia-13 kinetics in lung, positron emission computed tomography, smokers and non-smokers, 866ab(5)
 - effects of anti-anginal agents, PET, 866ab(5)
- Nitrogen-13 ammonia**
 - aqueous, proton irradiation of water, hydrogen pressure, 926ab(5)
 - PET, rest-stress value, preoperative prediction of reversible asynergy, 1302
 - relief of chronic ischemia, recovery of myocardial metabolism, 838ab(5)
 - visual analysis of PET images, reproducibility, reliability, 846ab(5)
- Nitrogen-13 glutamate, F-18 uracil and, perfusion and shunting, colorectal carcinoma, 910ab(5)**
- Nitroglycerin, effects with PET, 866ab(5)**
- Norepinephrine, tracer, synthesis, F-19/F-18-m-hydroxyphenylserine, 929ab(5)**
- Nuclear magnetic resonance**
 - behavior of EHPG complexes, metal ions, 848ab(5)
 - blind biopsy and, Hodgkin's and non-Hodgkin's lymphoma, 843ab(5)
 - blood-brain barrier integrity, Gd-DTPA and In-DTPA-IgG brain uptake, 839ab(5)
 - bone scintigraphy and, early stage, Legg-Calve-Perthes disease, 1755ab(10)
 - carbon-13, cellular redox, 814ab(5)
 - cardiac, dipyridamole effects, coronary artery disease, 840ab(5)
 - cervical, detection, recurrent thyroid carcinomas, 841ab(5)
 - cine, pulse sequence, heart, 4ab(2)
 - constraining SPECT reconstruction to body volume, 835ab(5)
 - correction of spatial distortions, MR and PET, structure-function registration, 1746ab(10)
 - correlative pediatric imaging, 15
 - CT and PET, Alzheimer's dementia, normal aging, 1607
 - 3D brain imaging, I-123 IMP, 961ab(5)
 - dynamic MRI, shunt size determination, atrial and ventricular levels, 903ab(5)
 - evaluation of viability, human organ transplants, 813ab(5)
- F-19**
 - drug targeting, animal tumor models, 814ab(5)
 - S-fluorouracil pharmacokinetics, 813ab(5)
 - S-fluorouracil trapping, therapeutic effectiveness, 813ab(5)
- FDG-PET and, pathologic findings, complex partial seizures, 752ab(5)**
- gadolinium-labeled microspheres and liposomes, lung parenchyma, 901ab(5)**
- global uniformity index, 1.5 tesla imager, 5ab(2)**
- localization of pheochromocytoma, correlation with CT and MIBG, 328**
- metabolic PET correlates, anatomic lesions, head trauma, 802ab(5)**
- MR contrast agent, magnetite particles, liver, 840ab(5)**
- MRI contrast agent, Gd-153 clearance and organ distribution, 840ab(5)**
- observer reliability, 840ab(5)**
- PET and CT, evaluation, neuropsychiatric disorders, 1589**
- PET-MRI volume matching algorithm, evalua-**
- tion, 875ab(5)**
- P-31 MR spectroscopy and, dermatomyositis, 5ab(11)**
- principal axis transformation, image registration, 776ab(5)**
- quantitative imaging, image registration system, 894ab(5)**
- radiography and bone scintigraphy, sacroiliitis, 842ab(5)**
- superimposed PET and MR images, simple and precise method, 876ab(5)**
- T1 and T2 relaxation times, Gd-DTPA enhanced brain tumor imaging, 902ab(5)**
- T1 and T2 weighted, multi-weighted linear combination, 902ab(5)**
- Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, 106**
- three-dimensional brain surface image, 902ab(5)**
- tumor response to chemotherapy, bone and soft tissue, 813ab(5)**
- velocity measurements, small arterial vessels, 1753ab(10)**
- volumetric PET/MRI image matching and displays, 776ab(5)**
- vs. In-111 white blood cells, chronic complicated osteomyelitis, 754ab(5)**
- white blood cell scan, infection, lower extremity, 856ab(5)**
- Nuclear medicine**
 - diagnostic role, acquired immunodeficiency syndrome, 1935
 - facilities, survey, N1
 - history, St. Louis, N569
 - procedural and cognitive, N276
- Nuclear Medicine Week, 1989, N574**
- Nuclear Regulatory Commission (NRC)**
 - issuance of final rules, emergency access, LLRW sites, N1143
 - SNM/ACNP petition to change 10 CFR 35, N1296
- Nuclear stethoscope, computer-controlled miniature scintillation detector system, 891ab(5)**
- O**
- Obsessive-compulsive disorder, neuropsychological and PET study, 897ab(5)**
- Octreotide, I-123 labeling, metabolism, clinical applications, 768ab(5)**
- Oncology, PET studies, N1292**
- Opioids, sex-dependent differences in distribution, N-3-[F-18]propyl diprenorphine, 732ab(5)**
- Optic nerve, damage, regional cerebral glucose metabolism, 802ab(5)**
- Osmium-191, -Ir-191m generator based on silica gel, impregnation, tridodecylmethylammonium chloride, 538**
- Osteitis fibrosa cystica, false-positive Tl-201 localization, 1264**
- Osteocalcin**
 - serum
 - bone scintigram, prostate carcinoma, 918ab(5)
 - concurrent bone scintigraphic findings, 1748ab(10)
- Osteomyelitis**
 - chronic complicated, In-111 white blood cells, MRI, 754ab(5)
 - diagnostic accuracy of skeletal infection, blood pool sign, gallium scintiscan, 774ab(5)
 - In-111 white blood cell scintigraphy, three-phase bone scintigraphy, diabetics, 753ab(5)
 - Klebsiella pneumoniae*, three-phase radionuclide bone imaging, 1412
 - prediction of cure, three-phase bone and Ga-67 scans, 754ab(5)
- P**
- PACS, operation of, 873ab(5)**
- Paget's disease**
 - appearance on In-111 leukocyte images, 754ab(5)
 - scintigraphic findings, bone mineral content, 855ab(5)
- Palladium-109, immunosuppression, local lymphoid irradiation, 890ab(5)**
- Palmitate, ketone bodies and, competition as fuels, heart, 797ab(5)**
- Pan-American Development Foundation, donations, N1587**
- Pancreas**
 - cancer, chronic pancreatitis differentiation, F-18
 - subperiosteal abscess, "cold" spot, bone scan, 857ab(5)
- Osteoporosis**
 - dual energy radiography, comparison, quantitative computed tomography, 774ab(5)
 - postmenopausal, bone mineral density, non-hormonal cyclic therapy, 774ab(5)
 - regional migratory, scintigraphic findings, 858ab(5)
- Ouabain, hypoxia and, myocardial uptake kinetics, Tc-99m HEXAMIBI and Tl-201, 1500**
- Ovarian cancer**
 - I-131 HMFG1 monoclonal antibody
 - CA 125 radioimmunoassay, 918ab(5)
 - kinetics, nude mice and patients, 883ab(5)
 - intraperitoneal radioiodinated OC 125, 904ab(5)
 - intraperitoneal yttrium-90 immunotherapy, 828ab(5)
 - remote high level iodinations of antibodies, 932ab(5)
- Ovary, metastatic malignant struma ovarii, spinal metastasis, 407**
- Oxygen, myocardial consumption, PET, C-11 acetate, 1798**
- Oxygen-2, LCMRO2 and LCBF measurements, on-line plasma separation, PET, 791ab(5)**
- Oxygen-15**
 - amino acid uptake in brain, kinetic modeling approaches, 880ab(5)
 - autoradiography, realtime correction for dead-time, PET, 878ab(5)
 - high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
- Oxygen-15 butanol, improved routine synthesis, positron tomography, 927ab(5)**
- Oxygen-15 water**
 - arterial dispersion time constant, direct estimation, PET CBF data, 900ab(5)
 - autoradiography and dynamic PET, tracer arrival delay correction, cerebral blood flow, 1069
 - C-11 butanol and, cerebral blood flow, PET, 901ab(5)
- F-18 uracil and, PET, regional chemotherapy of liver metastases, 1754ab(10)**
- FDG PET, colorectal carcinoma, radiation therapy, 909ab(5)**
- noninvasive functional brain mapping, change-distribution analysis, PET, 141**
- PET**
 - metastatic colorectal cancer, 910ab(5)
 - myocardial blood flow, 807ab(5)
 - myocardial blood flow, novel mathematical approach, 825ab(5)
 - relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)
 - renal plasma flow, PET, 824ab(5)
- Oxygen-18 water, extraction of F-18 fluoride, fibrous ion exchange resin, 926ab(5)**

Parathyroid

- FDG PET, 887ab(5)
human organ transplants, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
transplant monitoring, In-111 platelets, 1470
- Parathyroid**
adenoma, radioiodinated toluidine blue, scintigraphy, 768ab(5)
detection of abnormalities, Tc-99m/Tl-201 subtraction technique, scintigraphy, 3ab(2)
I-123 MIBG uptake by chemodectomas, 769ab(5)
scintigraphy, low sensitivity, upper pole adenomata, 885ab(5)
thallium-technetium subtraction, global vs. regional image normalization, 769ab(5)
Tl-201 uptake, enhancement, thyroxine pretreatment, 886ab(5)
- Parenchyma**, transit time index, surgery evaluation, obstructive uropathy, 942ab(5)
- Parkinson's disease**
dopamine D-2 receptor imaging, I-123 iodobenzamide, SPECT, 731ab(5)
local cerebral blood flow, I-123 IMP SPECT, 830ab(5)
presynaptic nigrostriatal function, 761ab(5)
- PB-212 macroaggregate**, toxicity in dogs, 834ab(5)
- PEEP**: *see* Positive end-expiratory pressure
- Penis**
blood flow, Xe-133 washout, 1032
blood flow during early erection, radioisotope penile plethysmography, 784ab(5)
evaluation of male impotence, non-invasive technique, 784ab(5)
radioisotope plethysmography, corpora cavernosa blood flow, early tumescence, 466
- Pentamidine**, apical pattern of Ga-67 lung uptake, AIDS, 744ab(5)
- Peracetic acid**, superior oxidant, I-123 IBZM preparation, 926ab(5)
- Perfusion**
effect on PEEP on regional ventilation, mechanically ventilated preterm lamb, 1342
lung scan hot spots, 734ab(5)
metal-labeled tracers, structure-activity relationships, 742ab(5)
myocardial
functionalized diphosphine complexes, Tc-99m, 773ab(5)
late reversibility, Tl-201 stress studies, 740ab(5)
- Peritoneal cavity**, model for use in internal dosimetry, 2002
- PET**: *see* Positron emission tomography (PET)
- Phantom**, realistic dynamic cardiac, evaluation, radionuclide ventriculography, 542
- Pharmaceuticals**, research centers, N1295
- Phenols**, resin-supported C-11 methylation approach, 822ab(5)
- Pheochromocytoma**
localization with MIBG, CT and MRI correlation, 328
occult lung metastasis, detection, I-131 MIBG scintigraphy, 885ab(5)
reduction of I-131 MIBG uptake, labetalol, 481
- Phosphate**, -containing compounds, In-111 and Ga-67 transfer, transferrin to ferritin, 70
- Phosphines**
new class of mixed ligand radiopharmaceuticals, Tc-99m, 772ab(5)
technetium-nitride cations, synthesis, myocardial imaging agents, 773ab(5)
- Phospholipid ethers**, radioiodinated, tumor imaging agents, 849ab(5)
- Phosphorus-31**, MR spectroscopy and MRI, dermatomyositis, 5ab(11)
- Phosphorus-32 beta dose point kernels**, potential use in radioimmunotherapy, 1036
- Phosphorus-32 chromic phosphate colloid**
intraarterial, radiation splenectomy, 884ab(5)
treatment of cystic brain tumor, 833ab(5)
- Photopenia**, bone, clinical significance, In-111 leukocyte scintigraphy, 1749ab(10)
- Physicians**, nuclear medicine, survey, N1
- Pituitary**, imaging agent, C-11 MTRB, 932ab(5)
- Planar imaging**
Bayesian methods, ECT image reconstruction, 880ab(5)
liver scintigraphy, worth of SPECT, 57
new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
quantitative, Tc-99m MIBI, compared to Tl-201, 1456
Tl-201, perfusion defects, extent and severity, 863ab(5)
- Plasma**
clearance, Tc-99m MAG₃, one or two blood samples, 943ab(5)
clearance of Tc-99m MAG₃, estimation, one or two blood samples, 1955
metabolite analysis, internal surface-reverse phase chromatography, 920ab(5)
single sample value errors, renal plasma flow, distribution volume, 944ab(5)
Tc-99m RBC labeling interference, chronic renal failure patients, 869ab(5)
volume, dexamethasone effect, human brain tumors, 899ab(5)
- Plasminogen activator**, rapid clot uptake, animal model, deep vein thrombosis, 787ab(5)
- Platelets**
activation after balloon arterial injury, Tc-99m monoclonal antibody, atherosclerotic model, 787ab(5)
destruction in autoimmune thrombocytopenic purpura, clearance, In-111 autologous platelets, 629
efficient labeling method, Tc-99m, 737ab(5)
estimation of mean survival time, rapid method, 1550
inhibition of thrombosis on biomaterials, calcium ion sequestrants, 859ab(5)
labeling with Tc-99m pertechnetate, Sn(II)MPO, 922ab(5)
reaction with Tc-99m monoclonal antibody, monitoring thrombolysis, 1743ab(10)
scintigraphy, use of In-111 oxine, thrombocytopenia in children, 1819
splenic pool, response, vigorous exercise, 738ab(5)
uptake in liver and spleen, whole body, depth-independent build-up factor, 914ab(5)
- Plethysmography**
radioisotope penile
blood flow, early erection, 784ab(5)
corpora cavernosa blood flow, early tumescence, 466
- Pneumocystis carinii**
reversible pulmonary uptake, osteoarthropathic distribution, Tc-99m methylene diphosphonate, 1563
Tc-99m albumin and Ga-67 lung scanning, HIV-positive patients, 917ab(5)
- Pneumonitis**, amiodarone, Tc-99m DTPA aerosol washout rates, 916ab(5)
- Poisoning**, carbon monoxide, regional cerebral glucose metabolism, 802ab(5)
- Porphyrin**, bifunctional chelator, monoclonal antibody labeling, radioactive manganese, 935ab(5)
- Positive end-expiratory pressure**, effect on regional ventilation and perfusion, mechanically ventilated preterm lamb, 1342
- Positron emission tomography (PET)**
accuracy of quantitative measurements, myocardial blood flow, rubidium-82, 807ab(5)
 β -adrenergic receptors, CGP 12177, 766ab(5), 825ab(5)
Alzheimer-type dementia, regional cerebral blood flow, 895ab(5)
amino acid uptake in brain, kinetic modeling approaches, 880ab(5)
ammonia-13 kinetics in lung, smokers and non-smokers, 866ab(5)
anti-anginal agents, 866ab(5)
arterial dispersion time constant, 900ab(5)
assessment of myocardial viability, rest-redistribution thallium scintigraphy, 729ab(5)
attenuation correction, application, masked orbiting transmission source, 1056
automated three-dimensional, Rb-82, viable vs. infarcted myocardium, 865ab(5)
axial acceptance angle, effect, energy threshold, 766ab(5)
axial sampling and motion, 3D quantification, myocardial defects, 892ab(5)
brain glucose metabolism, psychiatric patients, summer affective disorders, 1752ab(10)
- C-11 acetate**
independence in dietary state, human heart, 837ab(5)
myocardial oxidative metabolism, substrate utilization, 187
regional myocardial oxygen consumption, 1798
serial imaging, regional myocardial oxidative metabolism, 867ab(5)
- C-11 acetate and dobutamine**, quantification, myocardial metabolic reserve, 837ab(5)
- N-[C-11-methyl]acyclovir synthesis**, 929ab(5)
- C-11 amino acids**
preparation, automated microprocessor-controlled reaction system, 4ab(11)
preparation, C-11 nitroalkanes, 783ab(5)
- C-11 and F-18 labeled 4-fluorodeprenyl**, probes, functional monoamine oxidase, 821ab(5)
- C-11 benztrapine**, possible muscarinic cholinergic receptor ligand, 741ab(5)
- C-11 carbon dioxide**, quantitative brain pH mapping, acute stroke, 782ab(5)
- C-11 citalopram**, facile synthesis, serotonin uptake sites, 1757ab(10)
- C-11 cocaine**
binding in human and baboon brain, 761ab(5)
kinetic analysis, baboon brain, 898ab(5)
- C-11 diprenorphine**, opiate receptor density, ligand affinity, 740ab(5)
- C-11 D-glucose**
remote automated synthesis, 928ab(5)
routine preparation method, C-11 ammonium cyanide, 927ab(5)
- C-11 L-methionine**
cerebral neutral amino acid uptake, 838ab(5)
F-18 fluorodeoxyglucose comparison, lung tumor diagnosis, 788ab(5)
histologic type, primary lung cancer, 33
tumor uptake, response to irradiation, 2012
uptake as a predictor of prognosis, bronchogenic carcinoma, 1420le(10)
- L-[methyl-C-11] methionine**, uptake in tumor, 1809
- C-11 8-methoxy-MK-801**
design, synthesis and evaluation, 930ab(5)
- NMDA receptor imaging**, 741ab(5)

- C-11 MK-329, cholecystokinin receptors, 931ab(5)
 C-11 phorbol ester, specific binding, protein kinase C, 783ab(5)
 C-11 thymidine, liver regeneration measurement, 929ab(5)
 C-15 oxygen, noninvasive detection, left-to-right shunts, 865ab(5)
 cardiovascular nuclear medicine, the next step, 1123
 central serotonin re-uptake sites, C-11 *N*-Me-paroxetine, 1753ab(10)
 cerebral glucose metabolism
 Alzheimer's disease, 771ab(5)
 thirty vs. forty-five-minute period, 899ab(5)
 cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
 characterization of fluorinated U-50488 analogs, 931ab(5)
 clinical
 economic analysis, Rb-82 and heart, 707
 manpower requirements, 1132(1e)
 reduction of radiation exposure, 962ab(5)
 study scheduling and coordination, 2ab(11)
 clinical and metabolic correlates, acute stroke, 898ab(5)
 clinical practice, 960ab(5)
 comparative study, regional cerebral blood flow, 157
 copper-PTSM
 cerebral blood flow, 791ab(5)
 microsphere-like retention in heart, blood flow, 768ab(5)
 regional blood flow, 807ab(5)
 coronary artery disease severity, comparison, quantitative arteriography, 846ab(5)
 coronary artery stenosis reversal, cholesterol lowering, arteriography, 845ab(5)
 cortical and thalamic glucose consumption, reduction, Huntington's disease, 771ab(5)
 CT and MR, Alzheimer's dementia, normal aging, 1607
 CT and MRI, evaluation, neuropsychiatric disorders, 1589
 data analysis with Macintosh computer, 873ab(5)
 defense of quantitative techniques, 564(1e)
 detection
 residual or recurrent brain and liver tumors, 909ab(5)
 residual viable tissue, myocardial infarctions of different ages, 869ab(5)
 striatal functional impairment, Huntington's disease, 762ab(5)
 viable hypoxic myocardium, F-18 fluoromisonidazole, 846ab(5)
 determination of liver regeneration, radiothymidine, 815ab(5)
 development
 Co-55 as an antibody label, 923ab(5)
 image display, analysis workstation, 873ab(5)
 nuclear medicine history, St. Louis, N569
 developmental brain plasticity, 801ab(5)
 diagnosis of coronary artery disease, correlation, coronary angioplasty, 845ab(5)
 diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
 differentiation of recurrent colorectal carcinoma, scar, 789ab(5)
 dipyridamole perfusion, assessment, myocardial ischemia, 760ab(5)
 dopamine D-2 receptors
 densities, neuropsychiatric disorders, 731ab(5)
 imaging, F-18 benzamide analogs, 899ab(5)
 quantification, caudate nucleus, 736ab(5)
 quantification, C-11 NMSP and schizophrenia, 731ab(5)
 dopamine receptors, post-synaptic, cocaine abusers, 730ab(5)
 dynamic
 isosorbide dinitrate, myocardial blood flow, 866ab(5)
 O-15 water and C-11 butanol, cerebral blood flow, 901ab(5)
 early tumor response to therapy, 789ab(5)
 evaluation of F-18 2-deoxy-2-fluoro-D-glucose, malignant melanoma, 738ab(5)
 event pileup, 2-D modular detector systems, multiplane, 745ab(5)
 F-18 2-deoxy-2-fluoro-D-glucose, therapeutic effect, malignant lymphoma, 910ab(5)
 F-18 deoxyglucose
 myocardial glucose utilization, 359
 small cell carcinoma, 1754ab(10)
 F-18 estrogens, 17 α -ethynyl-11 β -substitution, 753ab(5)
 F-18 fluoride radiotracer, dopamine D2 receptors, 1757ab(10)
 F-18 fluorodeoxyglucose
 kinetic rate constants, brain tumor and dementia, 900ab(5)
 pancreas cancer, chronic pancreatitis differentiation, 887ab(5)
 residual or recurrent brain and liver tumors, 966ab(5)
 TI-201 and I-123 IMP SPECT, brain tumor, 895ab(5)
 6-[F-18]fluoro-L-DOPA
 importance of carbidopa, 761ab(5)
 quality control procedure, brain dopamine neurons, 1249
 16 α -[F-18]fluoroestradiol, uptake, metastatic breast carcinoma, 788ab(5)
 F-18 fluoromisonidazole, enhanced extraction, jeopardized myocardium, 730ab(5)
 16 α -substituted 21-[F-18]fluoro-(19-nor)-progesterones, receptor binding ligands, 929ab(5)
N-3-[F-18]fluoropropylputrescine, prostate and prostate-derived tumors, 1205
 L-[2-F-18]fluorotyrosine, cerebral metabolism, protein synthesis, 1367
 F-18 pipamperone synthesis, baboon, 932ab(5)
 F-18 uracil and O-15 water
 metastatic colorectal cancer, 910ab(5)
 regional chemotherapy, liver metastases, 1754ab(10)
 finite tomograph resolution, tracer kinetics, compartmental modeling, 825ab(5)
 "first session" effects, 899ab(5)
 fluoroalkyl amphetamine analogs, synthesis, serotonin 5-HT2 agonists, 822ab(5)
 fluorodeoxyglucose
 evaluation of seizures, primary brain tumors, 2ab(11)
 optimal experimental design, tissue data, 879ab(5)
 pathologic findings, complex partial seizures, 752ab(5)
 two behavioral states, single procedure, 93
 fluorodeoxyglucose and O-15 water, colorectal carcinoma, radiation therapy, 909ab(5)
 focus on the heart, N1289
 Fourier-gated, wall motion analysis, 771ab(5)
 gated, subendocardial ischemia detection, left ventricular hypertrophy, 866ab(5)
 gated myocardial, quantitative analysis, regional wall motion, 1775
 HCFA coverage, N580
 high current electrostatic accelerator, 964ab(5)
 high-resolution
 clinical efficacy, 765ab(5)
 kinetic determination, FDG model parameters, 879ab(5)
 high-resolution multi-plane animal tomograph, modular detector system, 892ab(5)
 high-resolution scanner
 brain imaging, three dimensions, 765ab(5)
 development, preliminary results, 892ab(5)
 high spatial resolution time-of-flight, physical performances, clinical images, 766ab(5)
 HPLC injection, radiopharmaceutical purification, 923ab(5)
 I-124, immunotherapeutic radiopharmaceuticals, 922ab(5)
 imaging histamine H1 receptors, baboon brain, 741ab(5)
 imaging *in vivo* chemistry, N1283
 imaging positron emitting radionuclides, radiation therapy, 911ab(5)
 initial results from prototype tomograph, solid-state scintillation detectors, 766ab(5)
 intraoperative electrocorticography and, epilepsy surgery, children, 896ab(5)
 intravascular streaming, intracarotid infusion, glioma, 839ab(5)
 kinetics of copper-PTSM in heart, 1843
 LCMRO2 and LCBF measurements, on-line plasma separation, 791ab(5)
 least-squares optimization, reconstruction filters, brain imaging, 745ab(5)
 lesion detectability, axial resolution and sampling, 746ab(5)
 ligand-receptor model influence, injection protocol, identifiability analysis, 877ab(5)
 localization of epileptogenic foci, 2ab(11)
 longitudinal, CT studies and, normal aging and Alzheimer's disease, 772ab(5)
 maximum likelihood image reconstruction, 776ab(5)
 metabolic and electrophysiologic manifestations, recognition memory, 894ab(5)
 metabolic characterization of brain states, partial sensory limitation, 899ab(5)
 metabolic correlates, anatomic lesions, head trauma, 802ab(5)
 metabolic liver tumor image analysis, 878ab(5)
 metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
 MR and, correction of spatial distortions, structure-function registration, 1746ab(10)
 -MRI volume matching algorithm, evaluation, 875ab(5)
 multiplanar, long-term performance, 1378
 multiresolution method, attenuation correction, 880ab(5)
 multi-slice, axial positioning, recovery coefficient, 893ab(5)
 myocardial blood flow
 myocardial infarction, 945ab(5)
 new quantitation method, 808ab(5)
 O-15 water, novel mathematical approach, 825ab(5)
 O-15 water, without bloodpool scan, 807ab(5)
 myocardial glucose uptake, dopamine infusion, regional ischemia, 859ab(5)
 myocardial oxidative metabolic reserve, C-11 acetate, 1489
 Newsline Commentary, developments, RVSS and ICFR35, N992
 nicotine binding in brain, 742ab(5)
 nitrogen-13 ammonia, rest-stress value, preoperative prediction of reversible synergy, 1302
 no-carrier-added synthesis

Positron imaging

- aryl [F-18]fluorides, nucleophilic aromatic substitution, 753ab(5)
C-11 HECNU, 783ab(5)
L-[5-C-11]ornithine, 782(ab), 783ab(5)
F-18 fluoroethylketanserin, serotonin S-2 receptors, 822ab(5)
obsessive-compulsive disorder, 897ab(5)
O-15 butanol, improved routine synthesis, 927ab(5)
O-15 water
 brain mapping, change-distribution analysis, 141
 renal plasma flow, 824ab(5)
oncology, N1292
parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)
partial volume and spillover correction, cardiac scans, 824ab(5)
potential L-dopa tracers, radiofluorinated *m*-tyrosine analogs, 930ab(5)
presynaptic nigrostriatal function, Parkinson's disease, 761ab(5)
principial axis transformation, image registration, 776ab(5)
procedure protocols, 960ab(5)
quantitative
 correction, blessing and curse, 129(1e)
 critically ischemic myocardial mass, acute coronary occlusion, 866ab(5)
 glucose utilization, ischemic myocardium, 867ab(5)
 relative maximum flow, stenosis, 846ab(5)
quantitative 3-D, multiwire proportional chamber positron camera, 766ab(5)
radiation exposure reduction, 4ab(11)
radiopharmaceuticals
 regulation, N137
 routine, laboratory robotics, 968ab(5)
Zn-62 Cu-62 generator, Cu-62 source, 1838
Rb-81, quantitative tumor perfusion measurement, 911ab(5)
Rb-82
 importance of timing, heart, 871ab(5)
Tl-201 SPECT, coronary artery disease detection, 829ab(5)
Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)
two-compartment model, brain tumor patient data, 839ab(5)
realtime correction for deadtime and decay, cerebral blood flow, O-15 water autoradiography, 878ab(5)
reimbursement, N1931
reimbursement and budget, N277
relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)
reversal of brain metabolic abnormalities, treatment, AIDS dementia complex, 581
rotating pin transmission sources, physical effects, 745ab(5)
scatter effects, model parameter estimation, 824ab(5)
semi-quantitative incorporation quotient images, simple method for creation, 776ab(5)
set-up in major cities, Mallinckrodt and CSI plan, N1147
simple positron imaging, time-of-flight, iterative deblurring, 746ab(5)
simultaneous emission and transmission scans, masked orbiting transmission source, 1751ab(10)
SP3000 TOFPET, characterization, multiple coincidences, 893ab(5)
stereotactic method, anatomical mapping, brain, 961ab(5)
Strategic Defense Initiative and, N14 studies during reading, dyslexics and controls, 802ab(5)
superimposed MR images, simple and precise method, 876ab(5)
synthesis of aqueous N-13 ammonia, proton irradiation of water, hydrogen pressure, 926ab(5)
tellerr-118/antimony-118 generator development, 849ab(5)
three-dimensional cardiac
 automated quantitation, routine clinical use, 775ab(5), 1787
 cardiac metabolism and function, 808ab(5)
three-dimensional data analysis, customizable volume of interest atlas, 839ab(5)
tissue atrophy and parietal hypometabolism, Alzheimer's disease, 895ab(5)
two tomographs, quantitative comparison, cerebral glucose metabolic rates, 1386
United States Pharmacopeial Convention, N1587
validation
 brain SPECT, 3-[I-123]iodo- α -methyltyrosine, 895ab(5)
 post-injection transmission measurements, 825ab(5)
visual analysis, reproducibility, reliability, 846ab(5)
visual cortex metabolism, affected arm movement, traumatic brain injury, 965ab(5)
volumetric, MRI image matching, displays, 776ab(5)
whole-body
 attenuation correction, adaptive filtering, 1751ab(10)
 imaging technique, 1750ab(10)
Zr-89, production, purification, 935ab(5)
- Positron imaging**
- C-11 betamethylheptadecanoic acid, synthesis, biodistribution, 928ab(5)
C-11 MTRB, pituitary imaging agent, 932ab(5)
Cu-64 *p*-carboxyalkylphenylidithiocarbamoyl zones, antibody labeling, 848ab(5)
decreased brain metabolism, alcohol intoxication, 801ab(5)
quantitative accuracy of scanner, 892ab(5)
whole-body staggered detector positron camera, design and performance, 964ab(5)
- Probes, novel approaches**, N1293
- Progesterins**, fluorine-substituted, uptake selectivity, 928ab(5)
- Propranolol**, portasystemic shunt fraction quantification, I-123 IMP, 1702
- Prostate**
- cancer
 PAP and PSA as markers of disease, 786ab(5)
 186-Re(Sn)-HEDP palliation, painful skeletal metastases, 837ab(5)
 painful bone metastases
 improved clinical response, strontium-89, 843ab(5)
 palliative therapy, strontium-89, 836ab(5)
 potential PET imaging agent, N-3-[F-18]fluoropropylputrescine, 1205
 prostatic specific antigen, bone scanning, prostate cancer follow-up, 9ab(4)
- Prostheses**, porous coated hip arthroplasty, three-phase bone scan, indium white blood cell scintigraphy, 1321
- Protein**
- labeling, Tc-99m complex, bifunctional ligand, 940ab(5)
radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)
radiolabeled, autoradiographic quantitation, In-111, 1538
rate of valine incorporation, brain tumor model, autoradiography, 913ab(5)
synthesis
 brain tumors, C-11 L-methionine, 910ab(5)
 cerebral metabolism, L-[2-F-18]fluorotyrosine, 1367
- Protein kinase C**, C-11 phorbol ester binding, PET, 783ab(5)
- Psychiatric disorders**, pediatric, quantification, HMPOA distribution, 812ab(5)
- Psychiatry**
- "beam" brain mapping, SPECT iofetamine scans, 966ab(5)
 obsessive-compulsive disorder and PET, 897ab(5)
 schizophrenia, F-18 haloperidol binding, kinetic analysis, 898ab(5)
- Psychology**, panic attacks, head trauma patients, Tc-99m D,L-HM-PAO, 965ab(5)
- Psychosis**, mescaline-induced, right hemisphere involvement, 812ab(5)
- Pulmonary embolism**
- central, perfusion distribution patterns, 734ab(5)
clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
evaluation, urinary fibrinopeptide, 733ab(5)
lung parenchyma, gadolinium-labeled microspheres, MRI, 901ab(5)
non-thromboembolic lung disease, reversed mismatch, ventilation-perfusion ratio, 734ab(5)
PIOPED study, lung scans, pulmonary arteriography, N279
- pre-operative ventilation and perfusion scans, relative value, 733ab(5)
ventilation/perfusion mismatch, positive pressure ventilatory support, 1268
- Purpura**, idiopathic thrombocytopenic, splenic dynamics, In-111 platelets, 1546

R

Radiation

- blood flow, lung vascular permeability, 852ab(5)
exposure reduction, clinical PET, 4ab(11)
Protection Award announced by NCRP, N1934
reduction of exposure, clinical PET, 962ab(5)
scatter and background suppression, nuclear medicine imaging, 1747ab(10)
synovectomy, new agent, holmium-166 FHMA, 856ab(5)
therapy, FDG and O-15 water PET, colorectal carcinoma, 909ab(5)

Radiation dose

- beta dose kernel in water, EGS4 Monte Carlo determination, 883ab(5)
bladder wall, 2-[F-18]-fluoro-2-deoxy-D-glucose, dynamic bladder model, 1747ab(10)
Bremstrahlung, estimation in organs, 1373
development of treatment planning program, radioimmunotherapy, 884ab(5)
exposure and risk, performance of radiologic studies, radioactive patients, 884ab(5)
exposure from Tc-99m MAG₃, 720(1e)
failure of percholate to inhibit Tc-99m isonitrile binding, myocardial perfusion studies, 885ab(5)
quantitative measurement, In-111 anti-melanoma monoclonal antibody, 885ab(5)
Tc-99m-labeled bone imaging agents, 1117
- Radiation therapy**, imaging positron emitting radio-

- nuclides, 911ab(5)
- Radioactive waste**, low-level compacts, N133
- Radioaerosol**, containment system, lab(2)
- Radioangiography**, biventricular forward and regurgitant flows, 560(lc)
- Radioassay**, receptor biochemistry, Tc-99m galactosyl-neoglycoalbumin, 733ab(5)
- Radiocolloids**, PB-212 macroaggregate toxicity in dogs, 834ab(5)
- Radiography**
- acute myelofibrosis, 251
 - dual energy, comparison, quantitative computed tomography, 774ab(5)
 - magnetic resonance imaging and bone scintigraphy, sacroilitis, 842ab(5)
- Radioimmunoassay**
- CA125
 - co-expression of sialyl SSEA-1 antigen, variability, 919ab(5)
 - I-131 HMFG1 monoclonal antibody, ovarian cancer, 918ab(5)
 - monoclonal antibodies, different antigenic determinants, 785ab(5)
 - development of cardiac myosin light chain 1 mAb, synthetic peptide immunogens, 785ab(5)
 - effect on immunoscintigraphy, human anti-mouse antibodies, 786ab(5)
 - excellence in, Berson-Yalow Award, Robert C. Stadnik, N994
 - imaging of lung vessels, 1686
 - immunotherapeutic radiopharmaceuticals, I-124, PET applications, 922ab(5)
 - monoclonal antibodies
 - diagnosis, squamous cell carcinoma of lung, 918ab(5)
 - LH and FSH specificity, polyclonal antibodies, 919ab(5)
 - recognition, antigenic gangliosides, 919ab(5)
 - PAP and PSA as markers of disease, prostate cancer, 786ab(5)
 - preparation and characterization, Re-186 NR-CO-02 F(ab')₂, 793ab(5)
 - quo vadis imaging, 1911
 - recombinant human erythropoietin, 918ab(5)
 - simultaneous measurement of serum T3 and T4, 919ab(5)
 - valuable laboratory technique, N12
- Radioimmunoassayists**, new technology, 1571
- Radioimmundetection**
- adenocarcinoma, antibody cocktail development, 935ab(5)
 - anti-CA 12.5, follow-up, ovarian carcinoma, 758ab(5)
 - radioimmunotherapy and, B-cell lymphoma, monoclonal antibody, 828ab(5)
 - tumor, diester linkage, antibody and chelate, 1693
- Radioimmunoimaging**
- maleimidooethyl succinimidyl succinate, spacer, Ga-67 deferoxamine labeled antibody, 832ab(5)
 - rapid blood clearance, biotinylated IgG, avidin infusion, 66
- Radioimmunoscintigraphy**
- chimeric mouse-human anti-CEA antibody of IgG4, colorectal carcinoma, 809ab(5)
 - early and delayed, colorectal carcinoma evaluation, 890ab(5)
 - monoclonal antibody SM3, ovarian tumors, 758ab(5)
 - radioimmunotherapy and, monoclonal antibody labeling, Sm-153, 683
 - radiolabeled monovalent and divalent haptens,
- dual specificity monoclonal antibody conjugates, 1358
- Tc-99m monoclonal antibody, colorectal cancer, 748ab(5)
- Tc-99m monoclonal antibody Fab fragment, small cell lung carcinoma, 819ab(5)
- vs. standard X-rays, size-related diagnostic sensitivity, 749ab(5)
- Radioimmunotherapy**
- astatine-211 labeled antibodies, 832ab(5)
 - clinical, dosimetry, radiobiological efficacy, 827ab(5)
 - colorectal carcinoma xenografts, Y-90 CO17-1A, mouse IgG, 935ab(5)
 - combined with external beam irradiation, renal cell carcinoma xenografts, 826ab(5)
 - curative, mammary carcinoma xenografts, I-131 monoclonal antibodies, 531
 - Curie level iodinations, 969ab(5)
 - development of treatment planning program, 884ab(5)
 - estimation of bone marrow doses, 778ab(5)
 - gastrointestinal cancer, administration, monoclonal antibodies, 779ab(5)
 - human cancer peritoneal xenografts, bismuth-212 labeled antibody, 778ab(5)
 - human estimates based on mouse data, antibody carrier/radionuclide combinations, 777ab(5)
 - I-131 and Re-186 radiolabeled conjugates, monoclonal antibodies, urinary metabolites, 793ab(5)
 - I-131 anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
 - immunoglobulin complex formation, murine monoclonal antibodies, 888ab(5)
 - intraperitoneal, dose distributions, alpha and beta particle emitters, 777ab(5)
 - non-Hodgkin's lymphoma, I-131 anti-pan-B cell antibodies, 828ab(5)
 - potential use, beta dose point kernels, radionuclides, 1036, 1739(lc)
 - radioimmundetection and, B-cell lymphoma, monoclonal antibody, 828ab(5)
 - radioimmunoscintigraphy and, monoclonal antibody labeling, Sm-153, 683
 - Re-186, nude mouse model relevant to man, 779ab(5)
 - Re-186 NR-CO-02 anti-CEA F(ab')₂ fragment, preliminary clinical evaluation, 779ab(5)
 - remote high level iodinations of antibodies, 932ab(5)
 - serial, HAMA response, 827ab(5)
 - stage IV neuroblastoma, Tc-99m and I-131 monoclonal antibody, 904ab(5)
- Radioiodide**, colchicine-induced retention, iodine-deficient male rats, 737ab(5)
- Radioiodination**
- comparative radiolabeling, isotype switch variant anti-idiotype mAb, 227
 - effect on protein charge, electrophoretic mobility, 933ab(5)
 - iodoantipyrine labeled with radioactive iodine, dosimetry, lab(2)
 - monoclonal antibodies, iodogen particle suspensions, 933ab(5)
 - remote high level, antibodies, 932ab(5)
 - use of mercury-thiol resin, preparation, I-123 IPPA, 925ab(5)
- Radioiodine**, nonimmunogenic hyperthyroidism, 1960
- Radioisotopes**, solution to current shortage, N438
- Radioligands**
- cerebral regional metabolism, determination, binding parameters, 898ab(5)
- diffusional gradients, theoretical effects, neuro-receptors, 878ab(5)
- Radiology**, fully networked department, 2ab(11)
- Radionuclides**
- assessment of protein diet effect, glomerular filtration rate, 785ab(5)
 - beta dose point kernels, potential use, radioimmunotherapy, 1739(lc)
 - cardiovascular nuclear medicine, the next step, 1123
 - detection of duodenal ulcer, 700
 - effectiveness of treatment, differentiated thyroid cancer, 737ab(5)
 - emission standards proposed by EPA, N1435
 - features and clinical relevance, abnormal renal mobility, 3ab(4)
 - imaging in diagnosis, aortic dissection, 1727
 - measurement of renal function, 2054
 - monitoring, renal transplantation, 3ab(4)
 - positron emitting, generation during radiation therapy, 911ab(5)
 - renal studies of kidney depth, 1745ab(10)
 - 'salivagram', detection, pulmonary aspiration in children, 697
 - short-lived, nuclear medicine history, St. Louis, N569
 - therapeutic, "S" factors, self-dose to large tumors, 883ab(5)
- Radiopharmaceuticals**
- amine-phenol complexes, Tc-99m, 938ab(5)
 - automated production system, proton only cyclotron, 965ab(5)
 - behavior of EHPG complexes, metal ions, 848ab(5)
 - bone cancer, evolution, Sm-153 EDTMP, 966ab(5)
 - cell labeling, Tc-99m tetradeятate amine-phenols, 938ab(5)
 - comparison, cisplatin-induced tubular toxicity, 659
 - computer-aided design, 732ab(5)
 - cyclotron-produced, IAEA report, N1443
 - endotoxin testing with limulus amoebocyte lysate, chelated metallic radionuclides, chelating agents, 921ab(5)
 - F-18 fluoropropyl preclamol, mapping, cerebral sigma opiate receptors, 930ab(5)
 - HPLC injection for purification, remotely operated evaporation, 923ab(5)
 - I-124 2-iodoisonicotinic acid hydrazide, radiotracer for tuberculoma, 1756ab(10)
 - immunotherapeutic, I-124, PET applications, 922ab(5)
 - inhomogenous deposition, cellular level, dosimetry, 883ab(5)
 - internal surface-reverse phase chromatography, plasma metabolite analysis, 920ab(5)
 - irradiation of volunteers, nuclear medicine, 260
 - metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
 - mixed ligand technetium complexes
 - inorganic chemistry, 936ab(5)
 - new class, Tc-99m, 772ab(5)
 - no indemnification for licensees, N1444
 - PET**
 - laboratory robotics, 968ab(5)
 - regulation, N137
 - Zn-62 Cu-62 generator, Cu-62 source, 1838
 - radiation synovectomy, Y-90 particulate agents, 1047
 - receptor binding, discriminant analysis, Tc-99m NGA, 879ab(5)
 - renal, evaluation, 823ab(5)
 - skeletal, lesion to normal bone uptake ratios,

Radioscintigraphy

- QARG, 920ab(5)
structure/activity relationships, microcomputer-based molecular modeling, 877ab(5)
- Tc-99m
in situ formation, redox chemistry, 937ab(5)
practical HPLC method, quality control, 940ab(5)
structural identification, HPLC, 1240
- Tc-99m galactosyl-neoglycoalbumin, kinetic sensitivity, receptor binding, 1519
- Tc-99m HM-PAO and SPECT, pediatric brain imaging, 1917(le)
- Radioscintigraphy**, effect of film selection, lesion detectability curves, 890ab(5)
- Radiosynthesis**
6-[C-11]-D-glucose, 1756ab(10)
fluorine-18 fluoromisonidazole, 343
- Radiotherapy**
Auger electron, I-123 and Br-80m halodeoxyuridines, intraperitoneal cancer, 833ab(5)
cancer, radioiodinating reagent development, monoclonal antibodies, 216
C-11 L-methionine tumor uptake, response to irradiation, 2012
effect on L-[1-11C]tyrosine, 18FDG metabolism, PET, 789ab(5)
gastrointestinal functional disturbances, after abdominal irradiation, 765ab(5)
imaging of noncerebral tumors, F-18 fluorodeoxyglucose, Tc-99m HM-PAO, 912ab(5)
- I-123 MIBG uptake in children, neuroblastoma, tumor histopathology, 474
improved separation procedure of Cu-67, 921ab(5)
radiation effects on tumor, L-[methyl C-11] methionine uptake, 739ab(5)
- Radiothymidine**, labeled in carbon 2 position, determination, liver regeneration, 815ab(5)
- Radioventriculography**, first-pass, model, evaluation of ventricular insufficiency, 417(le)
- Radon**
continuing debate, N987
information for practicing physician, 961ab(5)
- Reading**, PET studies, dyslexics and controls, 802ab(5)
- Receiver operating characteristic (ROC) analysis**, collimator performance, use, hotelling trace, 892ab(5)
- Receptors**
adrenergic, scintigraphy, myocardial infarcts, 767ab(5)
 β -adrenergic
CGP 12177, PET, 766ab(5), 825ab(5)
high yield synthesis, I-123 iodocyanopindolol, 859ab(5)
anti-EGF, phase I, imaging trial, 746ab(5)
benzodiazepine, radioiodinated diazepam derivative, SPECT studies, 803ab(5)
binding of Tc-99m galactosyl-neoglycoalbumin, kinetic sensitivity, 1519
binding radiopharmaceuticals, discriminant analysis, Tc-99m NGA, 879ab(5)
biochemistry, Tc-99m galactosyl-neoglycoalbumin, 733ab(5)
cardiovascular nuclear medicine, the next step, 1123
cholecystokinin
C-11 MK-329 synthesis, PET, 931ab(5)
localization, MK 329, 849ab(5)
corticosteroid, F-18, 821ab(5)
dopamine
measurement, cocaine abusers, 730ab(5)
N-(ω -iodoalkenyl)spiroperidol analogs, SPECT, 925ab(5)
- dopamine D-1
F-18 fluoroethyl SCH-23390, no-carrier-added synthesis, 931ab(5)
- I-123 FISCH, characterization, 830ab(5)
I-125 FISCH, improved imaging ligand, 803ab(5)
I-123 SCH-23982, SPECT studies, 804ab(5)
- dopamine D-2
brain uptake, C-11 YM-09151-2, 515
density, neuropsychiatric disorders and PET, 731ab(5)
F-18 benzamide analogs, PET, 899ab(5)
F-18 haloperidol binding, kinetic analysis, 898ab(5)
- I-123 IBZM, evaluation, 88
I-123 IBZM biodistribution, dosimetry, 834ab(5)
I-123 IBZM preparation, peracetic acid, 926ab(5)
I-123 iodobenzamide imaging, SPECT, 731ab(5)
I-123 iodolisuride imaging agent, SPECT, 731ab(5)
I-123 spiperone, tracer for SPECT, 926ab(5)
new analogs of iodobenzamide, 803ab(5)
new [F-18]fluoride radiotracer, PET, 1757ab(10)
quantification, caudate nucleus and PET, 736ab(5)
quantification, PET C-11 NMSP in schizophrenia, 731ab(5)
robustness of models, 736ab(5)
synthesis, I-125/123 N-iodoallylpiperone, 803ab(5)
- epidermal growth factor, antibody guided diagnosis, glioma, 1636
estradiol, imaging, breast cancer detection, 844ab(5)
estrogen
astatine-211, biological behavior, 925ab(5)
biodistribution studies, I-123 IBHPE, 883ab(5)
concentration, tamoxifen and F-18 FES, 910ab(5)
16- α -[F-18]fluoroestradiol uptake, metastatic breast carcinoma, 788ab(5)
11 β -methoxy-[16 α -I-123]iodoestradiol interaction, 209
- histamine H1, PET imaging, baboon brain, 741ab(5)
imaging agents, F-18, binding assays, 931ab(5)
-ligand model influence, injection protocol, identifiability analysis, 877ab(5)
- lipoprotein
low-density, In-111 DTPA, 768ab(5)
PET quantification, Ga-68 DTPA-VLDL, 763ab(5)
- muscarinic
C-11 MTRB, pituitary imaging agent, 932ab(5)
synthesis, C-11 tropanyl benzilate methiodide, 930ab(5)
muscarinic acetylcholine, I-125 3-(R)-quinuclidinyl (S)-4-iodobenzilate, 1079
- muscarinic cholinergic, C-11 benztropine, PET, 741ab(5)
- NMDA
C-11 8-methoxy-MK-801, synthesis, 930ab(5)
[I-123]- and [I-125]-3-iodo-MK-801, SPECT, 923ab(5)
PET imaging, 8-[C-11] methoxy-MK-801, 741ab(5)
- opioid
density and ligand affinity, PET and C-11 diprenorphine, 740ab(5)
mapping, F-18 fluoropropyl preclamol,
- 930ab(5)
temporal lobe epilepsy, C-11 diprenorphine and PET, 750ab(5)
- progesterone, binding ligands, PET, 929ab(5)
- serotonin S-2
non-carrier-added synthesis, F-18 fluoroethylketanserin, 822ab(5)
SPECT, baboon brain, 741ab(5)
transferrin, vascular permeability, iron-59/In-111/Ga-69 transferrin, 1676
- TSH, antibody measurements, hyperthyroidism, 786ab(5)
- Reconstruction**
algorithms, non-stationary SPECT image noise, 1746ab(10)
efficient attenuated reprojection algorithm, SPECT, 817ab(5)
- Red blood cells**
new bifunctional synthon, Tc-99m carbonic anhydrase, 940ab(5)
- Tc-99m-labeled
early blood pool phases, hepatic hemangioma, 815ab(5)
first human studies, new kit, 811ab(5)
- Redox**, cellular, C-13 nuclear magnetic resonance, 814ab(5)
- Reflex**, sympathetic dystrophy, 959ab(5)
- Reflux**, duodenogastric, scintigraphic sign, 1568
- Regional wall motion**
assessment of ventricular topography, after acute myocardial infarction, 770ab(5)
automated detection of abnormalities, 961ab(5)
cardiac, synthetic classification images, 816ab(5)
evaluation of ventricular function, coronary artery disease, 1149
Fourier-gated PET, 771ab(5)
- left ventricular, quantification, radionuclide ventriculograms, 638
quantitative analysis, gated myocardial PET, compared to left ventriculography, 1775
- regional ejection fraction, definition, normal limits, 769ab(5)
- Relative value scales, Resource Based**, N1294
- Renal artery**, bilateral stenosis, captopril renal scintigraphy, 2042
- Remins**
renal vein
captopril-stimulated renography, hypertension, 5ab(4)
peripheral plasma, gamma camera renography, 6ab(4)
- Renography**
diuretic
antenatal hydronephrosis, 799ab(5)
early injection of furosemide, 841ab(5)
standard furosemide method, direct infusion comparison, 7ab(4)
quantitative, outcome of treatment, atherosclerotic renal artery stenosis, 1946
- Reperfusion**
C-14 deoxyglucose deposition, ischemia, 797ab(5)
myocardial, scintigraphy, percutaneous transluminal coronary angioplasty, 821ab(5)
serial Tc-99m MIBI myocardial SPECT studies, acute myocardial infarction, 800ab(5)
variability of response, thrombolysis, acute myocardial infarction, 820ab(5)
- Resin** -supported C-11 methylation approach, phenols, amides and acidic precursors, 822ab(5)
- Rhenium-186**
labeled NR-CO-02 anti-CEA F(ab')₂ fragment, potential radioimmunotherapeutic agent,

779ab(5)
radioimmunotherapy, nude mouse model relevant to man, 779ab(5)
radiolabeled conjugates of monoclonal antibodies, fragments, urinary metabolites, 793ab(5)
Tc-99m and, comparative renal handling, CO₂DADS, 743ab(5)
Rhenium-186 beta dose point kernels, potential use in radioimmunotherapy, 1036
Rhenium-186 HEDP, palliation of painful skeletal metastases, prostate cancer, 837ab(5)
Rhenium-186 N₃S antibody, immunoconjugates, N₃S chelating agents, kit preparation, 933ab(5)
Rhenium-186 NR-CO-02 F(ab')₂, preparation and characterization, 793ab(5)
Rhenium-186 (Sn)-HEDP
mechanism of action, painful skeletal metastases, 732ab(5)
palliation of painful skeletal metastases, prostate cancer, 837ab(5)
Rhenium-188, zirconium-tungsten gel generators, 849ab(5)
Rhenium-188 beta dose point kernels, potential use in radioimmunotherapy, 1036
Rhenium diphosphonates, extended X-ray absorption fine structure, 732ab(5)
Rhenium(V), compared to technetium(V), ligand substitution, 743ab(5)
Rheumatoid arthritis
In-111 chloride joint imaging, 855ab(5)
radiopharmaceuticals, radiation synovectomy, Y-90 particulate agents, 1047
Rhodamine, sulphydryl site-specific radiolabeling, monoclonal antibodies, 832ab(5)
Rhodium-105, labeling of human IgG, diethylene triamine derivatives, 832ab(5)
RP-30, mechanisms of redistribution, post-ischemic myocardium, 757ab(5)
Rubidium-81, PET, quantitative tumor perfusion measurement, 91lab(5)
Rubidium-82
accuracy of quantitative measurements, myocardial blood flow, 807ab(5)
assessment of reversible myocardial ischemia, dipyridamole perfusion PET, 760ab(5)
automated 3D cardiac PET, viable vs. infarcted myocardium, 865ab(5)
diagnosis of coronary artery disease, coronary angioplasty, PET, 845ab(5)
economic analysis, clinical PET, heart, 707 PET
arteriography and, coronary artery disease severity, 846ab(5)
importance of timing, heart, 871ab(5)
Tl-201 SPECT and, coronary artery disease, 829ab(5)
Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)
two-compartment model, brain tumor patient data, 839ab(5)
thallium-201 and, myocardial perfusion imaging, coronary artery disease, 759ab(5)

S

Sacroilitis, MRI and radiography, bone scintigraphy, 842ab(5)
Salmonella, -infected thrombus, left ventricular aneurysm, Ga-67 citrate scintigraphy, 1277(l)e
Samarium-153 EDTA, high specific activity, experimental tumor models, 202
Samarium-153 EDTMP

evolution, bone cancer radiopharmaceutical, 966ab(5)
human pharmacokinetics, metastatic cancer, 1814
Samarium-153 monoclonal antibody, combined radioimmunoscintigraphy, radioimmunotherapy and, 683
Sarcoma, musculoskeletal, evaluation, use of Gd-DTPA, 901ab(5)
Scatter
background suppression and, nuclear medicine imaging, 1747ab(10)
collimator, novel Monte Carlo simulation, 806ab(5)
Compton, distribution function, nonuniform attenuation media, 875ab(5)
fraction measurement, SPECT imaging, 876ab(5)
model parameter estimation, PET data, 824ab(5)
Monte Carlo simulation, non-uniform attenuating media, 875ab(5)
quantum noise and camera non-uniformity, analysis, holospectral imaging, 807ab(5)
-to-primary ratios, measurement, scintillation cameras, 876ab(5)
Schizophrenia
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
F-18 haloperidol binding, kinetic analysis, baboon and human brain, 898ab(5)
I-123 IMP imaging, brain perfusion, 1616
PET D2 dopamine receptor quantification, C-11 NMSP, 731ab(5)
Scintigraphy
accuracy of contour detection, small objects, 806ab(5)
adrenergic receptors and neurons, myocardial infarcts, 767ab(5)
bone
diagnosis, sacral fractures, 959ab(5)
non-osseous subtalar coalition, 799ab(5)
serum osteocalcin levels, 1748ab(10)
brain perfusion imaging, Tc-99m L,L-ECD, non-human primates, 1892
captopril
diagnosis, renovascular hypertension, 944ab(5)
neonatal hypertension, 798ab(5)
cardiac blood-pool, Tc-99m DTPA-HSA, 1713
complete duodenogastric reflux, 1568
computer simulation of scintigrams, 879ab(5)
detection of focal inflammation, polyclonal human immunoglobulin, 385
detection of parathyroid abnormalities, Tc-99m/Tl-201 subtraction technique, 3ab(2)
display and processing software, personal computer, 969ab(5)
energy weighted acquisition, finite spatial filters, 2029
evaluation of feet, 959ab(5)
features of choledochal cyst, 622
Ga-67 citrate, salmonella-infected thrombus, left ventricular aneurysm, 1277(l)e
gastroesophageal, barium exams, pH probe studies in children, 2ab(2)
hepatic arterial perfusion, detection of hepatic metastases, 4ab(11)
identification, inflammatory diseases, vertebral column, 856ab(5)
I-123 metiodobenzylguanidine, children with neuroblastoma, 799ab(5)
In-111 anti-myosin, after coronary bypass surgery, 780ab(5)
In-111 leukocyte
bone photopenia, clinical significance, 1749ab(10)
detection, myocardial abscess formation, 703
In-111 platelets, false-positive, 267(l)e
indium white blood cell, three-phase bone scan, porous coated hip arthroplasty, 1321
intraperitoneal, monoclonal antibody delivery, transdiaphragmatic blockade, 815ab(5)
kidney, special chair, upright position, 963ab(5)
L6 binding sites, autoradiography, 1754ab(10)
lung perfusion, right-to-left shunting, persistent left superior vena cava, 412
LV volume calculations, technical aspects, 869ab(5)
lymphoceles associated with renal transplant, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)
myocardial, Tl-201 chloride compared to Tc-99m MIBI, infants, 1176
myocardial sympathetic nerve development, I-123 MIBG, 810ab(5)
platelet, use of In-111 oxine, thrombocytopenia in children, 1819
pulmonary aspiration, evaluation, 967ab(5)
regional migratory osteoporosis, 858ab(5)
renal
captopril, Tc-99m DTPA and hypertension, 615
captopril pitfall, bilateral renal artery stenosis, 2042
Tc-99m MAG, and I-123 hippurate clearances, 2ab(4)
scrotal, varicocele, physical exam and renal venography, 943ab(5)
sonography correlation, obstructive renal disease, 944ab(5)
Tc-99m DISIDA and, quantification, tracer kinetic modeling approaches, 1507
Tc-99m MDP, relative renal function estimation, 941ab(5)
Tc-99m pyrophosphate, malignant hyperthermia, 718(l)e
Tc-99m (V) DMSA uptake, amyloidosis, 2050
Tl-201 and I-131, thyroid carcinoma follow-up, 914ab(5)
ultrasound features and, giant hemangiomas, liver, 181
unusual and subtle findings, evaluation, battered child, 4ab(2), 967ab(5)
ventilation/perfusion, CT comparison, emphysema in alpha-1 antitrypsin deficiency, 1755ab(10)
Scintillation cameras
clinical
evaluation, pulse tail extrapolation electronics, 1554
pulse tail extrapolation electronics, 797ab(5)
discrepancy sulfur colloid, radioparticle liver uptake, superior vena cava obstruction, 113
dual-headed extra wide field-of-view, 855ab(5)
electronically collimated SPECT, first experimental study, 851ab(5)
measurement of scatter-to-primary ratios, 876ab(5)
multiple-energy gamma camera system, dynamic transport studies, 852ab(5)
non-uniformity, analysis, holospectral imaging, 807ab(5)
quantitative quality control program, SPECT, 851ab(5)
solid-state detectors, initial results, prototype PET tomograph, 766ab(5)
stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
technique for evaluation of anisotropy, collima-

Seizures

- tors used for SPECT, 894ab(5)
Seizures, utility of FDG-PET, 2ab(11)
Serotonin
 5-HT2 agonists, synthesis, fluoroalkyl amphetamine analogs, 822ab(5)
 uptake sites, PET, facile synthesis of C-11 citalopram, 1757ab(10)
Serum amyloid P component
 diagnostic imaging of amyloidosis, 847ab(5)
 plasma turnover studies, quantitative test, 847ab(5)
Sex differences, N-3-(F-18)-propyl diprenorphine distribution, 732ab(5)
Sexual aggression, violent, evaluation of cerebral perfusion, 812ab(5)
Shunt
 colorectal carcinoma, F-18 uracil, N-13 glutamate, 910ab(5)
 left-to-right, noninvasive detection, C-15 oxygen cardiac PET study, 865ab(5)
 portal systemic
 camera- and well-counting techniques, 890ab(5)
 portal hypertensive rats, 887ab(5)
 portosystemic, fraction quantification, I-123 IMP, 1702
 right-to-left, persistent left superior vena cava, perfusion lung scintigraphy, 412
 size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
Sialyl SSEA-1 antigen, co-expression on CA125, variability of expression, 919ab(5)
Sickle cell-, related marrow infarction, nonspecificity, gallium citrate localization, 855ab(5)
Single photon emission computed tomography (SPECT)
 abnormal regional response to verbal stimulation, developmental dysphasia, Xe-133, 812ab(5)
 acetazolamide IMP imaging, regional ischemia, 782ab(5)
 acquisition parameters, Tc-99m MIBI, 795
 application of stopping criteria, iterative maximum likelihood-EM reconstruction, 882ab(5)
 assessment of ventricular topography, after acute myocardial infarction, 770ab(5)
 attenuation correction, Tc-99m cardiac phantom, 894ab(5)
 attenuation correction of thallium, differential attenuation, thallium photons, 1746ab(10)
 bone
 back pain, lumbar spine surgery, 490
 evaluation of persistent back pain, lumbar spinal fusion, 1739(le)
 studies of extremities, neuroblastoma, 858ab(5)
 bone imaging, lumbar facet joint, septic arthritis, 1408
 brain
 I-123 IMP scanning, HIV-positive encephalopathy, 811ab(5)
 imaging characteristics, ASPECT, 796ab(5)
 neonates, 915ab(5)
 Tc-99m HM-PAO, congenital dysphasia, 798ab(5)
 cardiac
 automatic superposition of images, 871ab(5)
 correction, nonuniform attenuation, 497
 causes of abnormal stress TI-201 SPECT, normal coronary arteries, 750ab(5)
 causes of geometric distortion, 180° and 360° angular sampling, 1666
 collimator angulation error, 852ab(5)
 combined CBF/CBV, recent and old strokes, 897ab(5)
 combined conjugate views, Wiener restoration, 756ab(5)
 commercially available systems
 assessment, 893ab(5)
 assessment, progress report, 963ab(5)
 comparison of images, stereographic projection, brain, 875ab(5)
 comparison of one and two day rest and treadmill tests, Cardiolite, 790ab(5)
 Compton scatter distribution function, non-uniform attenuation media, 875ab(5)
 cone beam, attenuation compensation, maximum likelihood reconstruction, 881ab(5)
 constraining reconstruction to body volume, CT or MR scans, 835ab(5)
 correction of bladder artifact, hip SPECT, 857ab(5)
 3D attenuation coefficients, distribution, chest, 128(le)
 dental bone scans, orthopan-tomosintigram, 835ab(5)
 detection of breast cancer, imageable estradiol, 844ab(5)
 detection of residual viable tissue, myocardial infarctions, different ages, 869ab(5)
 development of MUMPI, 964ab(5)
 diagnostic patterns of post-ictal cerebral blood flow, temporal lobe epilepsy, Tc-99m HM-PAO, 751ab(5)
 diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
 differentiation, suspected malignant pulmonary lesions, 844ab(5)
 diffuse nonuniformity, liver studies, leukemia, 905ab(5)
 dipyridamole-thallium 201, left bundle branch block, 2ab(11)
 3D non-stationary simulation, 881ab(5)
 dopamine D2 receptor imaging, I-123 iodobenzamide, 731ab(5)
 dosimetry of I-125 seed implants, 1748ab(10)
 dual energy
 attenuation correction, optimum energies, 5ab(2)
 methods and applications, brain, 1750ab(10)
 dual radionuclide, flood radionuclide choice, Tc-99m based cardiac agent, 872ab(5)
 dynamic
 four-headed gamma camera, RCBF, 792ab(5)
 lung ventilation study, Xe-133, 916ab(5)
 myocardial perfusion imaging, Tc-99m teboroxime, 1ab(11)
 Tc-99m HM-PAO, meningiomas, 1101
 Tc-99m teboroxime, regional myocardial perfusion, 1744ab(10)
 early and delayed, I-123 IMP, acute brain injury, 1751ab(10)
 early detection of mechanical-overload heart failure, I-123 MIBG, clonidine pre-treatment, 810ab(5)
 effect of attenuation weighted backprojection, 3D MTF, 816ab(5)
 efficient attenuated reprojection algorithm, 817ab(5)
 electronically collimated, first experimental study, 851ab(5)
 emission and transmission data combination, interactive 3D image presentation, 835ab(5)
 exercise/rest Tc-99m MIBI, regional quantitation, coronary heart disease, 791ab(5)
 follow-up of cutaneous melanoma, immunoscintigraphy, 907ab(5)
 Ga-67, evaluation, recurrent lymphoma, 874ab(5)
 gated, aortic and mitral valve regurgitation, 870ab(5)
 'Harlequin' artifact, cause and correction, 1133(le)
 high-resolution renal imaging, Tc-99m DMSA, 1759ab(10)
 high spatial resolution, small-animal resolution, 796ab(5)
 HM-PAO, model for outcome-prediction, after stroke, 895ab(5)
 I-123 cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
 I-123 HIPDM, surgery candidates, refractory complex partial seizures, 751ab(5)
 I-123 IMP
 brain imaging in children, alternating hemiplegias, 965ab(5)
 craniosynostosis, 916ab(5)
 functional imaging, brain maturation, 1982
 validity of microsphere model, cerebral blood flow, 878ab(5)
 Xe-133 and, critical cerebral blood flow thresholds, 337
 I-123 6-iododopa, potential brain imaging agent, 924ab(5)
 I-123 iodoluride imaging agent, brain dopamine D-2 receptors, 731ab(5)
 I-123 iodo- α -methyl tyrosine
 brain tumor imaging, 110
 validation with PET, brain, 895ab(5)
 I-123 and I-125-3-iodo-MK-801, NMDA receptor-ion channel complex, 923ab(5)
 I-123 SCH-23982, dopamine D1 receptors, 804ab(5)
 I-123 spiperone, dopamine D-2 receptor studies, 926ab(5)
 I-131 anti-CEA/CA 19-9, immunoscintigraphy efficacy, colorectal cancer, 907ab(5)
 IBG as improbable potential tracer, glucose metabolism, 921ab(5)
 imaging *in vivo* chemistry, N1283
 improved quantification, Wiener filtering, myocardial ischemia, 755ab(5)
 influence of collimators, center of rotation measurements, 265(le)
 inherent limitations in LV wall thickness, mass measurements, myocardial perfusion scans, 796ab(5)
 interictal and ictal, cerebral blood flow, seizure focus localization, 751ab(5)
 interictal and immediate postictal, Tc-99m HM-PAO, localization of seizure foci, 831ab(5)
 iodine-substituted benzamides, high affinity, 803ab(5)
 N-(ω -iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, 925ab(5)
 iofetamine scans, child psychiatry, "beam" brain mapping, 966ab(5)
 iterated radial post correction method, non-uniform attenuation correction, 870ab(5)
 liver, automated body contour, 266(le)
 liver/spleen scans, leukemia, 3ab(2)
 measurement of cerebral perfusion reserve, minor ischemic stroke, 897ab(5)
 methods of scatter fraction measurement, 876ab(5)
 MIBI, reperfusion response, myocardial infarction, 820ab(5)
 modern gamma camera systems, comparison, imaging parameters, 3ab(2)
 Monte Carlo simulation, non-uniform attenuating media, 875ab(5)

- multi-crystal cylindrical detector designs, 851ab(5)
myocardial, color-coded surface image display, 872ab(5)
myocardial fatty acid utilization, recurrent chest pain, normal coronary arteriography, 828ab(5)
myocardial perfusion images, model based quantification, 1992
myocardial sectional images, rotating patient chair, 1ab(2)
myocardial sympathetic nervous function, angina pectoris, I-123 MIBG, 811ab(5)
neonatal brain, 1337
new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
new tracer for cerebral perfusion studies, Tc-99m D,L-CB-PAO, 831ab(5)
non-osseous subtalar coalitions, bone scintigraphy, 799ab(5)
non-stationary, image noise, reconstruction algorithms, 1746ab(10)
optimization of Tc-MIBI acquisition, processing parameters, 757ab(5)
positioning of cortical region of interest, isocontour method, 877ab(5)
postexercise lung TI-201 uptake, 288
potential CNS D-2 dopamine imaging agent, I-123 IBF, 762ab(5)
principal axis transformation, image registration, 776ab(5)
quantification
 3D left ventricular segmental wall motion, 638
 HM-PAO distribution, pediatric psychiatric patients, 812ab(5)
 myocardial perfusion and thickness, tomographic phantom studies, 871ab(5)
quantitative
 bone scintigraphy, 240
 clinical use, Tc-99m and In-111, 881ab(5)
 image registration system, 894ab(5)
 quality control program, 851ab(5)
 therapeutic radioiodine concentration, 737ab(5)
quantitative stress-redistribution TI-201, myocardial infarction, 780ab(5)
radial long-axis tomography, new reconstruction algorithm, 881ab(5)
radioiodinated diazepam derivative, benzodiazepine receptor, 803ab(5)
reconstructed, effect, differential washout, 870ab(5)
reconstruction of truncated fan beam data, heart, 755ab(5)
regional cerebral blood flow
 acute ischemic stroke, 781ab(5)
 Alzheimer's disease, 771ab(5)
regional cerebral blood flow, drug abusers, 1ab(11)
regional ejection fraction, definition, normal limits, 769ab(5)
regularization, iterative least squares reconstruction algorithms, 880ab(5)
reimbursement for studies, SNM/ACNP statement, N995
reviewing projection displays, 963ab(5)
rotating slanthole collimator, 1737(1e)
serial Tc-99m MIBI myocardial studies, acute myocardial infarction, reperfusion, 800ab(5)
serotonin S₂ receptor mapping, baboon brain, 741ab(5)
simultaneous transmission/emission, moving line source, 964ab(5)
slant-hole, TI-201, 1ab(2)
SQ 32097, regional cerebral localization, lab(11)
stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
stress-redistribution thallium-201 studies, reproducibility, quantitative indices, 729ab(5)
symposium, SNM 8th Annual Winter Meeting, N11
Tc-99m, spatial resolution, quantification values, 508
Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, NMR techniques, 106
Tc-99m DMSA, quantitation, renal uptake, 246
Tc-99m ethyl cysteinate dimer, chronic cerebral infarction, 1018
Tc-99m HM-PAO
 abnormal blood flow patterns, cerebral atrophy, 896ab(5)
 brain, children, 966ab(5)
 brain blood flow, congenital dysphasia, 1825
 3D region of interest analysis, brain, 961ab(5)
 filling out phenomenon, cerebral ischemia, 591
 focal cerebral ischemia, 781ab(5)
 pediatric brain imaging, 1917(1e)
 quantitative analysis, Alzheimer's disease, 806ab(5)
Tc-99m MIBI
 180° and 360° data collection, myocardium, 295
 pre- and post-thrombolysis, myocardial infarction, 820ab(5)
technique for evaluation of anisotropy, collimators used for SPECT, 894ab(5)
thallium myocardial, prone vs. supine, 548
three-dimensional display, 834ab(5)
 accuracy, coronary disease detection, 834ab(5)
 gated blood-pool studies, 770ab(5)
TI-201
 adenosine infusion, ischemic heart disease, 1745ab(10)
 brain tumors, 913ab(5)
 compared to exercise RNV, jeopardized myocardium detection, 861ab(5)
 coronary artery disease, left bundle branch block, 419(1e)
 delayed images, viable or scarred myocardium, 864ab(5)
 denervated but viable canine myocardium, myocardial infarction, 767ab(5)
 evaluation, suspected lung cancer, 997
 exercise, myocardial perfusion abnormality, 749ab(5)
 false positive, exercise, 749ab(5)
 FDG imaging and, redistribution and metabolic activity, 863ab(5)
 flood field correction, reconstruction, 3ab(2)
 future cardiac events, angina pectoris, 861ab(5)
 high-risk patient identification, coronary artery disease, 862ab(5)
 kinetics, human myocardium, 863ab(5)
 left ventricular wall motion, Tc-99m MIBI, 864ab(5)
 low risk patients, coronary artery disease, 863ab(5)
 myocardium, polar probability map, 871ab(5)
 optimal specificity, imaging artifact recognition, 441
 percent hypoperfused myocardium, algorithm, 750ab(5)
 quantification, leg muscle perfusion, 458
 Rb-82 PET, coronary artery disease detection, 829ab(5)
 Rb-82 PET disparities, myocardial perfusion imaging, 861ab(5)
- silent myocardial ischemia, after myocardial infarction, 864ab(5)
Tc-99m HEXAMIBI, coronary artery disease, 4ab(2)
TI-201 and I-123 IMP, brain tumor usefulness, F-18 FDG PET, 895ab(5)
TI-201 and Tc-99m, 180° and 360° reconstructions, heart, 756ab(5)
TI-201 ECG-gated myocardial, clinical evaluation, 864ab(5)
TI-201 exercise, myocardial perfusion, Tc-99m RP-30A, 820ab(5)
TI-201 myocardial imaging
 prone position, 750ab(5)
 prone vs. supine position, 1738(1e)
TI-201 reversibility, quantitative analysis, 739ab(5)
TI-201 scintigraphy, maximal coronary vasodilation, adenosine, 760ab(5)
TI-201 stress-redistribution, false-positive reversible defects, "upward creep" of heart, 1718
TI-201 stress studies, frequency, late reversibility, 740ab(5)
tomographic mapping of kinetic rate constants, I-123 IMP, 805ab(5)
unstable angina patients, coronary stenosis, resting/redistribution TI-201, 740ab(5)
utility in evaluation of mandibular bone grafts, 843ab(5)
validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
ventricular function and perfusion, gated tomographic imaging, Tc-99m MIBI, 801ab(5)
volume quantitation, 2D vs. 3D image segmentation, 835(ab)
vs. planar liver scintigraphy, 57
whole body multidetector, variable aperture, 796ab(5)
workstation development, AT personal computer, 960ab(5)
Xe-133 and Tc-99m HMPAO
 cerebral blood flow, 1752ab(10)
 presurgical evaluation, temporal lobe epilepsy, 896ab(5)
Skull, hot, chemotherapy, radionuclide bone scans, 858ab(5)
Small-vessel disease, altered myocardial perfusion, free fatty acid utilization, 829ab(5)
Smoking
 imaging of *in vivo* chemistry, N1286
 lung cancer, radon debate, N987
Sn-117mDTPA, effect on marrow and tumor, 1754ab(10)
Society of Nuclear Medicine (SNM)
 Board of Trustees, relative value scale survey, N435
 HFCA and PET coverage, N580
 origin and The Journal, St. Louis, N569
 petition to change 10 CFR 35, N1296
 resignation of Henry Ernstthal, Executive Director, Education Post, N993
SNM Awards for young cardiovascular investigators, N1434
SNM 36th Annual Meeting, St. Louis, N572
 imaging *in vivo* chemistry, N1283
SNM 8th Annual Winter Meeting, SPECT symposium, N11
 testimony on DOE 1990 budget, N1148
Sodium-potassium-ATPase, myocardial imaging agent, radioiodinated digoxin derivative, 923ab(5)
Somatostatin, octreotide, I-123 labeling, metabolism, 768ab(5)
Sonography

Spermatozoa

scintigraphy correlation, obstructive renal disease, 944ab(5)
sensitivity, cholecintigraphy, gallbladder perforation, 850ab(5)

Spermatozoa, Tc-99m HM-PAO labeling agent, 922ab(5)

Spinal cord

injury
bone mineral distribution, five years later, 857ab(5)
radioisotopic evaluation, kidney, 944ab(5)

Spine

fracture probability, single and multi-site bone mineral content measurements, 1166
lumbar, back pain after surgery, bone SPECT, 490
lumbar spinal fusion, evaluation of persistent back pain, bone SPECT, 1739(le)

Spiroperidol, D-2 dopamine receptor, brain uptake, C-11 YM-09151-2, 515

Spleen

correlative pediatric imaging, 15
dynamics of In-111 labeled platelets, idiopathic thrombocytopenic purpura, 1546
liver uptake and, monoclonal antibody study, Sab(11)
noncalcified hemangioma, detection, radio-nuclide bone scan, 1111
platelet uptake, whole body, depth-independent build-up factor, 914ab(5)
radiation splenectomy, intraarterial P-32 chromic phosphate, 884ab(5)
response of platelet pool, vigorous exercise, 738ab(5)
SPECT, leukemia, 3ab(2)
Tc-99m colloid, interferon therapy, hairy-cell leukemia, 2ab(2)

SQ 30217, Tc-99m labeled, myocardial retention, canine heart, 860ab(5)

SQ 32097

cerebral blood flow, cytoarchitectural pattern, 1751ab(10)
preliminary kinetics, regional cerebral blood flow, 792ab(5)
regional cerebral localization, SPECT, normal volunteers, lab(11)

Stadalmik, Robert C., Berson-Yalow Award recipient, excellence, radioassay, N994

Stark Referrals Bill, Newsline article, N1579

Stenosis

bilateral renal artery, pitfall, captopril renal scintigraphy, 2042
coronary artery, cholesterol lowering, arteriography and PET, 845ab(5)
portal vein, portal systemic shunting, 887ab(5)
relative maximum flow, quantitative PET, 846ab(5)

Renal artery

captopril effect, glucoheptonate scintrogram, 1759ab(10)
captopril renography, Tc-99m DTPA, 6ab(4)
diagnostic use, angiotensin converting enzyme inhibitor, 605

Gates' technique, captopril test in hypertension, 51
I-131 OIH and Tc-99m MAG₃, clearances, lab(4)

outcome of treatment, quantitative renography, 1946

Steroid hormone, -secreting tissues, radioiodinated cholestryl ester uptake, lipoprotein, 1088

St. Louis

city of nuclear medicine landmarks, innovators, N569

36th Annual Meeting of SNM, N572

Strategic Defense Initiative

accelerator projects awarded, N580
PET and, N14

Strauss, H. William, election as editor, *The Journal of Nuclear Medicine*, N1146

Streptavidin

biotin and
radioimmunotargeting of tumor, 819ab(5)
sulfhydryl site-specific radiolabeling, monoclonal antibodies, 832ab(5)

Stress

flow and distribution response, normal coronary arteries, 818ab(5)
imaging of *in vivo* chemistry, N1288
influence on gastric emptying, 794ab(5)

Stroke

acute, clinical and metabolic correlates, 898ab(5)
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
ischemic, regional cerebral blood flow, SPECT, 781ab(5)
occult deep vein thrombosis, radioparticle venography, 917ab(5)
quantitative brain pH mapping, C-11 carbon dioxide, PET, 782ab(5)
recent and old, combined CBF/CBV SPECT study, 897ab(5)

Strontium-89

improved clinical response, increasing dose, metastatic prostate and breast cancer in bone, 843ab(5)
palliation of painful bone metastases, phase II study, 2ab(2), 836ab(5)

Struma ovarii, metastatic malignant, paraparesis, spinal metastasis, 407

Sulcralfate, chemical aspects of labeling, Tc-99m, 523

Sulfhydryl, site-specific radiolabeling, monoclonal antibodies, 832ab(5)

Summer affective disorders, psychiatric patients, glucose metabolism in brain, 1752ab(10)

Surveys

manpower, history and methodology, N1
nuclear medicine physicians, scientists, facilities, N1

Sweden, thyroid cancer risk from Chernobyl, 721(le)

Sympathetic nerve

development in myocardium, scintigraphic assessment, I-123 MIBG, 810ab(5)
first pass extraction fraction, swine heart, 767ab(5)
myocardial function, angina pectoris, I-123 MIBG SPECT, 811ab(5)

Sympatho-adrenal system, correlative pediatric imaging, 15

Synovectomy

radiation
new agent, holmium-166 FHMA, 856ab(5)
radiopharmaceuticals, Y-90 particulate agents, 1047

Syringes, aluminum-hubbed needles, degradation, Tc-99m pertechnetate, 1758ab(10)

T

TA-4, serum level, localization, squamous cell carcinoma of lung, 918ab(5)

TAG-72, In-111 monoclonal antibody and, tumor expression, relationship, 908ab(5)

Tamoxifen, estrogen receptor concentration, F-18 FES, 910ab(5)

Technegas

lung inhalation scintigraphy, newborns, 744ab(5)

lung ventilation scintigraphy, ultra-fine aerosol, 744ab(5)

Technetium

-nitride cations, synthesis, myocardial imaging agents, 773ab(5)

-thallium parathyroid subtraction, global vs. regional image normalization, 769ab(5)

Technetium(III/II), new class of mixed ligand complexes, inorganic chemistry, 936ab(5)

Technetium(V)

amine-phenol complexes, synthesis, X-ray structures, 938ab(5)

compared to rhenium(V), ligand substitution, 743ab(5)

Technetium-99m

antibody-bifunctional chelator conjugates, 793ab(5)

-based cardiac agent, flood radionuclide choice, dual radionuclide SPECT, 872ab(5)

bifunctional ligand, protein labeling, synthesis, 940ab(5)

cardiac phantom, attenuation correction, SPECT quantitation, 894ab(5)

cationic complexes for myocardial imaging, 1415

D,L-CB-PAO, cerebral perfusion studies, 831ab(5)

clinically practical quantitative SPECT, 881ab(5)

complexes with ester analogues, 1,1,1-tris(4-methoxysalicylaldiminomethyl)ethane, 937ab(5)

device to automate elution and dispensing, Sab(11)

diphosphine complexes, myocardial imaging, 818ab(5)

efficient platelet labeling method, 737ab(5)

ester-linker, antibody-bifunctional chelator conjugates, whole-body clearance, 934ab(5)

evaluation of indwelling catheters, chemotherapy, 845ab(5)

extended X-ray absorption fine structure, 732ab(5)

generators, variations in labeling efficiency, anti-melanoma mAb, 1759ab(10)

genetically engineered chimeric metallothionein antibody, 794ab(5)

-labeled bone imaging agents, radiation absorbed dose, 1117

labeling of IgG antibodies, rapid and efficient method, 793ab(5)

low sensitivity of parathyroid scintigraphy, adenoma, new subtraction method, 885ab(5)

N-donor ligands, synthesis, low-oxidation state cations, 939ab(5)

neutral and cationic myocardial perfusion agents, mechanistic comparison, 757ab(5)

new antibody labeling method, initial clinical imaging, 809ab(5)

new class of mixed ligand radiopharmaceuticals, 772ab(5)

new functionalized diphosphine complexes, myocardial perfusion imaging, 773ab(5)

new labeled compound, visualization, experimental tumor model, 906ab(5)

novel Tc-N₃S₂ complex, synthesis, characterization, 773ab(5)

preparation and biodistribution, hexadentate Schiff base ligands, 773ab(5)

radiation dosimetry, radionuclide hysterosalpingography, 415(le)

radiopharmaceuticals

in situ formation, redox chemistry, 937ab(5)

practical HPLC method, quality control, 940ab(5)

structural identification, HPLC, 1240

- Re-186 and, comparative renal handling, CO₂DADS, 743ab(5)
- SPECT**
- 180° and 360° reconstructions, heart, 756ab(5)
 - spatial resolution, quantification values, 508
 - suspension of uranium shipments, Department of Energy, N1139
 - tetradeinate amine-phenols
 - cell labeling radiopharmaceuticals, 938ab(5)
 - radiochemical studies, 938ab(5) - Tl-201 subtraction technique, scintigraphic detection, parathyroid abnormalities, 3ab(2)
 - 1,1,l-tris(5-methylsalicylaldiminomethyl)ethane, biliary elimination, rat and guinea pig, 937ab(5)
 - tumor-specific mouse/human chimeric antibody, human γ 3 constant region, 934ab(5)
 - uptake, rejecting and nonrejecting cardiac implants, 1464
- Technetium-99m albumin**
- compared to Ga-67 citrate, lung scanning, HIV-positive patients, 917ab(5)
 - detection of focal inflammation, scintigraphy, 385
 - forearm blood flow measurements, after brachial arteriotomy, 45
 - immunospheres, intravascular targeting, 934ab(5)
 - surgical management, truncal melanoma, 844ab(5)
- Technetium-99m albumin colloid**
- peritoneo-pleural fluid communication, mediastinal lymph nodes, 559(ie)
 - rapid filtration, particle size and radiochemical purity, 3ab(11)
- Technetium-99m antibody**
- chemical modification, accelerated background clearance, 940ab(5)
 - labeling, use of thiocarbohydrazine, 793ab(5)
- Technetium-99m antifibrin, uptake in acute venous thrombosis model, 787ab(5)**
- Technetium-99m bis(aminoethanethiol), synthesis and biological evaluation, 939ab(5)**
- Technetium-99m carbonic anhydrase, new bifunctional synthon, 940ab(5)**
- Technetium-99m CDO-MEB**
- myocardial perfusion safety and efficacy, 959ab(5)
 - neutral complex for myocardial imaging, 1830
- Technetium-99m cellulose fiber, gastrointestinal transit, 402**
- Technetium-99m colloid, liver/spleen scans, interferon therapy, hairy-cell leukemia, 2ab(2)**
- Technetium-99m dimercaptosuccinic acid, uptake, head and neck squamous carcinoma, 174**
- Technetium-99m DISIDA**
- diagnosis of hepatocellular carcinoma, adenoma, focal nodular hyperplasia, 1278(ie)
 - scintigraphy and, quantification, tracer kinetic modeling approaches, 1507
- Technetium-99m disofenin, morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)**
- Technetium-99m DMSA**
- high-resolution SPECT renal imaging, 1759ab(10)
 - renal handling, glomerular filtration, peritubular uptake, 1219
 - scintigraphy, medullary carcinoma of thyroid, 1420(ie)
 - SPECT, quantitation, renal uptake, 246
 - Tc-99m GHA and, differing responses, renovascular hypertension after captopril, 841ab(5)
 - unilateral renal artery stenosis, diagnostic use, angiotensin converting enzyme inhibitor, 605
- Technetium-99m (V) DMSA, uptake in amyloidosis, 2050**
- Technetium-99m DTPA**
- aerosol lung scans, performance, ventilator patients, 9ab(4)
 - aerosol ventilation studies, pulmonary function testing, cystic fibrosis, 967ab(5)
 - aerosol washout rates, amiodarone pneumonitis, 916ab(5)
 - antenatally diagnosed pelviureteric junction obstruction, conservative management, 5ab(4)
 - assessment of inhalation lung imaging, I-123 IMP aerosol, 853ab(5)
 - camera images, quantitative calculations, GFR, 1747ab(10)
 - captopril-enhanced renal scintigraphy, hypertension evaluation, 615
 - decreased pulmonary clearance, comparison, Tc-99m imidodiphosphate, 853ab(5)
 - estimated differential renal clearance, compartmental model analysis, 877ab(5)
 - I-131 hippuran and, early detection, diabetic nephropathy, 941ab(5)
 - lung clearance and gallium scanning, HIV-related lymphocytic alveolitis, 746ab(5)
 - radioisotopic evaluation of kidney, spinal cord injury, 944ab(5)
 - re-evaluation as tumor-seeking agent, neurofibromatosis, 915ab(5)
 - renal artery stenosis, captopril renography, 6ab(4)
 - renal scintigraphy, therapeutic effect, percutaneous nephroureterolithotomy, 942ab(5)
 - renal transplant and lymphoceles, 3ab(11)
 - Tc-99m MAG₃ and I-131 OIH comparisons, follow-up renal transplants, 4ab(4)
 - unilateral renal artery stenosis, diagnostic use, angiotensin converting enzyme inhibitor, 605
- Technetium-99m DTPA aerosol, scans of ventilator-dependent patients, 743ab(5)**
- Technetium-99m DTPA-HSA, cardiac blood-pool scintigraphy, 1713**
- Technetium-99m ECD**
- extraction and kinetics, intracarotid injection, 742ab(5)
 - metabolism in isolated rat organs, 743ab(5)
 - new brain imaging agent, kinetics, biodistribution, 599
 - regional cerebral distribution, microspheres, non-human primates, 792ab(5)
 - TLC and HPLC analysis, 936ab(5)
- Technetium-99m L,L-ECD**
- brain perfusion imaging
 - biodistribution, humans, 1902
 - nonhuman primates, 1892
- Technetium-99m EHIDA, hepatobiliary dysfunction, cyclosporine A toxicity, 921ab(5)**
- Technetium-99m ethyl cysteinate dimer, biodistribution and dosimetry, chronic cerebral infarction, 1018**
- Technetium-99m galactosyl neoglycoalbumin**
- measurement of functional hepatic mass, after hepatic irradiation, 814ab(5)
 - receptor binding, kinetic sensitivity, 1519
 - receptor biochemistry, measurement validation, 733ab(5)
 - utility of discriminant analysis, receptor binding radiopharmaceuticals, 879ab(5)
- Technetium-99m GHA, Tc-99m DMSA and, differing responses, renovascular hypertension after captopril, 841ab(5)**
- Technetium-99m glucarate, marker of acute cerebral damage, 901ab(5)**
- Technetium-99m glucaric acid, detection of acute cardiac injury, 1743ab(10)**
- Technetium-99m glucoheptonate**
- importance in infants, first UTI, 915ab(5)
 - increased uptake, renovascular hypertension, 5ab(4)
 - N-benzyl-N-methyl-piperidinyl-bis(aminoethanethiol) and, kinetic study, ligand exchange, 939ab(5)
 - transport mechanism, renal and lung tumor cells, 912ab(5)
- Technetium-99m α -D-glucose 1-phosphate, lung carcinoma imaging, compared to Ga-67, 913ab(5)**
- Technetium-99m granulocytes, bone and joint diseases, 1743ab(10)**
- Technetium-99m p-halophenethyl diaminodithiol analogs, brain blood flow imaging, 939ab(5)**
- Technetium-99m HDP, bone scan, detection, non-calcified splenic hemangioma, 1111**
- Technetium-99m HEXAMIBI**
- comparison, one and two day rest and treadmill tests, 790ab(5)
 - comparison to TI-201, myocardial perfusion imaging, 301
 - labeling procedure and stability, Tc-99m MIBI, 865ab(5)
 - quantitative standards, 790ab(5)
 - Tl-201 and, hypoxia and ouabain effects, myocardial uptake kinetics, 1500
 - TI-201 SPECT and, diagnosis, coronary artery disease, 4ab(2)
- Technetium-99m HEXAMIBI isonitrile, increased lung uptake, discordant hemodynamic disturbances, 860ab(5)**
- Technetium-99m HM-PAO**
- agent for human spermatozoans, 922ab(5)
 - brain SPECT
 - children, 966ab(5)
 - congenital dysphasia, 798ab(5)
 - 3D region of interest analysis, 961ab(5)
 - brain SPECT in neonates, 1337
 - clinical use, determination of brain death, 1621, 1627
 - compared to CT, model for outcome-prediction, after stroke, 895ab(5)
 - diagnostic patterns of post-ictal cerebral blood flow, temporal lobe epilepsy, SPECT, 751ab(5)
 - distribution of cell-bound activity, human leukocytes, 804ab(5)
 - dynamic SPECT, meningiomas, compared with I-123 IMP, 1101
 - extraction and kinetics, intracarotid injection, 742ab(5)
 - ictal SPECT, focal epilepsy, 751ab(5)
 - I-123 IMP and, discordance, subacute cerebral infarct, 1752ab(10)
 - interictal and immediate postictal SPECT, localization, seizure foci, 831ab(5)
 - labeled leukocytes
 - infectious complications, orthopedic surgery, 804ab(5)
 - inflammation imaging, 805ab(5) - PET, regional cerebral blood flow, 157
 - pulmonary clearance of aerosols, new application, 743ab(5)
 - quantitative analysis of SPECT studies, Alzheimer's disease, 806ab(5)
 - quantitative blood flow tracer, focal cerebral ischemia, 781ab(5)
 - radiotherapy, imaging of noncerebral tumors, 912ab(5)
 - regulation of PET radiopharmaceuticals, N137
 - SPECT

- abnormal blood flow patterns, cerebral atrophy, 896ab(5)
 brain blood flow, congenital dysphasia, 1825
 filling out phenomenon, cerebral ischemia, 591
 pediatric brain imaging, 1917(le)
Xe-133 SPECT and
 cerebral blood flow, 1752ab(10)
 presurgical evaluation, temporal lobe epilepsy, 896ab(5)
- Technetium-99m D,L-HM-PAO**
 assessment of purity, diastereomeric mixtures, NMR techniques, 106
 evaluation of granulocyte labeling, 2022
 panic attacks, head trauma patients, 965ab(5)
 tomography, brain volume, neuroanatomy, 1752ab(10)
- Technetium-99m HM-PAO leukocytes**, detection of inflammatory lesions, compared to Ga-67 citrate, 1332
- Technetium-99m hydroxyethyl starch**, effect on lymph node uptake, 969ab(5)
- Technetium-99m IgG**, imaging of inflammatory arthritis, 2017
- Technetium-99m non-specific IgG**, inflammatory joint scintigraphy, 889ab(5)
- Technetium-99m imidodiphosphate**, decreased pulmonary clearance, comparison, Tc-99m DTPA, 853ab(5)
- Technetium-99m isonitrile**: *see also* Technetium-99m RP-30A
 comparison of one and two day rest and treadmill tests, Cardiolite, 790ab(5)
 effect of stereochemistry, 773ab(5)
 failure of percholate to inhibit binding, thyroid, myocardial perfusion studies, 885ab(5)
 improved uptake after thrombolysis, myocardial salvage, compared to TI-201, 800ab(5)
 scintigraphic assessment of myocardial reperfusion, percutaneous transluminal coronary angioplasty, 821ab(5)
- Technetium-99m MAA**
 camera- and well-counting techniques, portal systemic shunting, 890ab(5)
 portal systemic shunting, portal hypertensive rats, portal vein stenosis, 814ab(5)
 right-to-left shunting, left superior vena cava, perfusion lung scintigraphy, 412
 variable perfusion patterns, therapeutically embolized liver, 1012
- Technetium-99m MAG₃**,
 chemistry and biokinetics, by-products, lab(4)
 clearance after captopril, renovascular hypertension, 656
 clearance determined by simplified methods, 943ab(5)
 estimation of plasma clearance, 1955
 estimation of plasma clearance, adults, one or two blood samples, 943ab(5)
 evaluation as routine renal radiopharmaceutical, 823ab(5)
 evaluation of MAG₃-like compounds, renal agents, 937ab(5)
 glomerular filtration rate, tubular secretion, rat kidney, 1986
 handling by kidney, lab(4)
 I-123 hippurate clearance and, renal scintigraphy, 2ab(4)
 I-131 OIH and, clearances, renal plasma flow, 823ab(5)
 I-131 OIH and iothalamate comparisons, renal ischemia, lab(4)
 I-131 OIH and Tc-99m DTPA comparisons, follow-up renal transplants, 4ab(4)
 I-131 OIH clearances, renal plasma flow, renal artery stenosis, lab(4)
 radiation exposure, 720(le)
 renal ischemia, 823ab(5)
 renal parenchymal transit time, factor analysis, hydronephrosis, 3ab(4)
 renal transplant evaluation, 823ab(5)
 routine renal radiopharmaceutical, 1ab(4)
 Tc-99m MSG and, renal imaging, dogs, 937ab(5)
 uptake in renal transplant, measurements, 3ab(4)
- Technetium-99m MDP**
 detection of infected orthopedic implants, 754ab(5)
 In-111 leukocytes, false-positive, noninfected Charcot joints, 754ab(5)
 renal scintigraphy, functional assessment, 945ab(5)
 scintigraphy, relative renal function estimation, 941ab(5)
 utility of SPECT, evaluation, mandibular bone grafts, 843ab(5)
- Technetium-99m metallothionein**, -conjugated mouse monoclonal antibody B72.3, Rhesus monkeys, 1351
- Technetium-99m methylene diphosphonate**, renal uptake, therapeutic radiation, vertebral metastases, 1113
- Technetium-99m methylene diphosphonate**
 diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
 reversible pulmonary uptake, hypertrophic pulmonary osteoarthropathic distribution, 1563
- Technetium-99m MIBI**
 anatomical landmarking, myocardial infarction, In-111 antimyosin Fab, 800ab(5)
 compared to TI-201 chloride, myocardial scintigraphy, infants, 1176
 comparison of *in vitro* tumor cell labeling, 938ab(5)
 exercise/rest SPECT in 4-hour protocol, regional quantitation, coronary heart disease, 791ab(5)
 imaging in follow-up, differentiated thyroid carcinoma, 904ab(5)
 In-111 antimyosin antibodies and, post-infarction myocardial viability, 800ab(5)
 In-111 antimyosin Fab and, myocardial infarction, reperfusion, 757ab(5)
 labeling procedure and stability, 865ab(5)
 mechanisms of RP30 redistribution, post-ischemic myocardium, 757ab(5)
 myocardial perfusion imaging, 790ab(5)
 myocardial salvage, acute myocardial infarction, 801ab(5)
 myocardial uptake, coronary occlusion, reperfusion, 756ab(5)
 optimization of SPECT acquisition, processing parameters, 757ab(5)
 quantitative planar imaging, compared to TI-201, 1456
 radial shortening and myocardial thickening, compared to echocardiography, 821ab(5)
 serial myocardial SPECT studies, reperfusion, acute myocardial infarction, 800ab(5)
 simultaneous angiography, myocardial perfusion imaging, 38
- SPECT**
 acquisition parameters, 795ab(5)
 180° and 360° data collection, myocardium, 295
 pre- and post-thrombolysis, myocardial infarction, 820ab(5)
 stress myocardial perfusion, left ventricular wall motion, angina, 864ab(5)
- TI-201 and
- bronchial carcinoma, 845ab(5)
 cultured cardiac cells, 860ab(5)
 differences, coronary artery disease, 865ab(5)
 right ventricular uptake, 820ab(5)
 treadmill stress test and intravenous dipyradimole, myocardial perfusion imaging, coronary artery disease, 759ab(5)
 variability of response to reperfusion, thrombolysis, SPECT, 820ab(5)
 ventricular function and perfusion, gated tomographic imaging, ventriculography, 801ab(5)
- Technetium-99m monoclonal antibody**
 carcinoma of lung, lab(11)
 imaging of small cell lung carcinoma, 818ab(5)
 NR-Lu-10, small cell lung cancer, 1749ab(10)
 platelet activation after balloon arterial injury, experimental atherosclerotic model, 787ab(5)
 radioimmunoangiography, colorectal cancer, 748ab(5)
 stage IV neuroblastoma, 904ab(5)
 successful imaging, malignant melanoma, 25
- Technetium-99m monoclonal anti-CEA antibody**, immunoscintigraphy, liver metastases, colorectal carcinoma, 748ab(5)
- Technetium-99m monoclonal anti-NCA-antibodies**, localization, subacute and chronic inflammatory lesions, 805ab(5)
- Technetium-99m MSG**, Tc-99m MAG₃ and, renal imaging, dogs, 937ab(5)
- Technetium-99m N₃S antibody**, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, catabolite excretory route control, 933ab(5)
- Technetium-99m NCA-antibodies**, bone marrow scintigraphy, breast carcinoma, malignant lymphomas, 819ab(5)
- Technetium-99m PAO**, new cerebral perfusion agent, 742ab(5)
- Technetium-99m pertechnetate**
 absorption during nuclear cystography, bladder augmentation, 2ab(2)
 degradation in syringes, aluminum-hubbed needles, 1758ab(10)
 evaluation of testicular reperfusion, acute testicular torsion, 962ab(5)
 platelet labeling, Sn(II)MPO, 922ab(5)
- Technetium-99m phosphonate**, bone scanning, In-111 leukocytes, infected hip prosthesis, 562(le)
- Technetium-99m pyrophosphate**
 In-111 antimyosin and, detection of different stages, myocardial infarction, 862ab(5)
 scintigraphy, malignant hyperthermia, 718(le)
- Technetium-99m red blood cells**
 cardiac blood-pool scintigraphy, Tc-99m DTPA-HSA, 1713
 early blood pool phases, diagnosis, hepatic hemangioma, 815ab(5)
 interference in chronic renal failure patients, plasma-derived phenomenon, 869ab(5)
 labeling kit, first human studies, 811ab(5)
 left ventricular diastolic filling, left ventricular systolic dysfunction, 868ab(5)
 scanning in soft tissue hemangiomas, vascular malformation, 799ab(5)
 subtraction, In-111 WBC enhancement, hemodialysis fistulas, 10ab(4)
- Technetium-99m rhenium colloid**, simplified lymphoscintigraphic technique, breast cancer, 904ab(5)
- Technetium-99m RP-30**, detection of area at risk, coronary angioplasty, 791ab(5)
- Technetium-99m RP-30A**, myocardial perfusion

- and ventricular function, coronary arteriography, exercise Tl-201 SPECT, 820ab(5)
- Technetium-99m sestamibi**
- myocardial extraction, flow effects, thallium-201, 756ab(5)
 - myocardial perfusion imaging, 790ab(5)
 - treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, coronary artery disease, 759ab(5)
- Technetium-99m SnF₃ colloid, leukocyte labeling kit, preparation, evaluation, 1257**
- Technetium-99m SQ30217**
- compared to Tl-201, myocardial perfusion imaging, 312
 - diagnostic utility, rapid imaging protocol, 730ab(5)
 - myocardial retention and clearance, canine heart, 860ab(5)
- Technetium-99m sulcralfate, chemical aspects of labeling, 523**
- Technetium-99m sulfonamides, new bifunctional synthon, Tc-99m carbonic anhydrase, 940ab(5)**
- Technetium-99m sulfur colloid**
- bone marrow imaging, GM-CSF, 738ab(5)
 - detection of duodenal ulcer, 700
 - diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
 - diffuse lung uptake, malaria, 117
 - effect of meal energy content, gastric emptying, 1106
 - influence on stress, gastric emptying, 794ab(5)
 - liver perfusion system, R-E cell function, 4ab(2)
 - radioparticle liver uptake, superior vena cava obstruction, 113
 - short-term ethanol consumption, R-E cell function, liver, 1ab(2), 815ab(5)
 - SPECT vs. planar liver scintigraphy, 57
 - surgical management, truncal melanoma, 844ab(5)
- Technetium-99m teboroxime**
- multicenter clinical trial, perfusion agent, 1745ab(10)
 - regional myocardial perfusion imaging, dynamic SPECT, 1744ab(10), 1ab(11)
- Technetium-99m Technegas, lung ventilation scintigraphy, 744ab(5)**
- Technetium-99m white blood cells, detection of infected orthopedic implants, 754ab(5)**
- Tellurium-118, antimony-118 generator development, PET application, 849ab(5)**
- Testicles**
- evaluation of reperfusion, Tc-99m pertechnetate, acute testicular torsion, 962ab(5)
 - nuclear imaging, 968ab(5)
 - return of testicular perfusion, ligation of testicular vessels, Xe-133, 967ab(5)
- Tetraloman Memorial Award, Mark A. Mintun, 1141**
- Thallium-201**
- automatic superposition of cardiac SPECT images, 871ab(5)
 - autoradiographic estimation, tumor and normal organ flow, 913ab(5)
 - blood levels, reversible myocardial defects, 1172
 - compared to Tc-99m MIBI, quantitative planar imaging, 1456
 - computer subtracted cardiac images, 4ab(2)
 - diagnosis of coronary stenosis, application, machine intelligence, 816ab(5)
 - dipyridamole imaging
 - comparative efficacy, adenosine infusion, 730ab(5)
 - lazy man's stress test, 281
 - transient mitral regurgitation, myocardial is- - chemia, 1271
 - dipyridamole-redistribution ECT, children, Kawasaki disease, 760ab(5)
 - distribution, stress/delayed renal scintigraphy, 824ab(5)
 - dipyridamole SPECT, left bundle branch block, 2ab(11)
 - exercise SPECT, myocardial perfusion, Tc-99m RP-30A, 820ab(5)
 - false-positive localization, brown tumor of bone, 1264
 - flow effects, myocardial extraction, Tc-99m sestamibi, 756ab(5)
 - follow-up SPECT stress-redistribution studies, reproducibility, quantitative indices, 729ab(5)
 - I-123 fatty acid comparison, exercise-induced myocardial ischemia, 729ab(5)
 - I-131 scintigraphy comparison, follow-up, thyroid carcinoma, 914ab(5)
 - improved Tc-99m isonitrile uptake, myocardial salvage, thrombolysis, 800ab(5)
 - inherent limitations in LV wall thickness, SPECT, myocardial perfusion scans, 796ab(5)
 - kinetics in human myocardium, 863ab(5)
 - left ventricular dilation, importance, three-vessel disease, 749ab(5)
 - low sensitivity of parathyroid scintigraphy, adenoma, new subtraction method, 885ab(5)
 - myocardial imaging with SPECT, prone position, 750ab(5)
 - myocardial perfusion and regional wall motion, coronary anatomy, anterior infarction, 739ab(5)
 - myocardial SPECT, prone vs. supine position, 548, 1738(ab)
 - myocardial tomography
 - polar probability map, 871ab(5)
 - solution, inferior wall attenuation, 398 - myocardial uptake and clearance, effects of heart rate, 1972
 - parathyroid uptake, enhancement, thyroxine pretreatment, 886ab(5)
 - perfusion and radionuclide angiography, during exercise, coronary artery disease, 818ab(5)
 - planar perfusion defects, extent and severity, 863ab(5)
 - positive stress test, significance, silent ischemia, 863ab(5)
 - postexercise lung uptake, SPECT, 288
 - pulmonary uptake during exercise, 788ab(5)
 - radiiodinated fatty acid and, dual tracer autoradiography, cardiomyopathy, 80
 - redistribution, FDG imaging, metabolic activity, 863ab(5)
 - redistribution after thallium reinjection, relationship, coronary anatomy and regional wall motion, 740ab(5)
 - renal imaging, cardiac evaluation, 2ab(4)
 - resting/redistribution, coronary stenosis, unstable angina patients, 740ab(5)
 - rest-redistribution scintigraphy, myocardial viability, early post-thrombosis, 729ab(5)
 - rubidium-82 and, myocardial perfusion imaging, coronary artery disease, 759ab(5)
 - scintigraphy, primary breast carcinoma, axillary metastasis, 844ab(5)
 - scintigraphy after maximal coronary vasodilation, adenosine, 760ab(5)
 - scintigraphy in lymphoma, relationship, Ga-67, 915ab(5)
 - SPECT
 - abnormal stress test, normal coronary arteries, 750ab(5)

Thallium-201 chloride

- onary disease detection, 834ab(5)
tomographic reconstruction, automatic program, long axis of left ventricular myocardium, 806ab(5)
uptake, rejecting and nonrejecting cardiac implants, 1464
- Thallium-201 chloride**, compared to Tc-99m MIBI, myocardial scintigraphy, infants, 1176
- Thallium-201 colloid**, diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
- Therapeutic nuclear medicine**
development of treatment planning program, radioimmunotherapy, 884ab(5)
EGS4 Monte Carlo determination, beta dose kernel in water, 883ab(5)
estimation of bone marrow doses, delivery, radioimmunotherapy, 778ab(5)
Ho-165 activation, biodegradeable microspheres, 836ab(5)
human antimurine antibody responses, intraperitoneal radioimmunotherapy infusions, murine mAb, 827ab(5)
human pharmacokinetics of Sm-153 EDTMP, metastatic cancer, 1814
I-131 anti-idiotype monoclonal antibody, B cell lymphoma, 826ab(5)
I-131 lym-1, chronic lymphocytic leukemia, 827ab(5)
I-131 MIBG treatment
metastatic carcinoid tumor, 836ab(5)
resistant neuroblastoma, 903ab(5)
immunosuppression with local lymphoid irradiation, palladium-190, 890ab(5)
improved clinical response with strontium-89, increasing dose, metastatic prostate and breast cancer in bone, 843ab(5)
intraarterial yttrium-90 glass microspheres, therapy, hepatic metastasis, 836ab(5)
intraperitoneal yttrium-90 immunotherapy, ovarian cancer, 828ab(5)
labeling of human IgG, Rh-105 complexes, diethylenetriamine derivatives, 832ab(5)
palliation of painful skeletal metastases
186-Re(Sn)-HEDP, mechanism of action, 732ab(5)
186-Re(Sn)-HEDP, prostate cancer, 837ab(5)
radioimmunotherapy of colorectal carcinoma xenografts, Y-90 CO17-1A, mouse IgG, 935ab(5)
selected radionuclides, "S" factors, self-dose to large tumors, 883ab(5)
solitary autonomous thyroid nodules, iodine-131, long-term follow-up, 736ab(5)
Tc-99m and I-131 monoclonal antibody, stage IV neuroblastoma, 904ab(5)
- Thiocarbohydrazine**, antibodies labeled with Tc-99m, 793ab(5)
- Three Mile Island**, no health consequences seen, N427
- Thrombocytopenia**, use of In-111 oxine platelet scintigraphy, children, 1819
- Thrombocytopenic purpura**, autoimmune, platelet destruction, In-111 autologous platelet clearance, 629
- Thrombolysis**
coronary, metabolic and functional abnormalities, 837ab(5)
dipyridamole TI-201 SPECT, compared to exercise RNV, jeopardized myocardium detection, 862ab(5)
economic analysis of clinical PET, Rb-82, heart, 707
imaging before and after, myocardial infarction, Tc-99m MIBI SPECT, 820ab(5)
improved Tc-99m isonitrile uptake, myocardial salvage, compared to TI-201, 800ab(5)
Tc-99m monoclonal antibody, platelet reaction, 1743ab(10)
variability of response to reperfusion, acute myocardial infarction, MIBI-SPECT, 820ab(5)
- Thrombosis**
acute venous, model of, Tc-99m antifibrin uptake, 787ab(5)
deep vein
radionuclide blood pool venography, 1744ab(10)
rapid clot uptake, plasminogen activator, 787ab(5)
stroke, radioparticle venography, 917ab(5)
discrepant sulfur colloid, radioparticle liver uptake, superior vena cava obstruction, 113
- dural sinus, correlative pediatric imaging, 15
- efficient platelet labeling method, 737ab(5)
imaging
fibrin-specific monoclonal antibodies, 747ab(5)
radiolabeled anti-fibrin T2G1S monoclonal antibody, 963ab(5)
imaging with improved formulation, I-123 fragment E1, 817ab(5)
inhibition, platelets, calcium ion sequestrants, 859ab(5)
pitfalls in detection, transplanted grafts, Ga-67 DAS-DFO-fibrinogen, 914ab(5)
- Thyroid**
anti-thyroid medications, thyroid scan, Grave's disease, 1748ab(10)
cancer
effectiveness, radionuclide treatment, 737ab(5)
hepatic uptake of I-131, total body scans, 4ab(2)
risk from Chernobyl in Sweden, 721(l)e
TSH suppressive treatment, triiodothyroacetic acid and levothyroxin, 886ab(5)
carcinoma: *see* Carcinoma, thyroid
colchicine-induced radioiodide retention, iodine-deficient male rats, 737ab(5)
differentiated cancer, effectiveness, radionuclide treatment, 737ab(5)
failure of percholate to inhibit Tc-99m isonitrile binding, myocardial perfusion studies, 885ab(5)
hyperthyroidism
irradiation for Hodgkin's disease, low radioiodine uptake, 255
radioiodine treatment, extra-thyroidal absorbed doses, 833ab(5)
TSH-receptor antibody measurements, clinical significance, 786ab(5)
relative parathyroid TI-201 uptake, enhancement, thyroxine pretreatment, 886ab(5)
scan and/or fine needle aspiration, evaluation, solitary thyroid nodules, 9ab(4), 736ab(5)
simultaneous measurement of serum T3 and T4, new radioimmunoassay, 919ab(5)
solitary autonomous nodules, iodine-131, long-term follow-up, 736ab(5)
SPECT quantitation, therapeutic radioiodine concentration, 737ab(5)
uptake of I-123, techniques for measurement, 886ab(5)
- Thyroxine**, relative parathyroid TI-201 uptake, experimental enhancement, 886ab(5)
- Tin(II)-mercaptopyridine N-oxide**, platelet labeling, Tc-99m pertechnetate, 922ab(5)
- Transferrin**, transfer of In-111 and Ga-67, ferritin, phosphate-containing compounds, 70
- Transplantation**
cardiac
clinical utility, radionuclide ventriculography, 781ab(5)
coronary artery disease, 3ab(2)
diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
grafts, thrombi detection pitfalls, Ga-67 DAS-DFO-fibrinogen, 914ab(5)
heart, noninvasive follow-up, In-111 antimyosin scintigraphy, 862ab(5)
human heart-lung, regional pulmonary perfusion, 1297
human organ, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
human pancreas, In-111 platelets, 1470
liver, semiquantitative hepatobiliary scintigraphy, 888ab(5)
liver and kidney, In-111 DTPA plasma clearance, glomerular filtration rate, 942ab(5)
renal
measurements, Tc-99m MAG₃ uptake, 3ab(4)
radionuclide monitoring, 3ab(4)
Tc-99m MAG₃, I-131 OIH and Tc-99m DTPA comparisons, 4ab(4)
- Tridodecylmethylammonium chloride**, impregnation of silica gel, Os-191/Ir-191m generator, 538
- Triiodothyroacetic acid**, levothyroxin and, TSH suppressive treatment, thyroid cancer, 886ab(5)
- 1,1,1-Tris(4-methoxysalicylaldiminoethyl)ethane**, Tc-99m complexes with ester analogues, 937ab(5)
- 1,1,1-Tris(5-methylsalicylaldimonomethyl)ethane**, Tc-99m, biliary elimination, rat and guinea pigs, 937ab(5)
- Tritium**, bladder permeability to water, 2ab(4)
- Tuberculosis**, I-124 2-iodoisonicotinic acid hydrazide radiotracer, 1756ab(10)
- Tubulin**, colchicine-induced radioiodide retention, iodine-deficient male rats, 737ab(5)
- Tumor-associated antigens**, malignant melanoma, autoradiography, 906ab(5)
- Tumor necrosis factor**, indium-111-labeled, localization, breast carcinoma xenografts, 819ab(5)
- Tumors**: *see also* specific type
assessment of early response to therapy, metabolic imaging, PET, 789ab(5)
- brain
dexamehtasone effect, extracellular space, 899ab(5)
protein synthesis, C-11 L-methionine, 910ab(5)
TI-201 SPECT, 913ab(5)
- brain and liver, F-18 FDG PET, Posicam 6.5 camera, 966ab(5)
- C-11 L-methionine uptake, response to irradiation, 2012
- carcinoid, metastasis, I-131 MIBG treatment, 836ab(5)
- comparison of Tc-99m MIBI, *in vitro* tumor cell labeling, 938ab(5)
- detection, surgical imaging probe, 891ab(5)
- early ascites tumor model, 5-[¹²³I]iodo-2'-deoxyuridine, 882ab(5)
- effect of Sn-117mDTPA, 1754ab(10)
- experimental models
high specific activity, Sm-153 EDTA, 202
visualization, new Tc-99m labeled compound, 906ab(5)
- gastrointestinal cancer, radiolabeled antibody imaging, chelating agents, 909ab(5)
- Ga-67 uptake, whole body irradiated mice,

913ab(5)
glioma, intravascular streaming, intracarotid infusion, 839ab(5)
Hodgkin's and non-Hodgkin's lymphoma, bone marrow imaging, blind biopsy, 843ab(5)
imaging with In-111 metalloporphyrin, 738ab(5)
improved radiolabeled monoclonal antibody uptake, lavage, intraperitoneal carcinomatosis, 60
improved uptake with In-111/Ga-67/Ga-68, labeled bivalent haptens, immunoscintigraphy, 762ab(5)
lead-203-labeled immunoconjugates, 935ab(5)
liver, metabolic PET images, 878ab(5)
localization, epitope specificity, anti-CEA monoclonal antibodies, 747ab(5)
lung, C-11 methionine, F-18 fluorodeoxyglucose, 788ab(5)
measurement of tissue perfusion, Cu-64 PTSM, 1756ab(10)
mediastinal parathyroid adenoma, radioiodinated toluidine blue, scintigraphy, 768ab(5)
L-[methyl-C-11] methionine uptake quantitative evaluation, PET, 1809
radiation effects, 739ab(5)
model, localization, paramagnetically-labeled LDL, 902ab(5)
monoclonal antibody immunoreactivity, Lindmo double reciprocal analysis, 903ab(5)
percolation, modeling analysis, 903ab(5)
musculoskeletal sarcomas, evaluation, use of Gd-DTPA, 901ab(5)
no-carrier-added L-[5-C-11]ornithine synthesis, 782(ab), 783ab(5)
noncalcified splenic hemangioma, detection, radionuclide bone scan, 1111
noncerebral, Tc-99m HM-PAO and F-18 fluorodeoxyglucose, radiotherapy, 912ab(5)
ovarian carcinoma
 anti-CA 12.5 radioimmunodetection, 758ab(5)
 monoclonal antibody SM3, radioimmunoscin-
tigraphy, 758ab(5)
 prospective immunoscintigraphic study, 758ab(5)
palliation of painful skeletal metastases, 186-
 Re(Sn)-HEDP, prostate cancer, 837ab(5)
primary breast carcinoma and axillary metastasis, TI-201 scintigraphy, 844ab(5)
prostate cancer, PAP and PSA, disease markers, 786ab(5)
quantitative perfusion measurement, Rb-81 PET, 911ab(5)
radioimmunotargeting, streptavidin and biotin, 819ab(5)
renal and lung, transport mechanism, Tc-99m glucoheptonate, 912ab(5)
Re-186 NR-CO-02 anti-CEA F(ab')₂ fragment, radioimmunotherapy, 779ab(5)
-specific mouse/human chimeric antibody, Tc-99m labeling, human γ 3 constant region, 934ab(5)
squamous cell carcinoma of lung, diagnosis, monoclonal antibody radioimmunoassay, 918ab(5)
subcellular kinetics, In-111 monoclonal antibody, 907ab(5)
targeting, biotin conjugation to antibody, 832ab(5)
xenografts, localization, monoclonal antibody cocktails, 747ab(5)

Tumor-seeking agents
antibodies labeled with Tc-99m, use of thiocarbonylhydrazine, 793ab(5)

anti-CEA antibody, colorectal carcinoma, 908ab(5)
anti-CEA imaging, I-123 Fab' and F(ab')₂ fragments, 903ab(5)
astatine-211 labeled F(ab')₂ fragment, immunoreactivity, tumor uptake, 778ab(5)
biodistribution studies, novel non-steroidal estrogen, I-123 IBHPE, 883ab(5)
bismuth-212 labeled antibody, human cancer peritoneal xenografts, 778ab(5)
comparison of Tc-99m MIBI, *in vitro* tumor cell labeling, 938ab(5)
Cu-64 *p*-carboxyalkylphenyldithiocarbazones, antibody labeling, 848ab(5)
development of antibody cocktail, radioimmuno-detection, adenocarcinoma, 935ab(5)
enhanced regional delivery of monoclonal antibodies, peritoneal cavity, transdiaphragmatic blockade, 815ab(5)
estimate of immunoreactive fraction, curve fitting method, 915ab(5)
full retention of immunoreactivity, antibody labeling, site-specific methods, 831ab(5)
I-131 anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
I-131 HMFG1 monoclonal antibody dosimetry, whole body scanning, 884ab(5)
I-131 lym-1, chronic lymphocytic leukemia, 827ab(5)
IgM monoclonal antibodies, pharmacokinetics, 909ab(5)
imaging of small cell lung carcinoma, Tc-99m monoclonal antibody, 818ab(5)
In-111 anti-CEA ZCE 025 monoclonal antibody, primary lung cancer, 905ab(5)
In-111/Ga-67/Ga-68, improved tumor uptake, immunoscintigraphy, 762ab(5)
In-111 monoclonal antibody, detection, recurrent colorectal carcinoma, 748ab(5)
intraperitoneal yttrium-90 immunotherapy, ovarian cancer, 828ab(5)
lysosomal role in tumor accumulation, Ga-67, dual-tracer studies, 921ab(5)
maleimidooethyl succinimyl succinate, spacer, Ga-67 deferoxamine labeled antibody, 832ab(5)
N₃S chelating agents, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, 933ab(5)
octreotide, I-123 labeling, metabolism, 768ab(5)
patterns of HAMA development, In-111 ZCE 025 monoclonal antibody, colorectal carcinoma, 906ab(5)
preparation and characterization, Re-186 NR-CO-02 F(ab'), 793ab(5)
prospective immunoscintigraphic study, ovarian carcinoma, 758ab(5)
radioiodinated, yttrium-labeled anti-CEA mAb, radioimmunotherapy, 848ab(5)
radioiodinated phospholipid ethers, tumor imaging agents, 849ab(5)
TAG-72 and In-111 monoclonal antibody, tumor expression, relationship, 908ab(5)
Tc-99m DTPA, re-evaluation, neurofibromatosis, 915ab(5)
yttrium-90 EDTMP, 843ab(5)
Tungsten-188, zirconium-tungsten gel generators, 849ab(5)
***m*-Tyrosine analogs, radiofluorinated, potential L-dopa PET tracers,** 930ab(5)

U

U-50488 analogs, fluorinated, characterization, PET studies, 931ab(5)

Ulcer, duodenal, radionuclide detection, 700
Ulcerative colitis, colonic coverage, mesalamine enema, 764ab(5)
Ultrasound
 correlative pediatric imaging, 15
 scintigraphy and, giant hemangiomas, liver, 181
 serial furosemide renography, asymptomatic hydronephrosis, 4ab(4)
Uranium, suspension of shipments by DOE, jeopardized Mo-99/Tc-99m supply, N1139
Ureter, vesico-ureteral reflux, radionuclide voiding cystography, expert system, 5ab(2)
Urinary tract
 correlative pediatric imaging, 15
 DMSA studies, infants under one year old, 5ab(4)
 significance of activity, In-111 leukocyte scans, 889ab(5)
Uropathy
 obstructive
 position-dependent discrepancies, Whitaker test and diuresis renogram, 2ab(4)
 surgery evaluation, parenchymal transit time index, 942ab(5)

V

Valine, rate of incorporation into proteins, autoradiography, brain tumor model, 913ab(5)
Valvuloplasty, percutaneous aortic balloon, radionuclide ventriculography, 867ab(5)
Vanadium-48 vanadyl-chlorin, new tumor imaging agent, 930ab(5)
Venography
 best radionuclide, 564(lc)
 radionuclide blood pool, deep vein thrombosis, 1744ab(10)
 radionuclide evaluation of indwelling catheters, chemotherapy, 845ab(5)
 radioparticle, occult deep vein thrombosis, stroke, 917ab(5)
 renal, scrotal scintigraphy comparison, varicocele, 943ab(5)
Ventilation studies
 krypton-81m reservoir administration systems, evaluation methods, 650
 lung scintigraphy, Tc-99m Technegas, 744ab(5)
 pre-operative, relative value, perfusion scans, 733ab(5)
 pulmonary clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
 regional, PEEP effect, preterm lamb, 1342
 ventilation/perfusion mismatch
 clinical significance, 734ab(5)
 non-thromboembolic lung disease, 734ab(5)
 positive pressure ventilatory support, 1268
Ventricular function
 assisted circulation and artificial hearts, 780ab(5)
 biventricular forward and regurgitant flows, radioangiography, 560(lc)
 cardiovascular nuclear medicine, the next step, 1123
 evaluation, coronary artery disease, 1149
 evaluation of parameters, gated blood pool scans, sampling, 872ab(5)
 first-pass Ir-191m radionuclide angiography, phy, 450
 left
 anaerobic threshold, peak exercise, 1744ab(10)
 carbon-based generator system, Ir-191m clinical usefulness, 1025
 coronary artery disease diagnosis, radionuclide angiography, 1966
 impaired diastolic function, hypertension, 780ab(5)
 patient-borne CsI-photodiode detector, ST seg-

Ventriculography

ment, 868ab(5)
regional filling, myocardium, 165
salmonella-infected thrombus, Ga-67 citrate scintigraphy, 1277(le)
volume calculations, scintigraphy, 869ab(5)
left ventricular pressure-volume analysis, radio-nuclide angiography, 420(le)
model to evaluate ventricular insufficiency, first-pass radioventriculogram component analysis, 417(le)
myocardial perfusion and Tc-99m RP-30A, coronary arteriography, exercise Tl-201 SPECT, 820ab(5)
right
radionuclide evaluation, acute pulmonary emboli, 853ab(5)
uptake, Tc-99m MIBI and Tl-201, 820ab(5)

Ventriculography
cardiac RWMA, synthetic classification images, 816ab(5)
equilibrium gated radionuclide, post extra systolic potentiation, 870ab(5)
exercise radionuclide, cardiac events predictor, coronary insufficiency, 1745ab(10)
left, regional wall motion, gated myocardial PET, 1775
left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
left ventricular wall motion, stress myocardial perfusion, Tc-99m MIBI, 864ab(5)

Ventriculography, radionuclide
central aorta pressure change, myocardial performance, 1657
clinical utility, cardiac transplantation, 781ab(5)
epirubicin application schemes, breast cancer, 867ab(5)
nature of background, 872ab(5)
percutaneous aortic balloon valvuloplasty, 867ab(5)
realistic dynamic cardiac phantom, 542
ventricular function and perfusion, gated tomographic imaging, Tc-99m MIBI, 801ab(5)

Vertebral column, identification of inflammatory diseases, new scintigraphic technique, 856ab(5)

VEST: see Ambulatory cardiac monitoring device

Videofluoroscopy, pulmonary aspiration, evaluation, 967ab(5)

Volume rendering, gated cardiac blood-pool studies, three-dimensional display, 2036

Volunteers, irradiation, nuclear medicine, 260, T22(le)

W

Walker 256 carcinoma, radioiodinated phospholipid ethers, tumor imaging agents, 849ab(5)
Waste, regulations as "backdoor threat", N1431
Water, tritiated, bladder permeability, 2ab(4)
White blood cells, scan and magnetic resonance imaging, infection, lower extremity, 856ab(5)

X

Xenografts
breast carcinoma, localization, In-111 tumor necrosis factor, 819ab(5)
colon carcinoma, comparative biodistribution, Y- and In-labeled monoclonal antibody B72.3, 672
colorectal carcinoma, radioimmunotherapy, Y-90 CO17-1A, 935ab(5)
human cancer peritoneal, bismuth-212 labeled antibody, 778ab(5)
human leukemia, immunoscintigraphy, radiolabel and antigen modulation, 889ab(5)
human tumor
F-18 FDG uptake, cancer imaging, 912ab(5)
heterogeneity, monoclonal antibody uptake, 777ab(5)
influence of antibody protein dose, antibody distribution, autoradiography, 759ab(5)
mammary carcinoma, curative radioimmunotherapy, I-131 monoclonal antibodies, 531
murine-human, variations in absorbed dose, radiolabeled monoclonal antibodies, 777ab(5)
renal cell carcinoma, external beam irradiation, radioimmunotherapy, 826ab(5)
tumor, localization, monoclonal antibody cocktails, 747ab(5)

Xenon-133

abnormal regional response to verbal stimulation, developmental dysphasia, SPECT, 812ab(5)
back-flow testing of CPR airway valves, 1755ab(10)
central area of cerebral infarcts, spontaneous evolution, 781ab(5)
dynamic SPECT, obstructive pulmonary disease, 916ab(5)
hepatic retention ratio, 1708

PET, regional cerebral blood flow, 157
return of testicular perfusion, ligation of testicular vessels, 967ab(5)
reversed V/Q mismatch, clinical significance, 734ab(5)
SPECT
cerebral perfusion reserve, minor ischemic stroke, 897ab(5)
critical cerebral blood flow thresholds, 337
Tc-99m HMPAO uptake and, cerebral blood flow, 1752ab(10)
SPECT and Tc-99m HMPAO, presurgical evaluation, temporal lobe epilepsy, 896ab(5)
ventilation study, gastrointestinal visualization, tracheoesophageal fistula, 258
washout, penile blood flow, 1032

X-rays
bone mineral density analyzer, reproducibility, 1750ab(10)
vs. radioimmunoscopy, size-related diagnostic sensitivity, 749ab(5)

Y

Young Investigator Award, cardiovascular nuclear medicine, N14

Yttrium-88 monoclonal antibody, compared to In-III monoclonal antibody, biodistribution, colon carcinoma xenografts, 672

Yttrium-90
intraarterial glass microspheres, therapy, hepatic metastasis, 836ab(5)
intraperitoneal immunotherapy, ovarian cancer, 828ab(5)
radioimmunotherapy of colorectal carcinoma xenografts, mouse IgG co injection, 935ab(5)
radiolabeling of monoclonal antibodies, comparison, five bifunctional chelate techniques, 763ab(5)

Yttrium-90 anti-idiotype monoclonal antibody, therapy of non-Hodgkin's lymphoma, 778ab(5)

Yttrium-90 beta dose point kernels, potential use in radioimmunotherapy, 1036

Yttrium-90 EDTMP, bone-seeking radiotherapeutic agent, 843ab(5)

Yttrium-90 monoclonal antibody
effect of carrier IgG on biodistribution, 4ab(11)
macrocyclic bifunctional chelating agent, 763ab(5)

Z

Zinc-62, Cu-62 generator, PET radiopharmaceuticals, 1838

Zirconium-89, use as PET antibody label, 935ab(5)

Information for Authors

I. EDITORIAL POLICY

The *Journal of Nuclear Medicine* publishes material of interest to the practitioners and scientists in the broad field of nuclear medicine. Proffered articles describing original laboratory or clinical investigations, case reports, technical notes and letters to the editor will be considered for publication. From time to time invited articles, editorials, and reviews of selected topics will be published. Manuscripts, including illustrations and tables, must be original and not under consideration by another publication.

The *Journal of Nuclear Medicine* has agreed to receive manuscripts in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," as cited in the following sources: *Ann Intern Med* (1988; 108:258-265) and *Br Med J* (1988; 296:401-405). In preparing manuscripts, authors should follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," and specific author instructions detailed below. Also, helpful guidance in conforming to the "Uniform Requirements" may be found in *Medical Style & Format: An International Manual for Authors, Editors, and Publishers* by Edward J. Huth, MD (Philadelphia: ISI Press; 1987).

II. MANUSCRIPT SUBMISSION

Submit one original and three copies of the manuscript and four copies of the figures to:

H. William Strauss, MD, Editor-in-Chief
The Journal of Nuclear Medicine
Room 5406, MGH-EAST
Building 149, Thirteenth Street,
Charlestown, MA 02129

The Journal's phone number is (617)726-5785. Original manuscripts will not be accepted by Facsimile, but for other communications the Fax number is (617)726-5708.

All manuscripts should be accompanied by a covering letter from the author responsible for correspondence regarding the manuscript. The covering letter should contain the following copyright statement in compliance with the Copyright Revision Act of 1976, effective January 1, 1978.

Upon acceptance by The Journal of Nuclear Medicine, all copyright ownership for the article (include complete title of the article at this point) is transferred to The Society of Nuclear Medicine. On behalf of any and all co-authors, I accept the responsibility for release of any part or all of the material contained within the article noted above. The undersigned stipulates that the material submitted to The Journal of Nuclear Medicine is original and has not been submitted to another publication for concurrent consideration.

Copyright requirement does not apply to work prepared by United States government employees as part of their official duties.

You may suggest, in your cover letter, individuals who could serve as reviewers for your manuscript.

The covering letter should also contain a statement that the manuscript has been seen and approved by all authors and should give any additional information which may be helpful to the Editor. If there has been any prior publication of any part of the work, this should be acknowledged and appropriate written permission included. If color illustrations are included, a statement that the author(s) is (are) willing to assume the cost of color separation and reproduction is requested.

III. REVIEW PROCEDURE

Submitted manuscripts are reviewed for originality, significance, adequacy of documentation, reader interest, and composition.

Manuscripts not submitted according to author instructions will be returned to the author for correction prior to beginning the peer review process.

All manuscripts considered suitable for review are evaluated by a minimum of two reviewers. It is unusual for a manuscript to be accepted for publication without first undergoing a process of revision. Revised manuscripts are judged on the adequacy of responses to suggestions and criticisms made during the initial review.

All accepted manuscripts are subject to editing for scientific accuracy and clarity by the office of the Editor-in-Chief.

IV. FORMAT REQUIREMENTS

A. General Requirements

Manuscripts must be written in English. Type the manuscript on white bond paper, 8½ × 11 in. (21.6 × 27.9 cm), with margins of at least 1½ in. (4 cm). Type on one side of the paper only, double spacing every page. Begin each of the following sections on separate pages and in the following order: title page, abstract, text, acknowledgments, references, tables (each on a separate page), and legends. Number pages consecutively, beginning with the title page. Type the name of the senior author and page number in the upper right-hand corner of each page.

B. Title Page

The title page of the manuscript should include: (1) concise and informative title; (2) short running head or footline of no more than 40 characters (letters and spaces) placed at the bottom of the title page and identified; (3) complete byline, with first name, middle initial, and last name of each author and highest academic degree(s); (4) complete affiliation for each author, with the name of department(s) and institution(s) to which the work should be attributed; (5) disclaimer, if any; (6) name, address, and telephone number of one author responsible for correspondence about the manuscript; and (7) name and address of author to whom reprint requests should be directed, or statement that reprints are not available from the author.

C. Abstract

An abstract of no more than 150 words should state the purpose of the study or investigation, basic procedures (study subjects or experimental animals and observational and analytic methods), major findings (specific data and their statistical significance, if not too lengthy), and the principal conclusions. Emphasize new and important aspects of the study or observations. No abbreviations or reference citations are to be used in the abstract.

D. Text

-Presentation

The text of Original Scientific and Technical Articles is usually divided into the following sections: Introduction, Materials and Methods, Results, Discussion, and Summary or Conclusion.

Case Reports should contain a concise description, emphasizing the nuclear medicine aspects and including methodology, data, and correlative studies.

Letters should concern previously published material or matters of general interest and should be brief and to the point. All material is subject to editing.

In general, reference should not be made in the text to institutions or locales except when germane to that particular article. Generic names should be used throughout the text. Identify instruments and radiopharmaceuticals by manufacturer name and address in parentheses and describe procedures in sufficient detail to allow other investigators to reproduce the results.

-References

References should be cited in consecutive numerical order at first mention in the text and designated by the reference number underlined and in parentheses. References appearing in a table or figure should be numbered sequentially with those in the text.

The Reference list must be typed double-spaced and numbered consecutively, as in the text. The Journal follows *Index Medicus* style for references and abbreviates journal names according to the *List of Journals Indexed in Index Medicus*. "Unpublished observations" and "personal communications" should not be used as references, although written—not verbal—communications may be noted as such in the text. References cited as "in press" must have been accepted and not merely in preparation or submitted. The author is responsible for the accuracy of all references and must verify them against the original document.

For journal articles, list all authors when six or less; for seven or more authors, list the first three and et al:

Baumier PL, Krohn KA, Carrasquillo JA, et al. Melanoma local-

ization in nude mice with monoclonal Fab against p97. *J Nucl Med* 1985; 26:1172-1179.

Weissmann HS, Badia J, Sugarman LA, Kluger L, Rosenblatt R, Freeman LM. Spectrum of ^{99m}Tc-IDA cholescintigraphic patterns in acute cholecystitis. *Radiology* 1981; 138:167-175.

For books and book chapters, follow the examples below:

DeGroot LJ. Evaluation of thyroid function and thyroid disease. In: DeGroot LJ, Stanbury JB, eds. *The thyroid and its diseases*. 4th ed. New York: Wiley; 1975:196-248.

Dupont B. Bone marrow transplantation in severe combined immunodeficiency with an unrelated MLC compatible donor. In: White HJ, Smith R, eds. *Proceedings of the third annual meeting of the International Society of Experimental Hematology*. Houston: International Society for Experimental Hematology; 1974:44-46.

-Units of Measurement

The International System of Units (SI) is standard. Measurements of length, height, weight, and volume should be reported in metric units or their decimal multiples. Other measurements should be reported in the units in which they were made. Alternative units (SI or non-SI units) should be added in parentheses by the author if indicated.

-Abbreviations and Symbols

Use only standard abbreviations and symbols in the text. Avoid using abbreviations in the title and abstract. At first mention, the complete term, followed by the abbreviation in parentheses, should be used in the text. Standard units of measure should not be expanded at first mention. Consult the following sources for approved abbreviations: *CBE Style Manual: A Guide for Authors, Editors, and Publishers in the Biological Sciences*, 5th ed. (Bethesda, MD: Council of Biology Editors; 1983), and "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (*Ann Intern Med* 1982; 96:766-770).

E. Figures

-Tables

Type each table double-spaced on a separate page. Do not submit tables as photographs.

Tables should be self-explanatory and should supplement, not duplicate, the text. Each table must be cited in consecutive numerical order in the text. Number the tables consecutively with an arabic number following the word TABLE. The titles should be descriptive, brief, and typed centered in upper- and lower-case letters. Place horizontal rules below the title, column headings, and at the end of the table. *Do not use vertical lines*. Give each column a short or abbreviated heading.

Place explanatory matter in footnotes, not in the heading. Use the following symbols, in this sequence: *, †, ‡, §, ¶, **. Expand in the footnote all nonstandard abbreviations used in each table. For footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. If data from another published source are used, obtain written permission from the publisher of the original source and acknowledge fully. If data from an unpublished source are used, obtain permission from the principal investigator, and acknowledge fully.

-Illustrations

Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, the selection of sharp, high-quality illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement.

Submit three complete sets of glossy illustrations, no smaller than 3½ × 5 in. or larger than 8 × 10 in. Do not send original artwork. Glossy photographs of line drawings rendered professionally on white drawing paper in black India ink, with template or typeset lettering, should be submitted. No hand-drawn or typewritten art will be accepted. Letters, numbers, and symbols (typeset or template) must be clear and of sufficient size to retain legibility after reduction.

Each illustration must be numbered and cited in consecutive order in the text. Illustrations should be identified on a gummed label affixed to the back of each illustration, and containing the following information: figure number, part of figure (if more than one), senior author's name, and designation of "top."

Color illustrations will be considered for publication, but the author is responsible for all charges relating to separations and printing. An estimate of these charges will be sent to the author at the time of production. Author approval of charges is required before production will continue. Four complete sets of glossy color photographs (not transparencies) must be submitted for review. Polaroid prints are not acceptable.

All submitted illustrations become the property of *The Society of Nuclear Medicine* and will not be returned unless the manuscript is rejected.

-Legends for Illustrations

Type legends double-spaced on a separate page. Each figure should be cited in consecutive numerical order in the text. Number the figures with an arabic number following the word FIGURE. Use letters to designate parts of illustrations (e.g., A, B, C) and describe each part clearly in the legend. Any letter designations or arrows appearing on the illustration should be identified and described fully.

Original (not previously published) illustrations are preferred for publication in the Journal; however, if illustrations have been published previously, authors are responsible for obtaining written permission from the publisher to reprint. The source of the original material must be cited in the references and the following credit line included in the legend: (Reprinted by permission of Ref. X.) All permission releases must be submitted to the Editor at the time of manuscript submission.

F. Acknowledgements

Acknowledge persons or agencies contributing substantially to the work, including any grant support.

V. MANUSCRIPT CHECKLIST

- Original double-spaced typed manuscript and 3 copies.
- Four sets of *unmounted* glossy Figures (no smaller than 3½ × 5 in. or larger than 8 × 10 in.).
- Copyright transfer.
- Title page with title, authors' names, and complete affiliations; corresponding author, complete address, and telephone number; author for reprint requests and complete address.
- Abstract (maximum, 150 words).
- References in consecutive numerical order. Reference list typed double-spaced.
- Figures and Tables in consecutive numerical order.
- Legends for all Figures; typed double-spaced.
- Consent forms for patient photographs.
- Written permission from the publisher to reprint previously published Figures and Tables.

Index to Advertisers

Advertiser	Telephone Number	Page Number	Reader Service Number
Anzyo Sogyo Tokyo, Japan	03 473-1411	21A	94
Atomic Products, Inc. Shirley, NY	(516)924-9000	17A	6
Capintec, Inc. Ramsey, NJ	(800)631-3826	41A	11
Diversified Diagnostic Products, Inc. Houston, TX	(713)955-5323	24A	24
GE Medical Systems Milwaukee, WI	(800)624-5962	18A-19A	32
JD Technical Service San Jose, CA	(800)345-9920	16A	40
Medi-Physics, Inc. Paramus, NJ	(800)451-7732	IFC-1A, OBC	25, 50
Nuclear Associates Carle Place, NY	(516)741-6360	2A	60
Nuclear Fields Chicago, IL	(213)743-2680	20A	62
Picker International Bedford, OH	(216)475-1111	22A-23A	68
Scanditronix Essex, MA	(508)768-6994	11A	76
SELO Sesto San Giovanni MI, Italy	(39)-2-2423051	10A	95
Siemens Medical Systems Hoffman Estates, IL	(708)304-7252	8A-9A, 48A-IBC	75
Squibb Diagnostics Princeton, NJ	(800)257-5181	following page 1932	77
Syncor International Corporation Chatsworth, CA	(818)886-7400	7A	81
Trionix Research Laboratory Twinsburg, OH	(216)425-9055	following page 12A	83
Toshiba Medical Systems Tustin, CA	(800)421-1968	14A-15A	82
UGM Medical Systems Philadelphia, PA	(215)222-4999	13A	93
SNM Meeting		12A, 20A	
SNM Publications Lab Manual		46A	
MIRD Decay Schemes		43A	
MIRD Primer		44A	
New Publications		45A	
Scintillation Camera		42A	